{"488452e5c0d30e570f2dfc1507062cd9be14ef36": [["Study design and participantsThis was a survey conducted in collaboration with rehabilitation professionals working in pediatric clinics across India.", [["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29]]], ["A network of physiotherapists and occupational therapists known to the investigators were contacted and the study explained in detail.", [["the study", "TEST", 104, 113]]], ["The contact information of caregivers having children with special needs satisfying the inclusion criteria were collected from the professionals networks and reconfirmation on their understanding of English was done by the authors before participating in the survey.", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53]]], ["An online questionnaire was created to conduct data collection without risking participant exposure to the virus.", [["the virus", "PROBLEM", 103, 112]]], ["In this online survey participants older than 18 years of age and primary caregivers of children with special needs were allowed to participate.", [["children", "ORGANISM", 88, 96], ["participants", "SPECIES", 22, 34], ["children", "SPECIES", 88, 96]]], ["Other inclusion criteria included the ability to read and comprehend English along with their willingness to provide informed consent.Ethical statementThe study and protocol was approved by the institutional ethical committee, School of Physiotherapy, Delhi Pharmaceutical Sciences and Research University (10/876/Acad/DPSRU/2018, dated 27.04.2020) and was conducted in accordance with the Declaration of Helsinki guidelines.", [["The study", "TEST", 151, 160]]], ["DemographicsThe questionnaire was developed by the investigators and contained several sections (Appendix A).", [["sections", "ANATOMY", 87, 95]]], ["Then questions regarding presence of steady financial status, current workload, relationship between workload and care and whether the primary caregiver worked from home or the workplace were asked.Children's functional status and perception on tele-rehabilitationIn this section, the child's independent functioning in eating, dressing, hygiene and mobility were assessed.", [["Children", "ORGANISM", 198, 206], ["Children", "SPECIES", 198, 206], ["rehabilitation", "TREATMENT", 250, 264], ["dressing", "TREATMENT", 328, 336]]], ["The response for eating, dressing, hygiene function were dichotomized in to independent or dependent status where-as mobility were categorized to 5 levels.", [["dressing", "TREATMENT", 25, 33]]], ["Apart from this, the caregiver's perception about homecare therapy and tele-consulation and rehabilitation were also assessed.Depression, anxiety and stress levelsTo assess mental health symptoms during the pandemic outbreak, Depression Anxiety Stress-21scale (DASS-21) was used (Lovibond & Lovibond, 1995) .", [["Depression", "DISEASE", 126, 136], ["anxiety", "DISEASE", 138, 145], ["Depression", "DISEASE", 226, 236], ["homecare therapy", "TREATMENT", 50, 66], ["tele", "TEST", 71, 75], ["rehabilitation", "TREATMENT", 92, 106], ["Depression", "PROBLEM", 126, 136], ["anxiety", "PROBLEM", 138, 145], ["stress levels", "PROBLEM", 150, 163], ["mental health symptoms", "PROBLEM", 173, 195], ["the pandemic outbreak", "PROBLEM", 203, 224], ["Depression", "PROBLEM", 226, 236], ["Anxiety Stress", "PROBLEM", 237, 251]]], ["Participants responded to a 21 item Depression anxiety stress scale .", [["anxiety", "DISEASE", 47, 54], ["Participants", "SPECIES", 0, 12], ["Depression anxiety stress scale", "PROBLEM", 36, 67]]], ["The scale is divided in to three subsets (stress, anxiety and depression) and each domain contains 7 items.", [["anxiety", "DISEASE", 50, 57], ["depression", "DISEASE", 62, 72], ["anxiety", "PROBLEM", 50, 57], ["depression", "PROBLEM", 62, 72]]], ["Dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest / involvement, anhedonia and inertia were evaluated by the depression subscale.", [["Dysphoria", "DISEASE", 0, 9], ["hopelessness", "DISEASE", 11, 23], ["anhedonia", "DISEASE", 96, 105], ["depression", "DISEASE", 140, 150], ["Dysphoria", "PROBLEM", 0, 9], ["hopelessness", "PROBLEM", 11, 23], ["anhedonia", "PROBLEM", 96, 105], ["the depression subscale", "PROBLEM", 136, 159]]], ["The anxiety subscale assessed autonomic arousal, skeletal muscle effects, situational anxiety, and the subjective experience of anxious affect.", [["skeletal muscle", "ANATOMY", 49, 64], ["anxiety", "DISEASE", 4, 11], ["anxiety", "DISEASE", 86, 93], ["skeletal muscle", "TISSUE", 49, 64], ["The anxiety subscale", "PROBLEM", 0, 20], ["autonomic arousal", "PROBLEM", 30, 47], ["skeletal muscle effects", "PROBLEM", 49, 72], ["situational anxiety", "PROBLEM", 74, 93], ["anxious affect", "PROBLEM", 128, 142], ["skeletal muscle", "ANATOMY", 49, 64]]], ["To assess difficulty in relaxing, nervous arousal, and being easily upset / agitated, irritable / over-reactive and impatient the stress subscale was used.", [["nervous", "ANATOMY", 34, 41], ["nervous", "ANATOMICAL_SYSTEM", 34, 41], ["difficulty in relaxing", "PROBLEM", 10, 32], ["agitated", "PROBLEM", 76, 84], ["irritable", "PROBLEM", 86, 95]]], ["Scores for depression, anxiety and stress symptoms were calculated by summing the scores for the relevant items.", [["depression", "DISEASE", 11, 21], ["anxiety", "DISEASE", 23, 30], ["depression", "PROBLEM", 11, 21], ["anxiety", "PROBLEM", 23, 30], ["stress symptoms", "PROBLEM", 35, 50]]], ["Finally this short version DASS-21 scores were multiplied by 2 to find the severity of depression, anxiety and stress symptoms.", [["depression", "DISEASE", 87, 97], ["anxiety", "DISEASE", 99, 106], ["this short version DASS", "TEST", 8, 31], ["depression", "PROBLEM", 87, 97], ["anxiety", "PROBLEM", 99, 106], ["stress symptoms", "PROBLEM", 111, 126], ["depression", "OBSERVATION", 87, 97]]], ["The depression subscale is categorized as mild (10-13), moderate (14-20), severe (21-27) and extremely severe (28+).", [["depression", "DISEASE", 4, 14], ["The depression subscale", "PROBLEM", 0, 23], ["extremely severe", "PROBLEM", 93, 109], ["depression", "OBSERVATION", 4, 14], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["moderate", "OBSERVATION_MODIFIER", 56, 64], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["severe", "OBSERVATION_MODIFIER", 103, 109]]], ["The anxiety subscale is classified in to mild Please cite this article in press as: S. Dhiman (8-9), moderate (10-14), severe (15) (16) (17) (18) (19) and extremely severe (20+) to note the severity of anxiety symptoms.", [["anxiety", "DISEASE", 4, 11], ["anxiety", "DISEASE", 202, 209], ["The anxiety subscale", "PROBLEM", 0, 20], ["extremely severe", "PROBLEM", 155, 171], ["anxiety symptoms", "PROBLEM", 202, 218], ["moderate", "OBSERVATION_MODIFIER", 101, 109], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["severe", "OBSERVATION_MODIFIER", 165, 171]]], ["Finally, the severity of stress was assessed on mild (15-18), moderate (19-25), severe (26-33) and extremely severe (34+).", [["stress", "PROBLEM", 25, 31], ["severe (26", "PROBLEM", 80, 90], ["extremely severe (34+)", "PROBLEM", 99, 121], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["moderate", "OBSERVATION_MODIFIER", 62, 70], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["severe", "OBSERVATION_MODIFIER", 109, 115]]], ["The validity of this scale measuring depression, anxiety and stress symptoms was previously tested (Ng et al., 2007) .Caregiver strainCaregiver's strain during and before the COVID-19 outbreak were enquired by using a validated caregiver strain index (CSI) questionnaire (Robinson, 1983) .", [["depression", "DISEASE", 37, 47], ["anxiety", "DISEASE", 49, 56], ["depression", "PROBLEM", 37, 47], ["anxiety", "PROBLEM", 49, 56], ["stress symptoms", "PROBLEM", 61, 76]]], ["To observe the impact of the COVID-19 outbreak on caregiver strain, participants were asked to retrospectively note the strain they perceived one month before the pandemic.", [["participants", "SPECIES", 68, 80], ["the COVID", "TREATMENT", 25, 34]]], ["A score 7 or above indicates a greater level of strain.", [["A score", "TEST", 0, 7], ["strain", "PROBLEM", 48, 54], ["greater", "OBSERVATION_MODIFIER", 31, 38]]], ["This scale was developed and validated to measure strain perceived due to care of children with various neurological conditions such as cerebral palsy, Duchene muscular dystrophy and other serious illnesses (Byrne et al., 2011; Pangalila et al., 2012; Sharan et al., 2012) .Data analysisData were analysed with SPSS version 26.0.", [["neurological", "ANATOMY", 104, 116], ["cerebral", "ANATOMY", 136, 144], ["muscular", "ANATOMY", 160, 168], ["cerebral palsy", "DISEASE", 136, 150], ["Duchene muscular dystrophy", "DISEASE", 152, 178], ["children", "ORGANISM", 82, 90], ["cerebral", "ORGAN", 136, 144], ["children", "SPECIES", 82, 90], ["various neurological conditions", "PROBLEM", 96, 127], ["cerebral palsy", "PROBLEM", 136, 150], ["Duchene muscular dystrophy", "PROBLEM", 152, 178], ["Data analysisData", "TEST", 274, 291], ["SPSS version", "TEST", 311, 323], ["cerebral", "ANATOMY", 136, 144], ["palsy", "OBSERVATION", 145, 150], ["muscular", "ANATOMY", 160, 168], ["dystrophy", "OBSERVATION", 169, 178]]], ["Descriptive statistics were used to find the prevalence of depression, anxiety, stress symptoms and demographics of factors.", [["depression", "DISEASE", 59, 69], ["anxiety", "DISEASE", 71, 78], ["depression", "PROBLEM", 59, 69], ["anxiety", "PROBLEM", 71, 78], ["stress symptoms", "PROBLEM", 80, 95]]], ["The impact of COVID-19 outbreak on CSI was analysed using a paired t-test.", [["COVID", "TREATMENT", 14, 19], ["a paired t-test", "TEST", 58, 73]]], ["Bivariate pearson correlation testing was conducted to find the relationship among depression, anxiety, stress symptoms and CSI.", [["depression", "DISEASE", 83, 93], ["anxiety", "DISEASE", 95, 102], ["Bivariate pearson correlation testing", "TEST", 0, 37], ["depression", "PROBLEM", 83, 93], ["anxiety", "PROBLEM", 95, 102], ["stress symptoms", "PROBLEM", 104, 119], ["CSI", "PROBLEM", 124, 127]]], ["Multivariate ANOVA (MANOVA) was conducted to analyse the demographic, social and care related factors associated with DASS indices (depression, anxiety and stress symptoms).", [["depression", "DISEASE", 132, 142], ["anxiety", "DISEASE", 144, 151], ["DASS indices", "PROBLEM", 118, 130], ["depression", "PROBLEM", 132, 142], ["anxiety", "PROBLEM", 144, 151], ["stress symptoms", "PROBLEM", 156, 171]]], ["To test the demographic, social and care related factors associated with CSI, analysis of covariance (ANCOVA) was used where the CSI score one month before the pandemic outbreak (retrospective data) was considered as a covariate.General characteristicsContact information of 307 caregivers of children with special needs satisfying the inclusion criteria were received from the rehabilitation professional network and then participants were reconfirmed by the authors for knowledge in reading, understanding English and access to internet.", [["children", "ORGANISM", 293, 301], ["children", "SPECIES", 293, 301], ["participants", "SPECIES", 423, 435], ["the CSI score", "TEST", 125, 138]]], ["The 300 participants fitting study criterion were asked to complete the online form.", [["participants", "SPECIES", 8, 20]]], ["Finally, data from 264 respondents were recorded (response rate 88 %, no missing data) and analysed.", [["response rate", "TEST", 50, 63]]], ["All respondents had a minimum bachelor degree qualification and 85 % of our sample had above bachelor level education.", [["above bachelor level education", "TREATMENT", 87, 117]]], ["The mean age of children was 6.20 \u00b1 3.05 (mean \u00b1 SD) years and participants were from 9 major cities of India.Prevalence of depression, anxiety, stress symptoms and CSI among caregiversOverall, the prevalence of depressive symptoms was 62.5 % whereas prevalence of anxiety and stress symptoms were 20.5 % and 36.4 % respectively.", [["depression", "DISEASE", 124, 134], ["anxiety", "DISEASE", 136, 143], ["stress symptoms", "DISEASE", 145, 160], ["depressive symptoms", "DISEASE", 212, 231], ["anxiety", "DISEASE", 265, 272], ["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24], ["participants", "SPECIES", 63, 75], ["depression", "PROBLEM", 124, 134], ["anxiety", "PROBLEM", 136, 143], ["stress symptoms", "PROBLEM", 145, 160], ["depressive symptoms", "PROBLEM", 212, 231], ["anxiety", "PROBLEM", 265, 272], ["stress symptoms", "PROBLEM", 277, 292], ["depression", "OBSERVATION", 124, 134]]], ["The prevalence of psychological symptoms with their severity is presented in Table 2 andImpact of COVID-19 outbreak on CSITo evaluate the impact of COVID-19 on CSI, the CSI during the outbreak was compared with the retrospectively reported CSI score 1 month before the outbreak by a paired t-test.", [["psychological symptoms", "PROBLEM", 18, 40], ["COVID", "TREATMENT", 98, 103], ["COVID", "TEST", 148, 153], ["CSI", "TREATMENT", 160, 163], ["a paired t-test", "TEST", 281, 296]]], ["Table 3 and Fig. 2 indicates there was a statistical significant change (p < 0.001) with large effect size (0.93) from before to during the outbreak and a mean difference of 2.98\u00b13.83.Impact of COVID-19 outbreak on CSIPlease cite this article in press as: S. Dhiman, P.K. Sahu, W.R. Reed et al. Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs.", [["children", "ORGANISM", 386, 394], ["children", "SPECIES", 386, 394], ["a statistical significant change", "PROBLEM", 39, 71], ["large effect size", "PROBLEM", 89, 106], ["COVID", "TREATMENT", 194, 199], ["COVID", "TREATMENT", 305, 310], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["change", "OBSERVATION", 65, 71], ["large", "OBSERVATION_MODIFIER", 89, 94], ["effect", "OBSERVATION_MODIFIER", 95, 101], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["Research in Developmental Disabilities (xxxx), https://doi.org/10.1016/j.ridd.2020.103790 Table 3 Impact of COVID-19 outbreak on caregiver strain index analysed by paired t-test.VariableBefore outbreak (mean \u00b1 SD)Fig. 2.Graph showing mean change in CSI score before the outbreak (retrospectively reported) to during the outbreak.Correlation among depression, anxiety, stress symptoms and CSI among participantsThe results of correlation analysis are shown in Table 4 .", [["depression", "DISEASE", 347, 357], ["anxiety", "DISEASE", 359, 366], ["participants", "SPECIES", 398, 410], ["COVID", "TEST", 108, 113], ["caregiver strain index", "TEST", 129, 151], ["paired t-test", "TEST", 164, 177], ["Graph", "TEST", 220, 225], ["mean change in CSI score", "PROBLEM", 234, 258], ["depression", "PROBLEM", 347, 357], ["anxiety", "PROBLEM", 359, 366], ["stress symptoms", "PROBLEM", 368, 383], ["correlation analysis", "TEST", 425, 445], ["mean", "OBSERVATION_MODIFIER", 234, 238], ["change", "OBSERVATION_MODIFIER", 239, 245]]], ["Bivariate correlation testing was done among depression, anxiety, stress symptoms and CSI.", [["depression", "DISEASE", 45, 55], ["anxiety", "DISEASE", 57, 64], ["Bivariate correlation testing", "TEST", 0, 29], ["depression", "PROBLEM", 45, 55], ["anxiety", "PROBLEM", 57, 64], ["stress symptoms", "PROBLEM", 66, 81], ["CSI", "PROBLEM", 86, 89]]], ["The results showed a weak but statistically significant correlation between depression (r = 0.25, P < 0.001) and anxiety symptoms (r = 0.21, P < 0.001) with CSI, while a moderate, statistical significant correlation (r = 0.40, P < 0.001) was found between CSI and stress symptoms.", [["depression", "DISEASE", 76, 86], ["anxiety", "DISEASE", 113, 120], ["a weak", "PROBLEM", 19, 25], ["depression", "PROBLEM", 76, 86], ["P", "TEST", 98, 99], ["anxiety symptoms", "PROBLEM", 113, 129], ["CSI", "TEST", 157, 160], ["CSI", "PROBLEM", 256, 259], ["stress symptoms", "PROBLEM", 264, 279], ["moderate", "OBSERVATION_MODIFIER", 170, 178]]], ["Moreover, a statistical significant and strong correlation were observed between depression, anxiety symptoms (r = 0.64, P < 0.001), depression, stress symptoms (r = 0.61, P < 0.001) and anxiety, stress symptoms (r = 0.73, P < 0.001).Factors associated with depression, anxiety and stress symptoms among caregivers of children with special needsTo explore the demographic, social and care related factors associated with DASS indices (depression, anxiety and stress symptoms), MANOVA was used.", [["depression", "DISEASE", 81, 91], ["anxiety", "DISEASE", 93, 100], ["depression", "DISEASE", 133, 143], ["stress symptoms", "DISEASE", 145, 160], ["anxiety", "DISEASE", 187, 194], ["depression", "DISEASE", 258, 268], ["anxiety", "DISEASE", 270, 277], ["stress symptoms", "DISEASE", 282, 297], ["depression", "DISEASE", 435, 445], ["anxiety", "DISEASE", 447, 454], ["children", "ORGANISM", 318, 326], ["children", "SPECIES", 318, 326], ["depression", "PROBLEM", 81, 91], ["anxiety symptoms", "PROBLEM", 93, 109], ["P", "TEST", 121, 122], ["depression", "PROBLEM", 133, 143], ["stress symptoms", "PROBLEM", 145, 160], ["P", "TEST", 172, 173], ["anxiety", "PROBLEM", 187, 194], ["stress symptoms", "PROBLEM", 196, 211], ["P", "TEST", 223, 224], ["depression", "PROBLEM", 258, 268], ["anxiety", "PROBLEM", 270, 277], ["stress symptoms", "PROBLEM", 282, 297], ["DASS indices", "PROBLEM", 421, 433], ["depression", "PROBLEM", 435, 445], ["anxiety", "PROBLEM", 447, 454], ["stress symptoms", "PROBLEM", 459, 474], ["MANOVA", "TREATMENT", 477, 483]]], ["The assumptions for MANOVA such as absence of outliers, linear relationship between each dependent variables and each group of independent variable, multivariate normality and absence of multi-collinearity (correlation coefficient 0.2 to 0.9 between each dependent variables) were met and the independent factors satisfying the assumptions were selected to be tested.Factors associated with depression, anxiety and stress symptoms among caregivers of children with special needsOne way MANOVA analysis with Wilk's lamda ( ), p value and effect sizes (partial Eta squared) are presented in Table 5 , which shows the difference across levels in various factors when depression, anxiety and stress symptoms considered together as a dependent variable.Factors associated with depression, anxiety and stress symptoms among caregivers of children with special needsAnalysis of variance (ANOVA) was conducted to test association of each independent factor on depression, anxiety and stress symptoms separately ( Table 6 ).", [["depression", "DISEASE", 391, 401], ["anxiety", "DISEASE", 403, 410], ["stress symptoms", "DISEASE", 415, 430], ["depression", "DISEASE", 664, 674], ["anxiety", "DISEASE", 676, 683], ["depression", "DISEASE", 772, 782], ["anxiety", "DISEASE", 784, 791], ["stress symptoms", "DISEASE", 796, 811], ["depression", "DISEASE", 952, 962], ["anxiety", "DISEASE", 964, 971], ["children", "ORGANISM", 451, 459], ["children", "ORGANISM", 832, 840], ["children", "SPECIES", 451, 459], ["children", "SPECIES", 832, 840], ["MANOVA", "PROBLEM", 20, 26], ["depression", "PROBLEM", 391, 401], ["anxiety", "PROBLEM", 403, 410], ["stress symptoms", "PROBLEM", 415, 430], ["MANOVA analysis", "TEST", 486, 501], ["depression", "PROBLEM", 664, 674], ["anxiety", "PROBLEM", 676, 683], ["stress symptoms", "PROBLEM", 688, 703], ["a dependent variable", "PROBLEM", 727, 747], ["depression", "PROBLEM", 772, 782], ["anxiety", "PROBLEM", 784, 791], ["stress symptoms", "PROBLEM", 796, 811], ["each independent factor", "PROBLEM", 925, 948], ["depression", "PROBLEM", 952, 962], ["anxiety", "PROBLEM", 964, 971], ["stress symptoms", "PROBLEM", 976, 991]]], ["The mean and standard deviation score of all psychological symptoms of each independent factor across levels is presented in Appendix B. To estimate the strength of associations estimates (B) is used.", [["all psychological symptoms", "PROBLEM", 41, 67], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["Appendix", "ANATOMY", 125, 133]]], ["Finally, a series of post-hoc analyses (Scheffe's test used because of unequal sample sizes) were performed to examine differences across three levels of perception on difficulty of home care therapy, five levels of mobility and three levels of work from home pattern during lock-down.", [["post-hoc analyses", "TEST", 21, 38], ["Scheffe's test", "TEST", 40, 54], ["unequal sample sizes", "PROBLEM", 71, 91], ["home care therapy", "TREATMENT", 182, 199]]], ["The mean differences and p value are presented in Table 7 .Factors associated with CSI among caregivers of children with special needsUnivariate ANCOVA was performed to test the demographic, social and care related factors associated with CSI during the outbreak among caregivers tending children with special needs.", [["children", "ORGANISM", 107, 115], ["children", "ORGANISM", 288, 296], ["children", "SPECIES", 107, 115], ["children", "SPECIES", 288, 296], ["Univariate ANCOVA", "TEST", 134, 151], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["After meeting the assumptions, CSI score before the pandemic outbreak was considered as a covariate in the model.", [["CSI score", "TEST", 31, 40], ["the pandemic outbreak", "PROBLEM", 48, 69]]], ["The mean and standard deviation score of CSI during the outbreak of each independent factor across levels is presented in Appendix B. The ANCOVA results including estimates (B), p value and effect sizes (partial Eta squared) after controlling CSI score before the outbreak, is presented in Table 8 .DiscussionThe overall result of the study shows a high prevalence of depressive symptoms among caregivers tending children with special needs during the COVID-19 pandemic outbreak.", [["depressive symptoms", "DISEASE", 368, 387], ["children", "ORGANISM", 413, 421], ["children", "SPECIES", 413, 421], ["standard deviation score of CSI", "PROBLEM", 13, 44], ["the study", "TEST", 331, 340], ["depressive symptoms", "PROBLEM", 368, 387], ["the COVID", "TEST", 448, 457], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["Appendix", "ANATOMY", 122, 130], ["sizes", "OBSERVATION_MODIFIER", 197, 202]]], ["A significant difference in caregiver strain was observed during the outbreak when the strain was retrospectively noted one month before the pandemic.", [["A significant difference in caregiver strain", "PROBLEM", 0, 44], ["the strain", "PROBLEM", 83, 93], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION_MODIFIER", 14, 24]]], ["Apart from it, we found several demographic, social factors and services related to care of child are associated with depression, stress, anxiety symptoms and perceived strain.DiscussionThe study observed a high prevalence of depressive symptoms (62.5 %) among caregivers whereas 20.5 % and 36.4 % were indicated for anxiety and stress symptoms respectively.", [["depression", "DISEASE", 118, 128], ["anxiety", "DISEASE", 138, 145], ["depressive symptoms", "DISEASE", 226, 245], ["anxiety", "DISEASE", 317, 324], ["child", "ORGANISM", 92, 97], ["depression", "PROBLEM", 118, 128], ["stress", "PROBLEM", 130, 136], ["anxiety symptoms", "PROBLEM", 138, 154], ["perceived strain", "PROBLEM", 159, 175], ["The study", "TEST", 186, 195], ["depressive symptoms", "PROBLEM", 226, 245], ["anxiety", "PROBLEM", 317, 324], ["stress symptoms", "PROBLEM", 329, 344], ["several", "OBSERVATION_MODIFIER", 24, 31]]], ["Our study reported a significantly high prevalence of depressive symptoms among caregivers in contrast to 37.1 % and 20.1 % reported by two Chinese studies conducted during the initial period of lockdown among the general population Huang & Zhao, 2020) .", [["depressive symptoms", "DISEASE", 54, 73], ["Our study", "TEST", 0, 9], ["depressive symptoms", "PROBLEM", 54, 73], ["Chinese studies", "TEST", 140, 155]]], ["It was also noted that an extended period of outbreak was not associated with a change in depression score among the general population (Wang, Pan et al., 2020; Wang, Hu et al., 2020) .", [["depression", "DISEASE", 90, 100], ["outbreak", "PROBLEM", 45, 53], ["a change in depression score", "PROBLEM", 78, 106]]], ["Caregivers of children with special needs face unique challenges in family, social life and are stigmatized in society because of their children's disability.", [["disability", "DISEASE", 147, 157], ["children", "ORGANISM", 14, 22], ["children", "ORGANISM", 136, 144], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 136, 144]]], ["Behavioral issues are also very common in this population (Martin et al., 2019; Vadivelan et al., 2020) .", [["Behavioral issues", "PROBLEM", 0, 17]]], ["However, in comparison to a low prevalence of depression reported by previous studies among caregivers of ASD (43 %), CP (26 %), intellectual and developmental disabilities (IDD) (29 %) children, a higher prevalence in our study was possibly because of the added burdens after the outbreak (Al-Farsi et al., 2016; Sajedi et al., 2010; Singer, 2006) .", [["depression", "DISEASE", 46, 56], ["ASD", "DISEASE", 106, 109], ["CP", "DISEASE", 118, 120], ["intellectual and developmental disabilities", "DISEASE", 129, 172], ["IDD", "DISEASE", 174, 177], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["depression", "PROBLEM", 46, 56], ["previous studies", "TEST", 69, 85], ["ASD", "TEST", 106, 109], ["CP", "PROBLEM", 118, 120], ["intellectual and developmental disabilities (IDD)", "PROBLEM", 129, 178], ["our study", "TEST", 219, 228]]], ["Moreover, the impact of the increase in death rate in India and the amount of pandemic media coverage during the time of data collection may have contributed to increased depression level.DiscussionThe low prevalence of anxiety symptoms in the present study is similar to the data reported by past research on parents of intellectual disabled (18.33 %) and IDD (31 %) (Tak et al., 2018; Scherer et al., 2019) .", [["death", "DISEASE", 40, 45], ["depression", "DISEASE", 171, 181], ["anxiety", "DISEASE", 220, 227], ["intellectual disabled", "DISEASE", 321, 342], ["IDD", "DISEASE", 357, 360], ["death rate", "PROBLEM", 40, 50], ["pandemic media coverage", "TREATMENT", 78, 101], ["increased depression level", "PROBLEM", 161, 187], ["anxiety symptoms", "PROBLEM", 220, 236], ["IDD", "PROBLEM", 357, 360], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["amount", "OBSERVATION_MODIFIER", 68, 74], ["increased", "OBSERVATION_MODIFIER", 161, 170], ["depression", "OBSERVATION", 171, 181]]], ["Although the Chinese and Iranian general population observed a high prevalence of anxiety during the pandemic, the lower prevalence in our caregivers might be related to the timing of the individual studies Moghanibashi-Mansourieh, 2020) .", [["anxiety", "DISEASE", 82, 89], ["anxiety", "PROBLEM", 82, 89]]], ["Fear of disease contagiousness, knowledge on safety measures are usually the main causes of anxiety apart from financial and social issues (Roy et al., 2020) .", [["contagiousness", "DISEASE", 16, 30], ["anxiety", "DISEASE", 92, 99], ["disease contagiousness", "PROBLEM", 8, 30], ["safety measures", "TREATMENT", 45, 60], ["anxiety", "PROBLEM", 92, 99], ["disease", "OBSERVATION", 8, 15]]], ["By the time this study was conducted, caregivers may have been more aware and better informed about the disease, the precautionary measures to be followed, and had partially adapted to the situation.", [["this study", "TEST", 12, 22], ["the disease", "PROBLEM", 100, 111]]], ["Furthermore, during the lockdown, living with the family members and increased interpersonal communication might have had a direct effect on anxiety scoring.", [["anxiety", "DISEASE", 141, 148], ["anxiety scoring", "PROBLEM", 141, 156]]], ["The same factors probably attributed to stress levels unlike to the previous study results ( , p \u2264 0.01* ; a -referent factor.", [["stress levels", "PROBLEM", 40, 53], ["the previous study", "TEST", 64, 82], ["probably attributed to", "UNCERTAINTY", 17, 39]]], ["Level 3: Can walk on their own using a walking aid (such as a walker, rollator, crutches, canes, etc.).", [["a walking aid", "TREATMENT", 37, 50], ["a walker, rollator", "TREATMENT", 60, 78], ["crutches", "TREATMENT", 80, 88]]], ["Level 5: Has difficulty sitting on their own and controlling their head and body posture in most position.", [["head", "ANATOMY", 67, 71], ["body", "ANATOMY", 76, 80], ["head", "ORGANISM_SUBDIVISION", 67, 71], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["head", "ANATOMY", 67, 71], ["body", "ANATOMY", 76, 80], ["most position", "OBSERVATION_MODIFIER", 92, 105]]], ["Recent research also identified a strong relationship between psychological and physical symptoms in the general population and among health workers during the COVID-19 pandemic (Chew et al., 2020; Wang, Pan et al., 2020; Wang, Hu et al., 2020) .", [["psychological and physical symptoms", "DISEASE", 62, 97], ["a strong relationship between psychological and physical symptoms", "PROBLEM", 32, 97]]], ["These common symptoms such as throat pain, headache, migraine and fatigue are often confused with associated symptoms of viral infection and may further aid in deteriorating mental health.DiscussionCaregivers not continuing tele-rehabilitation during the lockdown are associated with a high anxiety level and a strong association was found between a caregiver's perception on tele-consultation as an alternate medium for rehabilitation and psychological symptoms.", [["throat", "ANATOMY", 30, 36], ["throat pain", "DISEASE", 30, 41], ["headache", "DISEASE", 43, 51], ["migraine", "DISEASE", 53, 61], ["fatigue", "DISEASE", 66, 73], ["viral infection", "DISEASE", 121, 136], ["anxiety", "DISEASE", 291, 298], ["throat", "ORGANISM_SUBDIVISION", 30, 36], ["These common symptoms", "PROBLEM", 0, 21], ["throat pain", "PROBLEM", 30, 41], ["headache", "PROBLEM", 43, 51], ["migraine", "PROBLEM", 53, 61], ["fatigue", "PROBLEM", 66, 73], ["confused", "PROBLEM", 84, 92], ["associated symptoms", "PROBLEM", 98, 117], ["viral infection", "PROBLEM", 121, 136], ["rehabilitation", "TREATMENT", 229, 243], ["a high anxiety level", "PROBLEM", 284, 304], ["rehabilitation", "TREATMENT", 421, 435], ["psychological symptoms", "PROBLEM", 440, 462], ["throat", "ANATOMY", 30, 36], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["We found that subjects who responded with a perception against tele-consultation were at greater risk for depression, anxiety and stress symptoms.", [["depression", "DISEASE", 106, 116], ["anxiety", "DISEASE", 118, 125], ["depression", "PROBLEM", 106, 116], ["anxiety", "PROBLEM", 118, 125], ["stress symptoms", "PROBLEM", 130, 145]]], ["With the advancement in technology, tele-rehabilitation is considered as an alternative medium in health care.", [["rehabilitation", "TREATMENT", 41, 55]]], ["Moreover, to provide solutions to global disease and to better battle against this current pandemic, tele-rehabilitation should have a greater emphasis wherever feasible.", [["global disease", "PROBLEM", 34, 48], ["rehabilitation", "TREATMENT", 106, 120], ["disease", "OBSERVATION", 41, 48]]], ["The overlooked barriers in a developing country such as poverty, confidentiality, privacy and cross-cultural acceptance of tele-rehabilitation strategies are the probable factors for the negative perception of tele-rehabilitation warrant future exploration (Khan et al., 2015) .", [["tele", "TEST", 123, 127], ["rehabilitation strategies", "TREATMENT", 128, 153], ["rehabilitation", "TREATMENT", 215, 229], ["future exploration", "TEST", 238, 256]]], ["Moreover, caregiver's knowledge on the importance of tele-rehabilitation, patient and therapist bonding, communication between participants play a major role in creating acceptance of tele-rehabilitation and a positive perception in caregivers (Kairy et al., 2013; Mair et al., 2005) .", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["participants", "SPECIES", 127, 139], ["rehabilitation", "TREATMENT", 189, 203]]], ["Thus, the present work encourages greater urgency for policy makers and care providers to implement and strengthen greater use of tele-rehabilitation approaches and to provide better education on the benefits of tele-rehabilitation as a means to reduce depression, stress and anxiety symptoms among caregivers tending children with special needs.DiscussionParents/caregivers participation and engagement are major components in rehabilitation of children with disability as they spend more time with them (Phoenix et al., 2020) .", [["depression", "DISEASE", 253, 263], ["anxiety", "DISEASE", 276, 283], ["disability", "DISEASE", 460, 470], ["children", "ORGANISM", 318, 326], ["children", "ORGANISM", 446, 454], ["children", "SPECIES", 318, 326], ["children", "SPECIES", 446, 454], ["rehabilitation approaches", "TREATMENT", 135, 160], ["rehabilitation", "TREATMENT", 217, 231], ["depression", "PROBLEM", 253, 263], ["stress and anxiety symptoms", "PROBLEM", 265, 292]]], ["Thus, it is advisable that the caregivers should strive to learn homecare treatment techniques from the therapists to enhance their overall functional ability.", [["homecare treatment techniques", "TREATMENT", 65, 94]]], ["However, due to a sudden declaration of lockdown many caregivers were unable to learn homecare techniques in an appropriate manner that might have resulted in wrong perception about difficulties encountered during homecare therapy.", [["homecare techniques", "TREATMENT", 86, 105], ["homecare therapy", "TREATMENT", 214, 230]]], ["Caregivers who did not learn homecare therapy were associated with depression and who held a perception that homecare therapy is moderate to difficult was strongly associated with stress symptoms.", [["depression", "DISEASE", 67, 77], ["homecare therapy", "TREATMENT", 29, 45], ["depression", "PROBLEM", 67, 77], ["homecare therapy", "TREATMENT", 109, 125], ["stress symptoms", "PROBLEM", 180, 195]]], ["These findings indicate either lack of education on the importance of homecare therapy or ineffective home care training was provided to caregivers deserves greater consideration.", [["homecare therapy", "TREATMENT", 70, 86], ["ineffective home care training", "TREATMENT", 90, 120]]], ["We also found that certain immediate non-modifiable factors such as dependency in eating, dressing and hygiene were risk factors for depression, anxiety and stress symptoms similar to that reported in a previous study (Batool & Khurshid, 2015) .", [["depression", "DISEASE", 133, 143], ["anxiety", "DISEASE", 145, 152], ["dressing", "TREATMENT", 90, 98], ["risk factors", "PROBLEM", 116, 128], ["depression", "PROBLEM", 133, 143], ["anxiety", "PROBLEM", 145, 152], ["stress symptoms", "PROBLEM", 157, 172], ["a previous study", "TEST", 201, 217]]], ["We observed that both caregivers of children who could walk long outdoor distances without difficulty (mobility level 1) and with difficulty (level 2) were associated with poor mental health compared to those caregivers with children having only independent sitting ability (level 4).", [["children", "ORGANISM", 36, 44], ["children", "ORGANISM", 225, 233], ["children", "SPECIES", 36, 44], ["children", "SPECIES", 225, 233], ["difficulty (level 2", "PROBLEM", 130, 149], ["poor mental health", "PROBLEM", 172, 190]]], ["Most of the participants in level 1 and 2 were ASD and LD while in level 4 CP were the majority.", [["ASD", "DISEASE", 47, 50], ["participants", "SPECIES", 12, 24], ["ASD", "PROBLEM", 47, 50], ["level 4 CP", "PROBLEM", 67, 77]]], ["Therefore, we can assume that sensory and behavioral issues of children are the main contributors to poor psychological health in their caregivers.", [["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71]]], ["Working from home during the lockdown is also found to be a risk factor for poor mental health.", [["poor mental health", "PROBLEM", 76, 94]]], ["Caregivers of older children were less prone for depression, anxiety and stress symptoms because they are likely to be more autonomous, independent in function and less demanding for caregivers.", [["depression", "DISEASE", 49, 59], ["anxiety", "DISEASE", 61, 68], ["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["depression", "PROBLEM", 49, 59], ["anxiety", "PROBLEM", 61, 68], ["stress symptoms", "PROBLEM", 73, 88]]], ["This data was confirmed by the positive association between dependency in eating, dressing, hygiene and higher depression, anxiety and stress symptoms.", [["depression", "DISEASE", 111, 121], ["anxiety", "DISEASE", 123, 130], ["dressing", "TREATMENT", 82, 90], ["higher depression", "PROBLEM", 104, 121], ["anxiety", "PROBLEM", 123, 130], ["stress symptoms", "PROBLEM", 135, 150]]], ["Moreover, coping strategies learnt by parents over time might have aided in reducing the poor psychology associated with the children's disability.DiscussionHealth is defined as a state of complete physical, mental and social well-being and to observe all the three dimensions of caregiver's health, the CSI questionnaire was used (WHO definition of health, 2020).", [["disability", "DISEASE", 136, 146], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133]]], ["This level of increase demands that greater attention to be paid to effectively alleviate this added strain.", [["this added strain", "PROBLEM", 90, 107]]], ["We noticed children with indoor mobility with orthotic devices and lack of independent sitting ability groups were strongly associated with increased caregiver strain.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["orthotic devices", "TREATMENT", 46, 62], ["increased caregiver strain", "PROBLEM", 140, 166]]], ["On the other hand, a lower level of strain among caregiver's of children with dependency in dressing indicates it should not be an immediate primary goal by care providers to reduce strain in the caregivers during this pandemic.", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["dressing", "TREATMENT", 92, 100]]], ["Caregivers continuing tele-rehabilitation and homecare therapy scored these types of therapies to be physically strained and confining in CSI questionnaire.", [["rehabilitation", "TREATMENT", 27, 41], ["homecare therapy", "TREATMENT", 46, 62], ["therapies", "TREATMENT", 85, 94]]], ["This was supported by the findings that the strain was more in caregivers whose perception of homecare therapy was moderate to difficult.", [["homecare therapy", "TREATMENT", 94, 110]]], ["Thus, better communication between rehabilitation professionals and caregivers is needed to teach the strategies in an efficient manner to reduce strain.", [["rehabilitation professionals", "TREATMENT", 35, 63], ["the strategies", "TREATMENT", 98, 112], ["strain", "PROBLEM", 146, 152]]], ["Furthermore, there should be a call for greater attention among rehabilitation care providers and policy makers for increasing education in this area.", [["increasing education", "TREATMENT", 116, 136]]], ["Beside this, a higher strain in caregivers living with elder may be due to the burden related to additional care to them.LimitationsThis study has several limitations.", [["This study", "TEST", 132, 142]]], ["First of all, to ensure safety of participants, psychological testing and caregiver strain were self administered, and not recorded by health professionals.", [["participants", "SPECIES", 34, 46], ["psychological testing", "TEST", 48, 69]]], ["Second, a causal relationship between COVID-19 and psychological outcome is difficult to obtain because of the cross-sectional nature of study.", [["COVID", "TEST", 38, 43]]], ["Moreover, COVID-19 for some participants in itself may have contributed to levels of mental health symptoms, and this was not controlled for.", [["COVID-19", "DNA", 10, 18], ["participants", "SPECIES", 28, 40], ["COVID", "TEST", 10, 15], ["mental health symptoms", "PROBLEM", 85, 107]]], ["Third, because of the online nature questionnaire structure, and location of rehabilitation centres, the study was limited to participants in major cities who had adequate English comprehension skills.", [["participants", "SPECIES", 126, 138], ["rehabilitation centres", "TREATMENT", 77, 99], ["the study", "TEST", 101, 110]]], ["Thus, the results may not be generalizable to all caregivers tending children with special needs.", [["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77]]], ["Fourth, the study had not scrutinized the severity of the illness of the child and past history of mental symptoms in caregivers which likely contribute to the strain and mental health of caregivers.", [["the study", "TEST", 8, 17], ["mental symptoms", "PROBLEM", 99, 114]]], ["This aspect should be addressed in future studies.", [["future studies", "TEST", 35, 49]]], ["Finally, due to the time-constraint of pandemic outbreak, user involvement in instrument development was not solicited but this could be incorporated in future studies.", [["pandemic outbreak", "PROBLEM", 39, 56]]], ["The study represented the initial use of an on-line questionnaire that could possibly be further refined and used in future pandemics.", [["The study", "TEST", 0, 9], ["an on-line questionnaire", "TREATMENT", 41, 65], ["pandemics", "PROBLEM", 124, 133]]], ["Future investigations should longitudinally assess the mental health and strain on caregivers whenever an outbreak persists for a sufficient duration of time.ConclusionThis study identifies a high prevalence of depressive symptoms displayed by caregivers tending children with special needs.", [["depressive symptoms", "DISEASE", 211, 230], ["children", "ORGANISM", 263, 271], ["children", "SPECIES", 263, 271], ["Future investigations", "TEST", 0, 21], ["This study", "TEST", 168, 178], ["depressive symptoms", "PROBLEM", 211, 230]]], ["The COVID-19 outbreak has had a significant impact on caregiver strain when the perceived strain one month before the outbreak was measured retrospectively.", [["The COVID", "TEST", 0, 9], ["significant", "OBSERVATION_MODIFIER", 32, 43]]], ["Lack of tele-rehabilitation and its negative perception were found to be associated with caregiver's anxiety symptoms and poor mental health respectively whereas continuing tele-rehabilitation added more strain to the caregivers.", [["anxiety", "DISEASE", 101, 108], ["rehabilitation", "TREATMENT", 13, 27], ["caregiver's anxiety symptoms", "PROBLEM", 89, 117], ["poor mental health", "PROBLEM", 122, 140], ["rehabilitation", "TREATMENT", 178, 192]]], ["Caregivers who had not learned homecare therapy were more depressed, while those who learned homecare therapy methods experienced more strain.", [["depressed", "DISEASE", 58, 67], ["homecare therapy", "TREATMENT", 31, 47], ["homecare therapy methods", "TREATMENT", 93, 117]]], ["Moreover, a perception of homecare therapy as being moderate to difficult medium were significantly associated with higher stress and strain compared to those who perceived it as easy.", [["homecare therapy", "TREATMENT", 26, 42], ["higher stress and strain", "PROBLEM", 116, 140], ["moderate", "OBSERVATION_MODIFIER", 52, 60]]], ["Older children (\u2265 6 years), with better self-care abilities were protective factors against caregiver's poor mental health.", [["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14]]], ["Therefore, greater communication among service providers and caregivers regarding removal of barriers associated with an unfavorable perception of tele-rehabilitation, increasing education on the homecare therapy, and provision of psychological interventions/services may help to diminish mental health issues and strain associated with care-giving.", [["removal of barriers", "TREATMENT", 82, 101], ["rehabilitation", "TREATMENT", 152, 166], ["the homecare therapy", "TREATMENT", 192, 212], ["psychological interventions", "TREATMENT", 231, 258], ["mental health issues", "PROBLEM", 289, 309]]], ["Ultimately, by these caregiver implementations, children with special needs can receive better care during current (COVID-19) and future outbreaks.Financial disclosureThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Data sharingAll data relevant to the study are included in the article or are available as supplementary files.Declaration of Competing InterestThe authors report no declarations of interest.Declaration of Competing InterestPlease cite this article in press as: S. Dhiman, P.K. Sahu, W.R. Reed et al. Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs.", [["children", "ORGANISM", 48, 56], ["children", "ORGANISM", 683, 691], ["children", "SPECIES", 48, 56], ["children", "SPECIES", 683, 691], ["All data", "TEST", 303, 311], ["the study", "TEST", 324, 333], ["COVID", "TREATMENT", 602, 607]]], ["Research in Developmental Disabilities (xxxx), https://doi.org/10.1016/j.ridd.2020.103790 3 Age of the Child-4 What is the diagnosis of the child? (e.g., Cerebral palsy, Autism, ADHD, Attention Deficit Hyperactive Disorder, Learning disability, Spina Bifida etc.) 5 Detail address of caregiver 6 Do you have a steady financial income after the COVID19 outbreak?-Yes/No 7 Do any elderly member (above 60) live with you in your family-Yes/No 8 Occupation: 9 Are you working from home during COVID-19 outbreak?", [["Cerebral", "ANATOMY", 154, 162], ["Cerebral palsy", "DISEASE", 154, 168], ["Autism", "DISEASE", 170, 176], ["ADHD", "DISEASE", 178, 182], ["Attention Deficit Hyperactive Disorder", "DISEASE", 184, 222], ["Learning disability", "DISEASE", 224, 243], ["child", "ORGANISM", 140, 145], ["Cerebral palsy", "PROBLEM", 154, 168], ["Autism", "PROBLEM", 170, 176], ["ADHD", "PROBLEM", 178, 182], ["Attention Deficit", "PROBLEM", 184, 201], ["Hyperactive Disorder", "PROBLEM", 202, 222], ["Learning disability", "PROBLEM", 224, 243], ["Spina Bifida etc", "PROBLEM", 245, 261], ["Cerebral palsy", "ANATOMY", 154, 168], ["Spina Bifida", "ANATOMY", 245, 257]]], ["Yes/No 11 What are your child's functioning abilities in the following areas?Declaration of Competing Interesta Eating: Dependent/Independent b Dressing: Dependent/Independent c Hygiene: Dependent/Independent 12 Please read the following and mark only one box beside the description that best represents your child's movement abilities. a Has difficulty sitting on their own and controlling their head and body posture in most positions b Can sit on their own but does not stand or walk without significant support and adult supervision c Can walk on their own using a walking aid (such as a walker, rollator, crutches, canes, etc.) d Can walk on their own without using a walking aid, but has difficulty walking long distances or on uneven surfaces e Can walk on their own without using a walking aid, including fairly long distances, outdoors and on uneven surfaces 13 Have you learned homecare therapy of your child?", [["head", "ANATOMY", 397, 401], ["body", "ANATOMY", 406, 410], ["head", "ORGANISM_SUBDIVISION", 397, 401], ["body", "ORGANISM_SUBDIVISION", 406, 410], ["a walking aid", "TREATMENT", 567, 580], ["a walker, rollator", "TREATMENT", 590, 608], ["crutches", "TREATMENT", 610, 618], ["head", "ANATOMY", 397, 401]]], ["Yes/No 14 If yes, how you find homecare therapy?", [["homecare therapy", "TREATMENT", 31, 47]]], ["Easy / moderate / difficult.", [["Easy / moderate / difficult", "PROBLEM", 0, 27], ["moderate", "OBSERVATION_MODIFIER", 7, 15]]], ["Yes/No 16 Do you find tele-rehabilitation as an alternate option for rehabilitation?", [["rehabilitation", "TREATMENT", 69, 83]]], ["Answer the following questions according to your experience one month before and during the COVID-19 pandemic outbreak in Yes or No format.CAREGIVER STRAIN INDEX:Below is a list of things which other people have found to have difficulty with when helping care for a relative /friend.", [["people", "ORGANISM", 200, 206], ["people", "SPECIES", 200, 206]]], ["Please answer yes or no by placing a \u221a in the appropriate column Yes No1.Sleep is disturbed becauseis in and out of bed or wanders around at night 2.1.It is inconvenient because (e.g. helping takes so much time or its long drive over to help.) 3.1.It is a physical strain(e.g. because helping in and out of a chair, effort or concentration required) 4.1.It is confining (e.g. helping restricts free time or cannot go visiting) 5.1.There have been family adjustments (e.g. because helping has disrupted routine, there has been no privacy) 6.1.There have been changes in personal plans (e.g. had to turn down a job; could not go on vacation) 7.1.There have been other demands on my time (e.g. from other family members) 8.1.There have been other emotional adjustments (e.g. because of severe arguments) 9.1.Some behaviour is upsetting ( e.g. because of incontinence;has trouble remembering things; oraccuses people of taking things) 10.1.It is upsetting to findhas changed so much from his/her formal self (e.g. he/she is a different person than he/she used to be) 11.1.There have been work adjustments (e.g. having to take time off) 12.1.It is a financial strain 13.1.Feeing completely overwhelmed (e.g. because of worry about . . .. . .. . .. . .. . ...: concerns about how you will manage.)DEPRESSION ANXIETY STRESS SCALE -21(DASS-21):1.", [["incontinence", "DISEASE", 851, 863], ["people", "SPECIES", 906, 912], ["person", "SPECIES", 1032, 1038], ["a physical strain", "PROBLEM", 254, 271], ["emotional adjustments", "TREATMENT", 744, 765], ["severe arguments)", "PROBLEM", 783, 800], ["incontinence", "PROBLEM", 851, 863], ["a financial strain", "PROBLEM", 1143, 1161], ["DEPRESSION ANXIETY STRESS SCALE", "PROBLEM", 1291, 1322], ["disturbed", "OBSERVATION", 82, 91]]], ["Are you not experience any positive feeling a.DEPRESSION ANXIETY STRESS SCALE -21(DASS-21):1 (s) I found it hard to wind down 0 1 2 3 2 (a) I was aware of dryness of my mouth 0 1 2 3 3 (d) I couldn't seem to experience any positive feeling at all 0 1 2 3 4 (a) I experienced breathing difficulty (e.g. excessively rapid breathing, breathlessness in the absence of physical exertion) 0 1 2 3", [["breathlessness", "DISEASE", 331, 345], ["DEPRESSION ANXIETY STRESS SCALE", "PROBLEM", 46, 77], ["dryness", "PROBLEM", 155, 162], ["any positive feeling at all", "PROBLEM", 219, 246], ["breathing difficulty", "PROBLEM", 275, 295], ["excessively rapid breathing", "PROBLEM", 302, 329], ["breathlessness", "PROBLEM", 331, 345]]]], "84b24e451eb690f69255a94e0309caa3d0119674": [["approach evidences the relevance of microbiome in human homeostasis, accounting for the trillions of microorganisms from thousands of different species populating every part of the human body.", [["body", "ANATOMY", 187, 191], ["human", "ORGANISM", 50, 55], ["human", "ORGANISM", 181, 186], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 181, 186], ["the trillions of microorganisms", "PROBLEM", 84, 115], ["different species", "PROBLEM", 134, 151], ["microorganisms", "OBSERVATION", 101, 115], ["different", "OBSERVATION_MODIFIER", 134, 143], ["species", "OBSERVATION", 144, 151], ["human body", "ANATOMY_MODIFIER", 181, 191]]], ["A brave integration between the most primitive and the most advanced cells.", [["cells", "ANATOMY", 69, 74], ["cells", "CELL", 69, 74], ["A brave integration", "TREATMENT", 0, 19], ["most primitive", "OBSERVATION_MODIFIER", 32, 46], ["advanced cells", "OBSERVATION", 60, 74]]], ["Among them, some germs exert a positive effect on health and others are potential pathogens, even in the same population as effect of the environment pressures.", [["germs", "ANATOMY", 17, 22], ["some germs", "PROBLEM", 12, 22], ["potential pathogens", "PROBLEM", 72, 91], ["the environment pressures", "TREATMENT", 134, 159], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["effect", "OBSERVATION_MODIFIER", 40, 46], ["potential", "OBSERVATION_MODIFIER", 72, 81], ["pathogens", "OBSERVATION", 82, 91]]], ["This concept is here extended to report the interactions between organisms not necessarily living inside the same body at the same time, and the approach can result related to network of finalized activities, most of them unconscious and endured.", [["body", "ANATOMY", 114, 118], ["body", "ORGANISM_SUBDIVISION", 114, 118]]], ["Therefore, a common body is not necessary, because the same approach can be applied at an environmental level.", [["body", "ANATOMY", 20, 24], ["body", "ORGANISM_SUBDIVISION", 20, 24], ["common body", "ANATOMY", 13, 24], ["not necessary", "UNCERTAINTY", 28, 41]]], ["In the case of insect-borne diseases, we can apply the concept of the superorganism in a sequel of bodies and habitats, which must generate a coherent final result.", [["insect-borne diseases", "DISEASE", 15, 36], ["insect-borne diseases", "PROBLEM", 15, 36]]]], "PMC7159280": [["IntroductionSince September, 2012, WHO has been notified of 64 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.1 This new disease has many features reminiscent of severe acute respiratory syndrome (SARS)\u2014eg, predominance of respiratory symptoms, airborne transmission, high case-fatality ratio, and caused by a virus of the Betacoronavirus genus that is closely related to bat coronaviruses.2, 3, 4, 5 The SARS-CoV pandemic had been preceded by outbreaks in southeast China between November, 2002, and January, 2003.6, 7 During this period, the virus is thought to have been repeatedly introduced into human populations from its intermediate hosts (eg, the masked palm civet) before adapting to interhuman transmission.8, 9 The molecular events leading to the mutation that enabled the SARS-CoV spike protein to bind with the human ACE2 receptor have been particularly well described.10 The same sequence of events might be occurring with MERS-CoV, which has been repeatedly introduced into the human population for more than a year (from an unknown animal host) and might have human pandemic potential.", [["respiratory", "ANATOMY", 251, 262], ["Middle East respiratory syndrome coronavirus", "DISEASE", 72, 116], ["MERS-CoV) infection", "DISEASE", 118, 137], ["acute respiratory syndrome", "DISEASE", 197, 223], ["SARS", "DISEASE", 225, 229], ["respiratory symptoms", "DISEASE", 251, 271], ["SARS-CoV pandemic", "DISEASE", 433, 450], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 72, 116], ["MERS-CoV", "ORGANISM", 118, 126], ["Betacoronavirus genus", "ORGANISM", 351, 372], ["bat coronaviruses", "ORGANISM", 400, 417], ["SARS-CoV", "ORGANISM", 433, 441], ["human", "ORGANISM", 629, 634], ["palm", "ORGANISM_SUBDIVISION", 691, 695], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 813, 821], ["human", "ORGANISM", 853, 858], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 859, 872], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 966, 974], ["human", "ORGANISM", 1022, 1027], ["human", "ORGANISM", 1105, 1110], ["SARS-CoV spike protein", "PROTEIN", 813, 835], ["human ACE2 receptor", "PROTEIN", 853, 872], ["human", "SPECIES", 629, 634], ["human", "SPECIES", 853, 858], ["human", "SPECIES", 1022, 1027], ["human", "SPECIES", 1105, 1110], ["Middle East respiratory syndrome coronavirus", "SPECIES", 72, 116], ["MERS-CoV", "SPECIES", 118, 126], ["bat coronaviruses", "SPECIES", 400, 417], ["SARS-CoV", "SPECIES", 433, 441], ["human", "SPECIES", 629, 634], ["SARS-CoV", "SPECIES", 813, 821], ["human", "SPECIES", 853, 858], ["MERS-CoV", "SPECIES", 966, 974], ["human", "SPECIES", 1022, 1027], ["human", "SPECIES", 1105, 1110], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 72, 116], ["infection", "PROBLEM", 128, 137], ["This new disease", "PROBLEM", 140, 156], ["severe acute respiratory syndrome", "PROBLEM", 190, 223], ["SARS)\u2014eg", "PROBLEM", 225, 233], ["respiratory symptoms", "PROBLEM", 251, 271], ["airborne transmission", "TEST", 273, 294], ["a virus of the Betacoronavirus genus", "PROBLEM", 336, 372], ["bat coronaviruses", "PROBLEM", 400, 417], ["The SARS-CoV pandemic", "PROBLEM", 429, 450], ["the virus", "PROBLEM", 568, 577], ["The molecular events", "PROBLEM", 751, 771], ["the mutation", "PROBLEM", 783, 795], ["the SARS", "PROBLEM", 809, 817], ["CoV spike protein", "PROBLEM", 818, 835], ["the human ACE2 receptor", "TREATMENT", 849, 872], ["respiratory syndrome", "OBSERVATION", 84, 104], ["infection", "OBSERVATION", 128, 137], ["new", "OBSERVATION_MODIFIER", 145, 148], ["disease", "OBSERVATION", 149, 156], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["respiratory syndrome", "OBSERVATION", 203, 223], ["respiratory symptoms", "OBSERVATION", 251, 271], ["virus", "OBSERVATION", 338, 343]]], ["One useful indicator of virus transmissibility is the basic reproduction number (R0), which represents the number of secondary cases per index case in a fully susceptible population.", [["virus transmissibility", "PROBLEM", 24, 46], ["virus", "OBSERVATION", 24, 29]]], ["We aimed to adapt a recently published method of estimating R011 to the MERS-CoV outbreaks and compare the results with similar findings obtained for prepandemic SARS.Data sources ::: MethodsWe retrieved data for MERS-CoV clusters and clinical disease progression from various sources, including the WHO summary1 and subsequent reports, and published descriptions of cases in the UK,4 Jordan,12 France,13 and Saudi Arabia.14, 15 As of June 21, 2013, 64 laboratory-confirmed MERS-CoV cases have been reported.Data sources ::: MethodsThe earliest two confirmed cases appeared in a cluster of 13 individuals with respiratory symptoms in a hospital in Zarqa, Jordan, in April, 2012.", [["respiratory", "ANATOMY", 610, 621], ["SARS", "DISEASE", 162, 166], ["respiratory symptoms", "DISEASE", 610, 630], ["MERS-CoV", "ORGANISM", 474, 482], ["MERS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 213, 221], ["MERS-CoV", "SPECIES", 474, 482], ["prepandemic SARS", "PROBLEM", 150, 166], ["MERS", "PROBLEM", 213, 217], ["CoV clusters", "PROBLEM", 218, 230], ["clinical disease progression", "PROBLEM", 235, 263], ["Methods", "TREATMENT", 525, 532], ["respiratory symptoms", "PROBLEM", 610, 630]]], ["Diagnosis was done retrospectively, by analysis of samples from these patients; two patients, those who died, tested positive for MERS-CoV.12 Since then, other cases have occurred in and outside the Middle East (figure 1).", [["samples", "ANATOMY", 51, 58], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 84, 92], ["Middle", "ANATOMY_MODIFIER", 199, 205]]], ["19 of these cases were regarded as sporadic, including three cases in individuals who were admitted to hospital in the UK and Germany.", [["individuals", "ORGANISM", 70, 81]]], ["15 reported cases were grouped into six small clusters of two to four cases, including four clusters in which interhuman transmission occurred outside the Middle East (UK, France, Tunisia, and Italy).", [["Middle", "ANATOMY_MODIFIER", 155, 161]]], ["In May, 2013, a large cluster of 23 confirmed cases was reported in the Al-Hasa governorate, Saudi Arabia.", [["large", "OBSERVATION_MODIFIER", 16, 21]]], ["An unrelated cluster of five cases was later reported in the neighbouring city of Dammam, Saudi Arabia.Data sources ::: MethodsWe obtained data on prepandemic SARS clusters in the Guangdong province of China from the scientific literature.7 Between November, 2002, and January, 2003, seven clusters of one, two, three, five, seven, eight, and nine cases, each having one index patient, were reported.Data interpretation ::: MethodsOur data analysis is based on the concept of transmission tree, defined as all cases related to one index patient.", [["SARS", "DISEASE", 159, 163], ["patient", "ORGANISM", 377, 384], ["patient", "ORGANISM", 537, 544], ["patient", "SPECIES", 377, 384], ["patient", "SPECIES", 537, 544], ["prepandemic SARS clusters", "PROBLEM", 147, 172], ["Methods", "TREATMENT", 424, 431], ["Our data analysis", "TEST", 431, 448], ["cluster", "OBSERVATION_MODIFIER", 13, 20]]], ["By contrast, the concept of cluster is based on temporal and geographical grouping and might include one or more transmission trees, depending on the number of index patients belonging to the cluster.Data interpretation ::: MethodsFor the branching process analysis, we assumed that all MERS-CoV introductions into the human population occurred in the Middle East.", [["patients", "ORGANISM", 166, 174], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 287, 295], ["human", "ORGANISM", 319, 324], ["patients", "SPECIES", 166, 174], ["human", "SPECIES", 319, 324], ["human", "SPECIES", 319, 324], ["the branching process analysis", "TEST", 235, 265], ["cluster", "OBSERVATION", 28, 35], ["Middle", "ANATOMY_MODIFIER", 352, 358]]], ["We excluded the nine cases notified in the 2 weeks preceding June 21, 2013, because the incubation period of MERS-CoV could be up to 14 days, so these cases might belong to current transmission clusters.16 For improved modelling consistency, we also took into account seven probable cases: (1) one case, a patient who travelled from Saudi Arabia to Tunisia where two of his children, who had subsequent contact with him, tested positive; (2) the fourth case of the family cluster detected in Riyadh, Saudi Arabia, in October, 2012 (a patient aged 16 years who was symptomatic but was not tested for MERS-CoV);14 (3) cases A and C, reported as probable in the investigation of the Al-Hasa cluster;15 and (4) three cases in the Jordanian cluster.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 109, 117], ["patient", "ORGANISM", 306, 313], ["children", "ORGANISM", 374, 382], ["patient", "ORGANISM", 534, 541], ["patient", "SPECIES", 306, 313], ["children", "SPECIES", 374, 382], ["patient", "SPECIES", 534, 541], ["MERS-CoV", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 599, 607], ["MERS", "PROBLEM", 109, 113], ["CoV", "PROBLEM", 114, 117], ["symptomatic", "PROBLEM", 564, 575]]], ["The large number of unconfirmed cases (11 of 13) in the Jordanian cluster called for caution.", [["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["unconfirmed", "OBSERVATION_MODIFIER", 20, 31], ["cases", "OBSERVATION", 32, 37]]], ["On the basis of a 38% case-fatality ratio in individuals younger than 60 years (see summary statistics in the Results section), and considering that the patients with the two confirmed cases in the Jordanian cluster died, we estimated that the expected cluster size could be 2/0\u00b738, which is roughly 5.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["cluster", "OBSERVATION_MODIFIER", 253, 260], ["size", "OBSERVATION_MODIFIER", 261, 265]]], ["We also did a sensitivity analysis of our results, varying the size of the Jordanian cluster between two and 13 (appendix).Data interpretation ::: MethodsThe partition of clusters into transmission trees is often ambiguous when the data are insufficient.", [["appendix", "ORGAN", 113, 121], ["a sensitivity analysis", "TEST", 12, 34], ["Methods", "TREATMENT", 147, 154], ["size", "OBSERVATION_MODIFIER", 63, 67], ["Jordanian cluster", "OBSERVATION", 75, 92], ["appendix", "ANATOMY", 113, 121]]], ["First, we used published epidemiological investigations of MERS-CoV clusters (ie, the Jordanian,12 UK,4 French,13 Al-Hasa,15 and Riyadh14 clusters) to provide information about their tree structure.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["MERS-CoV", "SPECIES", 59, 67]]], ["Second, we regarded the MERS-CoV clusters detected outside the Middle East as trees generated by the patient travelling outside the Middle East.", [["patient", "ORGANISM", 101, 108], ["MERS-CoV clusters", "DNA", 24, 41], ["patient", "SPECIES", 101, 108], ["MERS-CoV", "SPECIES", 24, 32], ["Middle", "ANATOMY_MODIFIER", 63, 69], ["Middle", "ANATOMY_MODIFIER", 132, 138]]], ["Third, we made assumptions on the occurrence of transmission events on the basis of epidemiological links between cases to investigate the clusters that remained otherwise unresolved.", [["transmission events", "PROBLEM", 48, 67]]], ["We regarded cases as epidemiologically linked if the patients were either close family members or had documented contact and, furthermore, if the dates of onset were separated by the minimum incubation period (ie, 2 days15).", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Hence, we did not consider infectiousness outside the symptomatic period, since no data support it at present, and all transmission data available so far are compatible with transmission during the symptomatic phase.15 This feature was also true for SARS-CoV.2", [["SARS", "DISEASE", 250, 254], ["infectiousness", "PROBLEM", 27, 41], ["all transmission data", "TEST", 115, 136], ["SARS", "PROBLEM", 250, 254]]]], "PMC7335412": [["IntroductionIn December 2019, a novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, causing the serious epidemic COVID-19 (Zhang 2020).", [["infectious disease", "DISEASE", 38, 56], ["acute respiratory syndrome coronavirus", "DISEASE", 75, 113], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 68, 115], ["SARS-CoV-2", "ORGANISM", 117, 127], ["syndrome coronavirus", "SPECIES", 93, 113], ["severe acute respiratory syndrome coronavirus", "SPECIES", 68, 113], ["SARS-CoV-2", "SPECIES", 117, 127], ["a novel infectious disease", "PROBLEM", 30, 56], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 68, 113], ["SARS-CoV", "TEST", 117, 125], ["infectious", "OBSERVATION", 38, 48], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome", "OBSERVATION", 81, 101]]], ["Similar to the SARS coronavirus (SARS-CoV) that had caused outbreaks from 2002 to 2004, SARS-CoV-2 binds via its spikes to its receptor angiotensin-converting enzyme 2 (ACE2) with high affinity on cell surfaces (Hoffmann 2020; Walls 2020).", [["cell", "ANATOMY", 197, 201], ["SARS coronavirus", "DISEASE", 15, 31], ["SARS", "DISEASE", 33, 37], ["SARS", "DISEASE", 88, 92], ["angiotensin", "CHEMICAL", 136, 147], ["SARS coronavirus", "ORGANISM", 15, 31], ["SARS-CoV", "ORGANISM", 33, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 136, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["cell", "CELL", 197, 201], ["receptor angiotensin-converting enzyme 2", "PROTEIN", 127, 167], ["ACE2", "PROTEIN", 169, 173], ["SARS coronavirus", "SPECIES", 15, 31], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 88, 96], ["the SARS coronavirus", "PROBLEM", 11, 31], ["outbreaks", "PROBLEM", 59, 68], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["its receptor angiotensin", "TEST", 123, 147], ["converting enzyme", "TEST", 148, 165], ["ACE2", "TEST", 169, 173]]], ["This may enable SARS-CoV-2 to spread easily from person to person and make ACE2 a potential target for vaccines and therapies.", [["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["ACE2", "PROTEIN", 75, 79], ["person", "SPECIES", 49, 55], ["person", "SPECIES", 59, 65], ["SARS-CoV", "SPECIES", 16, 24], ["vaccines", "TREATMENT", 103, 111], ["therapies", "TREATMENT", 116, 125]]], ["ACE2 is abundantly present in humans on epithelial cells of the lung (alveolar epithelial type II cells), kidney, heart, blood, and the small intestine (Hamming et al. 2004).", [["epithelial cells", "ANATOMY", 40, 56], ["lung", "ANATOMY", 64, 68], ["alveolar epithelial type II cells", "ANATOMY", 70, 103], ["kidney", "ANATOMY", 106, 112], ["heart", "ANATOMY", 114, 119], ["blood", "ANATOMY", 121, 126], ["small intestine", "ANATOMY", 136, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["humans", "ORGANISM", 30, 36], ["epithelial cells", "CELL", 40, 56], ["lung", "ORGAN", 64, 68], ["alveolar epithelial type II cells", "CELL", 70, 103], ["kidney", "ORGAN", 106, 112], ["heart", "ORGAN", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["intestine", "ORGAN", 142, 151], ["ACE2", "PROTEIN", 0, 4], ["epithelial cells", "CELL_TYPE", 40, 56], ["alveolar epithelial type II cells", "CELL_TYPE", 70, 103], ["humans", "SPECIES", 30, 36], ["humans", "SPECIES", 30, 36], ["ACE2", "PROBLEM", 0, 4], ["kidney, heart, blood, and the small intestine", "PROBLEM", 106, 151], ["epithelial cells", "OBSERVATION", 40, 56], ["lung", "ANATOMY", 64, 68], ["alveolar", "ANATOMY_MODIFIER", 70, 78], ["epithelial", "ANATOMY_MODIFIER", 79, 89], ["II cells", "OBSERVATION", 95, 103], ["kidney", "ANATOMY", 106, 112], ["heart", "ANATOMY", 114, 119], ["blood", "ANATOMY", 121, 126], ["small intestine", "ANATOMY", 136, 151]]], ["In small intestinal enterocytes, ACE2 is necessary for the expression of luminal membrane amino acid transporters B0AT1 (SLC6A19) and SIT1 (SLC6A20) (Vuille-dit-Bille 2015; Meier 2018; Verrey 2009; Camargo 2009).", [["intestinal enterocytes", "ANATOMY", 9, 31], ["luminal membrane", "ANATOMY", 73, 89], ["luminal", "CHEMICAL", 73, 80], ["amino acid", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 90, 100], ["intestinal enterocytes", "MULTI-TISSUE_STRUCTURE", 9, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["luminal membrane", "CELLULAR_COMPONENT", 73, 89], ["amino acid", "AMINO_ACID", 90, 100], ["B0AT1", "GENE_OR_GENE_PRODUCT", 114, 119], ["SLC6A19", "GENE_OR_GENE_PRODUCT", 121, 128], ["SIT1", "GENE_OR_GENE_PRODUCT", 134, 138], ["small intestinal enterocytes", "CELL_TYPE", 3, 31], ["ACE2", "PROTEIN", 33, 37], ["luminal membrane amino acid transporters", "PROTEIN", 73, 113], ["B0AT1", "PROTEIN", 114, 119], ["SLC6A19", "PROTEIN", 121, 128], ["SIT1", "PROTEIN", 134, 138], ["SLC6A20", "PROTEIN", 140, 147], ["luminal membrane amino acid transporters", "TEST", 73, 113], ["SLC6A19", "TEST", 121, 128], ["SIT1", "TEST", 134, 138], ["SLC6A20", "TEST", 140, 147], ["Vuille", "TEST", 150, 156], ["Verrey", "TEST", 185, 191], ["Camargo", "TEST", 198, 205], ["small", "OBSERVATION_MODIFIER", 3, 8], ["intestinal enterocytes", "ANATOMY", 9, 31], ["luminal membrane", "ANATOMY", 73, 89]]], ["The intestine might therefore be an entry site for SARS-CoV-2, in particular when the protective role of gastric acid is reduced by drugs or surgically.", [["intestine", "ANATOMY", 4, 13], ["gastric", "ANATOMY", 105, 112], ["SARS", "DISEASE", 51, 55], ["gastric acid", "CHEMICAL", 105, 117], ["intestine", "ORGAN", 4, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["gastric acid", "SIMPLE_CHEMICAL", 105, 117], ["SARS", "PROBLEM", 51, 55], ["gastric acid", "TREATMENT", 105, 117], ["intestine", "ANATOMY", 4, 13], ["gastric", "ANATOMY", 105, 112]]], ["Infection of human might even have started by eating food from the Wuhan market (Zhang 2020).", [["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["Infection of human", "PROBLEM", 0, 18]]], ["The carboxymonopeptidase ACE2\u2014similar to its structural homolog angiotensin-converting enzyme ACE\u2014also acts as an enzyme that belongs to the renin\u2013angiotensin system (RAS) and whose expression is induced in many tissues by application of RAS-active medications including ACE inhibitors (ACE-Is) and angiotensin II AT1 receptor blockers (ARBs).", [["tissues", "ANATOMY", 212, 219], ["angiotensin", "CHEMICAL", 64, 75], ["ACE-Is", "CHEMICAL", 287, 293], ["angiotensin II", "CHEMICAL", 299, 313], ["carboxymonopeptidase ACE2", "GENE_OR_GENE_PRODUCT", 4, 29], ["angiotensin-converting enzyme ACE", "GENE_OR_GENE_PRODUCT", 64, 97], ["renin\u2013angiotensin", "GENE_OR_GENE_PRODUCT", 141, 158], ["RAS", "GENE_OR_GENE_PRODUCT", 167, 170], ["tissues", "TISSUE", 212, 219], ["RAS", "GENE_OR_GENE_PRODUCT", 238, 241], ["ACE", "GENE_OR_GENE_PRODUCT", 271, 274], ["ACE-Is", "SIMPLE_CHEMICAL", 287, 293], ["angiotensin II AT1 receptor blockers", "SIMPLE_CHEMICAL", 299, 335], ["ARBs", "SIMPLE_CHEMICAL", 337, 341], ["carboxymonopeptidase ACE2", "PROTEIN", 4, 29], ["structural homolog angiotensin-converting enzyme", "PROTEIN", 45, 93], ["ACE", "PROTEIN", 94, 97], ["renin\u2013angiotensin system", "PROTEIN", 141, 165], ["RAS", "PROTEIN", 167, 170], ["The carboxymonopeptidase ACE2\u2014similar", "TREATMENT", 0, 37], ["its structural homolog angiotensin", "TREATMENT", 41, 75], ["converting enzyme ACE", "TREATMENT", 76, 97], ["an enzyme", "TEST", 111, 120], ["RAS", "TREATMENT", 238, 241], ["active medications", "TREATMENT", 242, 260], ["ACE inhibitors", "TREATMENT", 271, 285], ["ACE-Is)", "TREATMENT", 287, 294], ["angiotensin II AT1 receptor blockers", "TREATMENT", 299, 335], ["ARBs", "TEST", 337, 341]]], ["The increased ACE2 expression could facilitate infection with SARS-CoV-2.", [["infection", "DISEASE", 47, 56], ["SARS", "DISEASE", 62, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["SARS-CoV-2", "ORGANISM", 62, 72], ["ACE2", "PROTEIN", 14, 18], ["SARS-CoV", "SPECIES", 62, 70], ["The increased ACE2 expression", "PROBLEM", 0, 29], ["infection", "PROBLEM", 47, 56], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["ACE2 expression", "OBSERVATION", 14, 29], ["infection", "OBSERVATION", 47, 56]]], ["We previously showed in healthy human adults that ACE2 is expressed in the brush border membrane of small intestinal enterocytes, as well as in colonic crypts (Vuille-dit-Bille 2015).", [["brush border membrane", "ANATOMY", 75, 96], ["small intestinal enterocytes", "ANATOMY", 100, 128], ["colonic crypts", "ANATOMY", 144, 158], ["human", "ORGANISM", 32, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["brush border membrane", "CELLULAR_COMPONENT", 75, 96], ["intestinal enterocytes", "MULTI-TISSUE_STRUCTURE", 106, 128], ["colonic crypts", "TISSUE", 144, 158], ["ACE2", "PROTEIN", 50, 54], ["small intestinal enterocytes", "CELL_TYPE", 100, 128], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["small intestinal enterocytes", "PROBLEM", 100, 128], ["brush", "ANATOMY_MODIFIER", 75, 80], ["small", "OBSERVATION_MODIFIER", 100, 105], ["intestinal enterocytes", "ANATOMY", 106, 128], ["colonic crypts", "ANATOMY", 144, 158]]], ["ACE2 mRNA expression was almost twice as high in patients treated with ACE-Is, when compared to patients without treatment (Vuille-dit-Bille 2015).", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 49, 57], ["ACE-Is", "GENE_OR_GENE_PRODUCT", 71, 77], ["patients", "ORGANISM", 96, 104], ["ACE2 mRNA", "RNA", 0, 9], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 96, 104], ["ACE2 mRNA expression", "TEST", 0, 20], ["ACE", "TREATMENT", 71, 74], ["treatment", "TREATMENT", 113, 122]]], ["More recently we could show that ACE2 protein is also expressed in the brush border membrane of small intestinal enterocytes in human neonates (aged 0\u20134 days) (Meier 2018).", [["brush border membrane", "ANATOMY", 71, 92], ["intestinal enterocytes", "ANATOMY", 102, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["brush border membrane", "CELLULAR_COMPONENT", 71, 92], ["intestinal enterocytes", "TISSUE", 102, 124], ["human", "ORGANISM", 128, 133], ["neonates", "ORGANISM", 134, 142], ["ACE2", "PROTEIN", 33, 37], ["small intestinal enterocytes", "CELL_TYPE", 96, 124], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["ACE2 protein", "TEST", 33, 45], ["small intestinal enterocytes in human neonates", "PROBLEM", 96, 142], ["brush", "ANATOMY_MODIFIER", 71, 76], ["small", "OBSERVATION_MODIFIER", 96, 101], ["intestinal enterocytes", "ANATOMY", 102, 124]]], ["Small intestinal ACE2 mRNA expression was almost 1.5 times higher in human adults versus neonates (Meier 2018).MethodsDuodenal biopsies were obtained from n = 43 healthy human adults undergoing routine upper endoscopies.", [["intestinal", "ANATOMY", 6, 16], ["MethodsDuodenal biopsies", "ANATOMY", 111, 135], ["intestinal", "ORGAN", 6, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 69, 74], ["MethodsDuodenal biopsies", "CANCER", 111, 135], ["human", "ORGANISM", 170, 175], ["intestinal ACE2 mRNA", "RNA", 6, 26], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 170, 175], ["Small intestinal ACE2 mRNA expression", "PROBLEM", 0, 37], ["MethodsDuodenal biopsies", "TEST", 111, 135], ["routine upper endoscopies", "TREATMENT", 194, 219], ["intestinal ACE2", "ANATOMY", 6, 21]]], ["Patients with gastrointestinal disorders and/or bleeding disorders, hepatic or kidney dysfunction and/or malignant disease were excluded.", [["gastrointestinal", "ANATOMY", 14, 30], ["hepatic", "ANATOMY", 68, 75], ["kidney", "ANATOMY", 79, 85], ["gastrointestinal disorders", "DISEASE", 14, 40], ["bleeding disorders", "DISEASE", 48, 66], ["hepatic or kidney dysfunction", "DISEASE", 68, 97], ["malignant disease", "DISEASE", 105, 122], ["Patients", "ORGANISM", 0, 8], ["gastrointestinal", "ORGAN", 14, 30], ["hepatic", "ORGAN", 68, 75], ["kidney", "ORGAN", 79, 85], ["malignant disease", "CANCER", 105, 122], ["Patients", "SPECIES", 0, 8], ["gastrointestinal disorders", "PROBLEM", 14, 40], ["bleeding disorders", "PROBLEM", 48, 66], ["hepatic or kidney dysfunction", "PROBLEM", 68, 97], ["malignant disease", "PROBLEM", 105, 122], ["gastrointestinal", "ANATOMY", 14, 30], ["disorders", "OBSERVATION", 31, 40], ["bleeding", "OBSERVATION", 48, 56], ["hepatic", "ANATOMY", 68, 75], ["kidney", "ANATOMY", 79, 85], ["dysfunction", "OBSERVATION", 86, 97], ["malignant", "OBSERVATION", 105, 114]]], ["Tissue sampling, RNA extraction and real-time PCR analysis were performed as described elsewhere (Vuille-dit-Bille 2015).MethodsDuodenal ACE2 mRNA expression was calculated relative to the housekeeping gene villin.", [["Tissue", "ANATOMY", 0, 6], ["Tissue", "TISSUE", 0, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["villin", "GENE_OR_GENE_PRODUCT", 207, 213], ["ACE2 mRNA", "RNA", 137, 146], ["housekeeping gene villin", "DNA", 189, 213], ["Tissue sampling", "TEST", 0, 15], ["RNA extraction", "TEST", 17, 31], ["real-time PCR analysis", "TEST", 36, 58], ["MethodsDuodenal ACE2 mRNA expression", "PROBLEM", 121, 157]]], ["The study was approved by the local ethics committee (EK-1744).MethodsCorrelation with different patient-related factors (including age, BMI, weight, height, diabetes mellitus, use of arterial blood pressure medications (ACE-Is and ARBs)) was assessed with Spearman\u2019s rank correlation, and predictors of ACE2 mRNA expression were examined with univariable linear regression.MethodsThe effect of ACE inhibitors and angiotensin II AT1 receptor blockers on intestinal ACE2 and amino acid transporter expression has been published elsewhere (Vuille-dit-Bille 2015).ResultsThe baseline characteristics of the specimen donors are displayed in Table 1.", [["arterial", "ANATOMY", 184, 192], ["blood", "ANATOMY", 193, 198], ["intestinal", "ANATOMY", 454, 464], ["specimen", "ANATOMY", 604, 612], ["EK-1744", "CHEMICAL", 54, 61], ["diabetes mellitus", "DISEASE", 158, 175], ["angiotensin II", "CHEMICAL", 414, 428], ["amino acid", "CHEMICAL", 474, 484], ["amino acid", "CHEMICAL", 474, 484], ["patient", "ORGANISM", 97, 104], ["arterial", "MULTI-TISSUE_STRUCTURE", 184, 192], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["ACE-Is", "GENE_OR_GENE_PRODUCT", 221, 227], ["ACE2", "GENE_OR_GENE_PRODUCT", 304, 308], ["ACE", "GENE_OR_GENE_PRODUCT", 395, 398], ["angiotensin II AT1 receptor blockers", "GENE_OR_GENE_PRODUCT", 414, 450], ["intestinal", "ORGAN", 454, 464], ["ACE2", "GENE_OR_GENE_PRODUCT", 465, 469], ["amino acid", "AMINO_ACID", 474, 484], ["donors", "ORGANISM", 613, 619], ["ACE2 mRNA", "RNA", 304, 313], ["angiotensin II AT1 receptor", "PROTEIN", 414, 441], ["intestinal ACE2", "PROTEIN", 454, 469], ["amino acid transporter", "PROTEIN", 474, 496], ["patient", "SPECIES", 97, 104], ["The study", "TEST", 0, 9], ["MethodsCorrelation", "TREATMENT", 63, 81], ["BMI", "TEST", 137, 140], ["weight", "TEST", 142, 148], ["diabetes mellitus", "PROBLEM", 158, 175], ["arterial blood pressure medications", "TREATMENT", 184, 219], ["ACE", "TREATMENT", 221, 224], ["ARBs", "TREATMENT", 232, 236], ["ACE2 mRNA expression", "TEST", 304, 324], ["univariable linear regression", "PROBLEM", 344, 373], ["Methods", "TREATMENT", 374, 381], ["ACE inhibitors", "TREATMENT", 395, 409], ["angiotensin II AT1 receptor blockers", "TREATMENT", 414, 450], ["intestinal ACE2", "TREATMENT", 454, 469], ["amino acid transporter expression", "TREATMENT", 474, 507], ["the specimen donors", "TEST", 600, 619], ["intestinal", "ANATOMY", 454, 464]]], ["The analysis of n = 43 specimens revealed that ACE2 gene expression was directly correlated with patient\u2019s age (Spearman\u2019s r = 0.317, p = 0.039; Fig. 1).", [["specimens", "ANATOMY", 23, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["patient", "ORGANISM", 97, 104], ["ACE2", "PROTEIN", 47, 51], ["patient", "SPECIES", 97, 104], ["The analysis of n = 43 specimens", "TEST", 0, 32], ["ACE2 gene expression", "PROBLEM", 47, 67], ["p", "TEST", 134, 135]]], ["In univariable linear regression, each increment (of a year) in age was related to an increase of the duodenal ACE 2 mRNA expression of 0.083 RU.", [["duodenal", "ANATOMY", 102, 110], ["duodenal ACE 2", "GENE_OR_GENE_PRODUCT", 102, 116], ["duodenal ACE 2 mRNA", "RNA", 102, 121], ["univariable linear regression", "PROBLEM", 3, 32], ["the duodenal ACE", "TREATMENT", 98, 114], ["linear", "OBSERVATION_MODIFIER", 15, 21], ["regression", "OBSERVATION", 22, 32], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["duodenal", "ANATOMY", 102, 110]]], ["Patients < 60 years had a 2.009 RU lower duodenal ACE 2 mRNA expression than patients 60 years and older.", [["duodenal", "ANATOMY", 41, 49], ["Patients", "ORGANISM", 0, 8], ["duodenal ACE 2", "GENE_OR_GENE_PRODUCT", 41, 55], ["patients", "ORGANISM", 77, 85], ["duodenal ACE 2 mRNA", "RNA", 41, 60], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 77, 85], ["a 2.009 RU lower duodenal ACE", "TREATMENT", 24, 53], ["duodenal", "ANATOMY", 41, 49], ["ACE", "OBSERVATION", 50, 53]]], ["Age as scale variable, with an R2 of 0.173, showed a strong effect.ResultsAge ranged from 22 to 77 years and did not significantly correlate with the use of ACE inhibitors (Spearman\u2019s r = 0.268, p = 0.083).", [["ACE", "GENE_OR_GENE_PRODUCT", 157, 160], ["an R2", "TEST", 28, 33], ["ACE inhibitors", "TREATMENT", 157, 171], ["Spearman\u2019s r", "TEST", 173, 185], ["strong effect", "OBSERVATION", 53, 66]]], ["In Fig. 1, ACE 2 mRNA expression according to age was dichotomized for patients with (stars) and without ACE-I treatment (circles).DiscussionThe small bowel may be an important entry site for SARS-CoV-2, as small intestinal enterocytes highly express ACE2 in the brush border membrane (Vuille-dit-Bille 2015; Camargo 2009).", [["bowel", "ANATOMY", 151, 156], ["intestinal enterocytes", "ANATOMY", 213, 235], ["brush border membrane", "ANATOMY", 263, 284], ["ACE-I", "CHEMICAL", 105, 110], ["SARS", "DISEASE", 192, 196], ["ACE 2", "GENE_OR_GENE_PRODUCT", 11, 16], ["patients", "ORGANISM", 71, 79], ["ACE-I", "GENE_OR_GENE_PRODUCT", 105, 110], ["bowel", "ORGAN", 151, 156], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 192, 202], ["intestinal enterocytes", "CELL", 213, 235], ["ACE2", "GENE_OR_GENE_PRODUCT", 251, 255], ["brush border membrane", "CELLULAR_COMPONENT", 263, 284], ["ACE 2 mRNA", "RNA", 11, 21], ["ACE2", "PROTEIN", 251, 255], ["patients", "SPECIES", 71, 79], ["ACE 2 mRNA expression", "TREATMENT", 11, 32], ["ACE-I treatment", "TREATMENT", 105, 120], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["small intestinal enterocytes", "PROBLEM", 207, 235], ["small bowel", "ANATOMY", 145, 156], ["small", "OBSERVATION_MODIFIER", 207, 212], ["intestinal enterocytes", "ANATOMY", 213, 235], ["brush", "ANATOMY_MODIFIER", 263, 268]]], ["Furthermore, viral mRNA may be detected in rectal swabs (even for a longer time period than in nasopharyngeal swabs) suggesting the possibility of fecal\u2013oral disease transmission (Wang 2020; Xiao et al. 2020; Holshue 2020).", [["rectal swabs", "ANATOMY", 43, 55], ["nasopharyngeal swabs", "ANATOMY", 95, 115], ["fecal\u2013oral", "ANATOMY", 147, 157], ["fecal\u2013oral disease transmission", "DISEASE", 147, 178], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 43, 55], ["nasopharyngeal swabs", "ORGAN", 95, 115], ["viral mRNA", "RNA", 13, 23], ["viral mRNA", "TEST", 13, 23], ["rectal swabs", "TEST", 43, 55], ["nasopharyngeal swabs", "TEST", 95, 115], ["fecal\u2013oral disease transmission", "PROBLEM", 147, 178], ["viral mRNA", "OBSERVATION", 13, 23], ["rectal", "ANATOMY", 43, 49], ["suggesting the possibility of", "UNCERTAINTY", 117, 146], ["fecal\u2013oral disease", "OBSERVATION", 147, 165]]], ["Reported gastrointestinal manifestations of COVID-19 are common and range from nausea and vomiting to diarrhea and abdominal discomfort with more than 10% of patients presenting with diarrhea (Jin 2020; Gu et al. 2020).", [["gastrointestinal", "ANATOMY", 9, 25], ["abdominal", "ANATOMY", 115, 124], ["nausea", "DISEASE", 79, 85], ["vomiting", "DISEASE", 90, 98], ["diarrhea", "DISEASE", 102, 110], ["abdominal discomfort", "DISEASE", 115, 135], ["diarrhea", "DISEASE", 183, 191], ["COVID-19", "CHEMICAL", 44, 52], ["gastrointestinal", "ORGAN", 9, 25], ["abdominal", "ORGANISM_SUBDIVISION", 115, 124], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["gastrointestinal manifestations", "PROBLEM", 9, 40], ["COVID", "TEST", 44, 49], ["nausea", "PROBLEM", 79, 85], ["vomiting", "PROBLEM", 90, 98], ["diarrhea", "PROBLEM", 102, 110], ["abdominal discomfort", "PROBLEM", 115, 135], ["diarrhea", "PROBLEM", 183, 191], ["gastrointestinal", "ANATOMY", 9, 25], ["abdominal", "ANATOMY", 115, 124], ["discomfort", "OBSERVATION", 125, 135]]], ["Gastrointestinal symptoms seem to be even more pronounced in children (Tian 2020; D'Amico et al. 2020).", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal", "ORGAN", 0, 16], ["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69], ["Gastrointestinal symptoms", "PROBLEM", 0, 25]]], ["The pathophysiology of diarrhea in COVID-19 patients remains unclear, but might be reflective of damage to the gastrointestinal tract and/or altered intestinal permeability resulting in malabsorption and diarrhea.", [["gastrointestinal tract", "ANATOMY", 111, 133], ["intestinal", "ANATOMY", 149, 159], ["diarrhea", "DISEASE", 23, 31], ["damage to the gastrointestinal tract", "DISEASE", 97, 133], ["malabsorption", "DISEASE", 186, 199], ["diarrhea", "DISEASE", 204, 212], ["patients", "ORGANISM", 44, 52], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 111, 133], ["intestinal", "ORGAN", 149, 159], ["patients", "SPECIES", 44, 52], ["diarrhea", "PROBLEM", 23, 31], ["COVID", "TEST", 35, 40], ["damage to the gastrointestinal tract", "PROBLEM", 97, 133], ["altered intestinal permeability", "PROBLEM", 141, 172], ["malabsorption", "PROBLEM", 186, 199], ["diarrhea", "PROBLEM", 204, 212], ["diarrhea", "OBSERVATION", 23, 31], ["damage", "OBSERVATION", 97, 103], ["gastrointestinal tract", "ANATOMY", 111, 133], ["intestinal", "ANATOMY", 149, 159], ["permeability", "OBSERVATION", 160, 172], ["malabsorption", "OBSERVATION", 186, 199], ["diarrhea", "OBSERVATION", 204, 212]]], ["As shown in the present study, small intestinal ACE2 mRNA expression correlates with age in healthy adults.", [["intestinal", "ANATOMY", 37, 47], ["intestinal", "ORGAN", 37, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["ACE2 mRNA", "RNA", 48, 57], ["the present study", "TEST", 12, 29], ["small intestinal ACE2 mRNA expression", "PROBLEM", 31, 68], ["small", "OBSERVATION_MODIFIER", 31, 36], ["intestinal ACE2", "ANATOMY", 37, 52]]], ["In addition, we could recently show that small intestinal ACE2 mRNA expression in adults was about 1.5 times as high as in newborns, whereas its expression in older children has not been tested (Meier 2018).", [["intestinal", "ANATOMY", 47, 57], ["intestinal", "ORGAN", 47, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["newborns", "ORGANISM", 123, 131], ["children", "ORGANISM", 165, 173], ["ACE2 mRNA", "RNA", 58, 67], ["children", "SPECIES", 165, 173], ["small intestinal ACE2 mRNA expression", "PROBLEM", 41, 78], ["small", "OBSERVATION_MODIFIER", 41, 46], ["intestinal ACE2", "ANATOMY", 47, 62], ["mRNA expression", "OBSERVATION", 63, 78]]], ["ACE2 is known to function as a brush border membrane-bound peptidase, and is required for the expression of amino acid transporters B0AT1 (SLC6A19) and SIT1 (SLC6A20) for which it functions as an associated chaperon protein (Vuille-dit-Bille 2015; Camargo 2009).", [["brush border membrane", "ANATOMY", 31, 52], ["amino acid", "CHEMICAL", 108, 118], ["amino acid", "CHEMICAL", 108, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 44, 52], ["B0AT1", "GENE_OR_GENE_PRODUCT", 132, 137], ["SLC6A19", "GENE_OR_GENE_PRODUCT", 139, 146], ["SIT1", "GENE_OR_GENE_PRODUCT", 152, 156], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 158, 165], ["ACE2", "PROTEIN", 0, 4], ["brush border membrane-bound peptidase", "PROTEIN", 31, 68], ["amino acid transporters", "PROTEIN", 108, 131], ["B0AT1", "PROTEIN", 132, 137], ["SLC6A19", "PROTEIN", 139, 146], ["SIT1", "PROTEIN", 152, 156], ["SLC6A20", "PROTEIN", 158, 165], ["chaperon protein", "PROTEIN", 207, 223], ["amino acid transporters", "TREATMENT", 108, 131]]], ["It is noteworthy to mention that we have recently shown that the amino acid transporter SIT1 [similar to the fructose transporter GLUT 5 (SLC2A5)(Meier 2019)] is not yet expressed in newborn humans (Meier 2018), and that the association of ACE2 with amino acid transporters has been suggested to interfere with its proteolytic cleavage and thereby with its ability to support SARS-CoV-2 infection (Yan 2020).", [["amino acid", "CHEMICAL", 65, 75], ["fructose", "CHEMICAL", 109, 117], ["amino acid", "CHEMICAL", 250, 260], ["infection", "DISEASE", 387, 396], ["amino acid", "CHEMICAL", 65, 75], ["fructose", "CHEMICAL", 109, 117], ["amino acid", "CHEMICAL", 250, 260], ["amino acid", "AMINO_ACID", 65, 75], ["SIT1", "GENE_OR_GENE_PRODUCT", 88, 92], ["fructose transporter GLUT 5", "GENE_OR_GENE_PRODUCT", 109, 136], ["SLC2A5", "GENE_OR_GENE_PRODUCT", 138, 144], ["humans", "ORGANISM", 191, 197], ["ACE2", "GENE_OR_GENE_PRODUCT", 240, 244], ["amino acid", "AMINO_ACID", 250, 260], ["CoV-2", "ORGANISM", 381, 386], ["amino acid transporter", "PROTEIN", 65, 87], ["SIT1", "PROTEIN", 88, 92], ["fructose transporter GLUT 5", "PROTEIN", 109, 136], ["SLC2A5", "PROTEIN", 138, 144], ["ACE2", "PROTEIN", 240, 244], ["amino acid transporters", "PROTEIN", 250, 273], ["humans", "SPECIES", 191, 197], ["humans", "SPECIES", 191, 197], ["the amino acid transporter SIT1", "TEST", 61, 92], ["the fructose transporter GLUT", "TEST", 105, 134], ["amino acid transporters", "TREATMENT", 250, 273], ["its proteolytic cleavage", "PROBLEM", 311, 335], ["SARS", "PROBLEM", 376, 380], ["CoV-2 infection", "PROBLEM", 381, 396]]], ["Thus, differential amino acid transporter expression in children versus adults may impact on the susceptibility to intestinal SARS-CoV-2 infection.", [["intestinal", "ANATOMY", 115, 125], ["amino acid", "CHEMICAL", 19, 29], ["infection", "DISEASE", 137, 146], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["children", "ORGANISM", 56, 64], ["intestinal", "ORGAN", 115, 125], ["CoV-2", "ORGANISM", 131, 136], ["amino acid transporter", "PROTEIN", 19, 41], ["children", "SPECIES", 56, 64], ["SARS-CoV-2", "SPECIES", 126, 136], ["differential amino acid transporter expression", "TREATMENT", 6, 52], ["intestinal SARS", "PROBLEM", 115, 130], ["CoV-2 infection", "PROBLEM", 131, 146], ["intestinal", "ANATOMY", 115, 125], ["SARS", "OBSERVATION", 126, 130], ["infection", "OBSERVATION", 137, 146]]], ["Additionally, the expression of ACE2 in small intestine may impact on the susceptibility to SARS-CoV-2-mediated infection and symptoms via its demonstrated effects on intestinal innate immunity and microbiota composition (Hashimoto 2012).DiscussionTaken together, our results suggest the possibility that age-dependent changes in intestinal ACE2 expression may impact on the susceptibility to gastrointestinal SARS-CoV-2 infection and symptoms.LimitationsSince the samples analyzed for this study were collected prior to the onset of the COVID-19 pandemic, intestinal ACE2 expression was not assessed in COVID-19 patients, and it was not determined whether older patients exhibit a higher viral load.", [["small intestine", "ANATOMY", 40, 55], ["intestinal", "ANATOMY", 167, 177], ["intestinal", "ANATOMY", 330, 340], ["gastrointestinal", "ANATOMY", 393, 409], ["samples", "ANATOMY", 465, 472], ["intestinal", "ANATOMY", 557, 567], ["SARS", "DISEASE", 92, 96], ["infection", "DISEASE", 112, 121], ["gastrointestinal SARS-CoV-2 infection", "DISEASE", 393, 430], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["small intestine", "ORGAN", 40, 55], ["CoV-2", "ORGANISM", 97, 102], ["intestinal", "ORGAN", 167, 177], ["intestinal", "ORGAN", 330, 340], ["ACE2", "GENE_OR_GENE_PRODUCT", 341, 345], ["CoV-2", "ORGANISM", 415, 420], ["intestinal", "ORGAN", 557, 567], ["ACE2", "GENE_OR_GENE_PRODUCT", 568, 572], ["patients", "ORGANISM", 613, 621], ["patients", "ORGANISM", 663, 671], ["ACE2", "PROTEIN", 32, 36], ["ACE2", "PROTEIN", 341, 345], ["ACE2", "PROTEIN", 568, 572], ["patients", "SPECIES", 613, 621], ["patients", "SPECIES", 663, 671], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 410, 418], ["ACE2 in small intestine", "PROBLEM", 32, 55], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["mediated infection", "PROBLEM", 103, 121], ["symptoms", "PROBLEM", 126, 134], ["intestinal innate immunity", "TREATMENT", 167, 193], ["age-dependent changes", "PROBLEM", 305, 326], ["intestinal ACE2 expression", "TREATMENT", 330, 356], ["gastrointestinal SARS", "PROBLEM", 393, 414], ["CoV", "PROBLEM", 415, 418], ["2 infection", "PROBLEM", 419, 430], ["symptoms", "PROBLEM", 435, 443], ["the samples", "TEST", 461, 472], ["this study", "TEST", 486, 496], ["the COVID", "TEST", 534, 543], ["pandemic", "PROBLEM", 547, 555], ["intestinal ACE2 expression", "PROBLEM", 557, 583], ["a higher viral load", "PROBLEM", 680, 699], ["small intestine", "ANATOMY", 40, 55], ["infection", "OBSERVATION", 112, 121], ["intestinal", "ANATOMY", 167, 177], ["suggest the possibility", "UNCERTAINTY", 276, 299], ["dependent", "OBSERVATION_MODIFIER", 309, 318], ["intestinal ACE2", "ANATOMY", 330, 345], ["gastrointestinal", "ANATOMY", 393, 409], ["SARS", "OBSERVATION", 410, 414], ["infection", "OBSERVATION", 421, 430], ["intestinal", "ANATOMY", 557, 567], ["viral load", "OBSERVATION", 689, 699]]], ["Further studies are needed to analyze ACE2 mRNA and protein expression in intestinal samples of COVID-19 patients of different age groups and according to the severity of the disease.", [["intestinal samples", "ANATOMY", 74, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["intestinal samples", "CANCER", 74, 92], ["patients", "ORGANISM", 105, 113], ["ACE2 mRNA", "RNA", 38, 47], ["patients", "SPECIES", 105, 113], ["Further studies", "TEST", 0, 15], ["ACE2 mRNA", "TEST", 38, 47], ["protein expression", "TEST", 52, 70], ["intestinal samples", "TEST", 74, 92], ["COVID", "TEST", 96, 101], ["the disease", "PROBLEM", 171, 182], ["intestinal", "ANATOMY", 74, 84], ["disease", "OBSERVATION", 175, 182]]]], "PMC7117390": [["IntroductionCoronaviruses (CoVs) are enveloped, positive-sense RNA viruses found in a wide range of animals, including mammals and birds.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["birds", "ORGANISM", 131, 136], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["sense RNA viruses", "PROBLEM", 57, 74], ["wide", "OBSERVATION_MODIFIER", 86, 90]]], ["CoVs exhibit marked tropism for epithelial cells in the respiratory, digestive, and urogenital tracts, and are responsible for a diverse spectrum of enteric, hepatic, neurological, and respiratory illnesses of differing severities.", [["epithelial cells", "ANATOMY", 32, 48], ["respiratory", "ANATOMY", 56, 67], ["digestive", "ANATOMY", 69, 78], ["urogenital tracts", "ANATOMY", 84, 101], ["hepatic", "ANATOMY", 158, 165], ["neurological", "ANATOMY", 167, 179], ["respiratory", "ANATOMY", 185, 196], ["respiratory, digestive, and urogenital tracts", "DISEASE", 56, 101], ["enteric, hepatic, neurological, and respiratory illnesses", "DISEASE", 149, 206], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["epithelial cells", "CELL", 32, 48], ["respiratory", "ORGAN", 56, 67], ["digestive", "ORGAN", 69, 78], ["urogenital tracts", "MULTI-TISSUE_STRUCTURE", 84, 101], ["hepatic", "ORGAN", 158, 165], ["CoVs", "PROTEIN", 0, 4], ["epithelial cells", "CELL_TYPE", 32, 48], ["CoVs", "PROBLEM", 0, 4], ["marked tropism", "PROBLEM", 13, 27], ["epithelial cells in the respiratory, digestive, and urogenital tracts", "PROBLEM", 32, 101], ["enteric, hepatic, neurological", "PROBLEM", 149, 179], ["respiratory illnesses of differing severities", "PROBLEM", 185, 230], ["marked", "OBSERVATION_MODIFIER", 13, 19], ["tropism", "OBSERVATION", 20, 27], ["epithelial cells", "OBSERVATION", 32, 48], ["respiratory", "ANATOMY", 56, 67], ["digestive", "ANATOMY", 69, 78], ["urogenital tracts", "ANATOMY", 84, 101], ["enteric", "ANATOMY", 149, 156], ["hepatic", "ANATOMY", 158, 165], ["neurological", "OBSERVATION", 167, 179], ["respiratory illnesses", "OBSERVATION", 185, 206]]], ["CoVs, classified in the subfamily Coronavirinae, family Coronaviridae, order Nidovirales, are now recognized as emerging viruses with a propensity to cross into new host species (Leopardi et al., 2018).", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 34, 47], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 77, 88], ["CoVs", "PROTEIN", 0, 4], ["CoVs", "PROBLEM", 0, 4], ["Nidovirales", "TREATMENT", 77, 88]]], ["CoVs are subdivided into four genera on the basis of genotypic and serological characterization: alpha and beta coronaviruses, which are found mainly in mammals; gamma coronaviruses, detected in birds and marine mammals; and delta coronaviruses found mainly in birds and swine (de Groot, 2012).", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["alpha", "GENE_OR_GENE_PRODUCT", 97, 102], ["beta", "GENE_OR_GENE_PRODUCT", 107, 111], ["gamma coronaviruses", "ORGANISM", 162, 181], ["marine mammals", "ORGANISM", 205, 219], ["delta coronaviruses", "ORGANISM", 225, 244], ["CoVs", "PROTEIN", 0, 4], ["swine", "SPECIES", 271, 276], ["swine", "SPECIES", 271, 276], ["CoVs", "PROBLEM", 0, 4], ["serological characterization", "TEST", 67, 95], ["alpha and beta coronaviruses", "PROBLEM", 97, 125], ["gamma coronaviruses", "PROBLEM", 162, 181], ["delta coronaviruses", "PROBLEM", 225, 244], ["beta coronaviruses", "OBSERVATION_MODIFIER", 107, 125], ["gamma coronaviruses", "OBSERVATION", 162, 181], ["delta coronaviruses", "OBSERVATION", 225, 244]]], ["The 5\u2032 two-thirds of the CoV genome encodes proteins involved in viral RNA synthesis.", [["CoV", "ORGANISM", 25, 28], ["CoV genome", "DNA", 25, 35], ["viral RNA", "RNA", 65, 74], ["the CoV genome encodes proteins", "PROBLEM", 21, 52], ["viral RNA synthesis", "PROBLEM", 65, 84], ["CoV genome", "OBSERVATION", 25, 35], ["viral RNA synthesis", "OBSERVATION", 65, 84]]], ["Most of these proteins are characteristically encoded by the partially-overlapping open reading frames (ORFs), ORF1a and ORF1b, and are translated as the polyproteins pp1a and pp1ab, which are then processed by virus-encoded proteinases into 15 or 16 non-structural proteins (nsps) (Ziebuhr, 2005).", [["ORF1a", "GENE_OR_GENE_PRODUCT", 111, 116], ["ORF1b", "GENE_OR_GENE_PRODUCT", 121, 126], ["pp1a", "GENE_OR_GENE_PRODUCT", 167, 171], ["pp1ab", "GENE_OR_GENE_PRODUCT", 176, 181], ["open reading frames", "DNA", 83, 102], ["ORFs", "DNA", 104, 108], ["ORF1a", "DNA", 111, 116], ["ORF1b", "DNA", 121, 126], ["pp1a", "PROTEIN", 167, 171], ["pp1ab", "DNA", 176, 181], ["virus-encoded proteinases", "PROTEIN", 211, 236], ["structural proteins", "PROTEIN", 255, 274], ["nsps", "PROTEIN", 276, 280], ["the polyproteins pp1a", "TEST", 150, 171]]], ["The remaining 3\u2032 one-third of the genome encodes virus structural proteins, including the spike (S) glycoprotein, membrane (M) glycoprotein, small envelope (E) protein, and phosphorylated nucleocapsid (N) proteins.", [["membrane", "ANATOMY", 114, 122], ["spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 90, 112], ["membrane", "CELLULAR_COMPONENT", 114, 122], ["(M) glycoprotein", "GENE_OR_GENE_PRODUCT", 123, 139], ["small envelope (E)", "GENE_OR_GENE_PRODUCT", 141, 159], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 188, 213], ["virus structural proteins", "PROTEIN", 49, 74], ["spike (S) glycoprotein", "PROTEIN", 90, 112], ["membrane (M) glycoprotein", "PROTEIN", 114, 139], ["small envelope (E) protein", "PROTEIN", 141, 167], ["phosphorylated nucleocapsid (N) proteins", "PROTEIN", 173, 213], ["the genome encodes virus structural proteins", "PROBLEM", 30, 74], ["the spike (S) glycoprotein, membrane (M) glycoprotein", "TEST", 86, 139], ["small envelope (E) protein", "TEST", 141, 167], ["phosphorylated nucleocapsid (N) proteins", "PROBLEM", 173, 213], ["virus structural proteins", "OBSERVATION", 49, 74]]], ["The CoV S protein can be divided into an amino-proximal half (S1 subunit or domain) containing the receptor-binding domain, and a carboxyl-proximal half (S2 subunit or domain) containing elements involved in membrane fusion (Lewis et al., 2015).", [["membrane", "ANATOMY", 208, 216], ["amino", "CHEMICAL", 41, 46], ["carboxyl", "CHEMICAL", 130, 138], ["CoV S", "GENE_OR_GENE_PRODUCT", 4, 9], ["membrane", "CELLULAR_COMPONENT", 208, 216], ["CoV S protein", "PROTEIN", 4, 17], ["amino-proximal half", "PROTEIN", 41, 60], ["S1 subunit or domain", "PROTEIN", 62, 82], ["receptor-binding domain", "PROTEIN", 99, 122], ["carboxyl-proximal half", "PROTEIN", 130, 152], ["S2 subunit or domain", "PROTEIN", 154, 174], ["The CoV S protein", "TEST", 0, 17], ["an amino-proximal half (S1 subunit", "TREATMENT", 38, 72], ["the receptor-binding domain", "TREATMENT", 95, 122], ["a carboxyl-proximal half (S2 subunit or domain) containing elements", "TREATMENT", 128, 195], ["proximal", "ANATOMY_MODIFIER", 139, 147], ["membrane fusion", "OBSERVATION", 208, 223]]], ["The S protein is an important target for T cell responses and is the major inducer of virus-neutralizing antibodies, which are elicited by epitopes located mostly in the molecule\u2019s S1 domain (Reguera et al., 2012; Satoh et al., 2011).", [["T cell", "ANATOMY", 41, 47], ["T cell", "CELL", 41, 47], ["S protein", "PROTEIN", 4, 13], ["virus-neutralizing antibodies", "PROTEIN", 86, 115], ["epitopes", "PROTEIN", 139, 147], ["S1 domain", "PROTEIN", 181, 190], ["The S protein", "TEST", 0, 13], ["neutralizing antibodies", "PROBLEM", 92, 115], ["virus", "OBSERVATION", 86, 91]]], ["The S1 and S2 domains in some CoVs, e.g. avian CoVs (AvCoVs), are cleaved by a cellular furin-like enzyme (de Haan et al., 2004).IntroductionMost viruses in the genus Gammacoronavirus are isolated from birds, including Galliformes (chicken, turkey, quail, guinea fowl, pheasant, and peafowl) (Brown et al., 2016; Cavanagh et al., 2002; Guy, 2008; Liu et al., 2005; Sun et al., 2007; Torres et al., 2017), Anseriformes (duck, goose, teal, swan, and pintail) (Liu et al., 2005; Papineau et al., 2019), Columbiformes (pigeon) (Jonassen et al., 2005), Pelecaniformes (spoonbill and heron), Suliformes (cormorant), Charadriiformes (red knot, oystercatcher, and black-headed gull), and Passeriformes (bulbul) (Chu et al., 2011), although they have also been identified in the beluga whale (Mihindukulasuriya et al., 2008) and in bottlenose dolphins (Woo et al., 2014).", [["cellular", "ANATOMY", 79, 87], ["bottlenose dolphins", "DISEASE", 823, 842], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S2", "GENE_OR_GENE_PRODUCT", 11, 13], ["CoVs", "GENE_OR_GENE_PRODUCT", 30, 34], ["CoVs", "GENE_OR_GENE_PRODUCT", 47, 51], ["AvCoVs", "GENE_OR_GENE_PRODUCT", 53, 59], ["cellular", "CELL", 79, 87], ["furin", "GENE_OR_GENE_PRODUCT", 88, 93], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 167, 183], ["birds", "ORGANISM", 202, 207], ["chicken", "ORGANISM", 232, 239], ["turkey", "ORGANISM", 241, 247], ["quail", "ORGANISM", 249, 254], ["guinea fowl", "ORGANISM", 256, 267], ["pheasant", "ORGANISM", 269, 277], ["duck", "ORGANISM", 419, 423], ["pigeon", "ORGANISM", 515, 521], ["bottlenose dolphins", "ORGANISM", 823, 842], ["S1 and S2 domains", "PROTEIN", 4, 21], ["CoVs", "PROTEIN", 30, 34], ["avian CoVs", "PROTEIN", 41, 51], ["AvCoVs", "PROTEIN", 53, 59], ["cellular furin-like enzyme", "PROTEIN", 79, 105], ["chicken", "SPECIES", 232, 239], ["turkey", "SPECIES", 241, 247], ["quail", "SPECIES", 249, 254], ["guinea fowl", "SPECIES", 256, 267], ["pheasant", "SPECIES", 269, 277], ["duck", "SPECIES", 419, 423], ["goose", "SPECIES", 425, 430], ["pigeon", "SPECIES", 515, 521], ["chicken", "SPECIES", 232, 239], ["turkey", "SPECIES", 241, 247], ["quail", "SPECIES", 249, 254], ["guinea fowl, pheasant", "SPECIES", 256, 277], ["black-headed gull", "SPECIES", 656, 673], ["The S1 and S2 domains", "PROBLEM", 0, 21], ["some CoVs", "PROBLEM", 25, 34], ["avian CoVs (AvCoVs)", "PROBLEM", 41, 60], ["a cellular furin", "TEST", 77, 93], ["swan", "TREATMENT", 438, 442], ["oystercatcher", "TEST", 637, 650], ["S1", "ANATOMY", 4, 6], ["S2", "ANATOMY", 11, 13], ["some CoVs", "OBSERVATION", 25, 34], ["avian CoVs", "OBSERVATION", 41, 51], ["swan", "ANATOMY", 438, 442]]], ["Infectious bronchitis virus (IBV) and turkey coronavirus (TCoV) are among the most economically important avian coronaviruses (AvCoVs).", [["Infectious bronchitis virus (IBV) and turkey coronavirus", "DISEASE", 0, 56], ["avian coronaviruses", "DISEASE", 106, 125], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["turkey coronavirus", "ORGANISM", 38, 56], ["TCoV", "CANCER", 58, 62], ["avian coronaviruses", "ORGANISM", 106, 125], ["AvCoVs", "CANCER", 127, 133], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["turkey coronavirus", "SPECIES", 38, 56], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["turkey coronavirus", "SPECIES", 38, 56], ["TCoV", "SPECIES", 58, 62], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["turkey coronavirus (TCoV)", "PROBLEM", 38, 63]]], ["IBV was the first recognized CoV in the United States in 1931 (Schalk and Hawn, 1931).", [["IBV", "ORGANISM", 0, 3], ["CoV", "ORGANISM", 29, 32], ["IBV", "SPECIES", 0, 3]]], ["IBV is traditionally considered to be a host-specific pathogen in chickens, responsible for respiratory, renal, and genital diseases, with heavy economic consequences worldwide (Cavanagh, 2007).", [["respiratory", "ANATOMY", 92, 103], ["renal", "ANATOMY", 105, 110], ["genital", "ANATOMY", 116, 123], ["respiratory, renal, and genital diseases", "DISEASE", 92, 132], ["IBV", "ORGANISM", 0, 3], ["chickens", "ORGANISM", 66, 74], ["renal", "ORGAN", 105, 110], ["genital", "ORGANISM_SUBDIVISION", 116, 123], ["chickens", "SPECIES", 66, 74], ["IBV", "SPECIES", 0, 3], ["chickens", "SPECIES", 66, 74], ["IBV", "PROBLEM", 0, 3], ["respiratory, renal, and genital diseases", "PROBLEM", 92, 132], ["renal", "ANATOMY", 105, 110], ["genital", "ANATOMY", 116, 123], ["diseases", "OBSERVATION", 124, 132]]], ["In contrast to alpha and beta coronaviruses, which only occur as one or two different serotypes, IBV has many different serotypes, genotypes, lineages, and variants (Valastro et al., 2016).", [["alpha", "GENE_OR_GENE_PRODUCT", 15, 20], ["beta", "GENE_OR_GENE_PRODUCT", 25, 29], ["IBV", "ORGANISM", 97, 100], ["IBV", "SPECIES", 97, 100], ["alpha and beta coronaviruses", "PROBLEM", 15, 43], ["two different serotypes", "PROBLEM", 72, 95], ["IBV", "PROBLEM", 97, 100], ["many different serotypes", "PROBLEM", 105, 129], ["beta coronaviruses", "OBSERVATION_MODIFIER", 25, 43], ["serotypes", "OBSERVATION", 86, 95], ["different", "OBSERVATION_MODIFIER", 110, 119], ["serotypes", "OBSERVATION_MODIFIER", 120, 129], ["lineages", "OBSERVATION_MODIFIER", 142, 150]]], ["Furthermore, new IBV genotypes/lineages and variants are continuing to emerge due to its high rate of evolution.", [["IBV", "ORGANISM", 17, 20], ["IBV", "SPECIES", 17, 20], ["new IBV genotypes/lineages and variants", "PROBLEM", 13, 52], ["new", "OBSERVATION_MODIFIER", 13, 16], ["IBV", "OBSERVATION", 17, 20]]], ["This is expressed as an accelerated rate at which viable point mutations, nucleotide insertions, or deletions accumulate in the genome, especially in the S1 gene, associated with a lack of proofreading viral polymerase in IBVs (Cavanagh, 2007), as well as the high rate of virus replication.", [["nucleotide", "CHEMICAL", 74, 84], ["nucleotide", "CHEMICAL", 74, 84], ["S1", "GENE_OR_GENE_PRODUCT", 154, 156], ["IBVs", "PATHOLOGICAL_FORMATION", 222, 226], ["S1 gene", "DNA", 154, 161], ["proofreading viral polymerase", "PROTEIN", 189, 218], ["an accelerated rate", "PROBLEM", 21, 40], ["nucleotide insertions", "PROBLEM", 74, 95], ["deletions accumulate", "PROBLEM", 100, 120], ["proofreading viral polymerase in IBVs", "PROBLEM", 189, 226], ["virus replication", "TREATMENT", 273, 290], ["genome", "OBSERVATION_MODIFIER", 128, 134], ["S1", "ANATOMY", 154, 156], ["viral polymerase", "OBSERVATION", 202, 218], ["virus replication", "OBSERVATION", 273, 290]]], ["In addition, evidence suggests that some IBV strains may have arisen by genetic recombination (Cavanagh et al., 1992; Kusters et al., 1989, 1990), or by a combination of mutation and recombination (Jia et al., 1995; Chen et al., 2017; Jiang et al., 2017).", [["IBV", "ORGANISM", 41, 44], ["IBV", "SPECIES", 41, 44], ["some IBV strains", "PROBLEM", 36, 52], ["mutation", "PROBLEM", 170, 178], ["evidence suggests", "UNCERTAINTY", 13, 30], ["IBV", "OBSERVATION", 41, 44]]], ["TCoV, initially found in the 1970s, is associated with the enteric disease known as transmissible enteritis, coronaviral enteritis of turkeys, or bluecomb (Guy, 2008).", [["TCoV", "CHEMICAL", 0, 4], ["enteric disease", "DISEASE", 59, 74], ["transmissible enteritis", "DISEASE", 84, 107], ["coronaviral enteritis", "DISEASE", 109, 130], ["TCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["turkeys", "SPECIES", 134, 141], ["TCoV", "TEST", 0, 4], ["the enteric disease", "PROBLEM", 55, 74], ["transmissible enteritis", "PROBLEM", 84, 107], ["coronaviral enteritis of turkeys", "PROBLEM", 109, 141], ["enteric", "ANATOMY", 59, 66], ["disease", "OBSERVATION", 67, 74], ["transmissible", "OBSERVATION_MODIFIER", 84, 97], ["enteritis", "OBSERVATION", 98, 107], ["coronaviral", "OBSERVATION_MODIFIER", 109, 120], ["enteritis", "OBSERVATION", 121, 130]]], ["TCoV infection was also recently found to be associated with a syndrome comprising several intestinal disorders, usually occurring in turkeys within the first 3 weeks of life and referred to as poult enteritis complex (Barnes et al., 2000).", [["intestinal", "ANATOMY", 91, 101], ["TCoV infection", "DISEASE", 0, 14], ["intestinal disorders", "DISEASE", 91, 111], ["poult enteritis", "DISEASE", 194, 209], ["TCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["intestinal", "ORGAN", 91, 101], ["turkeys", "SPECIES", 134, 141], ["TCoV", "SPECIES", 0, 4], ["turkeys", "SPECIES", 134, 141], ["TCoV infection", "PROBLEM", 0, 14], ["a syndrome", "PROBLEM", 61, 71], ["several intestinal disorders", "PROBLEM", 83, 111], ["infection", "OBSERVATION", 5, 14], ["syndrome", "OBSERVATION", 63, 71], ["intestinal", "ANATOMY", 91, 101], ["disorders", "OBSERVATION", 102, 111], ["enteritis", "OBSERVATION", 200, 209]]], ["TCoV emergence was proposed to be the result of recombination events involving IBVs and an unidenti\ufb01ed CoV, which donated an S gene encoding a protein of low amino acid identity to those of IBVs (Hughes, 2011; Jackwood et al., 2010).", [["TCoV", "CHEMICAL", 0, 4], ["amino acid", "CHEMICAL", 158, 168], ["amino acid", "CHEMICAL", 158, 168], ["TCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["IBVs", "GENE_OR_GENE_PRODUCT", 79, 83], ["CoV", "GENE_OR_GENE_PRODUCT", 103, 106], ["amino acid", "AMINO_ACID", 158, 168], ["S gene", "DNA", 125, 131], ["recombination events", "PROBLEM", 48, 68], ["IBVs", "PROBLEM", 79, 83], ["an unidenti\ufb01ed CoV", "PROBLEM", 88, 106], ["low amino acid identity", "PROBLEM", 154, 177]]], ["These recombinations resulted in a host shift from chickens to turkeys, and in a change in tissue tropism of the virus from the upper respiratory tract to the intestine.IntroductionOutbreaks initially associated with CoV infection in pheasants were first reported in the UK in 1980 (Spackman and Cameron, 1983).", [["tissue", "ANATOMY", 91, 97], ["upper respiratory tract", "ANATOMY", 128, 151], ["intestine", "ANATOMY", 159, 168], ["CoV infection", "DISEASE", 217, 230], ["chickens", "ORGANISM", 51, 59], ["turkeys", "ORGANISM", 63, 70], ["tissue", "TISSUE", 91, 97], ["upper respiratory", "ORGANISM_SUBDIVISION", 128, 145], ["tract", "ORGANISM_SUBDIVISION", 146, 151], ["intestine", "ORGAN", 159, 168], ["CoV", "ORGANISM", 217, 220], ["pheasants", "ORGANISM", 234, 243], ["chickens", "SPECIES", 51, 59], ["turkeys", "SPECIES", 63, 70], ["chickens", "SPECIES", 51, 59], ["turkeys", "SPECIES", 63, 70], ["a change in tissue tropism of the virus", "PROBLEM", 79, 118], ["IntroductionOutbreaks", "TREATMENT", 169, 190], ["CoV infection", "PROBLEM", 217, 230], ["tissue tropism", "OBSERVATION", 91, 105], ["virus", "OBSERVATION", 113, 118], ["upper", "ANATOMY_MODIFIER", 128, 133], ["respiratory tract", "ANATOMY", 134, 151], ["intestine", "ANATOMY", 159, 168], ["CoV", "OBSERVATION_MODIFIER", 217, 220], ["infection", "OBSERVATION", 221, 230]]], ["Affected birds exhibited reduced egg production among breeding hens, accompanied by loss of shell pigmentation and some abnormal shell quality, with later outbreaks of respiratory signs among affected pheasants.", [["egg", "ANATOMY", 33, 36], ["respiratory", "ANATOMY", 168, 179], ["loss of shell pigmentation", "DISEASE", 84, 110], ["respiratory signs", "DISEASE", 168, 185], ["birds", "ORGANISM", 9, 14], ["egg", "ORGANISM_SUBSTANCE", 33, 36], ["pheasants", "ORGANISM", 201, 210], ["Affected birds", "PROBLEM", 0, 14], ["reduced egg production", "PROBLEM", 25, 47], ["shell pigmentation", "PROBLEM", 92, 110], ["some abnormal shell quality", "PROBLEM", 115, 142], ["respiratory signs", "PROBLEM", 168, 185], ["affected pheasants", "PROBLEM", 192, 210], ["reduced egg production", "OBSERVATION", 25, 47], ["shell pigmentation", "OBSERVATION", 92, 110], ["abnormal", "OBSERVATION_MODIFIER", 120, 128], ["shell quality", "OBSERVATION_MODIFIER", 129, 142], ["respiratory", "ANATOMY", 168, 179]]], ["However, there was no evidence of kidney damage in the affected birds.", [["kidney", "ANATOMY", 34, 40], ["kidney damage", "DISEASE", 34, 47], ["kidney", "ORGAN", 34, 40], ["birds", "ORGANISM", 64, 69], ["kidney damage in the affected birds", "PROBLEM", 34, 69], ["no evidence of", "UNCERTAINTY", 19, 33], ["kidney", "ANATOMY", 34, 40], ["damage", "OBSERVATION", 41, 47], ["affected", "OBSERVATION_MODIFIER", 55, 63], ["birds", "OBSERVATION_MODIFIER", 64, 69]]], ["Antibodies against IBV were detected by the hemagglutination inhibition (HI) test in 80% of tested pheasants and a CoV was isolated that proved to be identical to the agent responsible for infectious bronchitis (IB) in chickens.", [["infectious bronchitis (IB)", "DISEASE", 189, 215], ["IBV", "ORGANISM", 19, 22], ["pheasants", "ORGANISM", 99, 108], ["CoV", "ORGANISM", 115, 118], ["chickens", "ORGANISM", 219, 227], ["chickens", "SPECIES", 219, 227], ["IBV", "SPECIES", 19, 22], ["pheasants", "SPECIES", 99, 108], ["CoV", "SPECIES", 115, 118], ["chickens", "SPECIES", 219, 227], ["Antibodies", "TEST", 0, 10], ["IBV", "PROBLEM", 19, 22], ["the hemagglutination inhibition", "TEST", 40, 71], ["test", "TEST", 77, 81], ["tested pheasants", "PROBLEM", 92, 108], ["a CoV", "PROBLEM", 113, 118], ["infectious bronchitis", "PROBLEM", 189, 210]]], ["Two later outbreaks of nephritis occurred in the UK in 1983 and 1984, resulting in the deaths of 450 out of 1000 8-week-old pheasants and 15 out of 160 adult pheasants, respectively, from which CoVs were isolated using 8\u20139-day-old embryonating eggs (Lister et al., 1985).", [["nephritis", "DISEASE", 23, 32], ["deaths", "DISEASE", 87, 93], ["pheasants", "ORGANISM", 124, 133], ["pheasants", "ORGANISM", 158, 167], ["CoVs", "GENE_OR_GENE_PRODUCT", 194, 198], ["eggs", "ORGANISM", 244, 248], ["nephritis", "PROBLEM", 23, 32], ["outbreaks", "OBSERVATION_MODIFIER", 10, 19], ["nephritis", "OBSERVATION", 23, 32]]], ["However, intranasal instillation of specific-pathogen-free (SPF) chickens with the virus failed to produce any clinical signs of disease.", [["chickens", "ORGANISM", 65, 73], ["chickens", "SPECIES", 65, 73], ["chickens", "SPECIES", 65, 73], ["intranasal instillation", "TREATMENT", 9, 32], ["the virus", "PROBLEM", 79, 88], ["disease", "PROBLEM", 129, 136], ["disease", "OBSERVATION", 129, 136]]], ["A similar outbreak of nephritis in 1994 resulting in the deaths of over 1000 breeding pheasants out of a total stock of approximately 7000 birds in the UK was considered to be linked to avian IBV (Gough et al., 1996).", [["nephritis", "DISEASE", 22, 31], ["deaths", "DISEASE", 57, 63], ["pheasants", "ORGANISM", 86, 95], ["UK", "GENE_OR_GENE_PRODUCT", 152, 154], ["avian IBV", "ORGANISM", 186, 195], ["nephritis", "PROBLEM", 22, 31], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["outbreak", "OBSERVATION_MODIFIER", 10, 18], ["nephritis", "OBSERVATION", 22, 31]]], ["Sneezing and reduced egg production and hatchability were also reported, but the egg quality was unaffected.", [["egg", "ANATOMY", 21, 24], ["egg", "ANATOMY", 81, 84], ["Sneezing", "DISEASE", 0, 8], ["egg", "ORGANISM_SUBSTANCE", 21, 24], ["egg", "ORGANISM_SUBDIVISION", 81, 84], ["Sneezing", "PROBLEM", 0, 8], ["reduced egg production", "PROBLEM", 13, 35], ["hatchability", "PROBLEM", 40, 52], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["egg production", "OBSERVATION", 21, 35]]], ["Pheasant coronavirus (PhCoV)-associated nephritis and respiratory disease were also subsequently reported in the UK (Pennycott, 2000; Cavanagh et al., 2002).", [["respiratory", "ANATOMY", 54, 65], ["PhCoV", "CHEMICAL", 22, 27], ["nephritis", "DISEASE", 40, 49], ["respiratory disease", "DISEASE", 54, 73], ["Pheasant coronavirus", "ORGANISM", 0, 20], ["PhCoV", "ORGANISM", 22, 27], ["Pheasant coronavirus", "SPECIES", 0, 20], ["Pheasant coronavirus", "SPECIES", 0, 20], ["PhCoV", "SPECIES", 22, 27], ["Pheasant coronavirus (PhCoV)", "PROBLEM", 0, 28], ["associated nephritis", "PROBLEM", 29, 49], ["respiratory disease", "PROBLEM", 54, 73], ["coronavirus", "OBSERVATION", 9, 20], ["nephritis", "OBSERVATION", 40, 49], ["respiratory disease", "OBSERVATION", 54, 73]]], ["Partial genomic sequence analysis showed that the gene sequences of the pheasant viruses differed from those of IBV to a similar extent as the sequence of one serotype of IBV differs from another (Cavanagh et al., 2002).", [["pheasant viruses", "ORGANISM", 72, 88], ["IBV", "ORGANISM", 112, 115], ["IBV", "ORGANISM", 171, 174], ["pheasant viruses", "SPECIES", 72, 88], ["IBV", "SPECIES", 112, 115], ["IBV", "SPECIES", 171, 174], ["Partial genomic sequence analysis", "TEST", 0, 33], ["the pheasant viruses", "PROBLEM", 68, 88], ["IBV", "TREATMENT", 112, 115]]], ["The above results showed that the CoVs involved in these pheasant infections were closely related to avian IBV; however, the clinical signs and mortality associated with CoV infections in pheasants and the isolated viruses differed from each other and from IBVs.", [["infections", "DISEASE", 66, 76], ["CoV infections", "DISEASE", 170, 184], ["CoVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["pheasant", "ORGANISM", 57, 65], ["avian IBV", "ORGANISM", 101, 110], ["CoV", "ORGANISM", 170, 173], ["pheasants", "ORGANISM", 188, 197], ["IBVs", "CANCER", 257, 261], ["CoVs", "PROTEIN", 34, 38], ["avian IBV", "SPECIES", 101, 110], ["pheasant", "SPECIES", 57, 65], ["IBV", "SPECIES", 107, 110], ["CoV", "SPECIES", 170, 173], ["pheasants", "SPECIES", 188, 197], ["the CoVs", "PROBLEM", 30, 38], ["these pheasant infections", "PROBLEM", 51, 76], ["avian IBV", "TREATMENT", 101, 110], ["the clinical signs", "PROBLEM", 121, 139], ["CoV infections in pheasants", "PROBLEM", 170, 197], ["the isolated viruses", "PROBLEM", 202, 222], ["IBVs", "TREATMENT", 257, 261], ["pheasant", "OBSERVATION_MODIFIER", 57, 65], ["infections", "OBSERVATION", 66, 76], ["infections", "OBSERVATION", 174, 184], ["viruses", "OBSERVATION", 215, 222]]], ["Further studies using molecular techniques are therefore required to determine the complete genomic sequences of CoVs from different outbreaks in pheasants, to compare and fully elucidate their origins and antigenic relationships with strains of IBV.IntroductionIn this study, we isolated two CoVs from pheasants with nephritis and high mortality for the first time in China.", [["nephritis", "DISEASE", 318, 327], ["CoVs", "GENE_OR_GENE_PRODUCT", 113, 117], ["pheasants", "ORGANISM", 146, 155], ["IBV", "ORGANISM", 246, 249], ["CoVs", "GENE_OR_GENE_PRODUCT", 293, 297], ["pheasants", "ORGANISM", 303, 312], ["IBV", "SPECIES", 246, 249], ["Further studies", "TEST", 0, 15], ["molecular techniques", "TEST", 22, 42], ["CoVs", "PROBLEM", 113, 117], ["IBV", "PROBLEM", 246, 249], ["this study", "TEST", 265, 275], ["nephritis", "PROBLEM", 318, 327], ["nephritis", "OBSERVATION", 318, 327], ["high mortality", "OBSERVATION_MODIFIER", 332, 346]]], ["We aimed to determine the full genome sequences of the two isolates and compare them with IBVs, evaluate the pathogenicity of the isolates in pheasants and chickens, and investigate the cross-antigenicity with IBVs, to clarify the origin of PhCoVs and their relationships with strains of IBV.Chicken embryos, chickens, and pheasants ::: Materials and methodsWhite leghorn chickens were hatched from specific pathogen-free (SPF) embryonated eggs (Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences), maintained in Hosfall-type isolators, and provided with food and water ad libitum.", [["embryos", "ANATOMY", 300, 307], ["pheasants", "ORGANISM", 142, 151], ["chickens", "ORGANISM", 156, 164], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 241, 247], ["IBV", "ORGANISM", 288, 291], ["Chicken", "ORGANISM", 292, 299], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 300, 307], ["chickens", "ORGANISM", 309, 317], ["pheasants", "ORGANISM", 323, 332], ["leghorn chickens", "ORGANISM", 364, 380], ["PhCoVs", "PROTEIN", 241, 247], ["chickens", "SPECIES", 156, 164], ["Chicken", "SPECIES", 292, 299], ["chickens", "SPECIES", 309, 317], ["chickens", "SPECIES", 372, 380], ["pheasants", "SPECIES", 142, 151], ["chickens", "SPECIES", 156, 164], ["IBV", "SPECIES", 288, 291], ["Chicken", "SPECIES", 292, 299], ["chickens", "SPECIES", 309, 317], ["White leghorn chickens", "SPECIES", 358, 380], ["IBVs", "TREATMENT", 90, 94], ["IBVs", "TREATMENT", 210, 214], ["IBV", "PROBLEM", 288, 291], ["White leghorn chickens", "PROBLEM", 358, 380]]], ["Chicken embryonated eggs were used for primary isolation of viruses from the diseased pheasants, viral seed stock preparation and titration, virus-neutralization (VN) tests, re-isolation attempts from oropharyngeal and cloacal swabs, and titration of viruses from selected tissues from chickens and pheasants in the challenge trials.", [["eggs", "ANATOMY", 20, 24], ["oropharyngeal", "ANATOMY", 201, 214], ["cloacal swabs", "ANATOMY", 219, 232], ["tissues", "ANATOMY", 273, 280], ["Chicken", "ORGANISM", 0, 7], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 20, 24], ["pheasants", "ORGANISM", 86, 95], ["oropharyngeal", "ORGANISM_SUBDIVISION", 201, 214], ["tissues", "TISSUE", 273, 280], ["chickens", "ORGANISM", 286, 294], ["Chicken", "SPECIES", 0, 7], ["chickens", "SPECIES", 286, 294], ["Chicken", "SPECIES", 0, 7], ["chickens", "SPECIES", 286, 294], ["Chicken embryonated eggs", "TREATMENT", 0, 24], ["primary isolation of viruses", "PROBLEM", 39, 67], ["the diseased pheasants", "PROBLEM", 73, 95], ["viral seed stock preparation", "TREATMENT", 97, 125], ["virus", "TREATMENT", 141, 146], ["tests", "TEST", 167, 172], ["re-isolation attempts", "TREATMENT", 174, 195], ["oropharyngeal and cloacal swabs", "TEST", 201, 232], ["viruses", "TREATMENT", 251, 258], ["pheasants", "TREATMENT", 299, 308], ["viruses", "OBSERVATION", 60, 67], ["diseased pheasants", "OBSERVATION", 77, 95], ["oropharyngeal", "ANATOMY", 201, 214]]], ["SPF chickens were used for antisera production and challenge trials.", [["SPF chickens", "ORGANISM", 0, 12], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 4, 12], ["SPF chickens", "TREATMENT", 0, 12], ["antisera production", "TREATMENT", 27, 46]]], ["One-day-old commercial pheasants (Phasianus colchicus) were purchased from a pheasant-producing company in Shandong province, China, and used in the challenge trials.", [["pheasants", "ORGANISM", 23, 32], ["Phasianus colchicus", "ORGANISM", 34, 53], ["pheasants", "SPECIES", 23, 32], ["Phasianus colchicus", "SPECIES", 34, 53], ["pheasants", "SPECIES", 23, 32], ["Phasianus colchicus", "SPECIES", 34, 53]]], ["All experimental procedures and animal care were approved by the Ethical and Animal Welfare Committee of Heilongjiang province, China (License nos.", [["All experimental procedures", "TREATMENT", 0, 27], ["animal care", "TREATMENT", 32, 43]]], ["HSY-IACUC-2017-167, -168, -169, and -170).Clinical information and sample collection ::: Materials and methodsSeveral new episodes of serious respiratory diseases occurred in commercial pheasant flocks in China between September 2016 and June 2017.", [["respiratory", "ANATOMY", 142, 153], ["respiratory diseases", "DISEASE", 142, 162], ["IACUC-", "TEST", 4, 10], ["serious respiratory diseases", "PROBLEM", 134, 162], ["new", "OBSERVATION_MODIFIER", 118, 121], ["serious", "OBSERVATION_MODIFIER", 134, 141], ["respiratory diseases", "OBSERVATION", 142, 162], ["pheasant flocks", "OBSERVATION", 186, 201]]], ["The outbreaks were characterized by clinical signs compatible with IB in chickens, including respiratory signs (all flocks) and kidney lesions (nephritis), leading to economic losses in different geographical locations among the major pheasant-farming areas in Shandong, Anhui, and Henan provinces in China.", [["respiratory", "ANATOMY", 93, 104], ["kidney lesions", "ANATOMY", 128, 142], ["respiratory signs", "DISEASE", 93, 110], ["kidney lesions", "DISEASE", 128, 142], ["nephritis", "DISEASE", 144, 153], ["chickens", "ORGANISM", 73, 81], ["kidney lesions", "PATHOLOGICAL_FORMATION", 128, 142], ["chickens", "SPECIES", 73, 81], ["chickens", "SPECIES", 73, 81], ["clinical signs", "PROBLEM", 36, 50], ["IB in chickens", "PROBLEM", 67, 81], ["respiratory signs", "PROBLEM", 93, 110], ["all flocks)", "PROBLEM", 112, 123], ["kidney lesions", "PROBLEM", 128, 142], ["nephritis", "PROBLEM", 144, 153], ["economic losses", "PROBLEM", 167, 182], ["compatible with", "UNCERTAINTY", 51, 66], ["IB", "OBSERVATION_MODIFIER", 67, 69], ["chickens", "OBSERVATION", 73, 81], ["respiratory signs", "OBSERVATION", 93, 110], ["kidney", "ANATOMY", 128, 134], ["lesions", "OBSERVATION", 135, 142], ["nephritis", "OBSERVATION", 144, 153], ["economic", "OBSERVATION_MODIFIER", 167, 175], ["losses", "OBSERVATION", 176, 182], ["major", "OBSERVATION_MODIFIER", 229, 234], ["pheasant", "OBSERVATION_MODIFIER", 235, 243]]], ["The birds showed early signs of respiratory disease at around 17 days old, most birds in the flocks showed obvious clinical signs at 20\u201340 days old, and the clinical signs disappeared at around 55 days old.", [["respiratory", "ANATOMY", 32, 43], ["respiratory disease", "DISEASE", 32, 51], ["birds", "ORGANISM", 4, 9], ["birds", "ORGANISM", 80, 85], ["respiratory disease", "PROBLEM", 32, 51], ["obvious clinical signs", "PROBLEM", 107, 129], ["the clinical signs", "PROBLEM", 153, 171], ["early", "OBSERVATION_MODIFIER", 17, 22], ["signs", "OBSERVATION_MODIFIER", 23, 28], ["respiratory disease", "OBSERVATION", 32, 51]]], ["Gross examination showed severe tracheitis and nephritis.", [["tracheitis", "DISEASE", 32, 42], ["nephritis", "DISEASE", 47, 56], ["Gross examination", "TEST", 0, 17], ["severe tracheitis", "PROBLEM", 25, 42], ["nephritis", "PROBLEM", 47, 56], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["tracheitis", "OBSERVATION", 32, 42], ["nephritis", "OBSERVATION", 47, 56]]], ["Trachea, kidney, and proventriculus samples from two selected farms in Shandong and Anhui provinces were sent to our laboratory for virus detection in early 2017.", [["Trachea", "ANATOMY", 0, 7], ["kidney", "ANATOMY", 9, 15], ["proventriculus samples", "ANATOMY", 21, 43], ["Trachea", "MULTI-TISSUE_STRUCTURE", 0, 7], ["kidney", "ORGAN", 9, 15], ["proventriculus samples", "CANCER", 21, 43], ["virus detection", "TEST", 132, 147], ["kidney", "ANATOMY", 9, 15], ["proventriculus", "ANATOMY", 21, 35]]], ["The two farms contained 13,500 and 7000 birds, respectively, of which more than 4000 and 2500 died, respectively, during the disease outbreaks.Virus detection and isolation ::: Materials and methodsTracheal and kidney samples from 10 dead birds from the farm in Shandong province, and kidney and proventriculus samples from five dead birds from the farm in Anhui province, respectively, were collected.", [["Tracheal", "ANATOMY", 198, 206], ["kidney samples", "ANATOMY", 211, 225], ["kidney", "ANATOMY", 285, 291], ["proventriculus samples", "ANATOMY", 296, 318], ["Virus", "ORGANISM", 143, 148], ["Tracheal", "MULTI-TISSUE_STRUCTURE", 198, 206], ["kidney samples", "CANCER", 211, 225], ["kidney", "ORGAN", 285, 291], ["proventriculus samples", "MULTI-TISSUE_STRUCTURE", 296, 318], ["the disease outbreaks", "PROBLEM", 121, 142], ["methodsTracheal and kidney samples", "PROBLEM", 191, 225], ["kidney and proventriculus samples", "TEST", 285, 318], ["Tracheal", "ANATOMY", 198, 206], ["kidney", "ANATOMY", 211, 217], ["kidney", "ANATOMY", 285, 291], ["proventriculus", "ANATOMY", 296, 310]]], ["Samples of each farm were pooled together, ending up with 2 different pools.", [["Samples", "ANATOMY", 0, 7]]], ["The samples tested negative for Newcastle disease virus (NDV) (Gohm et al., 2000) and avian influenza virus (AIV) subtypes H5 and H9 by reverse transcription polymerase chain reaction (RT-PCR) (Chaharaein et al., 2009).", [["samples", "ANATOMY", 4, 11], ["Newcastle disease virus", "DISEASE", 32, 55], ["avian influenza", "DISEASE", 86, 101], ["Newcastle disease virus", "ORGANISM", 32, 55], ["NDV", "ORGANISM", 57, 60], ["avian influenza virus", "ORGANISM", 86, 107], ["AIV", "ORGANISM", 109, 112], ["H9", "CELL", 130, 132], ["avian influenza virus", "SPECIES", 86, 107], ["Newcastle disease virus", "SPECIES", 32, 55], ["NDV", "SPECIES", 57, 60], ["avian influenza virus", "SPECIES", 86, 107], ["AIV", "SPECIES", 109, 112], ["The samples", "TEST", 0, 11], ["Newcastle disease virus", "PROBLEM", 32, 55], ["avian influenza virus (AIV) subtypes H5", "PROBLEM", 86, 125], ["reverse transcription polymerase chain reaction", "PROBLEM", 136, 183], ["RT-PCR", "TEST", 185, 191], ["negative for", "UNCERTAINTY", 19, 31]]], ["However, the samples tested positive by RT-PCR using primers initially designed to detect the 3\u2032 end of the IBV N gene (Liu et al., 2009).Virus detection and isolation ::: Materials and methodsPhCoVs can replicate and be isolated in embryonated chicken eggs (Cavanagh et al., 2002).", [["samples", "ANATOMY", 13, 20], ["IBV", "ORGANISM", 108, 111], ["Virus", "ORGANISM", 138, 143], ["methodsPhCoVs", "GENE_OR_GENE_PRODUCT", 186, 199], ["chicken", "ORGANISM", 245, 252], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 253, 257], ["3\u2032 end", "DNA", 94, 100], ["IBV N gene", "DNA", 108, 118], ["methodsPhCoVs", "DNA", 186, 199], ["chicken", "SPECIES", 245, 252], ["IBV", "SPECIES", 108, 111], ["chicken", "SPECIES", 245, 252], ["the samples", "TEST", 9, 20], ["primers", "TEST", 53, 60], ["methodsPhCoVs", "TREATMENT", 186, 199]]], ["Therefore, each pooled sample was used to inoculate five 9-day-old embryonated eggs (0.2 mL/egg) via the allantoic route.", [["sample", "ANATOMY", 23, 29], ["eggs", "ANATOMY", 79, 83], ["egg", "ANATOMY", 92, 95], ["eggs", "ORGANISM", 79, 83], ["allantoic route", "MULTI-TISSUE_STRUCTURE", 105, 120], ["embryonated eggs", "TREATMENT", 67, 83], ["the allantoic route", "TREATMENT", 101, 120]]], ["Allantoic fluid was harvested from two inoculated eggs for each pooled sample at 72 h post-inoculation, pooled, and used for virus detection by RT-PCR and direct electron microscopy (Liu and Kong, 2004).", [["Allantoic fluid", "ANATOMY", 0, 15], ["eggs", "ANATOMY", 50, 54], ["sample", "ANATOMY", 71, 77], ["Allantoic fluid", "ORGANISM_SUBSTANCE", 0, 15], ["Allantoic fluid", "TREATMENT", 0, 15], ["each pooled sample", "TEST", 59, 77], ["virus detection", "TEST", 125, 140], ["RT", "TEST", 144, 146], ["PCR", "TEST", 147, 150], ["direct electron microscopy", "TEST", 155, 181], ["fluid", "OBSERVATION", 10, 15]]], ["The remaining three eggs were incubated at 37 \u00b0C, candled daily, and examined for specific lesions at 7 days post-inoculation (dpi).", [["eggs", "ANATOMY", 20, 24], ["lesions", "ANATOMY", 91, 98], ["lesions", "PATHOLOGICAL_FORMATION", 91, 98], ["specific lesions", "PROBLEM", 82, 98], ["lesions", "OBSERVATION", 91, 98]]], ["Further blind passages were performed until embryo dwarfing and death were observed at 2\u20137 dpi.Virus detection and isolation ::: Materials and methodsTwo CoVs were isolated from samples from pheasants from Shandong and Anhui provinces, respectively.", [["embryo", "ANATOMY", 44, 50], ["samples", "ANATOMY", 178, 185], ["death", "DISEASE", 64, 69], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 44, 50], ["Virus", "ORGANISM", 95, 100], ["CoVs", "GENE_OR_GENE_PRODUCT", 154, 158], ["pheasants", "ORGANISM", 191, 200], ["CoVs", "PROTEIN", 154, 158], ["Further blind passages", "TEST", 0, 22], ["embryo dwarfing", "PROBLEM", 44, 59], ["death", "PROBLEM", 64, 69], ["Two CoVs", "PROBLEM", 150, 158]]], ["These PhCoVs were designated \u03b3CoV/ph/China/I0623/17 (I0623/17) and \u03b3CoV/ph/China/I0710/17 (I0710/17), respectively, according to the standard nomenclature adopted for PhCoV isolates in this study (Ducatez and European Union COST Action FA1207, 2016).", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 6, 12], ["\u03b3CoV", "ORGANISM", 29, 33], ["ph", "GENE_OR_GENE_PRODUCT", 34, 36], ["\u03b3CoV", "ORGANISM", 67, 71], ["PhCoVs", "PROTEIN", 6, 12], ["\u03b3CoV/ph/China/I0623/17", "SPECIES", 29, 51], ["\u03b3CoV/ph/China/I0710/17", "SPECIES", 67, 89], ["These PhCoVs", "TEST", 0, 12], ["CoV/ph", "TEST", 30, 36], ["CoV/ph", "TEST", 68, 74], ["PhCoV isolates", "TREATMENT", 167, 181], ["this study", "TEST", 185, 195]]], ["The two PhCoVs were isolated and propagated by inoculating and passaging in the allantoic cavity of 9-day-old SPF embryonated chicken eggs (Liu and Kong, 2004).", [["allantoic cavity", "ANATOMY", 80, 96], ["eggs", "ANATOMY", 134, 138], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 8, 14], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 80, 96], ["SPF", "ORGANISM", 110, 113], ["chicken", "ORGANISM", 126, 133], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 134, 138], ["PhCoVs", "PROTEIN", 8, 14], ["chicken", "SPECIES", 126, 133], ["chicken", "SPECIES", 126, 133], ["the allantoic cavity", "TEST", 76, 96], ["two", "OBSERVATION_MODIFIER", 4, 7], ["PhCoVs", "OBSERVATION", 8, 14], ["allantoic cavity", "ANATOMY", 80, 96]]], ["The allantoic fluids from each passage incubated with isolates I0623/17 and I0710/17 were tested for NDV and AIV by hemagglutination (HA) activity.", [["allantoic fluids", "ANATOMY", 4, 20], ["allantoic fluids", "ORGANISM_SUBSTANCE", 4, 20], ["NDV", "ORGANISM", 101, 104], ["AIV", "ORGANISM", 109, 112], ["NDV", "SPECIES", 101, 104], ["AIV", "SPECIES", 109, 112], ["The allantoic fluids", "TREATMENT", 0, 20], ["isolates", "TEST", 54, 62], ["NDV", "PROBLEM", 101, 104], ["AIV", "PROBLEM", 109, 112], ["allantoic", "OBSERVATION_MODIFIER", 4, 13], ["fluids", "OBSERVATION", 14, 20]]], ["The median titers of isolates I0623/17 and I0710/17 at the final passage (3rd) were 106\u00b76 and 106.2 egg infectious doses (EID50), respectively, determined using the method of Reed and Muench (1938).Detection of antibody against IBV in commercial pheasants ::: Materials and methodsBlood samples were collected from six male (A and C) and six layer hen pheasants (B and D) from each of two affected commercial pheasant flocks in Shandong and Anhui provinces, respectively, approximately 2 months after the disappearance of clinical signs.", [["Blood samples", "ANATOMY", 281, 294], ["IBV", "ORGANISM", 228, 231], ["Blood samples", "ORGANISM_SUBSTANCE", 281, 294], ["pheasants", "ORGANISM", 352, 361], ["B", "CELL", 363, 364], ["hen", "SPECIES", 348, 351], ["IBV", "SPECIES", 228, 231], ["hen pheasants", "SPECIES", 348, 361], ["isolates", "TEST", 21, 29], ["Blood samples", "TEST", 281, 294], ["six layer hen pheasants (B and D)", "TREATMENT", 338, 371], ["clinical signs", "TEST", 522, 536], ["pheasant flocks", "OBSERVATION", 409, 424]]], ["These samples were used for the detection of antibodies against IBV using a commercial enzyme-linked immunosorbent assay (ELISA; IDEXX Corporation, Westbrook, ME, USA) following the manufacturer\u2019s instructions (Liu et al., 2013).", [["samples", "ANATOMY", 6, 13], ["IBV", "ORGANISM", 64, 67], ["antibodies", "PROTEIN", 45, 55], ["IBV", "SPECIES", 64, 67], ["These samples", "TEST", 0, 13], ["the detection", "TEST", 28, 41], ["antibodies", "PROBLEM", 45, 55], ["IBV", "PROBLEM", 64, 67], ["a commercial enzyme", "TEST", 74, 93], ["immunosorbent assay", "TEST", 101, 120]]], ["Blood samples were also collected from an additional six commercial male (E) and six layer pheasants (F) from another flock without clinical signs, from the same farms as the affected commercial pheasant flocks in Shandong province.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["pheasants", "ORGANISM", 91, 100], ["Blood samples", "TEST", 0, 13], ["clinical signs", "TEST", 132, 146], ["pheasant flocks", "OBSERVATION", 195, 210]]], ["None of these birds had received IBV vaccines.RNA extraction, RT-PCR amplification, and sequencing of the complete genome ::: Materials and methodsThe complete genomic RNAs of isolates I0623/17 and I0710/17 were extracted, from the respective infective allantoic fluids using a viral RNA extraction kit (Takara Bio Inc., Shiga, Japan), according to the manufacturer\u2019s instructions.", [["birds", "ORGANISM", 14, 19], ["IBV", "ORGANISM", 33, 36], ["IBV", "SPECIES", 33, 36], ["IBV vaccines", "TREATMENT", 33, 45], ["RNA extraction", "TREATMENT", 46, 60], ["RT-PCR amplification", "TREATMENT", 62, 82], ["isolates", "TEST", 176, 184], ["the respective infective allantoic fluids", "TREATMENT", 228, 269], ["a viral RNA extraction", "TREATMENT", 276, 298], ["genomic RNAs", "OBSERVATION", 160, 172], ["infective", "OBSERVATION_MODIFIER", 243, 252]]], ["We initially amplified the complete genomes of the two PhCoV isolates using 14 pairs of partly overlapping primers, originally used to amplify the complete IBV genome (Liu et al., 2013).", [["IBV", "ORGANISM", 156, 159], ["IBV genome", "DNA", 156, 166], ["IBV", "SPECIES", 156, 159], ["the two PhCoV isolates", "TREATMENT", 47, 69], ["partly overlapping primers", "TREATMENT", 88, 114]]], ["The sense and antisense primers were also used to amplify the 3\u2032 and 5\u2032 ends of the IBV genome (Liu et al., 2013), together with a PrimeScript\u2122 One-Step RT-PCR Kit ver.", [["3\u2032", "GENE_OR_GENE_PRODUCT", 62, 64], ["IBV", "ORGANISM", 84, 87], ["3\u2032 and 5\u2032 ends", "DNA", 62, 76], ["IBV genome", "DNA", 84, 94], ["IBV", "SPECIES", 84, 87], ["antisense primers", "TREATMENT", 14, 31], ["a PrimeScript\u2122 One-Step RT", "TREATMENT", 129, 155]]], ["2 (Takara) and a 3\u2032/5\u2032 RACE kit (Takara), according to the manufacturer\u2019s instructions.", [["a 3\u2032/5\u2032 RACE kit (Takara)", "TREATMENT", 15, 40]]], ["Two pairs of primers and the sense primer for amplifying the 3\u2032 end of the virus genome were then redesigned to replace the previous corresponding primers, which were unable to amplify the gene fragments of isolates I0623/17 and I0710/17.", [["3\u2032 end", "DNA", 61, 67], ["virus genome", "DNA", 75, 87], ["Two pairs of primers", "PROBLEM", 0, 20], ["the sense primer", "TREATMENT", 25, 41], ["the virus genome", "TREATMENT", 71, 87]]], ["All primers used in the following procedures are available on request from the authors.RNA extraction, RT-PCR amplification, and sequencing of the complete genome ::: Materials and methodsThe RT-PCR products were resolved by electrophoresis in 1% agarose gels.", [["agarose", "SIMPLE_CHEMICAL", 247, 254], ["RT-PCR products", "DNA", 192, 207], ["All primers", "TREATMENT", 0, 11], ["RNA extraction", "TREATMENT", 87, 101], ["RT-PCR amplification", "TREATMENT", 103, 123], ["The RT-PCR products", "TREATMENT", 188, 207], ["electrophoresis", "TEST", 225, 240], ["1% agarose gels", "TREATMENT", 244, 259], ["resolved", "OBSERVATION_MODIFIER", 213, 221]]], ["The gel-purified RT-PCR products were subjected to direct sequencing or ligated into the PMD-18 T cloning vector (Takara), following the manufacturer\u2019s instructions.", [["gel-purified RT-PCR products", "DNA", 4, 32], ["PMD-18 T cloning vector", "DNA", 89, 112], ["The gel", "TREATMENT", 0, 7], ["purified RT-PCR products", "TREATMENT", 8, 32]]], ["Three to five clones per amplicon were sequenced to determine the consensus sequence for any given genomic region.", [["consensus sequence", "DNA", 66, 84], ["genomic region", "DNA", 99, 113], ["the consensus sequence", "TEST", 62, 84]]], ["Consensus sequences were assembled from both forward and reverse sequences, edited manually, and corrected on the basis of the different clones of a fragment.", [["fragment", "CELLULAR_COMPONENT", 149, 157], ["forward and reverse sequences", "DNA", 45, 74], ["Consensus sequences", "TEST", 0, 19], ["a fragment", "PROBLEM", 147, 157], ["different clones", "OBSERVATION", 127, 143], ["fragment", "OBSERVATION", 149, 157]]], ["The ORFs and deduced proteins were analyzed using Molecular Evolutionary Genetics Analysis 6.0 (Mega 6.0) (Tamura et al., 2013) and BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium), by comparison with the complete genomic sequences of IBV LX4 (GenBank accession numberAY338732) and H120 (FJ888351) strains, and TCoV TCoV-ATCC (EU022526) and TCoV/TX-GL/01 (GQ427174) strains.", [["IBV", "ORGANISM", 243, 246], ["TCoV TCoV-ATCC", "CELL", 319, 333], ["TCoV/TX-GL/01", "CELL", 349, 362], ["ORFs", "DNA", 4, 8], ["IBV LX4", "SPECIES", 243, 250], ["TCoV TCoV-ATCC", "SPECIES", 319, 333], ["TCoV/TX-GL/01", "SPECIES", 349, 362], ["The ORFs", "TEST", 0, 8], ["deduced proteins", "TEST", 13, 29], ["Analysis", "TEST", 82, 90], ["Mega", "TEST", 96, 100], ["Tamura et al.", "TEST", 107, 120], ["BioNumerics", "TEST", 132, 143], ["Maths", "TEST", 153, 158], ["H120", "TEST", 290, 294], ["strains", "TEST", 306, 313], ["TCoV", "TEST", 319, 323], ["ATCC", "TEST", 329, 333], ["TCoV", "TEST", 349, 353], ["TX", "TEST", 354, 356], ["strains", "PROBLEM", 374, 381]]], ["The sequences reported here have been deposited with the public access GenBank database (www.ncbi.nlm.nih.gov/genbank/).", [["The sequences", "TEST", 0, 13]]], ["The accession numbers of isolates I0623/17 and I0710/17 are MK423877 and MK423876, respectively.S1 gene/fragment analysis ::: Materials and methodsPhylogenetic trees were constructed by aligning sequences using the Clustal W multiple alignment algorithm and the maximum likelihood method with 1000 bootstrap replicates, employing the Kimura 2-parameter and nucleotide substitution model.", [["MK423877", "CHEMICAL", 60, 68], ["MK423876", "CHEMICAL", 73, 81], ["nucleotide", "CHEMICAL", 357, 367], ["MK423877", "CHEMICAL", 60, 68], ["MK423876", "CHEMICAL", 73, 81], ["nucleotide", "CHEMICAL", 357, 367], ["S1", "GENE_OR_GENE_PRODUCT", 96, 98], ["S1 gene", "DNA", 96, 103], ["isolates", "TEST", 25, 33], ["fragment analysis", "TEST", 104, 121], ["aligning sequences", "TEST", 186, 204], ["the Clustal W multiple alignment algorithm", "TREATMENT", 211, 253], ["nucleotide substitution model", "TREATMENT", 357, 386], ["fragment", "OBSERVATION", 104, 112]]], ["The S1 gene sequences of 213 reference AvCoV strains were used for phylogenetic analysis, together with those of the two new isolates I0623/17 and I0710/17.", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S1 gene sequences", "DNA", 4, 21], ["The S1 gene sequences", "TEST", 0, 21], ["AvCoV strains", "PROBLEM", 39, 52], ["phylogenetic analysis", "TEST", 67, 88]]], ["The 213 viruses included 199 reference IBV strains reported by Valastro et al. (2016), three IBV GI-28 strains (Chen et al., 2017), three IBV GI-29 strains (Jiang et al., 2018), two IBV GVII-1 strains (Ma et al., 2019), two additional IBV GI-19 strains, ck/CH/LDL/091022 (LDL/091022) (Liu et al., 2013) and ck/CH/LJL/140734 (LJL/140734) (Zhao et al., 2017) which were used the virus-neutralization (VN) test, three TCoVs and one guinea fowl CoV (Brown et al., 2016).S1 gene/fragment analysis ::: Materials and methodsNine nucleotide sequences of S1 gene fragments of PhCoVs were retrieved from the GenBank database.", [["LJL/140734", "CHEMICAL", 325, 335], ["nucleotide", "CHEMICAL", 522, 532], ["IBV", "ORGANISM", 39, 42], ["IBV GI-28", "ORGANISM", 93, 102], ["IBV GI-29 strains", "ORGANISM", 138, 155], ["IBV", "ORGANISM", 182, 185], ["GVII-1", "ORGANISM", 186, 192], ["IBV", "ORGANISM", 235, 238], ["GI-19 strains", "ORGANISM", 239, 252], ["ck/CH/LDL/091022", "ORGANISM", 254, 270], ["guinea fowl CoV", "ORGANISM", 429, 444], ["S1", "GENE_OR_GENE_PRODUCT", 466, 468], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 567, 573], ["S1 gene", "DNA", 466, 473], ["S1 gene fragments", "DNA", 546, 563], ["PhCoVs", "DNA", 567, 573], ["guinea fowl CoV", "SPECIES", 429, 444], ["IBV", "SPECIES", 39, 42], ["IBV GI-28", "SPECIES", 93, 102], ["IBV GI-29", "SPECIES", 138, 147], ["IBV GVII-1", "SPECIES", 182, 192], ["IBV GI-19 strains, ck/CH/LDL/091022 (LDL/091022)", "SPECIES", 235, 283], ["ck/CH/LJL/140734 (LJL/140734)", "SPECIES", 307, 336], ["guinea fowl CoV", "SPECIES", 429, 444], ["IBV strains", "TEST", 39, 50], ["two IBV GVII", "TEST", 178, 190], ["additional IBV GI", "TEST", 224, 241], ["strains", "TEST", 245, 252], ["ck/CH", "TEST", 254, 259], ["LDL", "TEST", 260, 263], ["LDL", "TEST", 272, 275], ["Liu et al.", "TEST", 285, 295], ["ck/CH", "TEST", 307, 312], ["LJL", "TEST", 313, 316], ["LJL", "TEST", 325, 328], ["test", "TEST", 403, 407], ["fragment analysis", "TEST", 474, 491], ["Nine nucleotide sequences", "TEST", 517, 542], ["S1 gene fragments of PhCoVs", "PROBLEM", 546, 573], ["fragment", "OBSERVATION", 474, 482], ["fragments", "OBSERVATION_MODIFIER", 554, 563]]], ["The sequence fragments were then submitted to a BLAST search in the NCBI database to identify homologous sequences.", [["The sequence fragments", "PROBLEM", 0, 22], ["a BLAST search", "TEST", 46, 60]]], ["Six sequences of IBV strains that showed relatively close genetic relationships with the nine PhCoVs were selected for phylogenetic analysis and sequence alignment by comparison with our two isolates, eight GI-19 strains, and three GI-18 strains.", [["IBV", "ORGANISM", 17, 20], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 94, 100], ["GI-19", "ORGANISM", 207, 212], ["GI-18 strains", "ORGANISM", 232, 245], ["PhCoVs", "DNA", 94, 100], ["IBV", "SPECIES", 17, 20], ["Six sequences", "TEST", 0, 13], ["IBV strains", "TEST", 17, 28], ["phylogenetic analysis", "TEST", 119, 140], ["sequence alignment", "TEST", 145, 163], ["eight GI", "TEST", 201, 209]]], ["Similarly, 16 nucleotide sequences of 3\u2032 UTR fragments of PhCoVs were retrieved from the GenBank database and compared phylogenetically with 44 corresponding sequences from 43 IBV strains and one duck CoV, selected based on the results of phylogenetic analysis of the complete genomes.Comparison of complete genomes ::: Materials and methodsThe complete genomic sequences of PhCoV isolates I0623/17 and I0710/17 were compared with those of 84 IBV strains and one duck CoV (as an outgroup) from the GenBank database, representing sequences of IBV strains from all continents and each lineage.", [["nucleotide", "CHEMICAL", 14, 24], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 58, 64], ["IBV", "ORGANISM", 176, 179], ["duck CoV", "ORGANISM", 196, 204], ["IBV", "ORGANISM", 443, 446], ["duck CoV", "ORGANISM", 463, 471], ["IBV", "ORGANISM", 542, 545], ["16 nucleotide sequences", "DNA", 11, 34], ["3\u2032 UTR fragments", "DNA", 38, 54], ["PhCoVs", "DNA", 58, 64], ["duck CoV", "SPECIES", 196, 204], ["duck CoV", "SPECIES", 463, 471], ["IBV", "SPECIES", 176, 179], ["duck CoV", "SPECIES", 196, 204], ["IBV", "SPECIES", 443, 446], ["duck CoV", "SPECIES", 463, 471], ["IBV", "SPECIES", 542, 545], ["16 nucleotide sequences", "TEST", 11, 34], ["UTR fragments of PhCoVs", "PROBLEM", 41, 64], ["the GenBank database", "TEST", 85, 105], ["IBV strains", "TEST", 176, 187], ["one duck CoV", "TEST", 192, 204], ["phylogenetic analysis", "TEST", 239, 260], ["PhCoV isolates", "TEST", 375, 389], ["84 IBV strains", "PROBLEM", 440, 454], ["the GenBank database", "TEST", 494, 514], ["IBV strains", "PROBLEM", 542, 553], ["IBV strains", "OBSERVATION", 542, 553]]], ["In addition, the complete genomic sequence of isolate I0623/17 was compared with 39 IBV strains and one duck CoV from the GenBank database, which selected on the basis of the results of phylogenetic analysis of the complete genome, using Similarity Plot (SimPlot) version 3.5.1 (http://sray.med.som.jhmi.edu/SCRopftware/simplot/) to analyze possible recombination events.", [["IBV", "ORGANISM", 84, 87], ["duck CoV", "ORGANISM", 104, 112], ["duck", "SPECIES", 104, 108], ["IBV", "SPECIES", 84, 87], ["duck CoV", "SPECIES", 104, 112], ["39 IBV strains", "PROBLEM", 81, 95], ["the GenBank database", "TEST", 118, 138], ["phylogenetic analysis", "TEST", 186, 207], ["Similarity Plot", "TEST", 238, 253], ["recombination events", "PROBLEM", 350, 370]]], ["The PhCoV isolate I0710/17 was used as a query virus.", [["I0710/17", "CHEMICAL", 18, 26], ["The PhCoV isolate", "TREATMENT", 0, 17], ["a query virus", "PROBLEM", 39, 52]]], ["The window width and step size were set to 1000 bp and 50 bp, respectively.Virus cross-neutralization test ::: Materials and methodsIn addition to the two isolates I0623/17 and I0710/17 in this study, three additional IBV strains, LDL/091022, LJL/140734, and H120, were also used in the VN test.", [["Virus", "ORGANISM", 75, 80], ["IBV", "ORGANISM", 218, 221], ["LDL/091022", "CELL", 231, 241], ["LJL/140734", "CELL", 243, 253], ["IBV", "SPECIES", 218, 221], ["LDL/091022, LJL/140734", "SPECIES", 231, 253], ["bp", "TEST", 48, 50], ["bp", "TEST", 58, 60], ["Virus cross-neutralization test", "TEST", 75, 106], ["this study", "TEST", 189, 199], ["three additional IBV strains", "TEST", 201, 229], ["LDL", "TEST", 231, 234], ["LJL", "TEST", 243, 246], ["H120", "TEST", 259, 263], ["the VN test", "TEST", 283, 294], ["size", "OBSERVATION_MODIFIER", 26, 30]]], ["LDL/091022 and LJL/140734 were selected because they were genetically related to isolates I0623/17 and I0710/17 based on the phylogenetic trees using both S1 gene/fragment and complete genome sequences.", [["LDL/091022", "CHEMICAL", 0, 10], ["LJL/140734", "CHEMICAL", 15, 25], ["LDL", "GENE_OR_GENE_PRODUCT", 0, 3], ["LJL/140734", "GENE_OR_GENE_PRODUCT", 15, 25], ["S1 gene", "DNA", 155, 162], ["complete genome sequences", "DNA", 176, 201], ["LDL", "TEST", 0, 3], ["LJL", "TEST", 15, 18], ["isolates", "TEST", 81, 89], ["fragment", "PROBLEM", 163, 171], ["fragment", "OBSERVATION", 163, 171]]], ["The H120 vaccine was used because it was commonly employed in chicken flocks in China, and was also used for vaccination of some commercial pheasant flocks in China; the H120 vaccine was not used in the affected pheasant flocks in this study.", [["H120", "CHEMICAL", 4, 8], ["H120", "CHEMICAL", 170, 174], ["chicken", "ORGANISM", 62, 69], ["pheasant", "ORGANISM", 212, 220], ["chicken", "SPECIES", 62, 69], ["chicken", "SPECIES", 62, 69], ["H120", "SPECIES", 170, 174], ["The H120 vaccine", "TREATMENT", 0, 16], ["vaccination", "TREATMENT", 109, 120], ["some commercial pheasant flocks", "TREATMENT", 124, 155], ["the H120 vaccine", "TREATMENT", 166, 182], ["this study", "TEST", 231, 241]]], ["Relatedness values according to the Archetti and Horsfall method (1950) range from 0 for viruses that are antigenically unrelated to 100% for isolates that are identical.", [["Relatedness values", "PROBLEM", 0, 18], ["viruses", "PROBLEM", 89, 96], ["isolates", "PROBLEM", 142, 150]]], ["This method for assessing the antigenic relatedness of IBV means that viruses of the same serotype may have relatedness values ranging from 50%\u2013100%, whereas viruses of a different serotype typically have relatedness values ranging from 0%\u201320% (Archetti and Horsfall, 1950).Virus cross-neutralization test ::: Materials and methodsSera against the five virus strains were prepared as described previously (Guo et al., 2014).", [["IBV", "ORGANISM", 55, 58], ["Virus", "ORGANISM", 274, 279], ["Sera", "ORGANISM_SUBSTANCE", 331, 335], ["IBV", "SPECIES", 55, 58], ["This method", "TREATMENT", 0, 11], ["IBV", "PROBLEM", 55, 58], ["the same serotype", "PROBLEM", 81, 98], ["a different serotype", "PROBLEM", 169, 189], ["Virus cross-neutralization test", "TEST", 274, 305], ["methodsSera", "TEST", 324, 335], ["the five virus strains", "PROBLEM", 344, 366]]], ["For VN, sera were serially diluted two-fold with sterile phosphate-buffered saline and mixed with 100 EID50 of the virus strains.", [["sera", "ANATOMY", 8, 12], ["phosphate", "CHEMICAL", 57, 66], ["phosphate", "CHEMICAL", 57, 66], ["sera", "ORGANISM_SUBSTANCE", 8, 12], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 57, 82], ["VN", "PROTEIN", 4, 6], ["sera", "TEST", 8, 12], ["sterile phosphate-buffered saline", "TREATMENT", 49, 82], ["the virus strains", "TREATMENT", 111, 128]]], ["After incubation for 1 h at 37 \u00b0C, virus-serum mixtures were inoculated into the allantoic cavity of SPF chicken embryos and observed for 7 days.", [["serum", "ANATOMY", 41, 46], ["allantoic cavity", "ANATOMY", 81, 97], ["embryos", "ANATOMY", 113, 120], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 81, 97], ["chicken", "ORGANISM", 105, 112], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 113, 120], ["chicken", "SPECIES", 105, 112], ["SPF", "SPECIES", 101, 104], ["chicken", "SPECIES", 105, 112], ["virus", "PROBLEM", 35, 40], ["serum mixtures", "TEST", 41, 55], ["SPF chicken embryos", "TREATMENT", 101, 120], ["allantoic cavity", "ANATOMY", 81, 97], ["SPF chicken embryos", "OBSERVATION", 101, 120]]], ["Virus replication was determined by the appearance of typical lesions in the inoculated eggs, and by amplification of the IBV N gene from allantoic fluid by RT-PCR (Liu et al., 2009).", [["lesions", "ANATOMY", 62, 69], ["eggs", "ANATOMY", 88, 92], ["allantoic fluid", "ANATOMY", 138, 153], ["Virus", "ORGANISM", 0, 5], ["lesions", "PATHOLOGICAL_FORMATION", 62, 69], ["IBV", "ORGANISM", 122, 125], ["allantoic fluid", "ORGANISM_SUBSTANCE", 138, 153], ["IBV N gene", "DNA", 122, 132], ["IBV", "SPECIES", 122, 125], ["Virus replication", "TREATMENT", 0, 17], ["typical lesions", "PROBLEM", 54, 69], ["the inoculated eggs", "PROBLEM", 73, 92], ["the IBV N gene", "TREATMENT", 118, 132], ["allantoic fluid", "TEST", 138, 153], ["typical", "OBSERVATION_MODIFIER", 54, 61], ["lesions", "OBSERVATION", 62, 69], ["inoculated eggs", "ANATOMY", 77, 92]]], ["The tests were performed in the presence of appropriate controls.", [["The tests", "TEST", 0, 9]]], ["The end-point titer of each serum sample and the antigenic relatedness values were calculated using the method of Reed and Muench (1938).Virus cross-neutralization test ::: Materials and methodsIn addition, an aliquot of each serum from male and layer hens from each commercial pheasant flock was pooled and tested for PhCoV antibodies by VN, using I0623/17 virus.Chicks ::: Experimental design ::: Materials and methodsA total of 135 1-day-old SPF chicks were divided randomly into nine groups and kept in separate isolation units, with 15 chicks per group (Table 1).", [["serum sample", "ANATOMY", 28, 40], ["serum", "ANATOMY", 226, 231], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["Virus", "ORGANISM", 137, 142], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["hens", "ORGANISM", 252, 256], ["pheasant", "ORGANISM", 278, 286], ["PhCoV antibodies", "GENE_OR_GENE_PRODUCT", 319, 335], ["VN", "GENE_OR_GENE_PRODUCT", 339, 341], ["I0623/17 virus", "ORGANISM", 349, 363], ["Chicks", "ORGANISM", 364, 370], ["SPF", "ORGANISM", 445, 448], ["chicks", "ORGANISM", 449, 455], ["PhCoV antibodies", "PROTEIN", 319, 335], ["VN", "PROTEIN", 339, 341], ["pheasant", "SPECIES", 278, 286], ["Chicks", "SPECIES", 364, 370], ["chicks", "SPECIES", 449, 455], ["PhCoV", "SPECIES", 319, 324], ["I0623/17 virus", "SPECIES", 349, 363], ["each serum sample", "TEST", 23, 40], ["the antigenic relatedness values", "TEST", 45, 77], ["Virus cross-neutralization test", "TEST", 137, 168], ["each commercial pheasant flock", "TREATMENT", 262, 292], ["PhCoV antibodies", "PROBLEM", 319, 335], ["Materials", "TEST", 399, 408], ["methodsA", "TEST", 413, 421], ["old SPF chicks", "TREATMENT", 441, 455]]], ["Chickens in groups 1, 4, and 7 were administered 0.1 ml of 105.0 EID50 of the isolate I0623/17 via the ocular and nasal routes at 1, 30, and 45 day(s) of age, respectively.", [["ocular", "ANATOMY", 103, 109], ["nasal", "ANATOMY", 114, 119], ["Chickens", "ORGANISM", 0, 8], ["ocular", "ORGAN", 103, 109], ["Chickens", "SPECIES", 0, 8], ["Chickens in groups", "TREATMENT", 0, 18], ["the isolate", "TREATMENT", 74, 85], ["ocular", "ANATOMY", 103, 109], ["nasal", "ANATOMY", 114, 119]]], ["Chickens in groups 2, 5, and 8 were administered 0.1 ml of 105.0 EID50 of the isolate I0710/17 via the ocular and nasal routes at 1, 30, and 45 day(s) of age, respectively.", [["ocular", "ANATOMY", 103, 109], ["nasal", "ANATOMY", 114, 119], ["I0710/17", "CHEMICAL", 86, 94], ["Chickens", "ORGANISM", 0, 8], ["ocular", "ORGAN", 103, 109], ["Chickens", "SPECIES", 0, 8], ["Chickens in groups", "TREATMENT", 0, 18], ["the isolate", "TREATMENT", 74, 85], ["ocular", "ANATOMY", 103, 109], ["nasal", "ANATOMY", 114, 119]]], ["Chickens in groups 3, 6, and 9 were administered the same amount of sterilized allantoic fluid at the corresponding ages, as negative controls.", [["allantoic fluid", "ANATOMY", 79, 94], ["Chickens", "ORGANISM", 0, 8], ["allantoic fluid", "ORGANISM_SUBSTANCE", 79, 94], ["Chickens", "SPECIES", 0, 8], ["Chickens in groups", "TREATMENT", 0, 18], ["sterilized allantoic fluid", "TREATMENT", 68, 94], ["allantoic fluid", "OBSERVATION", 79, 94]]], ["Five chickens from each inoculated and control group were euthanized at 5 dpi, and trachea, lung, proventriculus, kidney, and cecal tonsil tissues were separated from the surrounding tissue, removed aseptically, and used for virus titration, as described previously (Liu et al., 2009).", [["trachea", "ANATOMY", 83, 90], ["lung", "ANATOMY", 92, 96], ["proventriculus", "ANATOMY", 98, 112], ["kidney", "ANATOMY", 114, 120], ["cecal tonsil tissues", "ANATOMY", 126, 146], ["tissue", "ANATOMY", 183, 189], ["aseptically", "ANATOMY", 199, 210], ["chickens", "ORGANISM", 5, 13], ["trachea", "MULTI-TISSUE_STRUCTURE", 83, 90], ["lung", "ORGAN", 92, 96], ["proventriculus", "ORGAN", 98, 112], ["kidney", "ORGAN", 114, 120], ["cecal tonsil tissues", "TISSUE", 126, 146], ["tissue", "TISSUE", 183, 189], ["chickens", "SPECIES", 5, 13], ["chickens", "SPECIES", 5, 13], ["Five chickens", "TREATMENT", 0, 13], ["trachea, lung, proventriculus, kidney, and cecal tonsil tissues", "PROBLEM", 83, 146], ["virus titration", "TREATMENT", 225, 240], ["chickens", "OBSERVATION", 5, 13], ["trachea", "ANATOMY", 83, 90], ["lung", "ANATOMY", 92, 96], ["proventriculus", "ANATOMY_MODIFIER", 98, 112], ["kidney", "ANATOMY", 114, 120], ["cecal tonsil", "ANATOMY", 126, 138], ["surrounding tissue", "ANATOMY", 171, 189]]], ["Trachea and kidney tissue samples were used for the detection of IBV antigen using immunohistochemistry (IHC) with the monoclonal antibody, 6D10 directed against the N protein, as described previously (Han et al., 2013, 2016).", [["Trachea", "ANATOMY", 0, 7], ["kidney tissue samples", "ANATOMY", 12, 33], ["Trachea", "TISSUE", 0, 7], ["kidney tissue samples", "TISSUE", 12, 33], ["IBV", "ORGANISM", 65, 68], ["IBV antigen", "PROTEIN", 65, 76], ["monoclonal antibody", "PROTEIN", 119, 138], ["6D10", "PROTEIN", 140, 144], ["N protein", "PROTEIN", 166, 175], ["IBV", "SPECIES", 65, 68], ["Trachea and kidney tissue samples", "TEST", 0, 33], ["the detection", "TEST", 48, 61], ["IBV antigen", "TEST", 65, 76], ["immunohistochemistry", "TEST", 83, 103], ["the monoclonal antibody", "TREATMENT", 115, 138], ["kidney", "ANATOMY", 12, 18]]], ["The remaining chicks were examined daily for signs of infection for another 25 days after inoculation.", [["infection", "DISEASE", 54, 63], ["chicks", "ORGANISM", 14, 20], ["chicks", "SPECIES", 14, 20], ["infection", "PROBLEM", 54, 63], ["inoculation", "PROBLEM", 90, 101], ["infection", "OBSERVATION", 54, 63]]], ["Signs, such as eye irritation and/or scratching of the inoculated eye, lethargy, mild coughing, and/or \u2018snicking\u2019, were monitored daily for a period of 30 days.", [["eye", "ANATOMY", 15, 18], ["eye", "ANATOMY", 66, 69], ["eye irritation", "DISEASE", 15, 29], ["scratching of the inoculated eye", "DISEASE", 37, 69], ["lethargy", "DISEASE", 71, 79], ["coughing", "DISEASE", 86, 94], ["eye", "ORGAN", 15, 18], ["eye", "ORGAN", 66, 69], ["Signs", "PROBLEM", 0, 5], ["eye irritation", "PROBLEM", 15, 29], ["scratching of the inoculated eye", "PROBLEM", 37, 69], ["lethargy", "PROBLEM", 71, 79], ["mild coughing", "PROBLEM", 81, 94], ["eye", "ANATOMY", 15, 18], ["irritation", "OBSERVATION", 19, 29], ["inoculated eye", "ANATOMY", 55, 69], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["coughing", "OBSERVATION", 86, 94]]], ["Blood samples and oropharyngeal and cloacal swabs were collected from the birds in each group at 4, 8, 12, 16, 20, 24, and 28 dpi.", [["Blood samples", "ANATOMY", 0, 13], ["oropharyngeal", "ANATOMY", 18, 31], ["cloacal swabs", "ANATOMY", 36, 49], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["oropharyngeal", "ORGANISM_SUBDIVISION", 18, 31], ["cloacal swabs", "ORGANISM_SUBSTANCE", 36, 49], ["birds", "ORGANISM", 74, 79], ["Blood samples", "TEST", 0, 13], ["oropharyngeal and cloacal swabs", "TEST", 18, 49], ["oropharyngeal", "ANATOMY", 18, 31]]], ["The blood samples were used for antibody detection (ELISA; IDEXX Corporation).", [["blood samples", "ANATOMY", 4, 17], ["blood samples", "ORGANISM_SUBSTANCE", 4, 17], ["The blood samples", "TEST", 0, 17], ["antibody detection", "TEST", 32, 50]]], ["The oropharyngeal and cloacal swabs were used for virus recovery in 9-day-old SPF chicken eggs (Liu and Kong, 2004).Commercial pheasants ::: Experimental design ::: Materials and methodsA total of 35 1-day-old commercial pheasants were used in the present study.", [["oropharyngeal", "ANATOMY", 4, 17], ["cloacal swabs", "ANATOMY", 22, 35], ["eggs", "ANATOMY", 90, 94], ["oropharyngeal", "ORGANISM_SUBDIVISION", 4, 17], ["cloacal swabs", "ORGANISM_SUBSTANCE", 22, 35], ["SPF", "ORGANISM", 78, 81], ["chicken", "ORGANISM", 82, 89], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 90, 94], ["pheasants", "ORGANISM", 127, 136], ["pheasants", "ORGANISM", 221, 230], ["chicken", "SPECIES", 82, 89], ["chicken", "SPECIES", 82, 89], ["The oropharyngeal and cloacal swabs", "TREATMENT", 0, 35], ["virus recovery", "TREATMENT", 50, 64], ["old commercial pheasants", "TREATMENT", 206, 230], ["the present study", "TEST", 244, 261], ["oropharyngeal", "ANATOMY", 4, 17]]], ["The birds were housed in isolators under negative pressure 1 week before experimental infection (Table 1).", [["infection", "DISEASE", 86, 95], ["birds", "ORGANISM", 4, 9], ["experimental infection", "PROBLEM", 73, 95], ["infection", "OBSERVATION", 86, 95]]], ["Blood samples were collected from all the birds at 5, 10, 15, 20, 25, 30, 35 and 40 days of age and used for IBV-specific antibody detection (ELISA; IDEXX Corporation).", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["birds", "ORGANISM", 42, 47], ["IBV", "ORGANISM", 109, 112], ["IBV", "SPECIES", 109, 112], ["Blood samples", "TEST", 0, 13], ["IBV", "TEST", 109, 112], ["specific antibody detection", "TEST", 113, 140]]], ["The IBV-specific antibodies had not been detected until 40 days of age.", [["IBV", "ORGANISM", 4, 7], ["IBV-specific antibodies", "PROTEIN", 4, 27], ["IBV", "SPECIES", 4, 7], ["The IBV-specific antibodies", "TEST", 0, 27]]], ["Five birds were selected randomly and euthanized at 40 days, and examined carefully for lesions in each of the tissues and organs.", [["lesions", "ANATOMY", 88, 95], ["tissues", "ANATOMY", 111, 118], ["organs", "ANATOMY", 123, 129], ["birds", "ORGANISM", 5, 10], ["lesions", "PATHOLOGICAL_FORMATION", 88, 95], ["tissues", "TISSUE", 111, 118], ["organs", "ORGAN", 123, 129], ["lesions", "PROBLEM", 88, 95], ["lesions", "OBSERVATION", 88, 95], ["tissues", "ANATOMY", 111, 118], ["organs", "ANATOMY", 123, 129]]], ["Trachea, lung, kidney, digestive tract, liver, oviduct, spleen, and bursa of Fabricius tissue samples were collected and examined by histopathology to confirm that the birds used in the study were clinically healthy.", [["Trachea", "ANATOMY", 0, 7], ["lung", "ANATOMY", 9, 13], ["kidney", "ANATOMY", 15, 21], ["digestive tract", "ANATOMY", 23, 38], ["liver", "ANATOMY", 40, 45], ["oviduct", "ANATOMY", 47, 54], ["spleen", "ANATOMY", 56, 62], ["bursa", "ANATOMY", 68, 73], ["Fabricius tissue samples", "ANATOMY", 77, 101], ["Trachea", "MULTI-TISSUE_STRUCTURE", 0, 7], ["lung", "ORGAN", 9, 13], ["kidney", "ORGAN", 15, 21], ["digestive tract", "ORGAN", 23, 38], ["liver", "ORGAN", 40, 45], ["oviduct", "ORGAN", 47, 54], ["spleen", "ORGAN", 56, 62], ["bursa", "ORGAN", 68, 73], ["Fabricius tissue samples", "TISSUE", 77, 101], ["birds", "ORGANISM", 168, 173], ["the study", "TEST", 182, 191], ["lung", "ANATOMY", 9, 13], ["kidney", "ANATOMY", 15, 21], ["digestive tract", "ANATOMY", 23, 38], ["liver", "ANATOMY", 40, 45], ["oviduct", "ANATOMY", 47, 54], ["spleen", "ANATOMY", 56, 62], ["bursa", "ANATOMY", 68, 73], ["Fabricius tissue", "ANATOMY", 77, 93]]], ["The samples tested for RT-PCR and PCR were processed differently and NDV (Gohm et al., 2000), IBV (Liu et al., 2009), the AIV subtypes H5, H7, and H9 (Chaharaein et al., 2009) and avian metapneumovirus (Cavanagh et al., 1999) were tested by RT-PCR, and fowl adenovirus (Li et al., 2016), Mycoplasma synoviae (MS), and Mycoplasma galliscepticum (MG) (Moscoso et al., 2004) were tested by PCR using the collected samples.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 411, 418], ["avian metapneumovirus", "DISEASE", 180, 201], ["Mycoplasma synoviae", "DISEASE", 288, 307], ["Mycoplasma galliscepticum", "DISEASE", 318, 343], ["NDV", "ORGANISM", 69, 72], ["IBV", "ORGANISM", 94, 97], ["AIV subtypes H5", "ORGANISM", 122, 137], ["H7", "ORGANISM", 139, 141], ["H9", "CELL", 147, 149], ["avian metapneumovirus", "ORGANISM", 180, 201], ["fowl adenovirus", "ORGANISM", 253, 268], ["Mycoplasma synoviae", "ORGANISM", 288, 307], ["Mycoplasma galliscepticum", "ORGANISM", 318, 343], ["avian metapneumovirus", "SPECIES", 180, 201], ["fowl", "SPECIES", 253, 257], ["Mycoplasma synoviae", "SPECIES", 288, 307], ["Mycoplasma galliscepticum", "SPECIES", 318, 343], ["NDV", "SPECIES", 69, 72], ["IBV", "SPECIES", 94, 97], ["fowl adenovirus", "SPECIES", 253, 268], ["Mycoplasma synoviae", "SPECIES", 288, 307], ["Mycoplasma galliscepticum", "SPECIES", 318, 343], ["The samples", "TEST", 0, 11], ["RT-PCR", "TEST", 23, 29], ["PCR", "TEST", 34, 37], ["the AIV subtypes H5", "PROBLEM", 118, 137], ["H7", "PROBLEM", 139, 141], ["avian metapneumovirus", "PROBLEM", 180, 201], ["RT", "TEST", 241, 243], ["PCR", "TEST", 244, 247], ["fowl adenovirus", "TEST", 253, 268], ["Li et al.", "TEST", 270, 279], ["Mycoplasma synoviae (MS)", "PROBLEM", 288, 312], ["Mycoplasma galliscepticum", "PROBLEM", 318, 343], ["the collected samples", "TEST", 397, 418], ["metapneumovirus", "OBSERVATION", 186, 201], ["Mycoplasma synoviae", "ANATOMY", 288, 307]]], ["The birds were shown to be free of these pathogen infections (data not shown).", [["pathogen infections", "DISEASE", 41, 60], ["birds", "ORGANISM", 4, 9], ["these pathogen infections", "PROBLEM", 35, 60], ["pathogen", "OBSERVATION_MODIFIER", 41, 49], ["infections", "OBSERVATION", 50, 60]]], ["Blood samples were collected from the remaining 30 birds.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["None of them had NDV- or AIV H5-, H7-, or H9-specific HI antibodies at 40 days of age, and none had antibodies against infectious bursal disease virus, avian leukosis virus, reticuloendotheliosis virus, chicken infectious anemia virus, fowl adenovirus, MS, or MG according to ELISAs (IDEXX Corporation).", [["infectious bursal disease", "DISEASE", 119, 144], ["avian leukosis", "DISEASE", 152, 166], ["infectious anemia", "DISEASE", 211, 228], ["MS", "DISEASE", 253, 255], ["MG", "DISEASE", 260, 262], ["NDV", "ORGANISM", 17, 20], ["AIV H5", "ORGANISM", 25, 31], ["H7", "ORGANISM", 34, 36], ["H9", "CELL", 42, 44], ["HI", "ORGANISM", 54, 56], ["infectious bursal disease virus", "ORGANISM", 119, 150], ["avian leukosis virus", "ORGANISM", 152, 172], ["reticuloendotheliosis virus", "ORGANISM", 174, 201], ["chicken infectious anemia virus", "ORGANISM", 203, 234], ["fowl adenovirus", "ORGANISM", 236, 251], ["HI antibodies", "PROTEIN", 54, 67], ["antibodies", "PROTEIN", 100, 110], ["infectious bursal disease virus", "SPECIES", 119, 150], ["avian leukosis virus", "SPECIES", 152, 172], ["reticuloendotheliosis virus", "SPECIES", 174, 201], ["chicken infectious anemia virus", "SPECIES", 203, 234], ["fowl", "SPECIES", 236, 240], ["NDV", "SPECIES", 17, 20], ["AIV", "SPECIES", 25, 28], ["infectious bursal disease virus", "SPECIES", 119, 150], ["avian leukosis virus", "SPECIES", 152, 172], ["reticuloendotheliosis virus", "SPECIES", 174, 201], ["chicken infectious anemia virus", "SPECIES", 203, 234], ["fowl adenovirus", "SPECIES", 236, 251], ["NDV", "PROBLEM", 17, 20], ["AIV H5", "PROBLEM", 25, 31], ["H7", "PROBLEM", 34, 36], ["H9", "PROBLEM", 42, 44], ["specific HI antibodies", "PROBLEM", 45, 67], ["antibodies", "TREATMENT", 100, 110], ["infectious bursal disease virus", "PROBLEM", 119, 150], ["avian leukosis virus", "PROBLEM", 152, 172], ["reticuloendotheliosis virus", "PROBLEM", 174, 201], ["chicken infectious anemia virus", "PROBLEM", 203, 234], ["fowl adenovirus", "PROBLEM", 236, 251], ["MS", "PROBLEM", 253, 255], ["MG", "TREATMENT", 260, 262], ["leukosis virus", "OBSERVATION", 158, 172], ["reticuloendotheliosis virus", "OBSERVATION", 174, 201]]], ["Then, the flock\u2019s health status was observed for another 5 days before the experiments were performed.Commercial pheasants ::: Experimental design ::: Materials and methodsThirty commercial pheasants were divided randomly into two groups of 15 birds per group.", [["pheasants", "ORGANISM", 113, 122], ["pheasants", "ORGANISM", 190, 199], ["birds", "ORGANISM", 244, 249], ["Thirty commercial pheasants", "TREATMENT", 172, 199]]], ["Isolate I0710/17 was selected to infect the pheasants in this study because it had the lower rate of virus replication than that of isolate I0623/17 in chickens based on the results of infection to SPF chickens.", [["infection", "DISEASE", 185, 194], ["pheasants", "ORGANISM", 44, 53], ["chickens", "ORGANISM", 152, 160], ["SPF chickens", "ORGANISM", 198, 210], ["chickens", "SPECIES", 152, 160], ["chickens", "SPECIES", 202, 210], ["chickens", "SPECIES", 152, 160], ["SPF", "SPECIES", 198, 201], ["chickens", "SPECIES", 202, 210], ["this study", "TEST", 57, 67], ["virus replication", "TREATMENT", 101, 118], ["infection", "PROBLEM", 185, 194], ["infection", "OBSERVATION", 185, 194]]], ["Birds in group 1 were administered 0.1 ml of 105.0 EID50 of the isolate I0710/17 via the ocular and nasal routes at 45 days of age.", [["ocular", "ANATOMY", 89, 95], ["nasal", "ANATOMY", 100, 105], ["I0710/17", "CHEMICAL", 72, 80], ["ocular", "ORGAN", 89, 95], ["the isolate", "TREATMENT", 60, 71], ["ocular", "ANATOMY", 89, 95], ["nasal", "ANATOMY", 100, 105]]], ["Birds in group 2 were administered the same amount of sterilized allantoic fluid at the same age, as a negative control.", [["allantoic fluid", "ANATOMY", 65, 80], ["allantoic fluid", "ORGANISM_SUBSTANCE", 65, 80], ["sterilized allantoic fluid", "TREATMENT", 54, 80]]], ["Five birds from each group were euthanized at 5 dpi, and trachea, lung, proventriculus, kidney, and cecal tonsil tissues were collected and used for virus titration.", [["trachea", "ANATOMY", 57, 64], ["lung", "ANATOMY", 66, 70], ["proventriculus", "ANATOMY", 72, 86], ["kidney", "ANATOMY", 88, 94], ["cecal tonsil tissues", "ANATOMY", 100, 120], ["birds", "ORGANISM", 5, 10], ["trachea", "MULTI-TISSUE_STRUCTURE", 57, 64], ["lung", "ORGAN", 66, 70], ["proventriculus", "ORGAN", 72, 86], ["kidney", "ORGAN", 88, 94], ["cecal tonsil tissues", "TISSUE", 100, 120], ["trachea, lung, proventriculus, kidney, and cecal tonsil tissues", "PROBLEM", 57, 120], ["virus titration", "TREATMENT", 149, 164], ["trachea", "ANATOMY", 57, 64], ["lung", "ANATOMY", 66, 70], ["proventriculus", "ANATOMY", 72, 86], ["kidney", "ANATOMY", 88, 94], ["cecal tonsil", "ANATOMY", 100, 112]]], ["The titers were calculated to include the total amount of infectious virus recovered from the entire organ.", [["organ", "ANATOMY", 101, 106], ["organ", "ORGAN", 101, 106], ["The titers", "TEST", 0, 10], ["infectious virus", "PROBLEM", 58, 74], ["infectious", "OBSERVATION", 58, 68]]], ["The tracheas and kidneys were also subjected to immunohistochemistry (IHC) for the detection of IBVCommercial pheasants ::: Experimental design ::: Materials and methodsTrachea and kidney samples were used to detect IBV antigen using IHC (Han et al., 2013, 2016).", [["tracheas", "ANATOMY", 4, 12], ["kidneys", "ANATOMY", 17, 24], ["Trachea", "ANATOMY", 169, 176], ["kidney samples", "ANATOMY", 181, 195], ["tracheas", "ORGAN", 4, 12], ["kidneys", "ORGAN", 17, 24], ["Trachea", "TISSUE", 169, 176], ["kidney samples", "CANCER", 181, 195], ["IBV", "ORGANISM", 216, 219], ["IBV antigen", "PROTEIN", 216, 227], ["IBVCommercial pheasants", "SPECIES", 96, 119], ["IBV", "SPECIES", 216, 219], ["immunohistochemistry", "TEST", 48, 68], ["methodsTrachea and kidney samples", "TEST", 162, 195], ["IBV antigen", "TEST", 216, 227], ["tracheas", "ANATOMY", 4, 12], ["kidneys", "ANATOMY", 17, 24], ["Trachea", "ANATOMY", 169, 176], ["kidney", "ANATOMY", 181, 187]]], ["The birds were examined daily for signs of infection for another 25 days after inoculation.", [["infection", "DISEASE", 43, 52], ["birds", "ORGANISM", 4, 9], ["infection", "PROBLEM", 43, 52], ["inoculation", "PROBLEM", 79, 90], ["infection", "OBSERVATION", 43, 52]]], ["Blood samples and oropharyngeal and cloacal swabs were collected from the remaining birds in each group at 4, 8, 12, 16, 20, 24, and 28 dpi.", [["Blood samples", "ANATOMY", 0, 13], ["oropharyngeal", "ANATOMY", 18, 31], ["cloacal swabs", "ANATOMY", 36, 49], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["oropharyngeal", "ORGANISM_SUBDIVISION", 18, 31], ["cloacal swabs", "ORGANISM_SUBSTANCE", 36, 49], ["Blood samples", "TEST", 0, 13], ["oropharyngeal and cloacal swabs", "TEST", 18, 49], ["oropharyngeal", "ANATOMY", 18, 31], ["cloacal swabs", "ANATOMY", 36, 49]]], ["The blood samples were used for antibody detection and the oropharyngeal and cloacal swabs were used for virus recovery in 9-day-old SPF chicken eggs (Han et al., 2016), as described above.Statistical analysis ::: Materials and methodsData are expressed as the mean \u00b1 standard deviation.", [["blood samples", "ANATOMY", 4, 17], ["oropharyngeal", "ANATOMY", 59, 72], ["cloacal swabs", "ANATOMY", 77, 90], ["blood samples", "ORGANISM_SUBSTANCE", 4, 17], ["oropharyngeal", "ORGANISM_SUBDIVISION", 59, 72], ["cloacal swabs", "ORGANISM_SUBSTANCE", 77, 90], ["SPF", "ORGANISM", 133, 136], ["chicken", "ORGANISM", 137, 144], ["chicken", "SPECIES", 137, 144], ["chicken", "SPECIES", 137, 144], ["The blood samples", "TEST", 0, 17], ["antibody detection", "TEST", 32, 50], ["cloacal swabs", "TREATMENT", 77, 90], ["virus recovery", "TEST", 105, 119], ["methodsData", "TEST", 228, 239], ["oropharyngeal", "ANATOMY", 59, 72], ["standard deviation", "OBSERVATION", 268, 286]]], ["Virus titers were analyzed by the Student\u2019s t-test using GraphPad Prism for Windows version 5 (GraphPad Software, La Jolla, CA, USA).", [["Virus", "ORGANISM", 0, 5], ["Virus titers", "TEST", 0, 12], ["Windows version", "TEST", 76, 91], ["Software", "TEST", 104, 112]]], ["Differences were considered significant if the p value was <0.05.IBV-like coronaviruses were isolated from the diseased commercial pheasants ::: ResultsTissues from each flock were pooled and inoculated into embryonated SPF chicken eggs, as described previously (Liu and Kong, 2004).", [["eggs", "ANATOMY", 232, 236], ["IBV-like coronaviruses", "ORGANISM", 65, 87], ["pheasants", "ORGANISM", 131, 140], ["chicken", "ORGANISM", 224, 231], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 232, 236], ["chicken", "SPECIES", 224, 231], ["IBV", "SPECIES", 65, 68], ["SPF", "SPECIES", 220, 223], ["chicken", "SPECIES", 224, 231], ["the p value", "TEST", 43, 54], ["IBV", "PROBLEM", 65, 68], ["coronaviruses", "PROBLEM", 74, 87], ["embryonated SPF chicken eggs", "PROBLEM", 208, 236], ["coronaviruses", "OBSERVATION", 74, 87], ["diseased", "OBSERVATION_MODIFIER", 111, 119], ["commercial pheasants", "OBSERVATION", 120, 140], ["chicken eggs", "OBSERVATION", 224, 236]]], ["No obvious lesions were observed at 7 dpi in the first and second passages.", [["lesions", "ANATOMY", 11, 18], ["lesions", "PATHOLOGICAL_FORMATION", 11, 18], ["obvious lesions", "PROBLEM", 3, 18], ["obvious", "OBSERVATION_MODIFIER", 3, 10], ["lesions", "OBSERVATION", 11, 18]]], ["However, stunting and curling of the embryo with urate deposits in the embryonic mesonephros appeared following two additional passages in the allantoic cavity of 9-day-old SPF eggs (Gough et al., 1996).", [["embryo", "ANATOMY", 37, 43], ["embryonic mesonephros", "ANATOMY", 71, 92], ["allantoic cavity", "ANATOMY", 143, 159], ["stunting", "DISEASE", 9, 17], ["urate", "CHEMICAL", 49, 54], ["urate", "CHEMICAL", 49, 54], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 43], ["urate", "SIMPLE_CHEMICAL", 49, 54], ["embryonic mesonephros", "ORGAN", 71, 92], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 143, 159], ["SPF", "ORGANISM", 173, 176], ["stunting", "PROBLEM", 9, 17], ["the embryo", "PROBLEM", 33, 43], ["urate deposits", "PROBLEM", 49, 63], ["the embryonic mesonephros", "PROBLEM", 67, 92], ["the allantoic cavity", "TEST", 139, 159], ["stunting", "OBSERVATION", 9, 17], ["embryo", "ANATOMY", 37, 43], ["urate deposits", "OBSERVATION", 49, 63], ["embryonic", "ANATOMY_MODIFIER", 71, 80], ["mesonephros", "ANATOMY", 81, 92], ["passages", "OBSERVATION_MODIFIER", 127, 135], ["allantoic cavity", "ANATOMY", 143, 159]]], ["The allantoic fluids from each passage showed no HA activity for chicken red cells.", [["allantoic fluids", "ANATOMY", 4, 20], ["red cells", "ANATOMY", 73, 82], ["allantoic fluids", "ORGANISM_SUBSTANCE", 4, 20], ["chicken", "ORGANISM", 65, 72], ["red cells", "CELL", 73, 82], ["chicken red cells", "CELL_TYPE", 65, 82], ["chicken", "SPECIES", 65, 72], ["chicken", "SPECIES", 65, 72], ["The allantoic fluids from each passage", "TEST", 0, 38], ["HA activity", "PROBLEM", 49, 60], ["chicken red cells", "PROBLEM", 65, 82], ["allantoic", "OBSERVATION_MODIFIER", 4, 13], ["fluids", "OBSERVATION", 14, 20], ["no", "UNCERTAINTY", 46, 48], ["HA activity", "OBSERVATION", 49, 60]]], ["Examination of the concentrated allantoic fluids from the third embryo passage by electron microscopy revealed CoV-like particles (Supplementary Fig. 1).IBV-like coronaviruses were isolated from the diseased commercial pheasants ::: ResultsThe allantoic fluids tested positive for IBV by RT-PCR using IBV-specific primers targeting the 3\u2032 end of the N gene, as described previously (Liu et al., 2013).", [["allantoic fluids", "ANATOMY", 32, 48], ["embryo", "ANATOMY", 64, 70], ["allantoic fluids", "ANATOMY", 244, 260], ["allantoic fluids", "MULTI-TISSUE_STRUCTURE", 32, 48], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 64, 70], ["IBV-like coronaviruses", "ORGANISM", 153, 175], ["pheasants", "ORGANISM", 219, 228], ["allantoic fluids", "ORGANISM_SUBSTANCE", 244, 260], ["IBV", "ORGANISM", 281, 284], ["IBV", "ORGANISM", 301, 304], ["3\u2032 end", "DNA", 336, 342], ["N gene", "DNA", 350, 356], ["IBV", "SPECIES", 153, 156], ["IBV", "SPECIES", 281, 284], ["IBV", "SPECIES", 301, 304], ["Examination", "TEST", 0, 11], ["the concentrated allantoic fluids", "TREATMENT", 15, 48], ["electron microscopy", "TEST", 82, 101], ["CoV-like particles", "PROBLEM", 111, 129], ["IBV", "PROBLEM", 153, 156], ["coronaviruses", "PROBLEM", 162, 175], ["The allantoic fluids", "TEST", 240, 260], ["IBV", "PROBLEM", 281, 284], ["RT", "TEST", 288, 290], ["PCR", "TEST", 291, 294], ["IBV", "TEST", 301, 304], ["specific primers", "TEST", 305, 321], ["CoV", "OBSERVATION", 111, 114], ["coronaviruses", "OBSERVATION", 162, 175], ["diseased", "OBSERVATION_MODIFIER", 199, 207], ["commercial pheasants", "OBSERVATION", 208, 228]]], ["To further identify the virus isolates, we sequenced the PCR products of the two isolates and used the sequences to search the GenBank database (https://blast.ncbi.nlm.nih.gov/Blast.cgi) for similar sequences using the BLASTN program.", [["PCR products", "DNA", 57, 69], ["the virus isolates", "PROBLEM", 20, 38], ["the PCR products", "TEST", 53, 69], ["the sequences", "TEST", 99, 112], ["the GenBank database", "TEST", 123, 143], ["the BLASTN program", "TREATMENT", 215, 233]]], ["The two sequences shared the highest nucleotide identities (90%) with two IBV strains, ck/CH/LDL/05II and ck/CH/LDL/05III, isolated in China in 2005 and belonging to the GI-19 lineage (Zhao et al., 2017).IBV-like coronaviruses were isolated from the diseased commercial pheasants ::: ResultsAll the affected pheasants collected from four commercial flocks 2 months after the disappearance of clinical signs were positive for the IBV-specific antibodies by ELISA, in contrast to the negative results for serum from pheasants that had not shown clinical signs (Fig. 1).IBV-like coronaviruses were isolated from the diseased commercial pheasants ::: ResultsTaken together, the embryopathic effect of the virus, the size and morphology of the virus particles, the sequence characteristics of the amplified gene fragments, and the antibody responses against IBV suggested that the agents I0623/17 and I0710/17 were AvCoVs most similar to IBV, and were provisionally designated as PhCoV.The two PhCoVs were genetically similar to those of IBVs ::: ResultsThe complete genome sequences of the isolates I0623/17 and I0710/17 were obtained by assembly of the fragment sequences.", [["serum", "ANATOMY", 503, 508], ["fragments", "ANATOMY", 807, 816], ["nucleotide", "CHEMICAL", 37, 47], ["nucleotide", "CHEMICAL", 37, 47], ["IBV", "ORGANISM", 74, 77], ["ck/CH/", "ORGANISM", 87, 93], ["LDL", "GENE_OR_GENE_PRODUCT", 93, 96], ["LDL", "GENE_OR_GENE_PRODUCT", 112, 115], ["GI-19 lineage", "CELL", 170, 183], ["IBV-like coronaviruses", "ORGANISM", 204, 226], ["pheasants", "ORGANISM", 270, 279], ["pheasants", "ORGANISM", 308, 317], ["IBV", "ORGANISM", 429, 432], ["serum", "ORGANISM_SUBSTANCE", 503, 508], ["pheasants", "ORGANISM", 514, 523], ["IBV-like coronaviruses", "ORGANISM", 567, 589], ["pheasants", "ORGANISM", 633, 642], ["IBV", "ORGANISM", 853, 856], ["AvCoVs", "GENE_OR_GENE_PRODUCT", 910, 916], ["IBV", "ORGANISM", 933, 936], ["PhCoV", "GENE_OR_GENE_PRODUCT", 975, 980], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 989, 995], ["LDL", "PROTEIN", 93, 96], ["LDL", "PROTEIN", 112, 115], ["05III", "PROTEIN", 116, 121], ["IBV-specific antibodies", "PROTEIN", 429, 452], ["amplified gene fragments", "DNA", 792, 816], ["PhCoV", "DNA", 975, 980], ["PhCoVs", "DNA", 989, 995], ["fragment sequences", "DNA", 1150, 1168], ["IBV", "SPECIES", 74, 77], ["ck/CH/LDL/05II and ck/CH/LDL/05III", "SPECIES", 87, 121], ["IBV", "SPECIES", 204, 207], ["IBV", "SPECIES", 429, 432], ["pheasants", "SPECIES", 514, 523], ["IBV", "SPECIES", 567, 570], ["IBV", "SPECIES", 853, 856], ["IBV", "SPECIES", 933, 936], ["The two sequences", "TEST", 0, 17], ["two IBV strains", "TEST", 70, 85], ["ck/CH", "TEST", 87, 92], ["LDL", "TEST", 93, 96], ["ck/CH", "TEST", 106, 111], ["LDL", "TEST", 112, 115], ["the GI", "TEST", 166, 172], ["IBV", "PROBLEM", 204, 207], ["coronaviruses", "PROBLEM", 213, 226], ["All the affected pheasants", "PROBLEM", 291, 317], ["clinical signs", "TEST", 392, 406], ["the IBV", "TEST", 425, 432], ["ELISA", "TEST", 456, 461], ["serum from pheasants", "TEST", 503, 523], ["IBV", "PROBLEM", 567, 570], ["coronaviruses", "PROBLEM", 576, 589], ["the virus", "PROBLEM", 697, 706], ["the virus particles", "PROBLEM", 735, 754], ["the amplified gene fragments", "PROBLEM", 788, 816], ["the antibody responses", "TEST", 822, 844], ["IBV", "TREATMENT", 853, 856], ["the agents", "TREATMENT", 872, 882], ["AvCoVs", "TREATMENT", 910, 916], ["the isolates", "TEST", 1082, 1094], ["the fragment sequences", "TEST", 1146, 1168], ["LDL", "ANATOMY", 112, 115], ["GI", "ANATOMY", 170, 172], ["coronaviruses", "OBSERVATION", 213, 226], ["diseased", "OBSERVATION_MODIFIER", 250, 258], ["commercial pheasants", "OBSERVATION", 259, 279], ["affected", "OBSERVATION_MODIFIER", 299, 307], ["pheasants", "OBSERVATION", 308, 317], ["coronaviruses", "OBSERVATION", 576, 589], ["diseased", "OBSERVATION_MODIFIER", 613, 621], ["commercial pheasants", "OBSERVATION", 622, 642], ["virus", "OBSERVATION", 701, 706], ["size", "OBSERVATION_MODIFIER", 712, 716], ["virus particles", "OBSERVATION", 739, 754], ["gene fragments", "OBSERVATION", 802, 816]]], ["The genome sizes of the two PhCoV isolates were both 27,640 bases.", [["the two PhCoV isolates", "TEST", 20, 42], ["genome", "OBSERVATION_MODIFIER", 4, 10], ["sizes", "OBSERVATION_MODIFIER", 11, 16]]], ["Their genome organizations were typical of AvCoVs, with the gene order (5\u2032 to 3\u2032) of replicase ORF1ab, S, E, M, and N (Fig. 2A).", [["AvCoVs", "GENE_OR_GENE_PRODUCT", 43, 49], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 95, 101], ["AvCoVs", "DNA", 43, 49], ["replicase ORF1ab", "DNA", 85, 101], ["replicase ORF1ab", "TEST", 85, 101]]], ["Both the 5\u2032 and 3\u2032 ends contained short untranslated regions.", [["5\u2032 and 3\u2032 ends", "DNA", 9, 23], ["short untranslated regions", "DNA", 34, 60], ["short untranslated regions", "PROBLEM", 34, 60], ["short", "OBSERVATION_MODIFIER", 34, 39], ["untranslated regions", "OBSERVATION", 40, 60]]], ["The replicase ORF1ab in both isolates occupied 19,892 bp of the genomes (Table 2).", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 14, 20], ["replicase ORF1ab", "DNA", 4, 20], ["The replicase ORF1ab", "TREATMENT", 0, 20]]], ["This ORF encodes a number of putative proteins, including nsp3, nsp5, nsp12, nsp13, and other proteins with unknown functions.The two PhCoVs were genetically similar to those of IBVs ::: ResultsThe two PhCoV isolates displayed similar genome organizations to IBV strains, and differed only in the number of ORFs downstream of 5a (Fig. 2A).", [["nsp3", "GENE_OR_GENE_PRODUCT", 58, 62], ["nsp5", "GENE_OR_GENE_PRODUCT", 64, 68], ["nsp12", "GENE_OR_GENE_PRODUCT", 70, 75], ["nsp13", "GENE_OR_GENE_PRODUCT", 77, 82], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 134, 140], ["PhCoV", "GENE_OR_GENE_PRODUCT", 202, 207], ["IBV", "ORGANISM", 259, 262], ["ORF", "DNA", 5, 8], ["putative proteins", "PROTEIN", 29, 46], ["nsp3", "PROTEIN", 58, 62], ["nsp5", "PROTEIN", 64, 68], ["nsp12", "PROTEIN", 70, 75], ["nsp13", "PROTEIN", 77, 82], ["PhCoVs", "DNA", 134, 140], ["ORFs", "DNA", 307, 311], ["IBV", "SPECIES", 259, 262], ["putative proteins", "TEST", 29, 46], ["nsp3", "TEST", 58, 62], ["nsp5", "TEST", 64, 68], ["nsp12", "TEST", 70, 75], ["nsp13", "TEST", 77, 82], ["The two PhCoV isolates", "TREATMENT", 194, 216], ["IBV strains", "PROBLEM", 259, 270], ["similar", "OBSERVATION_MODIFIER", 227, 234], ["genome organizations", "OBSERVATION", 235, 255], ["IBV strains", "OBSERVATION", 259, 270]]], ["A mutation (ATG\u2192GTG) occurred at a corresponding position to the start codon in our two PhCoV isolates, resulting in the viruses lacking ORF5b.", [["PhCoV", "GENE_OR_GENE_PRODUCT", 88, 93], ["ORF5b", "GENE_OR_GENE_PRODUCT", 137, 142], ["start codon", "DNA", 65, 76], ["ORF5b", "DNA", 137, 142], ["A mutation (ATG\u2192GTG", "TREATMENT", 0, 19], ["viruses", "OBSERVATION", 121, 128]]], ["Another ORF, provisionally designated as ORF6, was found between 5a and N in the genomes of the two PhCoVs, which overlapped with N. In addition, a 90-bp insertion sequence was found in the 5a\u2013ORF6 junction region (Fig. 2B).", [["5a\u2013ORF6 junction", "ANATOMY", 190, 206], ["ORF6", "GENE_OR_GENE_PRODUCT", 41, 45], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 100, 106], ["ORF", "DNA", 8, 11], ["ORF6", "DNA", 41, 45], ["PhCoVs", "DNA", 100, 106], ["90-bp insertion sequence", "DNA", 148, 172], ["5a\u2013ORF6 junction region", "DNA", 190, 213], ["Another ORF", "PROBLEM", 0, 11], ["a 90-bp insertion sequence", "TREATMENT", 146, 172]]], ["The genomes of the PhCoV isolates were therefore organized in a novel manner: 5\u2032-Gene 1-S-3a-3b-E-M-4b-5a-6-N-3\u2032, which differed from those in IBV and other AvCoVs (Fig. 2A).The two PhCoVs were genetically similar to those of IBVs ::: ResultsIn addition, recombination within the genomes of our two PhCoVs was analyzed using SimPlot by comparing them with 40 represented IBVs selected on the basis of the results of phylogenetic analysis.", [["PhCoV", "GENE_OR_GENE_PRODUCT", 19, 24], ["S-3a-3b-E-M-4b-5a-6-N-3\u2032", "GENE_OR_GENE_PRODUCT", 88, 112], ["IBV", "ORGANISM", 143, 146], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 182, 188], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 299, 305], ["IBVs", "CANCER", 371, 375], ["4b-5a-6-N-3\u2032", "DNA", 100, 112], ["PhCoVs", "DNA", 182, 188], ["PhCoVs", "DNA", 299, 305], ["SimPlot", "DNA", 325, 332], ["IBV", "SPECIES", 143, 146], ["S-3a-3b-E-M", "TEST", 88, 99], ["phylogenetic analysis", "TEST", 416, 437]]], ["No obvious recombination events were found in the genomes of the PhCoV isolates I0623/17 and I0710/17 (Fig. 2C).The PhCoVs differed from IBV to a similar extent as one lineage of IBV differed from another ::: ResultsThe maximum likelihood trees constructed using the S1 nucleotide sequences of our two PhCoV isolates and 213 reference AvCoV strains are shown in Fig. 3A.", [["3A.", "CHEMICAL", 367, 370], ["nucleotide", "CHEMICAL", 270, 280], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 116, 122], ["IBV", "ORGANISM", 137, 140], ["IBV", "ORGANISM", 179, 182], ["PhCoVs", "PROTEIN", 116, 122], ["S1 nucleotide sequences", "DNA", 267, 290], ["IBV", "SPECIES", 137, 140], ["IBV", "SPECIES", 179, 182], ["obvious recombination events", "PROBLEM", 3, 31], ["the PhCoV isolates", "TEST", 61, 79], ["IBV", "TREATMENT", 137, 140], ["the S1 nucleotide sequences", "TREATMENT", 263, 290], ["obvious", "UNCERTAINTY", 3, 10], ["recombination events", "OBSERVATION", 11, 31], ["IBV", "OBSERVATION", 179, 182]]], ["The two PhCoV isolates were clustered together and were not closely related to IBV and other AvCoV strains.", [["PhCoV", "GENE_OR_GENE_PRODUCT", 8, 13], ["IBV", "ORGANISM", 79, 82], ["AvCoV", "GENE_OR_GENE_PRODUCT", 93, 98], ["IBV", "SPECIES", 79, 82], ["The two PhCoV isolates", "TEST", 0, 22], ["IBV", "TREATMENT", 79, 82], ["other AvCoV strains", "PROBLEM", 87, 106]]], ["Comparatively, the two PhCoV isolates showed a relatively closer relationship with IBV GI-19 lineage strains (<92% and 92% nucleotide and amino acid identities, respectively).", [["amino acid", "CHEMICAL", 138, 148], ["amino acid", "CHEMICAL", 138, 148], ["PhCoV", "GENE_OR_GENE_PRODUCT", 23, 28], ["IBV GI-19", "ORGANISM", 83, 92], ["amino acid", "AMINO_ACID", 138, 148], ["IBV GI-19", "SPECIES", 83, 92], ["the two PhCoV isolates", "TEST", 15, 37], ["IBV GI", "TEST", 83, 89], ["lineage strains", "TEST", 93, 108], ["nucleotide", "TEST", 123, 133], ["amino acid identities", "TEST", 138, 159]]], ["According to the complete genomic sequences, the two PhCoV isolates also clustered together and were separate from other IBV strains (Fig. 3B).", [["PhCoV", "GENE_OR_GENE_PRODUCT", 53, 58], ["IBV", "ORGANISM", 121, 124], ["IBV", "SPECIES", 121, 124], ["the two PhCoV isolates", "TEST", 45, 67], ["other IBV strains", "PROBLEM", 115, 132]]], ["Isolate I0623/17 (I0710/17) showed the highest sequence identity with the GI-19 lineage (<91%).", [["GI-19 lineage", "ANATOMY", 74, 87], ["GI-19 lineage", "CELL", 74, 87], ["Isolate", "TEST", 0, 7], ["the GI", "TEST", 70, 76], ["GI", "ANATOMY", 74, 76]]], ["Trees based on both the S1 and complete genomic sequences, thus, showed that the PhCoVs differed from IBV to a similar extent as one lineage/genotype of IBV differed from another.The PhCoVs differed from IBV to a similar extent as one lineage of IBV differed from another ::: ResultsNine sequences of S1 gene fragments from PhCoV strains isolated in the UK were available in GenBank and used for comparison with our two PhCoV isolates and 17 IBV strains isolated in China and Europe.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 81, 87], ["IBV", "ORGANISM", 102, 105], ["IBV", "ORGANISM", 153, 156], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 183, 189], ["IBV", "ORGANISM", 204, 207], ["IBV", "ORGANISM", 246, 249], ["S1", "GENE_OR_GENE_PRODUCT", 301, 303], ["UK", "GENE_OR_GENE_PRODUCT", 354, 356], ["IBV", "ORGANISM", 442, 445], ["S1 and complete genomic sequences", "DNA", 24, 57], ["PhCoVs", "DNA", 81, 87], ["PhCoVs", "PROTEIN", 183, 189], ["S1 gene fragments", "DNA", 301, 318], ["IBV", "SPECIES", 102, 105], ["IBV", "SPECIES", 153, 156], ["IBV", "SPECIES", 204, 207], ["IBV", "SPECIES", 246, 249], ["IBV", "SPECIES", 442, 445], ["the S1 and complete genomic sequences", "TEST", 20, 57], ["the PhCoVs", "PROBLEM", 77, 87], ["IBV", "TREATMENT", 102, 105], ["IBV", "PROBLEM", 153, 156], ["IBV", "TREATMENT", 204, 207], ["S1 gene fragments", "PROBLEM", 301, 318], ["PhCoV strains", "PROBLEM", 324, 337], ["our two PhCoV isolates", "TEST", 412, 434], ["17 IBV strains", "PROBLEM", 439, 453], ["IBV", "OBSERVATION", 246, 249]]], ["All the PhCoVs were divided into three groups (Fig. 3C).", [["PhCoVs", "DNA", 8, 14], ["All the PhCoVs", "TREATMENT", 0, 14]]], ["Our two PhCoVs were genetically most closely related to GI-19 lineage viruses, which were believed to originate from China (Liu and Kong, 2004).", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 8, 14], ["GI-19 lineage", "CELL", 56, 69], ["PhCoVs", "DNA", 8, 14], ["GI-19 lineage viruses", "SPECIES", 56, 77], ["GI-19 lineage viruses", "PROBLEM", 56, 77], ["lineage viruses", "OBSERVATION", 62, 77]]], ["However, four UK PhCoV strains clustered together and showed a closer relationship with IBV GI-14 lineage strains isolated in Europe and Africa.", [["UK", "GENE_OR_GENE_PRODUCT", 14, 16], ["PhCoV", "GENE_OR_GENE_PRODUCT", 17, 22], ["IBV GI-14 lineage strains", "ORGANISM", 88, 113], ["IBV", "SPECIES", 88, 91], ["IBV GI", "TREATMENT", 88, 94], ["lineage strains", "PROBLEM", 98, 113]]], ["The remaining five UK PhCoV strains clustered together in a separate group and were most closely related to IBV GI-16 lineage viruses, which were isolated in Europe.", [["UK", "GENE_OR_GENE_PRODUCT", 19, 21], ["PhCoV", "GENE_OR_GENE_PRODUCT", 22, 27], ["IBV GI-16 lineage viruses", "ORGANISM", 108, 133], ["IBV GI-16 lineage viruses", "SPECIES", 108, 133], ["IBV GI-16 lineage viruses", "PROBLEM", 108, 133], ["lineage viruses", "OBSERVATION", 118, 133]]], ["Multiple alignments using these sequences confirmed these results and revealed that PhCoVs in each group showed similarities with different IBV lineages (Supplementary Fig. 2), rather than all PhCoVs being most closely related to each other.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 84, 90], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 193, 199], ["PhCoVs", "PROTEIN", 84, 90], ["these sequences", "TEST", 26, 41], ["different IBV lineages", "TREATMENT", 130, 152], ["all PhCoVs", "TREATMENT", 189, 199], ["IBV lineages", "OBSERVATION", 140, 152]]], ["Interestingly, phylogenetic trees using the 3\u2032 UTR sequences of our two PhCoV isolates, 16 UK PhCoV strains, and 40 IBV strains (selected based on the results of phylogenetic analysis of the complete genomic sequences) showed that most of the PhCoV strains were clustered in a group, but four of which clustered differently (Fig. 3D).The PhCoV was antigenically different from the selected IBVs ::: ResultsThe percentage of antigenic relatedness (r) values determined by VN between the isolate I0623/17 and other viruses, including isolate I0710/17 and three IBV strains, are given in Fig. 4A.", [["UK", "GENE_OR_GENE_PRODUCT", 91, 93], ["PhCoV", "GENE_OR_GENE_PRODUCT", 243, 248], ["PhCoV", "GENE_OR_GENE_PRODUCT", 338, 343], ["IBV", "ORGANISM", 559, 562], ["UTR sequences", "DNA", 47, 60], ["PhCoV strains", "DNA", 243, 256], ["PhCoV", "PROTEIN", 338, 343], ["VN", "PROTEIN", 471, 473], ["IBV", "SPECIES", 116, 119], ["IBV", "SPECIES", 559, 562], ["UTR sequences", "TEST", 47, 60], ["our two PhCoV isolates", "TEST", 64, 86], ["40 IBV strains", "PROBLEM", 113, 127], ["phylogenetic analysis", "TEST", 162, 183], ["the complete genomic sequences", "TEST", 187, 217], ["the PhCoV strains", "PROBLEM", 239, 256], ["antigenic relatedness (r) values", "PROBLEM", 424, 456], ["the isolate", "TEST", 482, 493], ["other viruses", "PROBLEM", 507, 520], ["three IBV strains", "TREATMENT", 553, 570], ["phylogenetic trees", "OBSERVATION", 15, 33], ["viruses", "OBSERVATION", 513, 520]]], ["The isolate I0623/17showed a strong antigenic relationship with the isolate I0710/17 on the basis of r value (67.3).", [["The isolate", "TEST", 0, 11]]], ["In contrast, the r values of the isolate I0623/17 and the IBV strains used in this study were all <18.2%, i.e. below the 50% cutoff value considered to indicate greater antigenic dissimilarity.The PhCoV was antigenically different from the selected IBVs ::: ResultsAn aliquot of each serum was pooled and tested by VN for PhCoV antibodies using I0623/17 virus.", [["serum", "ANATOMY", 284, 289], ["IBV", "ORGANISM", 58, 61], ["PhCoV", "GENE_OR_GENE_PRODUCT", 197, 202], ["serum", "ORGANISM_SUBSTANCE", 284, 289], ["PhCoV", "GENE_OR_GENE_PRODUCT", 322, 327], ["I0623/17 virus", "ORGANISM", 345, 359], ["PhCoV", "PROTEIN", 197, 202], ["VN", "PROTEIN", 315, 317], ["PhCoV antibodies", "PROTEIN", 322, 338], ["IBV", "SPECIES", 58, 61], ["PhCoV", "SPECIES", 322, 327], ["I0623/17 virus", "SPECIES", 345, 359], ["the r values", "TEST", 13, 25], ["the isolate", "TEST", 29, 40], ["the IBV strains", "PROBLEM", 54, 69], ["this study", "TEST", 78, 88], ["the 50% cutoff value", "TEST", 117, 137], ["greater antigenic dissimilarity", "PROBLEM", 161, 192], ["each serum", "TEST", 279, 289], ["PhCoV antibodies", "TEST", 322, 338], ["greater", "OBSERVATION_MODIFIER", 161, 168], ["antigenic dissimilarity", "OBSERVATION", 169, 192]]], ["Neutralization titers ranging from 84.5 (26.4) to 222.8 (27.8) were obtained from pheasant serum after the disappearance of clinical signs (Fig. 4B), indicating previous exposure to the virus.", [["serum", "ANATOMY", 91, 96], ["pheasant", "ORGANISM", 82, 90], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["pheasant", "SPECIES", 82, 90], ["Neutralization titers", "TEST", 0, 21], ["pheasant serum", "TEST", 82, 96], ["clinical signs", "TEST", 124, 138], ["the virus", "PROBLEM", 182, 191]]], ["In contrast, the neutralization antibody was negative in serum from pheasants that had not shown any clinical signs.The PhCoV was non-pathogenic to SPF chickens but highly pathogenic to commercial pheasants ::: ResultsNo clinical signs were observed in chickens inoculated with different PhCoVs at different ages (1, 30, and 45 days), comparable with chickens in the negative control groups.", [["serum", "ANATOMY", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["pheasants", "ORGANISM", 68, 77], ["PhCoV", "GENE_OR_GENE_PRODUCT", 120, 125], ["SPF chickens", "ORGANISM", 148, 160], ["pheasants", "ORGANISM", 197, 206], ["chickens", "ORGANISM", 253, 261], ["chickens", "ORGANISM", 351, 359], ["neutralization antibody", "PROTEIN", 17, 40], ["PhCoV", "PROTEIN", 120, 125], ["chickens", "SPECIES", 152, 160], ["chickens", "SPECIES", 253, 261], ["chickens", "SPECIES", 351, 359], ["pheasants", "SPECIES", 68, 77], ["chickens", "SPECIES", 152, 160], ["chickens", "SPECIES", 253, 261], ["chickens", "SPECIES", 351, 359], ["the neutralization antibody", "TEST", 13, 40], ["serum from pheasants", "TEST", 57, 77], ["clinical signs", "TEST", 221, 235]]], ["In contrast, the clinical signs were observed in all the pheasants from 2 to 14 dpi with isolate I0710/17 at 45 days of age.", [["the clinical signs", "TEST", 13, 31]]], ["The clinical signs, including snicking, watery eyes, nasal discharge, and rales.", [["eyes", "ANATOMY", 47, 51], ["nasal", "ANATOMY", 53, 58], ["eyes", "ORGAN", 47, 51], ["nasal", "ORGANISM_SUBDIVISION", 53, 58], ["The clinical signs", "TEST", 0, 18], ["snicking", "PROBLEM", 30, 38], ["watery eyes", "PROBLEM", 40, 51], ["nasal discharge", "PROBLEM", 53, 68], ["rales", "PROBLEM", 74, 79], ["watery eyes", "ANATOMY", 40, 51], ["nasal", "ANATOMY", 53, 58], ["discharge", "OBSERVATION", 59, 68], ["rales", "OBSERVATION", 74, 79]]], ["No gross lesions were observed in the five chickens inoculated with isolate I0710/17 necropsied at 5 dpi, however, gross kidney lesions were observed in three of the five pheasants inoculated with isolate I0710/17.", [["gross lesions", "ANATOMY", 3, 16], ["kidney lesions", "ANATOMY", 121, 135], ["kidney lesions", "DISEASE", 121, 135], ["gross lesions", "PATHOLOGICAL_FORMATION", 3, 16], ["chickens", "ORGANISM", 43, 51], ["kidney lesions", "PATHOLOGICAL_FORMATION", 121, 135], ["pheasants", "ORGANISM", 171, 180], ["chickens", "SPECIES", 43, 51], ["chickens", "SPECIES", 43, 51], ["gross lesions", "PROBLEM", 3, 16], ["gross kidney lesions", "PROBLEM", 115, 135], ["gross", "OBSERVATION_MODIFIER", 3, 8], ["lesions", "OBSERVATION", 9, 16], ["gross", "OBSERVATION_MODIFIER", 115, 120], ["kidney", "ANATOMY", 121, 127], ["lesions", "OBSERVATION", 128, 135]]], ["The kidney parenchyma was pale, swollen, and mottled, and the kidney tubules and urethras were distended with uric acid crystals.", [["kidney parenchyma", "ANATOMY", 4, 21], ["kidney tubules", "ANATOMY", 62, 76], ["urethras", "ANATOMY", 81, 89], ["uric acid", "CHEMICAL", 110, 119], ["uric acid", "CHEMICAL", 110, 119], ["kidney parenchyma", "MULTI-TISSUE_STRUCTURE", 4, 21], ["kidney tubules", "MULTI-TISSUE_STRUCTURE", 62, 76], ["urethras", "CANCER", 81, 89], ["uric acid", "SIMPLE_CHEMICAL", 110, 119], ["swollen", "PROBLEM", 32, 39], ["mottled", "PROBLEM", 45, 52], ["distended", "PROBLEM", 95, 104], ["uric acid crystals", "PROBLEM", 110, 128], ["kidney", "ANATOMY", 4, 10], ["parenchyma", "ANATOMY_MODIFIER", 11, 21], ["pale", "OBSERVATION", 26, 30], ["swollen", "OBSERVATION", 32, 39], ["mottled", "OBSERVATION_MODIFIER", 45, 52], ["kidney", "ANATOMY", 62, 68], ["tubules", "ANATOMY_MODIFIER", 69, 76], ["urethras", "ANATOMY", 81, 89], ["distended", "OBSERVATION", 95, 104], ["uric acid crystals", "OBSERVATION", 110, 128]]], ["Three pheasants died at 6 dpi following the clinical signs during the experiment.", [["pheasants", "ORGANISM", 6, 15], ["the clinical signs", "TEST", 40, 58]]], ["Gross lesions in the dead birds were also mainly confined to the kidneys.", [["Gross lesions", "ANATOMY", 0, 13], ["kidneys", "ANATOMY", 65, 72], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["birds", "ORGANISM", 26, 31], ["kidneys", "ORGAN", 65, 72], ["Gross lesions in the dead birds", "PROBLEM", 0, 31], ["lesions", "OBSERVATION", 6, 13], ["dead birds", "OBSERVATION", 21, 31], ["kidneys", "ANATOMY", 65, 72]]], ["Mild tracheitis was also observed in the dead birds.", [["tracheitis", "DISEASE", 5, 15], ["birds", "ORGANISM", 46, 51], ["Mild tracheitis", "PROBLEM", 0, 15], ["tracheitis", "OBSERVATION", 5, 15]]], ["No clinical signs were observed in the control pheasants.The PhCoV was non-pathogenic to SPF chickens but highly pathogenic to commercial pheasants ::: ResultsThe antibody responses are illustrated in Fig. 4C.", [["pheasants", "ORGANISM", 47, 56], ["PhCoV", "GENE_OR_GENE_PRODUCT", 61, 66], ["SPF chickens", "ORGANISM", 89, 101], ["pheasants", "ORGANISM", 138, 147], ["PhCoV", "PROTEIN", 61, 66], ["chickens", "SPECIES", 93, 101], ["chickens", "SPECIES", 93, 101], ["clinical signs", "PROBLEM", 3, 17], ["The antibody responses", "TEST", 159, 181]]], ["Both chickens and pheasants inoculated with the PhCoV isolates showed negative ELISA antibody results at 4 dpi.", [["chickens", "ORGANISM", 5, 13], ["pheasants", "ORGANISM", 18, 27], ["chickens", "SPECIES", 5, 13], ["pheasants", "SPECIES", 18, 27], ["chickens", "SPECIES", 5, 13], ["pheasants", "SPECIES", 18, 27], ["PhCoV", "SPECIES", 48, 53], ["the PhCoV isolates", "TEST", 44, 62], ["ELISA antibody", "TEST", 79, 93]]], ["No antibody responses were observed in any of the chickens inoculated with PhCoV isolates I0623/17 and I0710/17 at 8 dpi at different ages in ELISA tests; however, 50% of pheasants inoculated with I0710/17 showed seroconversion from 8 dpi.", [["I0710/17", "CHEMICAL", 197, 205], ["chickens", "ORGANISM", 50, 58], ["pheasants", "ORGANISM", 171, 180], ["chickens", "SPECIES", 50, 58], ["chickens", "SPECIES", 50, 58], ["PhCoV", "SPECIES", 75, 80], ["pheasants", "SPECIES", 171, 180], ["antibody responses", "PROBLEM", 3, 21], ["PhCoV isolates", "TEST", 75, 89], ["ELISA tests", "TEST", 142, 153], ["pheasants", "TEST", 171, 180], ["seroconversion", "PROBLEM", 213, 227], ["antibody responses", "OBSERVATION", 3, 21]]], ["The seroconversion rates were higher in pheasants than in chickens at the corresponding time points.", [["chickens", "ORGANISM", 58, 66], ["chickens", "SPECIES", 58, 66], ["pheasants", "SPECIES", 40, 49], ["chickens", "SPECIES", 58, 66], ["The seroconversion rates", "TEST", 0, 24], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["No antibody was detected in the negative control chickens or pheasants.The PhCoV had high replication capacity in commercial pheasants ::: ResultsShedding of the PhCoV isolate in the respiratory and digestive tracts of both chickens and pheasants was determined by virus re-isolation using oropharyngeal and cloacal swabs with 9-day-old SPF chicken eggs (Han et al., 2016).", [["respiratory", "ANATOMY", 183, 194], ["digestive tracts", "ANATOMY", 199, 215], ["oropharyngeal", "ANATOMY", 290, 303], ["cloacal swabs", "ANATOMY", 308, 321], ["PhCoV", "CHEMICAL", 75, 80], ["respiratory and digestive tracts", "DISEASE", 183, 215], ["chickens", "ORGANISM", 49, 57], ["pheasants", "ORGANISM", 61, 70], ["PhCoV", "GENE_OR_GENE_PRODUCT", 75, 80], ["pheasants", "ORGANISM", 125, 134], ["PhCoV", "GENE_OR_GENE_PRODUCT", 162, 167], ["respiratory", "ORGAN", 183, 194], ["digestive tracts", "MULTI-TISSUE_STRUCTURE", 199, 215], ["chickens", "ORGANISM", 224, 232], ["pheasants", "ORGANISM", 237, 246], ["oropharyngeal", "ORGANISM_SUBDIVISION", 290, 303], ["cloacal swabs", "MULTI-TISSUE_STRUCTURE", 308, 321], ["SPF", "ORGANISM", 337, 340], ["chicken", "ORGANISM", 341, 348], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 349, 353], ["PhCoV", "PROTEIN", 75, 80], ["chickens", "SPECIES", 49, 57], ["chickens", "SPECIES", 224, 232], ["chicken", "SPECIES", 341, 348], ["chickens", "SPECIES", 49, 57], ["chickens", "SPECIES", 224, 232], ["pheasants", "SPECIES", 237, 246], ["chicken", "SPECIES", 341, 348], ["antibody", "PROBLEM", 3, 11], ["the PhCoV isolate", "TREATMENT", 158, 175], ["pheasants", "TREATMENT", 237, 246], ["virus re-isolation", "TREATMENT", 265, 283], ["oropharyngeal and cloacal swabs", "TREATMENT", 290, 321], ["antibody", "OBSERVATION", 3, 11], ["high", "OBSERVATION_MODIFIER", 85, 89], ["replication capacity", "OBSERVATION", 90, 110], ["respiratory", "ANATOMY", 183, 194], ["digestive tracts", "ANATOMY", 199, 215], ["both chickens", "OBSERVATION", 219, 232]]], ["Prolonged virus replication and higher number of birds shedding virus in the respiratory and digestive tracts were observed in pheasants, compared to those of chickens inoculated with PhCoV I0710/17 at different time points (Fig. 5A).", [["respiratory", "ANATOMY", 77, 88], ["digestive tracts", "ANATOMY", 93, 109], ["respiratory and digestive tracts", "DISEASE", 77, 109], ["PhCoV I0710/17", "CHEMICAL", 184, 198], ["birds shedding virus", "ORGANISM", 49, 69], ["digestive tracts", "PATHOLOGICAL_FORMATION", 93, 109], ["pheasants", "ORGANISM", 127, 136], ["chickens", "ORGANISM", 159, 167], ["chickens", "SPECIES", 159, 167], ["chickens", "SPECIES", 159, 167], ["PhCoV", "SPECIES", 184, 189], ["Prolonged virus replication", "PROBLEM", 0, 27], ["birds shedding virus", "PROBLEM", 49, 69], ["PhCoV", "TREATMENT", 184, 189], ["virus replication", "OBSERVATION", 10, 27], ["higher", "OBSERVATION_MODIFIER", 32, 38], ["number", "OBSERVATION_MODIFIER", 39, 45], ["respiratory", "ANATOMY", 77, 88], ["digestive tracts", "ANATOMY", 93, 109]]], ["Replication of the challenge viruses was also determined at 5 dpi in the tracheas, kidneys, lungs, proventriculus, and cecal tonsils from chickens and pheasants (Ma et al., 2019) (Fig. 5B).", [["tracheas", "ANATOMY", 73, 81], ["kidneys", "ANATOMY", 83, 90], ["lungs", "ANATOMY", 92, 97], ["proventriculus", "ANATOMY", 99, 113], ["cecal tonsils", "ANATOMY", 119, 132], ["tracheas", "ORGAN", 73, 81], ["kidneys", "ORGAN", 83, 90], ["lungs", "ORGAN", 92, 97], ["proventriculus", "ORGAN", 99, 113], ["cecal tonsils", "MULTI-TISSUE_STRUCTURE", 119, 132], ["chickens", "ORGANISM", 138, 146], ["chickens", "SPECIES", 138, 146], ["chickens", "SPECIES", 138, 146], ["the challenge viruses", "TREATMENT", 15, 36], ["tracheas", "ANATOMY", 73, 81], ["kidneys", "ANATOMY", 83, 90], ["lungs", "ANATOMY", 92, 97], ["proventriculus", "ANATOMY", 99, 113], ["cecal tonsils", "ANATOMY", 119, 132]]], ["The replication capacity of the PhCoV I0623/17 isolate was detected in the tracheas of chickens and pheasants with comparable titers; however, the titers were somewhat lower in chickens inoculated with I0710/17.", [["tracheas", "ANATOMY", 75, 83], ["PhCoV I0623/17", "ORGANISM", 32, 46], ["tracheas", "ORGAN", 75, 83], ["chickens", "ORGANISM", 87, 95], ["pheasants", "ORGANISM", 100, 109], ["chickens", "ORGANISM", 177, 185], ["PhCoV I0623/17 isolate", "DNA", 32, 54], ["chickens", "SPECIES", 87, 95], ["chickens", "SPECIES", 177, 185], ["PhCoV I0623/17", "SPECIES", 32, 46], ["chickens", "SPECIES", 87, 95], ["pheasants", "SPECIES", 100, 109], ["chickens", "SPECIES", 177, 185], ["the titers", "TEST", 143, 153], ["replication", "OBSERVATION_MODIFIER", 4, 15], ["capacity", "OBSERVATION_MODIFIER", 16, 24], ["tracheas", "ANATOMY", 75, 83], ["lower", "OBSERVATION_MODIFIER", 168, 173]]], ["Virus titers in the lungs, proventriculus, and cecal tonsils were significantly lower in chickens than in pheasants, with no viruses detected in some chicken tissues.", [["lungs", "ANATOMY", 20, 25], ["proventriculus", "ANATOMY", 27, 41], ["cecal tonsils", "ANATOMY", 47, 60], ["tissues", "ANATOMY", 158, 165], ["Virus", "ORGANISM", 0, 5], ["lungs", "ORGAN", 20, 25], ["proventriculus", "ORGAN", 27, 41], ["cecal tonsils", "ORGAN", 47, 60], ["chickens", "ORGANISM", 89, 97], ["pheasants", "ORGANISM", 106, 115], ["chicken", "ORGANISM", 150, 157], ["tissues", "TISSUE", 158, 165], ["chickens", "SPECIES", 89, 97], ["chicken", "SPECIES", 150, 157], ["chickens", "SPECIES", 89, 97], ["pheasants", "SPECIES", 106, 115], ["chicken", "SPECIES", 150, 157], ["Virus titers", "TEST", 0, 12], ["cecal tonsils", "PROBLEM", 47, 60], ["viruses", "PROBLEM", 125, 132], ["lungs", "ANATOMY", 20, 25], ["proventriculus", "ANATOMY", 27, 41], ["cecal tonsils", "ANATOMY", 47, 60], ["significantly", "OBSERVATION_MODIFIER", 66, 79], ["lower", "OBSERVATION_MODIFIER", 80, 85], ["no", "UNCERTAINTY", 122, 124], ["viruses", "OBSERVATION", 125, 132], ["chicken tissues", "OBSERVATION", 150, 165]]], ["Notably, no virus was detected in the kidneys of chickens challenged with the two PhCoV isolates, in contrast to the high titers in the kidneys of pheasants challenged with I0710/17.", [["kidneys", "ANATOMY", 38, 45], ["kidneys", "ANATOMY", 136, 143], ["kidneys", "ORGAN", 38, 45], ["chickens", "ORGANISM", 49, 57], ["kidneys", "ORGAN", 136, 143], ["pheasants", "ORGANISM", 147, 156], ["chickens", "SPECIES", 49, 57], ["chickens", "SPECIES", 49, 57], ["pheasants", "SPECIES", 147, 156], ["virus", "PROBLEM", 12, 17], ["the two PhCoV isolates", "TREATMENT", 74, 96], ["no", "UNCERTAINTY", 9, 11], ["virus", "OBSERVATION", 12, 17], ["kidneys", "ANATOMY", 38, 45], ["high titers", "OBSERVATION", 117, 128], ["kidneys", "ANATOMY", 136, 143]]], ["In line with this result, viral antigens were detected by IHC in the kidneys of pheasants challenged with I0710/17 (Fig. 5C), but not in the kidneys of chickens inoculated with the two PhCoV isolates.", [["kidneys", "ANATOMY", 69, 76], ["kidneys", "ANATOMY", 141, 148], ["kidneys", "ORGAN", 69, 76], ["pheasants", "ORGANISM", 80, 89], ["kidneys", "ORGAN", 141, 148], ["chickens", "ORGANISM", 152, 160], ["viral antigens", "PROTEIN", 26, 40], ["chickens", "SPECIES", 152, 160], ["pheasants", "SPECIES", 80, 89], ["chickens", "SPECIES", 152, 160], ["viral antigens", "TEST", 26, 40], ["IHC", "TEST", 58, 61], ["kidneys", "ANATOMY", 69, 76], ["kidneys", "ANATOMY", 141, 148]]], ["The viral antigens were also detected by IHC in the tracheas of chickens challenged with I0623/17 and pheasants challenged with I0710/17 (Fig. 5C).", [["tracheas", "ANATOMY", 52, 60], ["tracheas", "ORGAN", 52, 60], ["chickens", "ORGANISM", 64, 72], ["pheasants", "ORGANISM", 102, 111], ["viral antigens", "PROTEIN", 4, 18], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["The viral antigens", "TEST", 0, 18], ["pheasants", "TREATMENT", 102, 111], ["viral antigens", "OBSERVATION", 4, 18], ["tracheas", "ANATOMY", 52, 60]]], ["No virus was detected in any tissues or in oropharyngeal and cloacal swabs from birds in the control group.DiscussionIn the current study, we isolated two AvCoVs from commercial pheasants at two respective farms in China in 2017 with disease outbreaks occurring within a 2-month period.", [["tissues", "ANATOMY", 29, 36], ["oropharyngeal", "ANATOMY", 43, 56], ["cloacal swabs", "ANATOMY", 61, 74], ["tissues", "TISSUE", 29, 36], ["oropharyngeal", "ORGANISM_SUBDIVISION", 43, 56], ["cloacal swabs", "ORGANISM_SUBDIVISION", 61, 74], ["AvCoVs", "GENE_OR_GENE_PRODUCT", 155, 161], ["virus", "PROBLEM", 3, 8], ["oropharyngeal and cloacal swabs", "PROBLEM", 43, 74], ["the current study", "TEST", 120, 137], ["commercial pheasants", "TREATMENT", 167, 187], ["disease outbreaks", "PROBLEM", 234, 251], ["virus", "OBSERVATION", 3, 8], ["oropharyngeal", "ANATOMY", 43, 56], ["cloacal swabs", "ANATOMY", 61, 74]]], ["The diseased birds showed early respiratory signs, suggesting that they may have been caused by respiratory pathogens, possibly including NDV, AIV subtypes H5 and H9, IBV, or PhCoVs.", [["respiratory", "ANATOMY", 32, 43], ["respiratory", "ANATOMY", 96, 107], ["respiratory signs", "DISEASE", 32, 49], ["respiratory pathogens", "DISEASE", 96, 117], ["birds", "ORGANISM", 13, 18], ["NDV", "ORGANISM", 138, 141], ["AIV subtypes H5", "ORGANISM", 143, 158], ["H9", "CELL", 163, 165], ["IBV", "ORGANISM", 167, 170], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 175, 181], ["NDV", "SPECIES", 138, 141], ["NDV", "SPECIES", 138, 141], ["AIV", "SPECIES", 143, 146], ["IBV", "SPECIES", 167, 170], ["The diseased birds", "PROBLEM", 0, 18], ["early respiratory signs", "PROBLEM", 26, 49], ["respiratory pathogens", "PROBLEM", 96, 117], ["NDV", "PROBLEM", 138, 141], ["H9", "PROBLEM", 163, 165], ["IBV", "PROBLEM", 167, 170], ["PhCoVs", "PROBLEM", 175, 181], ["diseased", "OBSERVATION", 4, 12], ["early", "OBSERVATION_MODIFIER", 26, 31], ["respiratory signs", "OBSERVATION", 32, 49], ["respiratory pathogens", "OBSERVATION", 96, 117]]], ["The embryopathic effects and morphologies of the isolated viruses and the sequence characteristics of the amplified gene fragments suggested that both agents were AvCoVs most similar to IBV.", [["AvCoVs", "GENE_OR_GENE_PRODUCT", 163, 169], ["IBV", "ORGANISM", 186, 189], ["amplified gene fragments", "DNA", 106, 130], ["IBV", "SPECIES", 186, 189], ["The embryopathic effects", "PROBLEM", 0, 24], ["the isolated viruses", "PROBLEM", 45, 65], ["the amplified gene fragments", "PROBLEM", 102, 130], ["AvCoVs", "TREATMENT", 163, 169], ["IBV", "TREATMENT", 186, 189], ["isolated viruses", "OBSERVATION", 49, 65]]], ["This was confirmed by serological ELISA evidence using IBV as the antigen and VN test using the isolate I0631/17.", [["IBV", "ORGANISM", 55, 58], ["VN", "PROTEIN", 78, 80], ["IBV", "SPECIES", 55, 58], ["serological ELISA", "TEST", 22, 39], ["IBV", "TREATMENT", 55, 58], ["the antigen", "TEST", 62, 73], ["VN test", "TEST", 78, 85]]], ["Since the original description of PhCoV in 1980 (Spackman and Cameron, 1983), the disease caused by PhCoV has become widespread in the UK (Lister et al., 1985; Pennycott, 2000; Cavanagh et al., 2002).", [["PhCoV", "CHEMICAL", 100, 105], ["PhCoV", "GENE_OR_GENE_PRODUCT", 100, 105], ["PhCoV", "SPECIES", 100, 105], ["the disease", "PROBLEM", 78, 89], ["disease", "OBSERVATION", 82, 89], ["widespread", "OBSERVATION_MODIFIER", 117, 127]]], ["Some viruses isolated from pheasants with respiratory disease, reduced egg production, renal problems, and high mortality were believed to be IBV (Spackman &Cameron, 1983; Gough et al., 1996; Lister et al., 1985; Pennycott, 2000), due to similarities with IBV in domestic fowl (Cook et al., 2012).", [["respiratory", "ANATOMY", 42, 53], ["egg", "ANATOMY", 71, 74], ["renal", "ANATOMY", 87, 92], ["respiratory disease", "DISEASE", 42, 61], ["renal problems", "DISEASE", 87, 101], ["pheasants", "ORGANISM", 27, 36], ["egg", "ORGANISM_SUBDIVISION", 71, 74], ["renal", "ORGAN", 87, 92], ["IBV", "ORGANISM", 142, 145], ["IBV", "ORGANISM", 256, 259], ["IBV", "SPECIES", 142, 145], ["Spackman &Cameron, 1983; Gough et al., 1996; Lister et al., 1985; Pennycott", "SPECIES", 147, 222], ["IBV", "SPECIES", 256, 259], ["fowl", "SPECIES", 272, 276], ["Some viruses", "PROBLEM", 0, 12], ["respiratory disease", "PROBLEM", 42, 61], ["reduced egg production", "PROBLEM", 63, 85], ["renal problems", "PROBLEM", 87, 101], ["high mortality", "PROBLEM", 107, 121], ["IBV", "PROBLEM", 256, 259], ["viruses", "OBSERVATION", 5, 12], ["respiratory disease", "OBSERVATION", 42, 61], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["egg production", "OBSERVATION", 71, 85], ["renal", "ANATOMY", 87, 92], ["IBV", "OBSERVATION", 256, 259]]], ["The mortality associated with the outbreaks at pheasant farms in China were comparable to or even higher than those of the outbreak at a large game farm in the UK in 1994, which resulted in the deaths of over 1000 breeding pheasants out of a total stock of approximately 7000 birds (Gough et al., 1996).", [["deaths", "DISEASE", 194, 200], ["pheasants", "ORGANISM", 223, 232], ["The mortality", "PROBLEM", 0, 13]]], ["The clinical signs and gross lesions in dead birds were also similar between the two outbreaks, with upper respiratory signs at the beginning of the outbreaks, and the birds dying rapidly after appearance of the signs of illness.", [["gross lesions", "ANATOMY", 23, 36], ["respiratory", "ANATOMY", 107, 118], ["illness", "DISEASE", 221, 228], ["gross lesions", "PATHOLOGICAL_FORMATION", 23, 36], ["birds", "ORGANISM", 168, 173], ["The clinical signs", "TEST", 0, 18], ["gross lesions in dead birds", "PROBLEM", 23, 50], ["upper respiratory signs", "PROBLEM", 101, 124], ["illness", "PROBLEM", 221, 228], ["gross", "OBSERVATION_MODIFIER", 23, 28], ["lesions", "OBSERVATION", 29, 36], ["dead birds", "OBSERVATION", 40, 50], ["two", "OBSERVATION_MODIFIER", 81, 84], ["outbreaks", "OBSERVATION", 85, 94], ["upper", "ANATOMY_MODIFIER", 101, 106], ["respiratory", "ANATOMY", 107, 118], ["signs", "OBSERVATION", 119, 124]]], ["Pale, swollen kidneys and ureters distended with urates were also found in both cases.", [["swollen kidneys", "ANATOMY", 6, 21], ["ureters", "ANATOMY", 26, 33], ["swollen kidneys", "MULTI-TISSUE_STRUCTURE", 6, 21], ["ureters", "ORGAN", 26, 33], ["swollen kidneys and ureters distended", "PROBLEM", 6, 43], ["swollen", "OBSERVATION", 6, 13], ["kidneys", "ANATOMY", 14, 21], ["ureters", "ANATOMY", 26, 33], ["distended", "OBSERVATION", 34, 43]]], ["Some viruses have been successfully isolated and propagated in embryonating domestic fowl eggs (Lister et al., 1985; Gough et al., 1996), as with the two PhCoVs isolated in this study.DiscussionPhylogenetic analysis showed that our PhCoVs represented a novel lineage in genotype I of IBV, according to the method of Valastro et al. (2016).", [["fowl", "ORGANISM", 85, 89], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 90, 94], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 154, 160], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 232, 238], ["IBV", "ORGANISM", 284, 287], ["PhCoVs", "DNA", 232, 238], ["fowl", "SPECIES", 85, 89], ["fowl", "SPECIES", 85, 89], ["IBV", "SPECIES", 284, 287], ["Some viruses", "PROBLEM", 0, 12], ["this study", "TEST", 173, 183], ["Phylogenetic analysis", "TEST", 194, 215], ["IBV", "TREATMENT", 284, 287], ["viruses", "OBSERVATION", 5, 12]]], ["The phylogenetic analyses were based on the S1 gene sequences of our PhCoVs and 213 reference AvCoV strains.", [["PhCoVs", "CANCER", 69, 75], ["AvCoV", "GENE_OR_GENE_PRODUCT", 94, 99], ["S1 gene sequences", "DNA", 44, 61], ["PhCoVs", "DNA", 69, 75], ["The phylogenetic analyses", "TEST", 0, 25], ["our PhCoVs", "TEST", 65, 75]]], ["The nucleotide and putative amino acid compositions of the S1 gene also showed approximately 10% differences between the two current PhCoVs isolates and other AvCoV strains, compared with 13% of nucleotides and 14% of amino acids in the S1 subdomain between IBV lineages, and 30% of nucleotides and 31% (occasionally even 40% or more) of amino acids in the S1 subdomain between IBV serotypes (Valastro et al., 2016).", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 28, 38], ["amino acids", "CHEMICAL", 218, 229], ["amino acids", "CHEMICAL", 338, 349], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 28, 38], ["nucleotides", "CHEMICAL", 195, 206], ["amino acids", "CHEMICAL", 218, 229], ["nucleotides", "CHEMICAL", 283, 294], ["amino acids", "CHEMICAL", 338, 349], ["amino acid", "AMINO_ACID", 28, 38], ["S1", "GENE_OR_GENE_PRODUCT", 59, 61], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 133, 139], ["AvCoV", "GENE_OR_GENE_PRODUCT", 159, 164], ["amino acids", "AMINO_ACID", 218, 229], ["IBV", "ORGANISM", 258, 261], ["amino acids", "AMINO_ACID", 338, 349], ["IBV", "ORGANISM", 378, 381], ["S1 gene", "DNA", 59, 66], ["S1 subdomain", "PROTEIN", 237, 249], ["S1 subdomain", "PROTEIN", 357, 369], ["The nucleotide and putative amino acid compositions", "TEST", 0, 51], ["other AvCoV strains", "PROBLEM", 153, 172], ["nucleotides", "TEST", 195, 206], ["amino acids", "TEST", 218, 229], ["IBV lineages", "TEST", 258, 270], ["nucleotides", "TEST", 283, 294], ["amino acids", "TEST", 338, 349], ["amino acid", "OBSERVATION", 28, 38], ["S1", "ANATOMY", 59, 61], ["S1 subdomain", "ANATOMY", 237, 249], ["IBV lineages", "OBSERVATION", 258, 270], ["S1 subdomain", "ANATOMY", 357, 369]]], ["Our PhCoVs thus differed from IBV to a similar extent as one lineage of IBV differed from another.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 4, 10], ["IBV", "ORGANISM", 30, 33], ["IBV", "ORGANISM", 72, 75], ["PhCoVs", "DNA", 4, 10], ["IBV", "SPECIES", 30, 33], ["IBV", "SPECIES", 72, 75], ["IBV", "PROBLEM", 72, 75], ["IBV", "OBSERVATION", 72, 75]]], ["We also found interesting branching of the phylogenetic tree based on the complete genomic sequences of our two PhCoVs and IBVs of different lineages/genotypes.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 112, 118], ["IBVs", "GENE_OR_GENE_PRODUCT", 123, 127], ["PhCoVs", "DNA", 112, 118], ["different lineages/genotypes", "PROBLEM", 131, 159], ["branching", "OBSERVATION_MODIFIER", 26, 35], ["phylogenetic tree", "OBSERVATION", 43, 60], ["different lineages", "OBSERVATION", 131, 149]]], ["Pairwise comparisons of the complete genomic sequences revealed that our PhCoVs differed by >10%, similar to many IBV lineages and serotypes, further supporting the similarity of the genetic relationship between our two PhCoVs and IBV strains was similar to that between IBV lineages and genotypes.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 73, 79], ["IBV", "ORGANISM", 114, 117], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 220, 226], ["IBV", "ORGANISM", 231, 234], ["IBV", "ORGANISM", 271, 274], ["PhCoVs", "DNA", 73, 79], ["IBV", "SPECIES", 114, 117], ["IBV", "SPECIES", 231, 234], ["IBV", "SPECIES", 271, 274], ["the complete genomic sequences", "TEST", 24, 54], ["serotypes", "PROBLEM", 131, 140], ["IBV strains", "PROBLEM", 231, 242], ["IBV lineages", "TREATMENT", 271, 283], ["IBV lineages", "OBSERVATION", 114, 126]]], ["In addition, the robust IBV-specific serum IgG titers in chickens inoculated with PhCoV isolates showed that PhCoV infection stimulated a humoral response in chickens (Raj and Jones, 1997; Aston et al., 2018).", [["serum", "ANATOMY", 37, 42], ["PhCoV", "CHEMICAL", 109, 114], ["infection", "DISEASE", 115, 124], ["IBV", "ORGANISM", 24, 27], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["chickens", "ORGANISM", 57, 65], ["PhCoV isolates", "ORGANISM", 82, 96], ["PhCoV", "GENE_OR_GENE_PRODUCT", 109, 114], ["chickens", "ORGANISM", 158, 166], ["serum IgG", "PROTEIN", 37, 46], ["chickens", "SPECIES", 57, 65], ["chickens", "SPECIES", 158, 166], ["IBV", "SPECIES", 24, 27], ["chickens", "SPECIES", 57, 65], ["PhCoV", "SPECIES", 82, 87], ["PhCoV", "SPECIES", 109, 114], ["chickens", "SPECIES", 158, 166], ["the robust IBV", "TEST", 13, 27], ["specific serum IgG titers", "TEST", 28, 53], ["chickens", "PROBLEM", 57, 65], ["PhCoV isolates", "TEST", 82, 96], ["PhCoV infection", "PROBLEM", 109, 124], ["infection", "OBSERVATION", 115, 124], ["humoral response", "OBSERVATION", 138, 154]]], ["However, PhCoVs were antigenically dissimilar to IBVs in the VN tests, suggesting that the antigenic relationship between our two PhCoVs and the IBV strains was similar to those between different IBV genotypes (Gao et al., 2016).", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 9, 15], ["IBVs", "PATHOLOGICAL_FORMATION", 49, 53], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 130, 136], ["IBV", "ORGANISM", 145, 148], ["IBV", "ORGANISM", 196, 199], ["PhCoVs", "PROTEIN", 9, 15], ["IBV", "SPECIES", 145, 148], ["IBV", "SPECIES", 196, 199], ["the VN tests", "TEST", 57, 69], ["the IBV strains", "PROBLEM", 141, 156]]], ["Viruses antigenically distinct from the investigated IBVs have also been isolated from pheasants in the UK on several occasions (Lister et al., 1985; Cavanagh et al., 2002).DiscussionCoVs typically have a restricted host range and only infect their natural host.", [["IBVs", "GENE_OR_GENE_PRODUCT", 53, 57], ["pheasants", "ORGANISM", 87, 96], ["Viruses", "PROBLEM", 0, 7], ["restricted host range", "OBSERVATION_MODIFIER", 205, 226]]], ["As an AvCoV, IBV is considered to be a highly contagious virus that only infects chickens (Gallus gallus) (Cavanagh, 2007); however, IBV has also been reported in other avian species including guinea fowl, partridge, peafowl, and teal, without producing any clinical detectable disease (Cavanagh, 2007; Liu et al., 2005; Sun et al., 2007).", [["AvCoV", "GENE_OR_GENE_PRODUCT", 6, 11], ["IBV", "ORGANISM", 13, 16], ["chickens", "ORGANISM", 81, 89], ["Gallus gallus", "ORGANISM", 91, 104], ["IBV", "ORGANISM", 133, 136], ["guinea fowl", "ORGANISM", 193, 204], ["chickens", "SPECIES", 81, 89], ["Gallus gallus", "SPECIES", 91, 104], ["guinea fowl", "SPECIES", 193, 204], ["IBV", "SPECIES", 13, 16], ["chickens", "SPECIES", 81, 89], ["Gallus gallus", "SPECIES", 91, 104], ["IBV", "SPECIES", 133, 136], ["guinea fowl", "SPECIES", 193, 204], ["IBV", "PROBLEM", 13, 16], ["a highly contagious virus", "PROBLEM", 37, 62], ["Cavanagh", "TEST", 107, 115], ["IBV", "PROBLEM", 133, 136], ["any clinical detectable disease", "PROBLEM", 254, 285], ["Gallus gallus", "ANATOMY", 91, 104]]], ["Pheasants (P. colchicus) differ from chickens (G. gallus), though both belong to the family Phasianidae, order Galliformes.", [["P. colchicus", "ORGANISM", 11, 23], ["chickens", "ORGANISM", 37, 45], ["G. gallus", "ORGANISM", 47, 56], ["Phasianidae", "GENE_OR_GENE_PRODUCT", 92, 103], ["P. colchicus", "SPECIES", 11, 23], ["chickens", "SPECIES", 37, 45], ["G. gallus", "SPECIES", 47, 56], ["P. colchicus", "SPECIES", 11, 23], ["chickens", "SPECIES", 37, 45], ["G. gallus", "SPECIES", 47, 56], ["Pheasants (P. colchicus)", "TREATMENT", 0, 24]]], ["Although the PhCoVs in this study were very similar to the IBVs, there were some obvious differences.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 13, 19], ["IBVs", "CANCER", 59, 63], ["PhCoVs", "DNA", 13, 19], ["this study", "TEST", 23, 33], ["some", "OBSERVATION_MODIFIER", 76, 80], ["obvious", "OBSERVATION_MODIFIER", 81, 88], ["differences", "OBSERVATION_MODIFIER", 89, 100]]], ["The IBV RNA genome is characterized by the organization 5\u2032-UTR-1a-1b-S-3a-3b-E-M-5a-5b-N-UTR-3\u2032, while the genomes of the PhCoV isolates were organized in a novel 5\u2032-UTR-1a-1b-S-3a-3b-E-M-5a-6-N-3\u2032UTR order, which differed from those of IBV and other AvCoVs.", [["IBV", "ORGANISM", 4, 7], ["PhCoV", "GENE_OR_GENE_PRODUCT", 122, 127], ["IBV", "ORGANISM", 237, 240], ["AvCoVs", "GENE_OR_GENE_PRODUCT", 251, 257], ["IBV RNA genome", "DNA", 4, 18], ["UTR", "DNA", 59, 62], ["1a-1b", "DNA", 63, 68], ["S", "DNA", 69, 70], ["3a-3b", "DNA", 71, 76], ["E-M", "DNA", 77, 80], ["5a-5b-N-UTR", "DNA", 81, 92], ["\u2032", "DNA", 94, 95], ["5\u2032-UTR", "DNA", 163, 169], ["AvCoVs", "DNA", 251, 257], ["IBV", "SPECIES", 4, 7], ["IBV", "SPECIES", 237, 240], ["the organization", "TEST", 39, 55], ["UTR", "TEST", 59, 62], ["1b", "TEST", 66, 68], ["S", "TEST", 69, 70], ["3b", "TEST", 74, 76], ["M", "TEST", 79, 80], ["UTR", "TEST", 89, 92], ["the PhCoV isolates", "TEST", 118, 136], ["UTR", "TEST", 166, 169], ["1b", "TEST", 173, 175], ["S", "TEST", 176, 177], ["3b", "TEST", 181, 183], ["N", "TEST", 193, 194], ["UTR order", "TEST", 197, 206], ["IBV", "TREATMENT", 237, 240], ["other AvCoVs", "TREATMENT", 245, 257], ["RNA genome", "OBSERVATION", 8, 18]]], ["Novel genomic organizations have also been found in other IBVs (Liu et al., 2008a,b; Mardani et al., 2008; Xu et al., 2016) and experiments with engineered mutants suggested that the native order was not functionally essential (Casais et al., 2005; Hodgson et al., 2006).", [["IBVs", "PATHOLOGICAL_FORMATION", 58, 62]]], ["Notably, the current study found differences in the pathogenicity and replication capacity of the PhCoV isolates between chickens and pheasants.", [["PhCoV", "GENE_OR_GENE_PRODUCT", 98, 103], ["chickens", "ORGANISM", 121, 129], ["pheasants", "ORGANISM", 134, 143], ["chickens", "SPECIES", 121, 129], ["chickens", "SPECIES", 121, 129], ["pheasants", "SPECIES", 134, 143], ["the current study", "TEST", 9, 26], ["the pathogenicity", "PROBLEM", 48, 65], ["the PhCoV isolates", "TREATMENT", 94, 112]]], ["Intranasal instillation of 10 3-week-old SPF chickens with 0.2 ml of infectious allantoic fluid containing 103.2 EID50 of PhCoV previously failed to produce any clinical signs of disease (Lister et al., 1985).", [["allantoic fluid", "ANATOMY", 80, 95], ["PhCoV", "CHEMICAL", 122, 127], ["SPF", "ORGANISM", 41, 44], ["chickens", "ORGANISM", 45, 53], ["PhCoV", "GENE_OR_GENE_PRODUCT", 122, 127], ["chickens", "SPECIES", 45, 53], ["chickens", "SPECIES", 45, 53], ["PhCoV", "SPECIES", 122, 127], ["Intranasal instillation", "TREATMENT", 0, 23], ["old SPF chickens", "TREATMENT", 37, 53], ["infectious allantoic fluid", "TREATMENT", 69, 95], ["PhCoV", "TREATMENT", 122, 127], ["disease", "PROBLEM", 179, 186], ["disease", "OBSERVATION", 179, 186]]], ["However, all birds had HI, but precipitating antibodies to IBV M41 strain.", [["birds", "ORGANISM", 13, 18], ["IBV M41 strain", "ORGANISM", 59, 73], ["IBV M41", "SPECIES", 59, 66], ["HI", "PROBLEM", 23, 25], ["IBV M41 strain", "PROBLEM", 59, 73]]], ["In this study, inoculation of chickens via the ocular and nasal routes with 0.1 ml of 105.0 EID50 of the PhCoV isolates I0623/17 and I0710/17 at 1, 30, and 45 days of age, respectively, also failed to produce any clinical signs of disease, while pheasants inoculated with I0710/17 showed obvious clinical signs and 30% mortality, similar to chickens infected with IBV strains (Liu and Kong, 2004).", [["ocular", "ANATOMY", 47, 53], ["nasal", "ANATOMY", 58, 63], ["I0710/17", "CHEMICAL", 272, 280], ["chickens", "ORGANISM", 30, 38], ["ocular", "ORGAN", 47, 53], ["pheasants", "ORGANISM", 246, 255], ["chickens", "ORGANISM", 341, 349], ["IBV", "ORGANISM", 364, 367], ["chickens", "SPECIES", 30, 38], ["chickens", "SPECIES", 341, 349], ["chickens", "SPECIES", 30, 38], ["pheasants", "SPECIES", 246, 255], ["chickens", "SPECIES", 341, 349], ["IBV", "SPECIES", 364, 367], ["this study", "TEST", 3, 13], ["inoculation of chickens", "TREATMENT", 15, 38], ["the PhCoV isolates", "TEST", 101, 119], ["disease", "PROBLEM", 231, 238], ["obvious clinical signs", "PROBLEM", 288, 310], ["30% mortality", "PROBLEM", 315, 328], ["IBV strains", "PROBLEM", 364, 375], ["ocular", "ANATOMY", 47, 53], ["nasal", "ANATOMY", 58, 63], ["disease", "OBSERVATION", 231, 238]]], ["The clinical signs were similar to those in the affected commercial pheasants from which the viruses were isolated, and to those in chickens infected with IBV strains (Cavanagh, 2007).", [["pheasants", "ORGANISM", 68, 77], ["chickens", "ORGANISM", 132, 140], ["IBV", "ORGANISM", 155, 158], ["chickens", "SPECIES", 132, 140], ["chickens", "SPECIES", 132, 140], ["IBV", "SPECIES", 155, 158], ["The clinical signs", "PROBLEM", 0, 18], ["the affected commercial pheasants", "PROBLEM", 44, 77], ["the viruses", "PROBLEM", 89, 100], ["IBV strains", "PROBLEM", 155, 166], ["viruses", "OBSERVATION", 93, 100]]], ["Furthermore, not all the inoculated chickens had ELISA-detected antibodies, compared with seroconversion of all pheasants inoculated with the PhCoV isolate.", [["chickens", "ORGANISM", 36, 44], ["pheasants", "ORGANISM", 112, 121], ["antibodies", "PROTEIN", 64, 74], ["chickens", "SPECIES", 36, 44], ["chickens", "SPECIES", 36, 44], ["pheasants", "SPECIES", 112, 121], ["PhCoV", "SPECIES", 142, 147], ["ELISA", "TEST", 49, 54], ["all pheasants", "TREATMENT", 108, 121], ["the PhCoV isolate", "TREATMENT", 138, 155]]], ["Strikingly, the viruses could be re-isolated from the tracheas of chickens inoculated with PhCoV isolates I0623/17 and I0710/17, but were absent or present at very low titers in other chicken tissues investigated in this study.", [["tracheas", "ANATOMY", 54, 62], ["tissues", "ANATOMY", 192, 199], ["tracheas", "ORGAN", 54, 62], ["chickens", "ORGANISM", 66, 74], ["chicken", "ORGANISM", 184, 191], ["tissues", "TISSUE", 192, 199], ["chickens", "SPECIES", 66, 74], ["chicken", "SPECIES", 184, 191], ["chickens", "SPECIES", 66, 74], ["PhCoV", "SPECIES", 91, 96], ["chicken", "SPECIES", 184, 191], ["the viruses", "PROBLEM", 12, 23], ["the tracheas of chickens", "PROBLEM", 50, 74], ["PhCoV isolates", "TEST", 91, 105], ["this study", "TEST", 216, 226], ["viruses", "OBSERVATION", 16, 23], ["tracheas", "ANATOMY", 54, 62], ["chicken tissues", "OBSERVATION_MODIFIER", 184, 199]]], ["In contrast, the PhCoV isolate I0710/17 could be re-isolated from, and had significantly higher viral titers in all pheasant tissues investigated in this study, especially the kidneys.", [["tissues", "ANATOMY", 125, 132], ["kidneys", "ANATOMY", 176, 183], ["tissues", "TISSUE", 125, 132], ["kidneys", "ORGAN", 176, 183], ["pheasant", "SPECIES", 116, 124], ["the PhCoV isolate", "TEST", 13, 30], ["significantly higher viral titers in all pheasant tissues", "PROBLEM", 75, 132], ["this study", "TEST", 149, 159], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["viral titers", "OBSERVATION", 96, 108], ["pheasant tissues", "OBSERVATION", 116, 132], ["kidneys", "ANATOMY", 176, 183]]], ["These results were in line with the IHC results, which showed that viral antigen-positive epithelial cells were intensely labeled in the kidneys of pheasants challenged with I0710/17.", [["epithelial cells", "ANATOMY", 90, 106], ["kidneys", "ANATOMY", 137, 144], ["kidneys", "ORGAN", 137, 144], ["pheasants", "ORGANISM", 148, 157], ["positive epithelial cells", "CELL_TYPE", 81, 106], ["the IHC", "TEST", 32, 39], ["viral antigen", "TEST", 67, 80], ["positive epithelial cells", "PROBLEM", 81, 106], ["epithelial cells", "OBSERVATION", 90, 106], ["kidneys", "ANATOMY", 137, 144]]], ["These results were also consistent with those for viral replication and shedding, which indicated prolonged virus replication and higher number of birds shedding virus in the respiratory and digestive tracts of pheasants compared with chickens inoculated with PhCoVs.", [["respiratory", "ANATOMY", 175, 186], ["digestive tracts", "ANATOMY", 191, 207], ["digestive tracts", "PATHOLOGICAL_FORMATION", 191, 207], ["pheasants", "ORGANISM", 211, 220], ["chickens", "ORGANISM", 235, 243], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 260, 266], ["chickens", "SPECIES", 235, 243], ["chickens", "SPECIES", 235, 243], ["viral replication", "PROBLEM", 50, 67], ["prolonged virus replication", "PROBLEM", 98, 125], ["birds shedding virus", "PROBLEM", 147, 167], ["consistent with", "UNCERTAINTY", 24, 39], ["virus replication", "OBSERVATION", 108, 125], ["higher", "OBSERVATION_MODIFIER", 130, 136], ["number", "OBSERVATION_MODIFIER", 137, 143], ["respiratory", "ANATOMY", 175, 186], ["digestive tracts", "ANATOMY", 191, 207]]], ["These findings support the different biological characteristics of PhCoVs compared with IBVs (Liu et al., 2008a,b).DiscussionThe close relationship\u2014but with obvious differences between PhCoVs and IBVs\u2014led us to speculate that the PhCoVs may have originated from IBVs.", [["PhCoVs", "SIMPLE_CHEMICAL", 67, 73], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 230, 236], ["IBVs", "CANCER", 262, 266], ["PhCoVs", "PROTEIN", 230, 236]]], ["This hypothesis was confirmed, at least in part, by the analyses of S1 fragments from PhCoVs isolated from different outbreaks and selected IBV strains.", [["S1", "GENE_OR_GENE_PRODUCT", 68, 70], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 86, 92], ["IBV", "ORGANISM", 140, 143], ["S1 fragments", "DNA", 68, 80], ["IBV", "SPECIES", 140, 143], ["S1 fragments", "PROBLEM", 68, 80], ["PhCoVs", "PROBLEM", 86, 92], ["selected IBV strains", "PROBLEM", 131, 151], ["S1 fragments", "OBSERVATION", 68, 80], ["different", "OBSERVATION_MODIFIER", 107, 116], ["outbreaks", "OBSERVATION_MODIFIER", 117, 126], ["IBV strains", "OBSERVATION", 140, 151]]], ["Instead of being clustered together and showing a close genetic relationship, the PhCoVs isolated from different outbreaks in different years clustered in different groups, with each group showing a relatively close relationship with the IBVs circulating in the regions from which the respective PhCoVs were isolated.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 82, 88], ["IBVs", "GENE_OR_GENE_PRODUCT", 238, 242], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 296, 302], ["PhCoVs", "PROTEIN", 82, 88], ["IBVs", "DNA", 238, 242], ["PhCoVs", "DNA", 296, 302], ["regions", "ANATOMY_MODIFIER", 262, 269]]], ["We speculated that the IBV strains may have been introduced into and adapted themselves in pheasants, and subsequently evolved independently to different extents resulting in different virulences in pheasants.", [["IBV", "ORGANISM", 23, 26], ["pheasants", "ORGANISM", 91, 100], ["pheasants", "ORGANISM", 199, 208], ["IBV", "SPECIES", 23, 26], ["the IBV strains", "TREATMENT", 19, 34], ["different virulences in pheasants", "PROBLEM", 175, 208], ["different virulences", "OBSERVATION", 175, 195]]], ["For example, a previous report on the isolation of a PhCoV reported that the only notable clinical features were respiratory signs, reduced egg production, and shell-quality problems (Spackman and Cameron, 1983).", [["respiratory", "ANATOMY", 113, 124], ["egg", "ANATOMY", 140, 143], ["respiratory signs", "DISEASE", 113, 130], ["egg", "ORGANISM_SUBDIVISION", 140, 143], ["respiratory signs", "PROBLEM", 113, 130], ["reduced egg production", "PROBLEM", 132, 154], ["respiratory signs", "OBSERVATION", 113, 130], ["reduced", "OBSERVATION_MODIFIER", 132, 139], ["egg production", "OBSERVATION", 140, 154]]], ["However, the PhCoVs in the current and other studies showed a high affinity to the kidney (Gough et al., 1996; Lister et al., 1985; Pennycott, 2000) and were highly pathogenic in pheasants.", [["kidney", "ANATOMY", 83, 89], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 13, 19], ["kidney", "ORGAN", 83, 89], ["pheasants", "ORGANISM", 179, 188], ["PhCoVs", "PROTEIN", 13, 19], ["the PhCoVs", "TEST", 9, 19], ["other studies", "TEST", 39, 52], ["a high affinity to the kidney", "PROBLEM", 60, 89], ["Pennycott", "TEST", 132, 141], ["high affinity", "OBSERVATION", 62, 75], ["kidney", "ANATOMY", 83, 89], ["highly", "OBSERVATION_MODIFIER", 158, 164], ["pathogenic", "OBSERVATION", 165, 175]]], ["The hypothesis that different introductions of the viruses from chickens to pheasants and the independent evolution of the resulting PhCoVs may account for the inconsistent phenotypes of the PhCoVs.DiscussionThe emergence of CoVs in turkeys was proposed to have resulted from recombination events involving IBVs and an as-yet-unidentified CoV, which donated an S gene encoding a protein with low amino acid identity to IBV (35%) (Jackwood et al., 2010; Brown et al., 2016).", [["CoVs", "CHEMICAL", 225, 229], ["amino acid", "CHEMICAL", 396, 406], ["amino acid", "CHEMICAL", 396, 406], ["chickens", "ORGANISM", 64, 72], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 133, 139], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 191, 197], ["CoVs", "GENE_OR_GENE_PRODUCT", 225, 229], ["turkeys", "ORGANISM", 233, 240], ["IBVs", "GENE_OR_GENE_PRODUCT", 307, 311], ["CoV", "ORGANISM", 339, 342], ["amino acid", "AMINO_ACID", 396, 406], ["IBV", "ORGANISM", 419, 422], ["PhCoVs", "DNA", 133, 139], ["PhCoVs", "DNA", 191, 197], ["CoVs", "DNA", 225, 229], ["S gene", "DNA", 361, 367], ["chickens", "SPECIES", 64, 72], ["turkeys", "SPECIES", 233, 240], ["chickens", "SPECIES", 64, 72], ["turkeys", "SPECIES", 233, 240], ["The hypothesis", "PROBLEM", 0, 14], ["the viruses", "PROBLEM", 47, 58], ["pheasants", "TREATMENT", 76, 85], ["the resulting PhCoVs", "PROBLEM", 119, 139], ["the inconsistent phenotypes of the PhCoVs", "PROBLEM", 156, 197], ["CoVs", "PROBLEM", 225, 229], ["recombination events", "PROBLEM", 276, 296], ["IBVs", "PROBLEM", 307, 311], ["unidentified CoV", "PROBLEM", 326, 342], ["low amino acid identity", "TREATMENT", 392, 415], ["IBV", "TEST", 419, 422], ["different", "OBSERVATION_MODIFIER", 20, 29], ["introductions", "OBSERVATION_MODIFIER", 30, 43], ["may account for", "UNCERTAINTY", 140, 155]]], ["This is suspected to have resulted in a host shift from chickens to turkeys, as well as switching the tissue tropism of the virus from the upper respiratory to the intestinal tract.", [["tissue", "ANATOMY", 102, 108], ["respiratory", "ANATOMY", 145, 156], ["intestinal tract", "ANATOMY", 164, 180], ["chickens", "ORGANISM", 56, 64], ["turkeys", "ORGANISM", 68, 75], ["tissue", "TISSUE", 102, 108], ["upper respiratory", "ORGANISM_SUBDIVISION", 139, 156], ["intestinal tract", "ORGAN", 164, 180], ["chickens", "SPECIES", 56, 64], ["turkeys", "SPECIES", 68, 75], ["chickens", "SPECIES", 56, 64], ["turkeys", "SPECIES", 68, 75], ["the tissue tropism of the virus", "TREATMENT", 98, 129], ["host shift", "OBSERVATION", 40, 50], ["upper", "ANATOMY_MODIFIER", 139, 144], ["respiratory", "ANATOMY", 145, 156], ["intestinal tract", "ANATOMY", 164, 180]]], ["In this study, we detected genome-wide differences, including point mutations, deletions, and insertions, in the ORFs and deduced protein sequences of our PhCoVs, compared with IBVs.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 155, 161], ["ORFs", "DNA", 113, 117], ["PhCoVs", "DNA", 155, 161], ["this study", "TEST", 3, 13], ["point mutations, deletions", "PROBLEM", 62, 88], ["the ORFs", "TEST", 109, 117], ["IBVs", "TREATMENT", 177, 181], ["wide", "OBSERVATION_MODIFIER", 34, 38]]], ["The accumulation of substitutions in multiple genes in the PhCoV genome resulted in a host shift from chickens to pheasants, but did not lead to a change in tissue tropism (nephropathogenicity).", [["tissue", "ANATOMY", 157, 163], ["PhCoV", "GENE_OR_GENE_PRODUCT", 59, 64], ["chickens", "ORGANISM", 102, 110], ["tissue", "TISSUE", 157, 163], ["PhCoV genome", "DNA", 59, 71], ["chickens", "SPECIES", 102, 110], ["chickens", "SPECIES", 102, 110], ["The accumulation of substitutions in multiple genes in the PhCoV genome", "PROBLEM", 0, 71], ["a change in tissue tropism (nephropathogenicity", "PROBLEM", 145, 192], ["accumulation of substitutions", "OBSERVATION", 4, 33], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["genes", "OBSERVATION_MODIFIER", 46, 51], ["PhCoV genome", "OBSERVATION", 59, 71], ["host shift", "OBSERVATION", 86, 96], ["tissue tropism", "OBSERVATION", 157, 171]]], ["In addition, we found no recombination events in the genomes of our PhCoVs compared with the IBV strains selected in this study.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 68, 74], ["IBV", "ORGANISM", 93, 96], ["PhCoVs", "DNA", 68, 74], ["IBV", "SPECIES", 93, 96], ["recombination events", "PROBLEM", 25, 45], ["the IBV strains", "PROBLEM", 89, 104], ["this study", "TEST", 117, 127], ["no", "UNCERTAINTY", 22, 24], ["recombination events", "OBSERVATION", 25, 45]]], ["In contrast, different phylogenetic topologies were observed when the S1 fragments and 3\u2032UTRs of some of the PhCoVs isolated in UK were compared, suggesting that possible recombination events might have occurred.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 109, 115], ["UK", "GENE_OR_GENE_PRODUCT", 128, 130], ["S1 fragments", "DNA", 70, 82], ["3\u2032UTRs", "DNA", 87, 93], ["PhCoVs", "DNA", 109, 115], ["different phylogenetic topologies", "PROBLEM", 13, 46], ["the S1 fragments", "PROBLEM", 66, 82], ["recombination events", "PROBLEM", 171, 191], ["phylogenetic topologies", "OBSERVATION", 23, 46], ["S1", "ANATOMY", 70, 72], ["fragments", "OBSERVATION", 73, 82]]], ["The different evolutionary patterns between our PhCoVs and those isolated in the UK might suggest that PhCoVs isolated in different outbreaks derived differently and have evolved independently.DiscussionThere is currently no information on the complete genome sequences of PhCoVs isolated in other countries.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 48, 54], ["UK", "GENE_OR_GENE_PRODUCT", 81, 83], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 103, 109], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 273, 279], ["genome sequences", "DNA", 253, 269], ["PhCoVs", "DNA", 273, 279], ["PhCoVs", "PROBLEM", 103, 109], ["different", "OBSERVATION_MODIFIER", 4, 13], ["evolutionary", "OBSERVATION_MODIFIER", 14, 26], ["patterns", "OBSERVATION_MODIFIER", 27, 35]]], ["Further molecular studies are therefore required to determine the complete genomic sequences of PhCoVs from different outbreaks in pheasants, to allow a thorough investigation of the relationships between PhCoVs and IBVs.", [["PhCoVs", "GENE_OR_GENE_PRODUCT", 96, 102], ["pheasants", "ORGANISM", 131, 140], ["PhCoVs", "GENE_OR_GENE_PRODUCT", 205, 211], ["IBVs", "CANCER", 216, 220], ["Further molecular studies", "TEST", 0, 25], ["a thorough investigation", "TEST", 151, 175], ["PhCoVs", "TREATMENT", 205, 211], ["IBVs", "TREATMENT", 216, 220]]], ["In addition, further research involving the infection of pheasants with IBVs is also required to ascertain its pathogenicity in pheasants and whether could pheasants be the potential asymptomatic vectors of IBV for possibly spreading the virus.", [["infection", "DISEASE", 44, 53], ["pheasants", "ORGANISM", 57, 66], ["pheasants", "ORGANISM", 128, 137], ["pheasants", "ORGANISM", 156, 165], ["IBV", "ORGANISM", 207, 210], ["pheasants", "SPECIES", 57, 66], ["pheasants", "SPECIES", 128, 137], ["IBV", "SPECIES", 207, 210], ["the infection of pheasants", "PROBLEM", 40, 66], ["IBVs", "TREATMENT", 72, 76], ["IBV", "TREATMENT", 207, 210], ["spreading the virus", "PROBLEM", 224, 243], ["infection", "OBSERVATION", 44, 53]]]], "PMC7318951": [["FundingNo funding was required for this paper.Declaration of Competing interestCOINo competing interests to disclose.Ethics approvalNot applicable.Consent to participateNot applicable.Consent for publicationNot applicable.Availability of data and materialNot applicable.Code availabilityNot applicable.Authors' contributionsI, Sagar Kulkarni made substantial contributions to the conception and design of the work.", [["No", "UNCERTAINTY", 7, 9], ["funding", "OBSERVATION", 10, 17]]], ["I gave final approval for this version to be published.", [["this version", "TREATMENT", 26, 38]]]], "814c32b43397b8ce77b8930066dabe3378edcbc9": [["Coronavirus disease (COVID-19) is a pandemic manifesting respiratory illness and first reported inWuhan, Hubei province of China in December 2019.", [["respiratory", "ANATOMY", 57, 68], ["Coronavirus disease", "DISEASE", 0, 19], ["respiratory illness", "DISEASE", 57, 76], ["Coronavirus disease", "PROBLEM", 0, 19], ["respiratory illness", "PROBLEM", 57, 76]]], ["The death toll rose to more than 68,000 among 1,250,000 confirmed cases around the Globe (until April 4, 2020) [1] .", [["death", "DISEASE", 4, 9], ["The death", "PROBLEM", 0, 9], ["Globe", "ANATOMY", 83, 88]]], ["The virus causing COVID-19 is named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["COVID-19", "CHEMICAL", 18, 26], ["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV-2", "SPECIES", 88, 98], ["The virus", "PROBLEM", 0, 9], ["COVID", "TEST", 18, 23], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 39, 84], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["virus", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome", "OBSERVATION", 52, 72]]], ["Based on the phylogenetic studies, the SARS-CoV-2 is categorized as a member of the genus Betacoronavirus, the same lineage that includes SARS coronavirus (SARS-CoV) [2] that caused SARS (Severe Acute Respiratory Syndrome) in China during 2002 [3] .", [["SARS", "DISEASE", 39, 43], ["SARS coronavirus", "DISEASE", 138, 154], ["SARS", "DISEASE", 156, 160], ["SARS", "DISEASE", 182, 186], ["Acute Respiratory Syndrome", "DISEASE", 195, 221], ["SARS-CoV-2", "ORGANISM", 39, 49], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 90, 105], ["SARS coronavirus", "ORGANISM", 138, 154], ["SARS-CoV", "ORGANISM", 156, 164], ["SARS coronavirus", "SPECIES", 138, 154], ["SARS-CoV", "SPECIES", 39, 47], ["SARS coronavirus", "SPECIES", 138, 154], ["SARS-CoV", "SPECIES", 156, 164], ["the phylogenetic studies", "TEST", 9, 33], ["the SARS", "TEST", 35, 43], ["SARS coronavirus", "PROBLEM", 138, 154], ["SARS (Severe Acute Respiratory Syndrome", "PROBLEM", 182, 221], ["Severe", "OBSERVATION_MODIFIER", 188, 194], ["Acute", "OBSERVATION_MODIFIER", 195, 200], ["Respiratory Syndrome", "OBSERVATION", 201, 221]]], ["Recent studies showed that SARS-CoV-2 has a close relationship with bat SARS-like CoVs [4, 5] [7] ].Coronavirus disease (COVID-19) is a pandemic manifesting respiratory illness and first reported inInterestingly, S glycoprotein is characterized as the critical determinant for viral entry into host cells which consists of two functional subunits namely S1 and S2.", [["respiratory", "ANATOMY", 157, 168], ["cells", "ANATOMY", 299, 304], ["SARS", "DISEASE", 72, 76], ["Coronavirus disease", "DISEASE", 100, 119], ["respiratory illness", "DISEASE", 157, 176], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 213, 227], ["host cells", "CELL", 294, 304], ["S1", "GENE_OR_GENE_PRODUCT", 354, 356], ["S2", "GENE_OR_GENE_PRODUCT", 361, 363], ["S glycoprotein", "PROTEIN", 213, 227], ["host cells", "CELL_TYPE", 294, 304], ["S1", "PROTEIN", 354, 356], ["S2", "PROTEIN", 361, 363], ["Recent studies", "TEST", 0, 14], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["bat SARS", "PROBLEM", 68, 76], ["Coronavirus disease", "PROBLEM", 100, 119], ["COVID", "TEST", 121, 126], ["a pandemic manifesting respiratory illness", "PROBLEM", 134, 176], ["viral entry into host cells", "PROBLEM", 277, 304], ["respiratory illness", "OBSERVATION", 157, 176], ["S2", "ANATOMY", 361, 363]]], ["The S1 subunit recognizes and binds to the host receptor through the receptor-binding domain (RBD) whereas S2 is responsible for fusion with the host cell membrane [ [8] , [9] , [10] ].", [["cell membrane", "ANATOMY", 150, 163], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["S2", "GENE_OR_GENE_PRODUCT", 107, 109], ["cell membrane", "CELLULAR_COMPONENT", 150, 163], ["S1 subunit", "PROTEIN", 4, 14], ["receptor-binding domain", "PROTEIN", 69, 92], ["RBD", "PROTEIN", 94, 97], ["S2", "PROTEIN", 107, 109], ["S1", "ANATOMY_MODIFIER", 4, 6]]], ["MERS-CoV uses dipeptidyl peptidase-4 (DPP4) as entry receptor [11] whereas SARS-CoV and SARS-CoV-2 utilize ACE-2 (angiotensin converting enzyme-2) [12] , abundantly available in lung alveolar epithelial cells and enterocytes, suggesting S glycoprotein as a potential drug target to halt the entry of SARS-with remarkable properties like glutamine-rich 42 aa long exclusive molecular signature (DSQQTVGQQDGSEDNQTTTIQTIVEVQPQLEMELTPVVQTIE) in position 983-1024 of polyprotein 1ab (pp1ab) [16] , diversified receptor-binding domain (RBD), unique furin cleavage site (PRRAR\u2193SV) at S1/S2 boundary in S glycoprotein which could play roles in viral pathogenesis, diagnosis and treatment [17] .", [["lung alveolar epithelial cells", "ANATOMY", 178, 208], ["enterocytes", "ANATOMY", 213, 224], ["angiotensin", "CHEMICAL", 114, 125], ["SARS", "DISEASE", 300, 304], ["glutamine", "CHEMICAL", 337, 346], ["glutamine", "CHEMICAL", 337, 346], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 14, 36], ["DPP4", "GENE_OR_GENE_PRODUCT", 38, 42], ["SARS-CoV", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 88, 98], ["ACE-2", "GENE_OR_GENE_PRODUCT", 107, 112], ["angiotensin converting enzyme-2", "GENE_OR_GENE_PRODUCT", 114, 145], ["[12]", "SIMPLE_CHEMICAL", 147, 151], ["lung alveolar epithelial cells", "CELL", 178, 208], ["enterocytes", "CELL", 213, 224], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 237, 251], ["glutamine", "AMINO_ACID", 337, 346], ["furin", "GENE_OR_GENE_PRODUCT", 543, 548], ["PRRAR\u2193SV", "GENE_OR_GENE_PRODUCT", 564, 572], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 595, 609], ["MERS-CoV", "PROTEIN", 0, 8], ["dipeptidyl peptidase-4", "PROTEIN", 14, 36], ["DPP4", "PROTEIN", 38, 42], ["ACE", "PROTEIN", 107, 110], ["lung alveolar epithelial cells", "CELL_TYPE", 178, 208], ["enterocytes", "CELL_TYPE", 213, 224], ["S glycoprotein", "PROTEIN", 237, 251], ["receptor-binding domain", "PROTEIN", 505, 528], ["RBD", "PROTEIN", 530, 533], ["furin cleavage site", "PROTEIN", 543, 562], ["PRRAR", "PROTEIN", 564, 569], ["SV", "PROTEIN", 570, 572], ["S1", "PROTEIN", 577, 579], ["S2", "PROTEIN", 580, 582], ["S glycoprotein", "PROTEIN", 595, 609], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 75, 83], ["dipeptidyl peptidase-4 (DPP4)", "TREATMENT", 14, 43], ["SARS", "TEST", 75, 79], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["ACE-2 (angiotensin converting enzyme-", "TREATMENT", 107, 144], ["S glycoprotein", "PROBLEM", 237, 251], ["a potential drug target", "TREATMENT", 255, 278], ["SARS", "PROBLEM", 300, 304], ["polyprotein 1ab (pp1ab)", "TREATMENT", 462, 485], ["diversified receptor-binding domain (RBD)", "TREATMENT", 493, 534], ["unique furin cleavage site", "PROBLEM", 536, 562], ["lung", "ANATOMY", 178, 182], ["alveolar", "ANATOMY_MODIFIER", 183, 191], ["epithelial cells", "OBSERVATION", 192, 208], ["enterocytes", "ANATOMY", 213, 224]]], ["To date, few genomic variations of SARS-CoV-2 are reported [ [18] , [19] ].", [["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["[ [18] , [19] ].", "SIMPLE_CHEMICAL", 59, 75], ["SARS-CoV", "SPECIES", 35, 43], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43]]], ["There is growing evidence that spike protein, a 1273 amino acid long glycoprotein having multiple domains, possibly plays a major role in SARS-CoV-2 pathogenesis.", [["amino acid", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 53, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 138, 148], ["spike protein", "PROTEIN", 31, 44], ["1273 amino acid long glycoprotein", "PROTEIN", 48, 81], ["spike protein", "PROBLEM", 31, 44], ["a 1273 amino acid long glycoprotein", "TREATMENT", 46, 81], ["SARS", "PROBLEM", 138, 142], ["spike", "OBSERVATION_MODIFIER", 31, 36], ["SARS", "OBSERVATION", 138, 142]]], ["Viral entry to the host cell is initiated by the receptor-binding domain (RBD) of S1 head.", [["cell", "ANATOMY", 24, 28], ["head", "ANATOMY", 85, 89], ["host cell", "CELL", 19, 28], ["head", "ORGAN", 85, 89], ["receptor-binding domain", "PROTEIN", 49, 72], ["RBD", "PROTEIN", 74, 77], ["S1 head", "PROTEIN", 82, 89], ["host cell", "OBSERVATION", 19, 28], ["S1", "ANATOMY_MODIFIER", 82, 84], ["head", "ANATOMY", 85, 89]]], ["Upon receptor-binding, proteolytic cleavage occurs at S1/S2 cleavage site and two heptad repeats (HR) of S2 stalk form a six-helix bundle structure triggering the release of the fusion peptide.Coronavirus disease (COVID-19) is a pandemic manifesting respiratory illness and first reported inAs it comes into close proximity to the transmembrane anchor (TM), the TM domain facilitates membrane destabilization required for fusion between virus-host membranes [ [20] , [21] ].", [["respiratory", "ANATOMY", 250, 261], ["transmembrane", "ANATOMY", 331, 344], ["membrane", "ANATOMY", 384, 392], ["membranes", "ANATOMY", 448, 457], ["Coronavirus disease", "DISEASE", 193, 212], ["respiratory illness", "DISEASE", 250, 269], ["S2", "GENE_OR_GENE_PRODUCT", 57, 59], ["transmembrane", "CELLULAR_COMPONENT", 331, 344], ["membrane", "CELLULAR_COMPONENT", 384, 392], ["S1", "PROTEIN", 54, 56], ["S2", "PROTEIN", 57, 59], ["heptad repeats", "PROTEIN", 82, 96], ["six-helix bundle structure", "PROTEIN", 121, 147], ["transmembrane anchor", "PROTEIN", 331, 351], ["TM", "PROTEIN", 353, 355], ["TM domain", "PROTEIN", 362, 371], ["proteolytic cleavage", "PROBLEM", 23, 43], ["two heptad repeats", "TEST", 78, 96], ["the fusion peptide", "TREATMENT", 174, 192], ["Coronavirus disease", "PROBLEM", 193, 212], ["a pandemic manifesting respiratory illness", "PROBLEM", 227, 269], ["the TM domain facilitates membrane destabilization", "TREATMENT", 358, 408], ["fusion between virus-host membranes", "TREATMENT", 422, 457]]], ["Insights into the sequence variations of S glycoprotein among available genomes are key to understanding the biology of SARS-CoV-2 infection, developing antiviral treatments and vaccines.", [["SARS-CoV-2 infection", "DISEASE", 120, 140], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 41, 55], ["SARS-CoV-2", "ORGANISM", 120, 130], ["S glycoprotein", "PROTEIN", 41, 55], ["CoV-2", "SPECIES", 125, 130], ["SARS-CoV-2", "SPECIES", 120, 130], ["S glycoprotein", "TREATMENT", 41, 55], ["SARS", "PROBLEM", 120, 124], ["CoV", "PROBLEM", 125, 128], ["2 infection", "PROBLEM", 129, 140], ["antiviral treatments", "TREATMENT", 153, 173], ["vaccines", "TREATMENT", 178, 186], ["infection", "OBSERVATION", 131, 140], ["antiviral treatments", "OBSERVATION", 153, 173]]], ["In this study, we have analyzed 320 genomic sequences of SARS-CoV-2 to identify mutations between the available genomes followed by the amino acid variations in the glycoprotein S to foresee their impact on the viral entry to host cell from structural biology viewpoint.Datasetanalysis.", [["cell", "ANATOMY", 231, 235], ["amino acid", "CHEMICAL", 136, 146], ["amino acid", "CHEMICAL", 136, 146], ["SARS-CoV-2", "ORGANISM", 57, 67], ["amino acid", "AMINO_ACID", 136, 146], ["host cell", "CELL", 226, 235], ["320 genomic sequences", "DNA", 32, 53], ["glycoprotein S", "PROTEIN", 165, 179], ["host cell", "CELL_TYPE", 226, 235], ["SARS-CoV", "SPECIES", 57, 65], ["this study", "TEST", 3, 13], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["mutations", "PROBLEM", 80, 89], ["the amino acid variations", "TREATMENT", 132, 157], ["the glycoprotein S", "TREATMENT", 161, 179], ["Datasetanalysis", "TREATMENT", 270, 285], ["host cell", "OBSERVATION", 226, 235]]], ["The NCBI reference sequence of SARS-CoV-2 S glycoprotein, accession number YP_009724390 was used as the canonical sequence for the analyses of spike protein variants.Phylogenetic analysisVariant analyses of SARS-CoV-2 genomes were performed in the Genome Detective Coronavirus Typing Tool Version 1.13 which is specially designed for this virus The dataset was then aligned with MUSCLE [24] .", [["SARS-CoV-2 S glycoprotein", "GENE_OR_GENE_PRODUCT", 31, 56], ["SARS-CoV-2", "ORGANISM", 207, 217], ["NCBI reference sequence", "DNA", 4, 27], ["SARS-CoV-2 S glycoprotein", "PROTEIN", 31, 56], ["spike protein variants", "PROTEIN", 143, 165], ["SARS-CoV-2 genomes", "DNA", 207, 225], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 207, 215], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["the canonical sequence", "TEST", 100, 122], ["spike protein variants", "PROBLEM", 143, 165], ["Phylogenetic analysisVariant analyses", "TEST", 166, 203], ["SARS", "PROBLEM", 207, 211], ["CoV-2 genomes", "PROBLEM", 212, 225], ["this virus", "PROBLEM", 334, 344], ["MUSCLE", "ANATOMY", 379, 385]]], ["Entropy (H(x)) plot of nucleotide variations in SARS-CoV-2 genome was constructed using BioEdit [25] .", [["nucleotide", "CHEMICAL", 23, 33], ["nucleotide", "CHEMICAL", 23, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["SARS-CoV-2 genome", "DNA", 48, 65], ["SARS-CoV", "SPECIES", 48, 56], ["Entropy (H(x)", "TREATMENT", 0, 13], ["nucleotide variations in SARS", "PROBLEM", 23, 52], ["CoV-2 genome", "TREATMENT", 53, 65]]], ["MEGA X (version 10.1.7) was used to construct the MSAs and the phylogenetic tree using pairwise alignment and neighborjoining methods in ClustalW [26, 27] .", [["MEGA X (version", "TREATMENT", 0, 15], ["phylogenetic tree", "OBSERVATION", 63, 80]]], ["Tree structure was validated by running the analysis on 1000 bootstraps [28] replications dataset and the evolutionary distances were calculated using the Poisson correction method [29] .Homology modeling of S glycoproteinVariant sequences of SARS-CoV-2 were modeled in Swiss-Model [30] using the Cryo-EM spike protein structure of SARS-CoV-2 (PDB ID 6VSB; [8] ) as a template.", [["SARS-CoV-2", "ORGANISM", 243, 253], ["S glycoproteinVariant sequences", "DNA", 208, 239], ["SARS-CoV-2", "DNA", 243, 253], ["SARS-CoV", "SPECIES", 243, 251], ["SARS-CoV", "SPECIES", 332, 340], ["S glycoproteinVariant sequences", "TEST", 208, 239], ["SARS", "TEST", 243, 247], ["CoV", "TEST", 248, 251], ["SARS", "TEST", 332, 336], ["CoV", "TEST", 337, 340]]], ["PyMol and BIOVIA Discovery Studio were used for structure visualization and superpose [32, 33] .Homology modeling of S glycoproteinJ o u r n a l P r e -p r o o f 3.", [["structure visualization", "TEST", 48, 71], ["Homology modeling", "TEST", 96, 113]]], ["ResultsGenomic variations of SARS-CoV-2Multiple sequence alignment of the available 320 genomes of SARS-CoV-2 were performed and 483 variations were found throughout the 29,903 bp long SARS-CoV-2 genome with in total 115 variations in UTR region, 130 synonymous variations that cause no amino acid alteration, 228 non-synonymous variations causing change in amino acid residue, 16 INDELs, and 2 variations in non-coding region (Supplementary Table 2 ).", [["amino acid", "CHEMICAL", 287, 297], ["amino acid", "CHEMICAL", 358, 368], ["amino acid", "CHEMICAL", 287, 297], ["amino acid", "CHEMICAL", 358, 368], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV-2", "ORGANISM", 99, 109], ["amino acid", "AMINO_ACID", 287, 297], ["amino acid", "AMINO_ACID", 358, 368], ["SARS-CoV-2Multiple sequence alignment", "DNA", 29, 66], ["320 genomes", "DNA", 84, 95], ["SARS-CoV-2", "DNA", 99, 109], ["29,903 bp long SARS-CoV-2 genome", "DNA", 170, 202], ["UTR region", "DNA", 235, 245], ["non-coding region", "DNA", 409, 426], ["SARS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "TEST", 29, 37], ["2Multiple sequence alignment", "TEST", 38, 66], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["bp long SARS", "TEST", 177, 189], ["CoV", "TEST", 190, 193], ["total 115 variations in UTR region", "PROBLEM", 211, 245], ["synonymous variations", "TEST", 251, 272], ["amino acid alteration", "PROBLEM", 287, 308], ["non-synonymous variations", "PROBLEM", 314, 339], ["change in amino acid residue", "PROBLEM", 348, 376], ["2 variations in non-coding region", "TREATMENT", 393, 426], ["no", "UNCERTAINTY", 284, 286], ["amino acid", "OBSERVATION", 287, 297], ["amino acid residue", "OBSERVATION", 358, 376]]], ["Among the 483 variations, 40 variations (14 synonymous, 25 non-synonymous mutations and one deletion) were observed in the region of ORF S that encodes S glycoprotein which is responsible for viral fusion and entry into the host cell [34] .", [["cell", "ANATOMY", 229, 233], ["ORF S", "GENE_OR_GENE_PRODUCT", 133, 138], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 152, 166], ["host cell", "CELL", 224, 233], ["ORF S", "DNA", 133, 138], ["S glycoprotein", "PROTEIN", 152, 166], ["40 variations", "TEST", 26, 39], ["synonymous", "TEST", 44, 54], ["25 non-synonymous mutations", "PROBLEM", 56, 83], ["ORF S", "PROBLEM", 133, 138], ["viral fusion", "TREATMENT", 192, 204]]], ["Notable that, most of the SARS-CoV-2 genome sequences were deposited from the USA (250) and China (50) (Supplementary Fig. 1 ).", [["SARS", "DISEASE", 26, 30], ["SARS-CoV", "ORGANISM", 26, 34], ["SARS-CoV-2 genome sequences", "DNA", 26, 53], ["SARS-CoV", "SPECIES", 26, 34], ["the SARS", "TEST", 22, 30]]], ["Positional variability of the SARS-CoV-2 genome was calculated from the MSA of 320 SARS-CoV-2 whole genomes as a measure of Entropy value (H(x)) [35] .", [["SARS", "DISEASE", 30, 34], ["SARS", "DISEASE", 83, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["SARS-CoV-2 genome", "DNA", 30, 47], ["320 SARS-CoV-2 whole genomes", "DNA", 79, 107], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 83, 91], ["Positional variability", "PROBLEM", 0, 22], ["the SARS", "PROBLEM", 26, 34], ["CoV", "TEST", 35, 38], ["the MSA", "TEST", 68, 75], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["Entropy value", "TEST", 124, 137], ["variability", "OBSERVATION_MODIFIER", 11, 22], ["SARS", "OBSERVATION", 30, 34]]], ["Excluding 5\u2032 and 3\u2032 UTR, ten hotspot of hypervariable position were identified, of which seven were located at ORF1ab (1059C>T, 3037C>T, 8782C>T, 14408C>T, 17747C>T, 17858A>G, 18060C>T) and one at ORF S (23403A>G), ORF3a (25563G>T), and ORF8 (28144T>C) respectively.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 111, 117], ["17858A>G", "GENE_OR_GENE_PRODUCT", 166, 174], ["18060C>T", "GENE_OR_GENE_PRODUCT", 176, 184], ["23403A>G", "GENE_OR_GENE_PRODUCT", 204, 212], ["ORF3a", "GENE_OR_GENE_PRODUCT", 215, 220], ["25563G>T", "GENE_OR_GENE_PRODUCT", 222, 230], ["ORF8", "GENE_OR_GENE_PRODUCT", 237, 241], ["UTR", "DNA", 20, 23], ["ORF1ab", "DNA", 111, 117], ["ORF S", "DNA", 197, 202], ["ORF8", "DNA", 237, 241], ["UTR", "PROBLEM", 20, 23], ["ORF S", "TEST", 197, 202], ["ORF3a", "TEST", 215, 220], ["ORF8", "TEST", 237, 241], ["hypervariable", "OBSERVATION_MODIFIER", 40, 53], ["position", "OBSERVATION_MODIFIER", 54, 62]]], ["The variability at position 8782 and 28144 were found to be the highest among the other hotspots ( Fig. 1 ).Phylogenetic Analysis of S glycoproteinThe phylogenetic analysis of a total of 66 sequences (26 unique SARS-CoV-2 and 40 different coronavirus S glycoprotein sequences) was performed.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 133, 147], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 211, 221], ["coronavirus S glycoprotein", "GENE_OR_GENE_PRODUCT", 239, 265], ["S glycoprotein", "PROTEIN", 133, 147], ["66 sequences", "DNA", 187, 199], ["SARS-CoV-2 and 40 different coronavirus S glycoprotein sequences", "DNA", 211, 275], ["Phylogenetic Analysis", "TEST", 108, 129], ["The phylogenetic analysis", "TEST", 147, 172], ["unique SARS", "TEST", 204, 215], ["CoV", "TEST", 216, 219], ["different coronavirus S glycoprotein sequences", "TEST", 229, 275], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["S glycoprotein", "OBSERVATION_MODIFIER", 133, 147]]], ["The evolutionary distances showed that all the SARS-CoV-2 spike proteins cluster in the same node of the phylogenetic tree confirming the sequences are similar to Refseq YP_009724390 (Fig. 2) .", [["node", "ANATOMY", 93, 97], ["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["SARS-CoV-2 spike proteins", "DNA", 47, 72], ["the SARS", "TEST", 43, 51], ["CoV", "TEST", 52, 55], ["2 spike proteins cluster", "PROBLEM", 56, 80], ["node", "OBSERVATION", 93, 97], ["phylogenetic", "ANATOMY_MODIFIER", 105, 117], ["tree", "ANATOMY_MODIFIER", 118, 122]]], ["Bat coronaviruses has a close evolutionary relationship as different strains were found in the nearest outgroups and clades (Bat coronavirus BM48-31, Bat hp-beta coronavirus, Bat coronavirus HKU9) conferring that J o u r n a l P r e -p r o o f Journal Pre-proof coronavirus has vast geographical spread and bat is the most prevalent host (Fig. 2) .", [["Pre-proof coronavirus", "DISEASE", 252, 273], ["Bat coronaviruses", "ORGANISM", 0, 17], ["Bat coronavirus BM48-31", "ORGANISM", 125, 148], ["Bat hp-beta coronavirus", "ORGANISM", 150, 173], ["Bat coronavirus HKU9", "ORGANISM", 175, 195], ["Pre-proof coronavirus", "ORGANISM", 252, 273], ["Bat coronavirus BM48", "SPECIES", 125, 145], ["beta coronavirus", "SPECIES", 157, 173], ["Bat coronavirus", "SPECIES", 175, 190], ["Bat coronaviruses", "SPECIES", 0, 17], ["Bat coronavirus", "SPECIES", 125, 140], ["Bat hp-beta coronavirus", "SPECIES", 150, 173], ["Bat coronavirus", "SPECIES", 175, 190], ["Pre-proof coronavirus", "SPECIES", 252, 273], ["Bat coronaviruses", "PROBLEM", 0, 17], ["different strains", "PROBLEM", 59, 76], ["Bat coronavirus BM48", "TEST", 125, 145], ["Bat hp", "TEST", 150, 156], ["beta coronavirus", "PROBLEM", 157, 173], ["coronavirus", "PROBLEM", 262, 273], ["vast geographical spread", "PROBLEM", 278, 302], ["most prevalent", "OBSERVATION_MODIFIER", 318, 332]]], ["In other clades, the clusters were speculated through different hosts which may describe the evolutionary changes of surface glycoprotein due to cross species transmission.", [["surface", "ANATOMY", 117, 124], ["surface glycoprotein", "GENE_OR_GENE_PRODUCT", 117, 137], ["surface glycoprotein", "PROTEIN", 117, 137], ["surface glycoprotein", "PROBLEM", 117, 137], ["cross species transmission", "PROBLEM", 145, 171], ["clades", "OBSERVATION_MODIFIER", 9, 15], ["clusters", "OBSERVATION_MODIFIER", 21, 29]]], ["Viral hosts reported from different spots at different times is indicative of possible recombination.SARS-CoV-2 Spike Protein Variation AnalysisThe S glycoprotein sequences of SARS-CoV-2 were retrieved from the NCBI Virus Variation Resource repository and aligned using ClustalW.", [["Viral hosts", "ORGANISM", 0, 11], ["SARS-CoV-2", "ORGANISM", 176, 186], ["S glycoprotein sequences", "DNA", 148, 172], ["SARS-CoV-2", "DNA", 176, 186], ["SARS-CoV", "SPECIES", 176, 184], ["Viral hosts", "PROBLEM", 0, 11], ["different spots", "PROBLEM", 26, 41], ["recombination", "PROBLEM", 87, 100], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["Variation Analysis", "TEST", 126, 144], ["The S glycoprotein sequences", "TEST", 144, 172], ["SARS", "TEST", 176, 180], ["different spots", "OBSERVATION_MODIFIER", 26, 41], ["indicative of", "UNCERTAINTY", 64, 77], ["possible", "UNCERTAINTY", 78, 86], ["recombination", "OBSERVATION", 87, 100]]], ["The position of SARS-CoV-2 spike protein domains was measured by aligning with the SARS-CoV spike protein (Fig. 3 ) [36, 37] .", [["SARS", "DISEASE", 16, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["SARS-CoV-2 spike protein domains", "PROTEIN", 16, 48], ["SARS-CoV spike protein", "PROTEIN", 83, 105], ["SARS-CoV", "SPECIES", 83, 91], ["SARS", "TEST", 16, 20], ["CoV", "TEST", 21, 24], ["2 spike protein domains", "PROBLEM", 25, 48], ["the SARS", "TEST", 79, 87], ["CoV spike protein", "TEST", 88, 105]]], ["From the sequence identity matrix, 26 unique variants among unique SARS-CoV-2 spike glycoprotein sequences were identified to have 25 substitutions and a deletion ( Fig. 4A and Supplementary Table 3 ).", [["matrix", "CELLULAR_COMPONENT", 27, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["SARS-CoV-2 spike glycoprotein sequences", "DNA", 67, 106], ["SARS-CoV", "SPECIES", 67, 75], ["unique SARS", "TEST", 60, 71], ["CoV", "TEST", 72, 75], ["spike glycoprotein sequences", "TEST", 78, 106], ["a deletion ( Fig. 4A", "TREATMENT", 152, 172]]], ["215 sequences were found identical with SARS-CoV-2 S protein reference sequence (YP_009724390) while 64 sequences were identical with the same variation of D614G (Supplementary Table 4 respectively due to substitution of amino acid that differs in charge.", [["amino acid", "CHEMICAL", 221, 231], ["amino acid", "CHEMICAL", 221, 231], ["amino acid", "AMINO_ACID", 221, 231], ["SARS-CoV-2 S protein reference sequence", "DNA", 40, 79], ["YP_009724390", "DNA", 81, 93], ["D614G", "DNA", 156, 161], ["SARS-CoV", "SPECIES", 40, 48], ["215 sequences", "TEST", 0, 13], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["D614G (Supplementary Table", "TREATMENT", 156, 182], ["substitution of amino acid", "TREATMENT", 205, 231]]], ["The remaining 15 variants were mutated with the amino acids that are similar in charge (Fig. 4 A) .", [["amino acids", "CHEMICAL", 48, 59], ["amino acids", "CHEMICAL", 48, 59], ["amino acids", "AMINO_ACID", 48, 59], ["the amino acids", "TREATMENT", 44, 59], ["15 variants", "OBSERVATION_MODIFIER", 14, 25]]], ["The SARS-CoV-2 spike protein variants were superposed with the cryo-electron microscopic structure of SARS-CoV-2 spike protein [8] .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 102, 112], ["SARS-CoV-2 spike protein variants", "DNA", 4, 37], ["SARS-CoV-2 spike protein", "PROTEIN", 102, 126], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["2 spike protein variants", "PROBLEM", 13, 37], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["spike protein", "TEST", 113, 126]]], ["The S2 subunit of spike protein, especially the heptad repeat region 2, fusion peptide domain, transmembrane domain, and cytoplasmic tail, were found to be highly conserved in the SARS-CoV and the SARS-CoV-2 variants while the S1 subunit was more diverse, specifically the N-terminal domain (NTD) and receptor-binding domain (RBD).SARS-CoV-2 Spike Protein Variation AnalysisThe spatial distribution of S protein sequences having different variation over time reveals that most of the variants (17 out of 240 S glycoprotein sequences) were reported from the US J o u r n a l P r e -p r o o f Journal Pre-proof followed by 3 out of 2 sequences (including Y145 deletion) and 2 out of 50 sequences from India and China, respectively (Fig. 5) .", [["cytoplasmic tail", "ANATOMY", 121, 137], ["SARS", "DISEASE", 180, 184], ["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["cytoplasmic tail", "CELLULAR_COMPONENT", 121, 137], ["SARS-CoV", "ORGANISM", 180, 188], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 197, 207], ["S1", "GENE_OR_GENE_PRODUCT", 227, 229], ["S2 subunit", "PROTEIN", 4, 14], ["spike protein", "PROTEIN", 18, 31], ["heptad repeat region 2", "PROTEIN", 48, 70], ["fusion peptide domain", "PROTEIN", 72, 93], ["transmembrane domain", "PROTEIN", 95, 115], ["cytoplasmic tail", "PROTEIN", 121, 137], ["SARS-CoV and the SARS-CoV-2 variants", "DNA", 180, 216], ["S1 subunit", "PROTEIN", 227, 237], ["N-terminal domain", "PROTEIN", 273, 290], ["NTD", "PROTEIN", 292, 295], ["receptor-binding domain", "PROTEIN", 301, 324], ["RBD", "PROTEIN", 326, 329], ["S protein sequences", "DNA", 402, 421], ["Y145 deletion", "DNA", 653, 666], ["SARS-CoV", "SPECIES", 180, 188], ["SARS-CoV", "SPECIES", 197, 205], ["spike protein", "PROBLEM", 18, 31], ["the heptad repeat region", "TEST", 44, 68], ["fusion peptide domain, transmembrane domain", "TEST", 72, 115], ["cytoplasmic tail", "TEST", 121, 137], ["the SARS", "TEST", 176, 184], ["CoV", "TEST", 185, 188], ["the SARS", "TEST", 193, 201], ["CoV", "TEST", 202, 205], ["the N-terminal domain (NTD)", "PROBLEM", 269, 296], ["receptor-binding domain (RBD)", "PROBLEM", 301, 330], ["SARS", "TEST", 331, 335], ["CoV", "TEST", 336, 339], ["Variation Analysis", "TEST", 356, 374], ["S protein sequences", "TEST", 402, 421], ["the variants", "TEST", 480, 492], ["S glycoprotein sequences", "TEST", 508, 532], ["spike protein", "OBSERVATION", 18, 31], ["cytoplasmic tail", "OBSERVATION", 121, 137]]], ["Interestingly, all sequences are unique among countries from the sequence reported except D614G, which was found in the US and Peru (Fig. 5) .", [["the sequence", "TEST", 61, 73]]], ["Moreover, we have also analyzed sequences from Brazil, Italy, Nepal, Pakistan, Spain, Taiwan and Vietnam but there is no variation in the S glycoprotein sequence was found when compared to Refseq YP_009724390.DiscussionCOVID 19 is one of the most contagious pandemics the world has ever had with 1,250,000 confirmed cases to date (April 4, 2020) and the cases have increased as high as 5 times in less than a month [1] .", [["S glycoprotein sequence", "DNA", 138, 161], ["Refseq YP_009724390", "DNA", 189, 208], ["the S glycoprotein sequence", "TEST", 134, 161], ["no", "UNCERTAINTY", 118, 120]]], ["Phylogenetic analysis showed that the SARS-CoV-2 is a unique coronavirus presumably related to Bat coronavirus (BM48-31, Hp-betacoronavirus).", [["SARS-CoV-2", "ORGANISM", 38, 48], ["coronavirus", "ORGANISM", 61, 72], ["Bat coronavirus", "ORGANISM", 95, 110], ["BM48-31", "ORGANISM", 112, 119], ["Hp-betacoronavirus", "ORGANISM", 121, 139], ["Bat coronavirus", "SPECIES", 95, 110], ["SARS-CoV-2", "SPECIES", 38, 48], ["Bat coronavirus", "SPECIES", 95, 110], ["Phylogenetic analysis", "TEST", 0, 21], ["the SARS", "TEST", 34, 42], ["CoV", "TEST", 43, 46], ["a unique coronavirus", "PROBLEM", 52, 72], ["Bat coronavirus", "TEST", 95, 110], ["BM48", "TEST", 112, 116], ["Hp", "TEST", 121, 123], ["coronavirus", "OBSERVATION", 61, 72]]], ["During this study, we [38] , [39] , [40] ].", [["[39] , [40] ].", "SIMPLE_CHEMICAL", 29, 43], ["this study", "TEST", 7, 17]]], ["Likewise, a number of studies targeting SARS-CoV-2 spike protein have been undertaken for the therapeutic measures [41] , but the unique structural and functional details of SARS-CoV-2 spike protein are still under scrutiny.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 174, 184], ["SARS-CoV-2 spike protein", "PROTEIN", 40, 64], ["SARS-CoV-2 spike protein", "PROTEIN", 174, 198], ["studies", "TEST", 22, 29], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["2 spike protein", "PROBLEM", 49, 64], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["2 spike protein", "PROBLEM", 183, 198]]], ["We also found a variant (R408I) at receptor binding domain (RBD) that mutated from positively charged Arginine residue to neutral and smaller sized Isoleucine residue (Fig. 4 I) .", [["Arginine", "CHEMICAL", 102, 110], ["Isoleucine", "CHEMICAL", 148, 158], ["Arginine", "CHEMICAL", 102, 110], ["Isoleucine", "CHEMICAL", 148, 158], ["Arginine", "AMINO_ACID", 102, 110], ["receptor binding domain", "PROTEIN", 35, 58], ["RBD", "PROTEIN", 60, 63], ["a variant (R408I) at receptor binding domain (RBD)", "PROBLEM", 14, 64], ["Arginine residue", "TREATMENT", 102, 118], ["neutral and smaller sized Isoleucine residue", "PROBLEM", 122, 166], ["smaller", "OBSERVATION_MODIFIER", 134, 141], ["sized", "OBSERVATION_MODIFIER", 142, 147], ["Isoleucine residue", "OBSERVATION", 148, 166]]], ["This change might alter the interaction of viral RBD with the host receptor because the R408 residue of SARS-CoV-2 is known to interact with the ACE2 receptor for viral entry [42] .", [["RBD", "GENE_OR_GENE_PRODUCT", 49, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["viral RBD", "PROTEIN", 43, 52], ["R408 residue", "PROTEIN", 88, 100], ["ACE2 receptor", "PROTEIN", 145, 158], ["SARS-CoV", "SPECIES", 104, 112], ["viral RBD", "PROBLEM", 43, 52], ["the host receptor", "TREATMENT", 58, 75], ["SARS", "PROBLEM", 104, 108]]], ["Similarly, alterations of RBD (G476S, V483A, H519Q, and A520S) also could affect the interaction of SARS-CoV-2 spike protein with other molecules J o u r n a l P r e -p r o o f which require further investigations.", [["SARS", "DISEASE", 100, 104], ["RBD", "GENE_OR_GENE_PRODUCT", 26, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["RBD", "PROTEIN", 26, 29], ["SARS-CoV-2 spike protein", "PROTEIN", 100, 124], ["RBD", "TEST", 26, 29], ["SARS", "TEST", 100, 104], ["CoV", "TEST", 105, 108], ["further investigations", "TEST", 191, 213], ["RBD", "OBSERVATION", 26, 29]]], ["QIA98583 and QIS30615 variants were found to have an alteration of Alanine to Valine (A930V), and Aspartic acid to Tyrosine (D936Y) respectively in the alpha helix of the HR1 domain.", [["QIA98583", "CHEMICAL", 0, 8], ["Alanine", "CHEMICAL", 67, 74], ["Valine", "CHEMICAL", 78, 84], ["Aspartic acid", "CHEMICAL", 98, 111], ["Tyrosine", "CHEMICAL", 115, 123], ["QIA98583", "CHEMICAL", 0, 8], ["Alanine", "CHEMICAL", 67, 74], ["Valine", "CHEMICAL", 78, 84], ["Aspartic acid", "CHEMICAL", 98, 111], ["Tyrosine", "CHEMICAL", 115, 123], ["QIA98583", "GENE_OR_GENE_PRODUCT", 0, 8], ["QIS30615", "GENE_OR_GENE_PRODUCT", 13, 21], ["Alanine", "AMINO_ACID", 67, 74], ["Valine", "SIMPLE_CHEMICAL", 78, 84], ["Aspartic acid", "SIMPLE_CHEMICAL", 98, 111], ["Tyrosine", "AMINO_ACID", 115, 123], ["D936Y", "AMINO_ACID", 125, 130], ["QIA98583 and QIS30615 variants", "DNA", 0, 30], ["alpha helix", "PROTEIN", 152, 163], ["HR1 domain", "PROTEIN", 171, 181], ["Alanine to Valine (A930V)", "TREATMENT", 67, 92], ["Aspartic acid to Tyrosine (D936Y)", "TREATMENT", 98, 131], ["alpha helix", "ANATOMY", 152, 163]]], ["Previous reports have indicated that HR1 domain plays a significant role in viral fusion and entry by forming helical bundles with HR2, and mutations including alanine substitution by valine (A1168V) in HR1 region are predominantly responsible for conferring resistance to mouse hepatitis coronaviruses against HR2 derived peptide entry inhibitors [43] .", [["alanine", "CHEMICAL", 160, 167], ["valine", "CHEMICAL", 184, 190], ["hepatitis coronaviruses", "DISEASE", 279, 302], ["alanine", "CHEMICAL", 160, 167], ["valine", "CHEMICAL", 184, 190], ["HR1", "GENE_OR_GENE_PRODUCT", 37, 40], ["HR2", "GENE_OR_GENE_PRODUCT", 131, 134], ["alanine", "AMINO_ACID", 160, 167], ["valine", "AMINO_ACID", 184, 190], ["A1168V", "AMINO_ACID", 192, 198], ["mouse", "ORGANISM", 273, 278], ["hepatitis coronaviruses", "ORGANISM", 279, 302], ["HR2 derived peptide", "SIMPLE_CHEMICAL", 311, 330], ["HR1 domain", "PROTEIN", 37, 47], ["HR2", "PROTEIN", 131, 134], ["HR1 region", "PROTEIN", 203, 213], ["HR2", "PROTEIN", 311, 314], ["mouse", "SPECIES", 273, 278], ["mouse hepatitis coronaviruses", "SPECIES", 273, 302], ["HR1 domain", "PROBLEM", 37, 47], ["viral fusion", "TREATMENT", 76, 88], ["alanine substitution", "TREATMENT", 160, 180], ["mouse hepatitis coronaviruses", "PROBLEM", 273, 302], ["viral fusion", "OBSERVATION", 76, 88]]], ["This study hypothesizes the mutation (A930V) found in that of SARS-CoV-2 might also have a role in the emergence of drug-resistance virus strains.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV", "SPECIES", 62, 70], ["This study", "TEST", 0, 10], ["the mutation", "PROBLEM", 24, 36], ["SARS", "PROBLEM", 62, 66], ["drug-resistance virus strains", "PROBLEM", 116, 145]]], ["Also, the mutation (D1168H) found in the heptad repeat 2 (HR) SARS-CoV-2 could play a vital role in viral pathogenesis.", [["heptad repeat 2", "GENE_OR_GENE_PRODUCT", 41, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["heptad repeat 2 (HR) SARS-CoV-2", "DNA", 41, 72], ["the heptad repeat", "TEST", 37, 54], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70], ["viral pathogenesis", "PROBLEM", 100, 118], ["viral pathogenesis", "OBSERVATION", 100, 118]]], ["Moreover, we found that 20 variants including one deletion out of 26 were located within S1 especially within NTD and RBD region of glycoprotein S (Fig. 4A) which region is responsible for the preliminary interaction with the host cell receptor ACE2.DiscussionThis indicates that the NTD and RBD are very prone to mutations.", [["cell", "ANATOMY", 231, 235], ["RBD", "DISEASE", 292, 295], ["glycoprotein S (Fig. 4A", "GENE_OR_GENE_PRODUCT", 132, 155], ["host cell receptor ACE2", "GENE_OR_GENE_PRODUCT", 226, 249], ["NTD and RBD region", "DNA", 110, 128], ["glycoprotein S", "PROTEIN", 132, 146], ["Fig. 4A", "PROTEIN", 148, 155], ["host cell receptor", "PROTEIN", 226, 244], ["ACE2", "PROTEIN", 245, 249], ["NTD", "PROTEIN", 284, 287], ["RBD", "PROTEIN", 292, 295], ["20 variants", "PROBLEM", 24, 35], ["one deletion", "PROBLEM", 46, 58], ["glycoprotein S", "PROBLEM", 132, 146], ["the NTD and RBD", "PROBLEM", 280, 295], ["S1", "ANATOMY_MODIFIER", 89, 91], ["RBD", "OBSERVATION", 118, 121], ["responsible for", "UNCERTAINTY", 173, 188]]], ["However, the NTD and RBD portions harbour potential epitopes that might serve as potential peptide vaccine candidates against SARS-CoV-2 as reported in different studies [44] [45] [46] .", [["SARS", "DISEASE", 126, 130], ["SARS-CoV-2", "ORGANISM", 126, 136], ["NTD", "PROTEIN", 13, 16], ["RBD", "PROTEIN", 21, 24], ["epitopes", "PROTEIN", 52, 60], ["SARS-CoV", "SPECIES", 126, 134], ["the NTD and RBD portions harbour potential epitopes", "PROBLEM", 9, 60], ["potential peptide vaccine", "TREATMENT", 81, 106], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134]]], ["The reason behind choosing the sequences from S protein domain NTD and RBD is they are situated in the outer surface of the virus that could be more accessible for the immune system (Fig. 3C ).", [["outer surface", "ANATOMY", 103, 116], ["immune system", "ANATOMY", 168, 181], ["RBD", "GENE_OR_GENE_PRODUCT", 71, 74], ["outer surface", "CELLULAR_COMPONENT", 103, 116], ["S protein domain", "PROTEIN", 46, 62], ["NTD", "PROTEIN", 63, 66], ["RBD", "PROTEIN", 71, 74], ["the sequences", "TEST", 27, 40], ["S protein domain NTD", "PROBLEM", 46, 66], ["RBD", "PROBLEM", 71, 74], ["the virus", "PROBLEM", 120, 129], ["RBD", "OBSERVATION", 71, 74], ["outer", "ANATOMY_MODIFIER", 103, 108], ["virus", "OBSERVATION", 124, 129]]], ["So the variations reported herein within the outer domains of S glycoprotein could help to design effective epitope-based vaccines or antivirals.DiscussionThe SARS-CoV-2 S protein contains additional furin protease cleavage site, PRRARS, in S1/S2 domain which is conserved among all 320 sequences as revealed during this study ( Supplementary Fig. 3 ).", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 62, 76], ["furin", "GENE_OR_GENE_PRODUCT", 200, 205], ["outer domains", "PROTEIN", 45, 58], ["S glycoprotein", "PROTEIN", 62, 76], ["SARS-CoV-2 S protein", "PROTEIN", 159, 179], ["furin protease cleavage site", "PROTEIN", 200, 228], ["PRRARS", "PROTEIN", 230, 236], ["S1", "PROTEIN", 241, 243], ["S2 domain", "PROTEIN", 244, 253], ["S glycoprotein", "TREATMENT", 62, 76], ["effective epitope-based vaccines", "TREATMENT", 98, 130], ["antivirals", "TREATMENT", 134, 144], ["The SARS", "TEST", 155, 163], ["CoV", "TEST", 164, 167], ["-2 S protein", "TREATMENT", 167, 179], ["additional furin protease cleavage site", "TREATMENT", 189, 228], ["this study", "TEST", 316, 326], ["S1", "ANATOMY", 241, 243], ["S2", "ANATOMY", 244, 246]]], ["This unique signature is thought to make the SARS-CoV-2 more virulent than SARS-CoV and regarded as novel features of the viral pathogenesis [9] .DiscussionAccording to previous reports the more the host cell protease can process the coronavirus S can accelerate viral tropism accordingly in influenza virus [[9] , [47] , [48] , [49] ].", [["cell", "ANATOMY", 204, 208], ["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 45, 55], ["SARS-CoV", "ORGANISM", 75, 83], ["host cell", "CELL", 199, 208], ["coronavirus", "ORGANISM", 234, 245], ["influenza virus", "ORGANISM", 292, 307], ["protease", "PROTEIN", 209, 217], ["influenza virus", "SPECIES", 292, 307], ["SARS-CoV", "SPECIES", 75, 83], ["the SARS", "TEST", 41, 49], ["CoV", "TEST", 50, 53], ["the viral pathogenesis", "PROBLEM", 118, 140], ["the host cell protease", "TREATMENT", 195, 217], ["the coronavirus S", "PROBLEM", 230, 247], ["viral tropism", "PROBLEM", 263, 276], ["influenza virus", "PROBLEM", 292, 307], ["viral", "OBSERVATION", 122, 127], ["viral tropism", "OBSERVATION", 263, 276]]], ["Apart from that, this could also promote viruses to escape antiviral therapies targeting transmembrane protease J o u r n a l P r e -p r o o f TMPRSS2 (ClinicalTrials.gov, NCT04321096) which is well reported protease to cleave at S1/S2 of S glycoprotein [50] .", [["transmembrane", "ANATOMY", 89, 102], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 239, 253], ["transmembrane protease", "PROTEIN", 89, 111], ["TMPRSS2", "DNA", 143, 150], ["ClinicalTrials", "DNA", 152, 166], ["protease", "PROTEIN", 208, 216], ["S1", "PROTEIN", 230, 232], ["S2", "PROTEIN", 233, 235], ["S glycoprotein", "PROTEIN", 239, 253], ["escape antiviral therapies", "TREATMENT", 52, 78], ["transmembrane protease", "TEST", 89, 111], ["TMPRSS2", "PROBLEM", 143, 150]]], ["Comparative analyses between SARS-CoV and SARS-CoV-2 spike glycoprotein showed 77% similarity between them where the most diverse region was", [["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV-2 spike glycoprotein", "GENE_OR_GENE_PRODUCT", 42, 71], ["SARS-CoV and SARS-CoV-2 spike glycoprotein", "PROTEIN", 29, 71], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 42, 50], ["Comparative analyses", "TEST", 0, 20], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["spike glycoprotein", "TEST", 53, 71]]]], "a2b8e6dee5f2d747a238ade86d283c7509bba252": [["IntroductionGenetic information derived from pathogens is an increasingly essential input for infectious disease control, public health and research 1 .", [["infectious disease", "DISEASE", 94, 112], ["infectious disease control", "TREATMENT", 94, 120]]], ["Although routine sequencing of pathogens was, until recently, unthinkable, the Centers for Disease Control (CDC), Food and Drug Administration (FDA), state, and global public health laboratories now routinely sequence more than 200 foodborne bacterial isolates a day and more than 6,000 influenza virus genomes a year 2,3 .", [["influenza virus", "SPECIES", 287, 302], ["pathogens", "PROBLEM", 31, 40]]], ["In the United Kingdom, Public Health England now engages in routine clinical genomic diagnostics and drug sensitivity testing for Mycobacterium tuberculosis 4 .", [["Mycobacterium tuberculosis", "DISEASE", 130, 156], ["Mycobacterium tuberculosis", "SPECIES", 130, 156], ["Mycobacterium tuberculosis", "SPECIES", 130, 156], ["routine clinical genomic diagnostics", "TEST", 60, 96], ["drug sensitivity testing", "TEST", 101, 125], ["Mycobacterium tuberculosis", "PROBLEM", 130, 156], ["Mycobacterium tuberculosis", "OBSERVATION", 130, 156]]], ["In the research setting, phylogenetic analysis (the study of evolutionary relationships among pathogens) is being used to track and understand factors associated with the spread of infections such as HIV 5 and to monitor the global spread of drug-resistant infections 6 .", [["infections", "DISEASE", 181, 191], ["infections", "DISEASE", 257, 267], ["HIV 5", "ORGANISM", 200, 205], ["HIV", "SPECIES", 200, 203], ["HIV", "SPECIES", 200, 203], ["phylogenetic analysis", "TEST", 25, 46], ["the study", "TEST", 48, 57], ["infections", "PROBLEM", 181, 191], ["HIV 5", "PROBLEM", 200, 205], ["drug-resistant infections", "PROBLEM", 242, 267], ["infections", "OBSERVATION", 181, 191], ["global", "OBSERVATION_MODIFIER", 225, 231], ["spread", "OBSERVATION_MODIFIER", 232, 238], ["resistant", "OBSERVATION_MODIFIER", 247, 256], ["infections", "OBSERVATION", 257, 267]]], ["Mobile genomic sequencing technology is also being applied to disease outbreak investigation, most publicly in the case of the Ebola outbreak in West Africa 7-9 .", [["Ebola", "DISEASE", 127, 132], ["Mobile genomic sequencing technology", "TREATMENT", 0, 36], ["Ebola", "OBSERVATION", 127, 132]]], ["Going forward, the routine implementation of genomic surveillance activities and outbreak investigation is to be expected.IntroductionWhile the technical developments of sequencing technology are being implemented at a rapid pace, the non-technical aspects of implementing this technology are still being broadly discussed between the different stakeholders involved 1 .", [["genomic surveillance activities", "TEST", 45, 76], ["outbreak investigation", "TEST", 81, 103], ["sequencing technology", "TREATMENT", 170, 191], ["a rapid pace", "TREATMENT", 217, 229]]], ["Importantly, the successful and appropriate response to these challenges will also require the systematic identification, analysis and addressing of a number of complex ethical, legal and social issues.", [["the systematic identification", "TEST", 91, 120], ["analysis", "TEST", 122, 130]]], ["A number of factors will contribute to the types of ethical issues that arise in different instances.", [["ethical issues", "PROBLEM", 52, 66]]], ["These are likely to include characteristics of the disease, the environmental, political and geographical context, existing laws and policies, public attitudes, and cultural differences 10 .", [["the disease", "PROBLEM", 47, 58], ["likely to include", "UNCERTAINTY", 10, 27], ["disease", "OBSERVATION", 51, 58]]], ["This study sought to review published literature on ethical aspects of pathogen sequencing.", [["This study", "TEST", 0, 10], ["pathogen sequencing", "TEST", 71, 90]]], ["Inclusion criteria for the study encompassed a broad range of article types, including empirical studies, news articles, opinion pieces, features, editorials, reports of practice, and theoretical articles.Search strategyWe systematically searched indexed academic literature from PubMed, Google Scholar, and Web of Science from 2000 to April 2019 for peer-reviewed articles that substantively engaged in discussion of ethical issues in the use of pathogen genome sequencing technologies for diagnostic, surveillance and outbreak investigation.", [["the study", "TEST", 23, 32], ["empirical studies", "TEST", 87, 104], ["ethical issues", "PROBLEM", 418, 432], ["surveillance", "TEST", 503, 515], ["outbreak investigation", "TEST", 520, 542]]], ["The initial search strategies were developed through an iterative process and used a combination of controlled vocabulary (MeSH terms) and free text words.", [["a combination of controlled vocabulary (MeSH terms", "TREATMENT", 83, 133]]], ["Reference lists of included articles were searched for relevant articles and further database searchers were conducted using the names of researchers commonly publishing in this field.", [["further database searchers", "TEST", 77, 103]]], ["Finally, we also reviewed relevant international research and clinical practice guidance for relevant guidelines e.g. website of the World Health Organization.Selection criteriaWe sought to maximize the literature included in the review by reviewing guidelines, frameworks, commentaries and original research reviews related to pathogen sequencing.", [["pathogen sequencing", "TEST", 328, 347]]], ["We also included studies on molecular typing where enough accuracy could be included to include transmission tracking, as this was thought to provide useful insights into the ethical challenges pathogen sequencing technologies may pose.", [["studies", "TEST", 17, 24], ["molecular typing", "TEST", 28, 44]]], ["We excluded studies considering genomics outside of infectious disease or focusing on host response studies as these were not deemed relevant or specific enough to the topic under investigation.Selection of studiesDuplicates were removed.", [["infectious disease", "DISEASE", 52, 70], ["infectious disease", "PROBLEM", 52, 70], ["host response studies", "TEST", 86, 107], ["Selection of studies", "TEST", 194, 214], ["infectious", "OBSERVATION", 52, 62]]], ["SJ undertook title and abstract screening to remove obviously irrelevant studies, borderline cases were discussed with MP and a decision reached by consensus.", [["MP", "DISEASE", 119, 121], ["abstract screening", "TEST", 23, 41], ["irrelevant studies", "TEST", 62, 80]]], ["Data was then abstracted by SJ and cross-checked for accuracy by MP.", [["MP", "DISEASE", 65, 67]]], ["Names of study authors, institutions, journals of publication and results were non-blinded.Selection of studiesAnalysis SJ initially inductively analysed all studies, recording the aims and main findings in Microsoft Excel 2016 (16.0.4699.1000), and developing descriptive codes to chart the broad themes describing the literature base.", [["Selection of studiesAnalysis", "TEST", 91, 119], ["all studies", "TEST", 154, 165], ["base", "ANATOMY_MODIFIER", 331, 335]]], ["Similar findings were then grouped according to topic area and a preliminary list of themes was developed in collaboration with MP.", [["MP", "DISEASE", 128, 130], ["MP", "GENE_OR_GENE_PRODUCT", 128, 130]]], ["SJ subsequently re-examined each study and extracted data using a standard format (design, results and recommendations).ResultsThe search produced 466 articles after duplicates were removed.", [["each study", "TEST", 28, 38]]], ["Twenty eight articles were included in the final analysis; three ethical guidelines or frameworks 14-17 ; seven empirical research studies 1,18-23 ; eight reviews of the ethics 2,17-21 ; and ten publications that contained a section on the ethical aspects of pathogen sequencing 24-33 .", [["the final analysis", "TEST", 39, 57], ["frameworks", "TEST", 87, 97], ["seven empirical research studies", "TEST", 106, 138], ["the ethics", "TEST", 166, 176], ["pathogen sequencing", "TEST", 259, 278]]], ["The literature largely originated from the US and other high-income countries (HICs, country determined by lead author institution): nine from the United States (US), five from the United Kingdom (UK), five from The Netherlands, three from Canada, two from Switzerland, one from Australia, and one from Italy.", [["the US", "TEST", 39, 45]]], ["Only two publications, by the same author, originated from the global south (South Africa).", [["two", "OBSERVATION_MODIFIER", 5, 8], ["publications", "OBSERVATION", 9, 21], ["global", "OBSERVATION_MODIFIER", 63, 69]]], ["Eight articles were specifically about the use of sequencing in HIV 14, 15, 17, 20, 22, 28, 34, 35 .", [["HIV", "SPECIES", 64, 67], ["sequencing", "TEST", 50, 60], ["HIV", "TEST", 64, 67]]], ["Eleven were not specific to a particular disease.", [["a particular disease", "PROBLEM", 28, 48]]], ["Table 2 presents a summary of studies.ResultsResults were organized into four themes: Tensions between public and private interests; difficulties with translation from research to clinical and public health practice; the importance of community trust and support; equity and global partnerships; and the importance of context.Theme 1: Tensions between private and public interestsWhen considering the implications of collecting, using and sharing pathogen genome sequence data, the interests and rights of individuals were universally acknowledged.", [["individuals", "ORGANISM", 506, 517], ["pathogen genome sequence", "DNA", 447, 471], ["pathogen genome sequence data", "TEST", 447, 476]]], ["In particular, the literature pointed to the importance of considering and/or protecting individual rights to autonomy 19,21,32,36 , and to privacy 18,21,22,28 .", [["autonomy", "TEST", 110, 118]]], ["Many pointed out that the potential of sequencing techniques to detect the origin and routes of transmission of an outbreak may result in negative consequences for the individuals involved 25 .", [["sequencing techniques", "TEST", 39, 60], ["an outbreak", "PROBLEM", 112, 123]]], ["Consequences may include stigmatization, penalties, economic risks, problems with interpersonal relationships (e.g. inadvertent disclosure of infidelity), emotional distress and the capacity for discrimination 19, 21, 22, 24, 25, 27, 30, 32, [37] [38] [39] .", [["emotional distress", "DISEASE", 155, 173], ["stigmatization", "PROBLEM", 25, 39], ["infidelity", "PROBLEM", 142, 152], ["emotional distress", "PROBLEM", 155, 173], ["the capacity", "TEST", 178, 190], ["discrimination", "TEST", 195, 209]]], ["There was also concern that sequencing could lead to serious legal consequences, particularly with regards to the criminalization of HIV transmission 14, 15, 17, 22, 24, 28, 34, 35 .", [["HIV transmission", "DISEASE", 133, 149], ["HIV", "SPECIES", 133, 136], ["serious legal consequences", "PROBLEM", 53, 79], ["HIV transmission", "TEST", 133, 149]]], ["It was also acknowledged that individuals may have an interest in avoiding the use of information about them for purposes they do not endorse, such as to support anti-gay sentiment or as part of a criminal investigation 20, 24 .", [["a criminal investigation", "TEST", 195, 219]]], ["Somewere concerned about forced testing either of certain groups such as gay men 28 or healthcare workers 19,21,38-40 .", [["men", "ORGANISM", 77, 80], ["men", "SPECIES", 77, 80], ["forced testing", "TEST", 25, 39]]], ["Many authors noted that certain groups can be placed at risk through characterization as high risk or likely to transmit virus (HIV), including geographically defined groups, sexual or gender minorities, or those defined by ethnicity, nationality, or migration status 14 .", [["HIV", "SPECIES", 128, 131], ["transmit virus (HIV)", "PROBLEM", 112, 132], ["migration status", "PROBLEM", 251, 267]]], ["Similarly, data regarding transmission patterns of multidrug-resistant tuberculosis (TB) could be used for discrimination based on ethnicity, and possible challenges to immigration 20 .", [["tuberculosis", "DISEASE", 71, 83], ["TB", "DISEASE", 85, 87], ["multidrug-resistant tuberculosis", "PROBLEM", 51, 83], ["resistant", "OBSERVATION_MODIFIER", 61, 70], ["tuberculosis", "OBSERVATION", 71, 83]]], ["Institutions could be subject to increasing numbers of legal claims, or companies could suffer reputational or economic damage 39 .", [["economic damage", "PROBLEM", 111, 126]]], ["It was also noted that some communities may be particularly at risk of being exploited by research, especially during emergency outbreak situations 14,32 .Theme 1: Tensions between private and public interestsOn the other hand, it was acknowledged that widespread availability and use of sequence data contributes important benefits to the clinical and research communities 17 .", [["sequence data", "TEST", 288, 301]]], ["In particular, the rapid sharing of data can help identify etiological factors, predict disease spread, evaluate existing and novel treatments, symptomatic care and preventive measures, and guide the deployment ofPermissibility of sequencing studies and conditions of useThere was strong support for the permissibility of conducting sequencing studies, as long as potential risks were thoughtfully mitigated 14,18,19,21,22 .", [["etiological factors", "PROBLEM", 59, 78], ["predict disease spread", "PROBLEM", 80, 102], ["novel treatments", "TREATMENT", 126, 142], ["symptomatic care", "TREATMENT", 144, 160], ["preventive measures", "TREATMENT", 165, 184], ["sequencing studies", "TEST", 231, 249], ["conducting sequencing studies", "TEST", 322, 351]]], ["In one empirical study, patients and healthcare workers were asked if the benefits of HIV molecular epidemiology outweigh the risks; all said yes 22 .", [["patients", "ORGANISM", 24, 32], ["HIV", "ORGANISM", 86, 89], ["patients", "SPECIES", 24, 32], ["HIV", "SPECIES", 86, 89], ["one empirical study", "TEST", 3, 22]]], ["In another study, expert Delphi panelists held that the protection of the public was of overriding importance, but that most of the potential harms could be managed 19 .Permissibility of sequencing studies and conditions of useThere were differences across the literature in the priority afforded to different conditions of use, and to the types of risk or amount of risk deemed acceptable.", [["another study", "TEST", 3, 16], ["sequencing studies", "TEST", 187, 205]]], ["It was broadly agreed that any research should have a favourable risk benefit ratio 14,20 , and that maximizing the utility of data must be weighed against concerns over interests of individuals and that policies on data collection and release should seek to align the interests of different parties 36 .", [["data collection", "TEST", 216, 231]]], ["There was, however, disagreement as to whether privacy concerns or public interest should take precedence 24,25,31 and some noted that the balance between the public health benefit and personal privacy risk for individuals whose genetic data (personal or pathogen) are included is difficult to delineate, since neither the true benefit nor the actual risk to participants has been adequately defined 27,35 .", [["participants", "SPECIES", 359, 371]]], ["Below we set out the key recommendations from the literature on the conditions of use for pathogen sequence data.", [["pathogen sequence data", "TEST", 90, 112]]], ["Recommendations to address such conflicts of interests included: that medical journals should update their policies to support pre-publication sharing of pathogen sequence data related to outbreaks 16 ; publication disclaimers prohibiting use of sequence data for publication without permission 16,32 ; acknowledgment of data sharing contributions and the inclusion of such criteria to the assessment of academic research credit 1 ; establishment of governance structures and dispute resolution mechanisms that can mediate where disagreements arise 16 .Anonymization and privacy protectionMuch of the literature suggested that traditional methods of de-identification or anonymization of data are insufficient to meet their purpose in the context of pathogen sequencing 2,14,17,23,28,33,39 .", [["pre-publication", "DISEASE", 127, 142], ["pathogen sequence data", "TEST", 154, 176], ["outbreaks", "PROBLEM", 188, 197], ["sequence data", "TEST", 246, 259], ["the assessment", "TEST", 386, 400], ["Anonymization", "TREATMENT", 553, 566], ["pathogen sequencing", "TEST", 750, 769]]], ["Existing approaches to minimize the risk of privacy loss to participants are based on de-identification of data by removal of a predefined set of identifiers 17 .", [["participants", "SPECIES", 60, 72], ["Existing approaches", "TREATMENT", 0, 19], ["privacy loss", "PROBLEM", 44, 56], ["removal", "TREATMENT", 115, 122], ["privacy loss", "OBSERVATION", 44, 56]]], ["However, this has three key limitations in the context of pathogen genomics.", [["pathogen genomics", "OBSERVATION", 58, 75]]], ["First, sharing of corresponding sample metadata (minimally time and place of collection, ideally with demographic, laboratory, and clinical data) is essential to enhance the interpretation and the value of genomic data 16 , therefore removal of key identifiers such as geographic location may severely limit the utility of genomic data 39 .", [["collection", "PROBLEM", 77, 87], ["genomic data", "TEST", 206, 218], ["removal", "TREATMENT", 234, 241], ["genomic data", "TEST", 323, 335]]], ["For example, one study demonstrated how sample collection dates associated with microbiological testing at a large tertiary hospital were highly correlated with patient admission date (protected health information), meaning data is re-identifiable 23 .", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["one study", "TEST", 13, 22], ["how sample collection", "PROBLEM", 36, 57], ["microbiological testing", "TEST", 80, 103]]], ["Small study populations may also mean that individuals who are part of a transmission chain may be able to identify others during the course of routine contact tracing (e.g. sexual partners) 17 .", [["Small study populations", "PROBLEM", 0, 23], ["routine contact tracing", "TEST", 144, 167]]], ["Perhaps a consequence there was clear support for re-visioning of existing privacy standards, and for privacy policies specific to the context of sequencing studies.ConsentThere was debate in the literature around the importance of consent to the use of sequence data and associated meta-data in epidemiological investigation.", [["sequencing studies", "TEST", 146, 164], ["sequence data", "TEST", 254, 267], ["epidemiological investigation", "TEST", 296, 325]]], ["In the research setting, Coltart et al. 14 state that research participants and patients whose samples are being used for phylogenetic analysis should ideally have consented to such use, but suggest that when using data from previous studies, where only broad consent for HIV-related research might have been obtained, waivers of specific consent are allowable when samples are no longer linked to identifiers, or when broad consent for sample collection for research and storage in future studies was given 14 .", [["participants", "ORGANISM", 63, 75], ["patients", "ORGANISM", 80, 88], ["samples", "CANCER", 95, 102], ["participants", "SPECIES", 63, 75], ["patients", "SPECIES", 80, 88], ["HIV", "SPECIES", 272, 275], ["phylogenetic analysis", "TEST", 122, 143], ["previous studies", "TEST", 225, 241], ["HIV", "PROBLEM", 272, 275], ["sample collection", "TEST", 437, 454], ["research and storage in future studies", "TEST", 459, 497]]], ["In the public health and clinical setting, an Australian study reported that one of the key differences amongst participants in a modified Delphi Social and behavioural research into conceptual and normative aspects should be backed up by empirical research 35 .", [["participants", "SPECIES", 112, 124], ["an Australian study", "TEST", 43, 62]]], ["6.ConsentAs real-time and other intervention strategies that build on HIV phylogenetic information continue to emerge, it will be critical to address questions of efficacy for cluster growth interventions to ensure that the benefits outweigh potential risks.", [["HIV", "SPECIES", 70, 73], ["other intervention strategies", "TREATMENT", 26, 55], ["cluster growth interventions", "TREATMENT", 176, 204]]], ["Implementation science research may also inform best practices for discussing the meaning and limitations of sequence data and cluster membership with community members and help to identify acceptable and evidence-based approaches that impose the least risk to persons within specific contexts.", [["persons", "ORGANISM", 261, 268], ["persons", "SPECIES", 261, 268], ["sequence data", "TEST", 109, 122]]], ["These might involve partnerships with providers for non-intrusive patient follow-up related to clusters, more detailed consent procedures for future follow-up related to HIV test results or partner services referrals, and specific guidelines and education to mitigate criminalization risks 28 .", [["criminalization", "DISEASE", 268, 283], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["HIV", "SPECIES", 170, 173], ["HIV test", "TEST", 170, 178]]], ["7.ConsentCommunication methods that increase the understanding of phylogenetic studies need to be designed and evaluated.", [["phylogenetic studies", "TEST", 66, 86]]], ["These must emphasise potential harms, thoughtful mitigation of harms to risk groups, processes for monitoring risk, and clear protection procedures to minimise risks 14 .", [["monitoring risk", "TEST", 99, 114], ["clear protection procedures", "TREATMENT", 120, 147]]], ["The first step, should be sought in creating awareness and consensus within sectors on the causal factors of barriers to sharing of sequence data 1 .ConsentEthical conduct of studies 9.", [["sequence data", "TEST", 132, 145], ["studies", "TEST", 175, 182]]], ["In order to maximize scientific validity, the researchers should ensure that they have all necessary resources, that the community accepts the protocol and that a competent and independent research ethics committee (REC) or institutional review board (IRB) reviews and approves the protocol 35 .", [["the protocol", "TREATMENT", 139, 151]]], ["The scientific objectives of research should guide the choice of participants and determine the inclusion criteria and appropriate recruitment strategies.", [["participants", "SPECIES", 65, 77], ["appropriate recruitment strategies", "TREATMENT", 119, 153]]], ["It is unethical to use privilege, convenience and/or vulnerability as criteria for selecting participants.", [["participants", "SPECIES", 93, 105]]], ["Exclusion of certain population sub-groups or communities in a research study without appropriate scientific justification is also considered unethical 35 .", [["a research study", "TEST", 61, 77], ["certain", "OBSERVATION_MODIFIER", 13, 20], ["population", "OBSERVATION_MODIFIER", 21, 31]]], ["Risk mitigation strategies must also provide for redress mechanisms in cases of abuse or misuse of phylogenetic data.", [["Risk mitigation strategies", "TREATMENT", 0, 26]]], ["These strategies might require the establishment of ties with local legal services, organisations working to protect people with HIV, and criminalised or stigmatised populations, to ensure that they have access to the means to protect their rights 14 .Consentstudy included the necessity for consent before testing and data-linkage.", [["HIV", "DISEASE", 129, 132], ["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["HIV", "SPECIES", 129, 132], ["HIV", "SPECIES", 129, 132], ["HIV", "PROBLEM", 129, 132], ["testing", "TEST", 307, 314]]], ["No panelists agreed with the statement \"under no conditions should a study be conducted without prior consent\", although only ten of thirty agreed that consent is not required under any conditions 21 .", [["a study", "TEST", 67, 74]]], ["In a Dutch study, outbreak managers thought intervention without seeking explicit consent of all individuals involved is justified when there is at least be a substantial public health threat, realistic expectation that deploying the techniques will help to mitigate the outbreak, and that source and contact tracing would most likely not be successful without the use of molecular typing techniques 21 .Data accessThere was a strong commitment to rapid and open data-sharing, particularly in emergency or outbreak situations 16,27,32 and in such conditions for incentives and safeguards to encourage rapid and unrestricted access to data release 16,27,32 .", [["a Dutch study", "TEST", 3, 16], ["contact tracing", "TEST", 301, 316], ["molecular typing techniques", "TREATMENT", 372, 399], ["incentives and safeguards", "TREATMENT", 562, 587]]], ["Sharing of corresponding anonymised sample metadata (minimally time and place of collection, ideally with demographic, laboratory, and clinical data) is essential to enhance the interpretation and the value of genomic data\" 16 .", [["collection", "PROBLEM", 81, 91], ["genomic data", "TEST", 210, 222], ["collection", "OBSERVATION", 81, 91]]], ["However, access to data gathered as part of clinical care was seen as ethically more contentious as \"publicly accessible databases are not an appropriate storage location for the level of metadata required to enable clinical and epidemiological analysis for the purposes of providing patient and population care\" 39 .", [["patient", "ORGANISM", 284, 291], ["patient", "SPECIES", 284, 291], ["epidemiological analysis", "TEST", 229, 253]]], ["Suggestions were made for a tiered approach to data release, whereby a separate database governed by appropriate public health authorities would collate and store metadata in a location to which access to data could be limited to users with a legitimate clinical or public health need to use it, and data that cannot be released into public domains but is needed by authorised healthcare and public health professionals for service delivery remains within a suitable secured access database 39 .Data accessA public survey on TB explored questions related to database access and the potential benefits and risks associated with it.", [["TB", "DISEASE", 525, 527], ["service delivery", "TREATMENT", 424, 440], ["database access", "TREATMENT", 558, 573]]], ["Most felt that medical professionals and the research community should have access to such a database; and a significant proportion thought that other agencies, such as the police (10%) and immigration officials (13%), should also have access to the genomic database.", [["a database", "TEST", 91, 101]]], ["Experts, however, were clear that they felt transmission data should not be used in litigation; this was partially because it was deemed too unreliable 24,27 and also because of the potential for 'abuse' of data 14,15,24 .Data accessOverall, there was broad support for further work in defining the conditions for collection use and storage of data and samples 2,27,30,32,37 and for policy and legal clarity to aid the ethical implementation of these technologies.", [["broad support", "TREATMENT", 252, 265], ["storage of data", "TEST", 333, 348], ["samples", "TEST", 353, 360], ["these technologies", "TREATMENT", 445, 463]]], ["This will require more work to carefully assess and understand risks 39 ; research to decide how much individual privacy might be risk in the name of public health 31 ; consideration of alternative strategies required to mitigate this risk, such as suppression of data in the public domain where it may cause serious harm; and adjustments to communication plans 14 .Themes 2: Difficulties of translation from research to clinical and public health practiceEffective phylogenetic work often occurs at the interface between research and public health practice because the same data can be used for both purposes 14 .", [["alternative strategies", "TREATMENT", 186, 208], ["serious harm", "PROBLEM", 309, 321], ["communication plans", "TREATMENT", 342, 361]]], ["In this regard, pathogen sequencing was described as 'straddling the boundary between research and clinical use' 27 .", [["pathogen sequencing", "TEST", 16, 35]]], ["Clinical implementation of metagenomics sequencing (un-targeted testing) has the potential to detect unexpected or incidental findings that may include infections with hepatitis or HIV 39 .", [["infections", "DISEASE", 152, 162], ["hepatitis", "DISEASE", 168, 177], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 181, 184], ["metagenomics sequencing", "TEST", 27, 50], ["un-targeted testing", "TEST", 52, 71], ["unexpected or incidental findings", "PROBLEM", 101, 134], ["infections", "PROBLEM", 152, 162], ["hepatitis", "PROBLEM", 168, 177], ["HIV", "PROBLEM", 181, 184], ["may include", "UNCERTAINTY", 140, 151], ["infections", "OBSERVATION", 152, 162], ["hepatitis", "OBSERVATION", 168, 177]]], ["Incidental findings of a different type may occur if non-germline samples (such as faecal samples) are contaminated with germline cells, which could potentially reveal predictive information about developing inherited disease 39 .", [["samples", "ANATOMY", 66, 73], ["faecal samples", "ANATOMY", 83, 97], ["cells", "ANATOMY", 130, 135], ["inherited disease", "DISEASE", 208, 225], ["samples", "CANCER", 66, 73], ["faecal samples", "CANCER", 83, 97], ["germline cells", "CELL", 121, 135], ["germline cells", "CELL_TYPE", 121, 135], ["non-germline samples", "PROBLEM", 53, 73], ["faecal samples", "TEST", 83, 97], ["germline cells", "PROBLEM", 121, 135], ["developing inherited disease", "PROBLEM", 197, 225], ["different type", "OBSERVATION_MODIFIER", 25, 39], ["germline cells", "OBSERVATION", 121, 135]]], ["Furthermore, informed consent for phylogenetic studies that are difficult complex and difficult to understand, and in which the benefits and risk may not be fully determined, may also be difficult to achieve 35 .", [["phylogenetic studies", "TEST", 34, 54]]], ["Mutenherwa suggests that where sequence data are generated for routine clinical management, its subsequent use for research and surveillance may be underestimated by patients 20 .", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["routine clinical management", "TREATMENT", 63, 90], ["surveillance", "TEST", 128, 140]]], ["Others suggested that the right to withdraw from research activities-a key indicator of voluntary participation in research-was overlooked by expert stakeholders 20 .Professional boundariesUnderstanding and interpreting phylogenetic data requires significant expertise 25,27 and presents a challenge to established professional boundaries.", [["research activities", "TEST", 49, 68], ["right", "ANATOMY_MODIFIER", 26, 31]]], ["Expertise in phylogenetic studies creates new obligations for researchers, such as deciding whether or not to participate in forensic investigations and potential prosecutions of individuals 24 , and to consider the down-stream uses and misuses of data 14 .", [["phylogenetic studies", "TEST", 13, 33], ["forensic investigations", "TEST", 125, 148], ["new", "OBSERVATION_MODIFIER", 42, 45]]], ["The routine implementation of pathogen sequencing studies may create new responsibilities for clinical microbiologists (related to public health) 2 , and require major changes in culture such that diagnostic interpretation, therapeutic management decisions and antimicrobial treatment regimes are delegated to physicians instead of microbiologists 31 .Theme 3: Truth-telling, trust and community engagementMany noted that there are important reasons to ensure that the public and individuals understand the uses of data collected as part of a sequencing studies, and the potential risks.", [["pathogen sequencing studies", "TEST", 30, 57], ["major changes in culture", "PROBLEM", 162, 186], ["diagnostic interpretation", "TEST", 197, 222], ["therapeutic management", "TREATMENT", 224, 246], ["antimicrobial treatment regimes", "TREATMENT", 261, 292], ["a sequencing studies", "TEST", 541, 561]]], ["First, this was seen to have some intrinsic value in that it supports patient autonomy and truth telling is a respected moral virtue 14,15,19,21 .", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77]]], ["In some cases, this was balanced by a number of practical challenges to telling people the truth, such as: risk of fear mongering 19 ; information needed for legal proceedings in public interest 14 ; and the fact that it may be difficult to adequately inform the public and/or ensure full understanding 20 .", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["None-the-less, there was a clear recommendation in the literature to raise public awareness and understanding of these techniques 19,22,30 , and for early and meaningful community engagement 15,22,32,34 prior to conducting sequencing studies.", [["these techniques", "TEST", 113, 129], ["conducting sequencing studies", "TEST", 212, 241]]], ["This was seen as particularly important when working with vulnerable groups or when the risks of participation are high.Theme 4: Justice and global partnershipsThe notion of justice appeared to be a widely recognized ethical principle in the field 1 .", [["widely", "OBSERVATION_MODIFIER", 199, 205]]], ["This included an ethical imperative that outbreak related research and countermeasures, such as diagnostics and vaccines, should be accessible to all affected countries 26 , and towards reciprocal arrangements such that countries that participate in sequencing activities should derive some corresponding local benefit 27 .CollaborationCollaboration between researchers from Africa and HICs was raised as an important ethical consideration 20 .", [["HICs", "DISEASE", 386, 390], ["HICs", "CANCER", 386, 390], ["vaccines", "TREATMENT", 112, 120]]], ["In one empirical study, interviewees were concerned that African researchers were not meaningfully engaged in the scientific research process in health research in general and phylogenetic research in particular, and that for equitable and mutually beneficial collaborative research partnerships to be realized, local researchers were encouraged to take leading and active roles throughout the research process 20 .", [["one empirical study", "TEST", 3, 22]]], ["Recommendations were made to conduct studies exploring the nature of existing collaborative partnerships between researchers from low-and middle-income countries (LMICS) and HICs to explore team composition and distribution of roles, including contribution to intellectual property 20 .", [["conduct studies", "TEST", 29, 44]]], ["Outbreak related research and countermeasures, such as diagnostics and vaccines, must be accessible to all affected countries not only as a legal obligation, but also as an ethical imperative 26 .Global cooperationIt was also noted that global and interdisciplinary partnerships are a necessary component of an effective genomic informed response to infectious disease.", [["infectious disease", "DISEASE", 350, 368], ["vaccines", "TREATMENT", 71, 79], ["global and interdisciplinary partnerships", "PROBLEM", 237, 278], ["infectious disease", "PROBLEM", 350, 368], ["cooperation", "OBSERVATION", 203, 214], ["global", "OBSERVATION_MODIFIER", 237, 243], ["infectious", "OBSERVATION", 350, 360]]], ["This was because of the vast range of stakeholders and varying interests involved in control of infectious disease outbreaks, and because issues may resist simple resolution and span multiple jurisdictions 27 .", [["infectious disease outbreaks", "DISEASE", 96, 124], ["infectious disease outbreaks", "PROBLEM", 96, 124], ["infectious", "OBSERVATION_MODIFIER", 96, 106]]], ["The Nagoya Protocol (NP), for example, was developed to facilitate access to genetic resources and the fair and equitable sharing of benefits arising from their utilization 1 .", [["The Nagoya Protocol (NP)", "TREATMENT", 0, 24]]], ["The problem for public health surveillance occurs when such appropriation is triggered at initial (upstream) phases of the research and innovation cycle, such as sampling and sequencing of microorganisms, instead of later stages, such as the actual product development (in this case drugs, diagnostics and vaccines).", [["sampling", "TEST", 162, 170], ["microorganisms", "PROBLEM", 189, 203], ["this case drugs", "TREATMENT", 273, 288], ["vaccines", "TREATMENT", 306, 314]]], ["As such, stakeholders are reluctant to share their (intangible) assets even in early phases of the innovation process, decreasing the scope of innovation efforts due to the lack of access to upstream research inputs.\"Global cooperationThe same authors suggest that standardized and simplified sharing agreements 26 , and collaboration between stakeholders with an active exchange of experiences and best practices 1 are required.Global cooperationIn general, recommendations were made for a global approach to ethics, policy and legal frameworks 16,27,29,32,37 .", [["innovation efforts", "TREATMENT", 143, 161], ["cooperation", "OBSERVATION", 224, 235], ["cooperation", "OBSERVATION", 436, 447]]], ["For example, it was suggested global data sharing arrangements should include \"a global data governance or ethical framework, supplemented by local memoranda of understanding that take into account the local context\" 29 ; or to investigate how the Global Alliance for Genomics and Health (GA4GH) framework for responsible data-sharing could be adapted for digital pathogen surveillance 27 .Themes 5: The importance of contextLastly, it was clear that the types of ethical issues likely to arise are in part dependent upon the contexts in which studies are conducted, as well as the nature of the pathogen under study.", [["digital pathogen surveillance", "TEST", 356, 385], ["ethical issues", "PROBLEM", 464, 478], ["the pathogen under study", "TEST", 592, 616]]], ["Examples included: sexually transmitted infections 14,20 ; consent requirements to use isolates collected from dead neonates for the purposes of epidemiological research 19 ; and disclosure of family members as the source of infection 38 .", [["sexually transmitted infections", "DISEASE", 19, 50], ["infection", "DISEASE", 225, 234], ["sexually transmitted infections", "PROBLEM", 19, 50], ["isolates", "TREATMENT", 87, 95], ["infection", "PROBLEM", 225, 234], ["infection", "OBSERVATION", 225, 234]]], ["It was suggested that the balance of risks to patients and public health benefits is likely to be affected by the characteristics of the pathogen, in terms of likely morbidity and mortality: infectivity; treatability and drug resistance 39 .", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the pathogen", "PROBLEM", 133, 145], ["infectivity", "PROBLEM", 191, 202], ["drug resistance", "TEST", 221, 236]]], ["Stakeholders also suggested that the ethical permissibility of sharing data about, particularly with regards to the source of transmission, may be different in professional contexts, where healthcare providers or companies are seen to carry a responsibility to control risk, as opposed to outside of professional contexts where protecting individuals from 'naming and shaming' may be of greater concern 21 .", [["shaming", "DISEASE", 368, 375]]], ["It was also noted that the legal and regulatory structures in which studies are conducted may also influence the implementation and ethics of conducting pathogen sequencing studies.", [["conducting pathogen sequencing studies", "TEST", 142, 180]]], ["In particular, use of phylogenetic analyses in criminal convictions was raised as an ethical risk 14,17,24 .Limitations of the reviewAlthough quality assessment of all included materials is desirable in systematic reviews, it was not possible in this case due to the inclusion of a diverse range of research formats and literature, such as commentaries and ethics guidelines.", [["phylogenetic analyses", "TEST", 22, 43], ["quality assessment", "TEST", 142, 160]]], ["A second limitation of this review is that a large proportion of the literature included related to phylogenetic and HIV specifically (8 out of 28), meaning that the issues relevant to this context may be over-represented.ConclusionThis review highlights that while pathogen sequencing has the potential to be transformative for public health and clinical practice and to bring about important health benefits, there are a number of key ethical issues that must be addressed.", [["HIV", "SPECIES", 117, 120], ["phylogenetic and HIV", "PROBLEM", 100, 120], ["large", "OBSERVATION_MODIFIER", 45, 50]]], ["In particular, there was clear support in the literature for innovative and critical thinking around the conditions of use for pathogen sequence data.", [["pathogen sequence data", "TEST", 127, 149]]], ["This should include experts in pathogen sequencing, patients and the general public, as well as end users such as public health professionals and clinicians.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["Lastly, it is both a scientific and an ethical imperative that development in the field is under-pinned by a strong commitment to values of justice, in particular global health equity.Data availabilityAll data underlying the results are available as part of the article and no additional source data are required.Center for Genomics and Policy (CGP), McGill University, Montreal, CanadaThis manuscript presents the results of a scoping review of the literature on the topic of the ethical issues in the use of pathogen genome sequencing technologies.", [["All data", "TEST", 201, 209], ["additional source data", "TEST", 277, 299], ["a scoping review", "TEST", 426, 442], ["pathogen genome sequencing technologies", "TREATMENT", 510, 549]]], ["4 under theme 1: Somewere concerned about forced testing either of certain groups such as gay men 28 or healthcare workers 19,21,38-40 .", [["men", "ORGANISM", 94, 97], ["men", "SPECIES", 94, 97], ["forced testing", "TEST", 42, 56]]], ["9 under theme 3: 'that may be specific to that them'Center for Genomics and Policy (CGP), McGill University, Montreal, CanadaThe main substantial issue is the substantial focus of the manuscript on the HIV context (8 articles out of 28) which the authors acknowledge.", [["HIV", "SPECIES", 202, 205], ["main", "OBSERVATION_MODIFIER", 129, 133], ["substantial", "OBSERVATION_MODIFIER", 134, 145], ["issue", "OBSERVATION", 146, 151], ["substantial", "OBSERVATION_MODIFIER", 159, 170], ["focus", "OBSERVATION_MODIFIER", 171, 176]]], ["HIV is a particularly stigmatized, serious condition, with lifelong consequences for patients which is not the case for many other communicable diseases.", [["HIV", "DISEASE", 0, 3], ["patients", "ORGANISM", 85, 93], ["HIV", "SPECIES", 0, 3], ["patients", "SPECIES", 85, 93], ["HIV", "SPECIES", 0, 3], ["many other communicable diseases", "PROBLEM", 120, 152]]], ["COVID-19 is both much more contagious but less stigmatizing and, for most people, less dangerous than HIV.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 102, 105], ["COVID", "TEST", 0, 5], ["HIV", "PROBLEM", 102, 105], ["much more", "OBSERVATION_MODIFIER", 17, 26], ["contagious", "OBSERVATION_MODIFIER", 27, 37], ["less stigmatizing", "OBSERVATION_MODIFIER", 42, 59]]], ["Considering that the last update to this scoping review was made in January 2020, none of the COVID-19 emerging literature was considered.", [["the COVID", "TEST", 90, 99]]], ["Otherwise, the publication maybe perceived as already outdated and not garner much attention from readers.Center for Genomics and Policy (CGP), McGill University, Montreal, CanadaA second issue of the manuscript is that while it acknowledges the tension and blurry demarcation between the research and the public health context, it doesn't really provide any solution in this regard.", [["the tension", "PROBLEM", 242, 253], ["blurry demarcation", "PROBLEM", 258, 276], ["blurry demarcation", "OBSERVATION", 258, 276]]], ["For example, in the context of pathogen genome sequencing for outbreak surveillance during a public health emergency, informed consent is often not required.", [["pathogen genome", "OBSERVATION", 31, 46]]], ["PartlyIs the study design appropriate and is the work technically sound?", [["the study", "TEST", 9, 18]]], ["YesIf applicable, is the statistical analysis and its interpretation appropriate?", [["Yes", "CHEMICAL", 0, 3], ["Yes", "SPECIES", 0, 3], ["the statistical analysis", "TEST", 21, 45]]], ["Yes Are the conclusions drawn adequately supported by the results?", [["Yes", "CHEMICAL", 0, 3], ["Yes", "SPECIES", 0, 3]]], ["Some additional concepts that weren't included, possibly because the article presents a review of already published ideas, are the following:If applicable, is the statistical analysis and its interpretation appropriate?", [["the statistical analysis", "TEST", 159, 183]]], ["YesThe potential for civil legal consequences from publication of genomic data.", [["genomic data", "TEST", 66, 78]]], ["The article discusses at a few different points the potential for criminal prosecution, but publication of data could also open up participants of a study to civil penalties as well.", [["participants", "SPECIES", 131, 143], ["a study", "TEST", 147, 154]]]], "929b5cd1c064a6bb9caf7ea3f127135096b69377": [["The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19.", [["respiratory tract", "ANATOMY", 76, 93], ["infection", "DISEASE", 59, 68], ["SARS-CoV-2", "ORGANISM", 21, 31], ["SARS-CoV-2", "SPECIES", 21, 31], ["The new Coronavirus (SARS-CoV", "PROBLEM", 0, 29], ["a serious infection in the respiratory tract", "PROBLEM", 49, 93], ["COVID", "TEST", 101, 106], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Coronavirus", "OBSERVATION", 8, 19], ["serious", "OBSERVATION_MODIFIER", 51, 58], ["infection", "OBSERVATION", 59, 68], ["respiratory tract", "ANATOMY", 76, 93]]], ["Structures of the main protease of SARS-CoV-2 (M pro ), responsible for the replication of the virus, have been solved and quickly made available, thus allowing the design of compounds that could interact with this protease and thus to prevent the progression of the disease by avoiding the viral peptide to be cleaved, so that smaller viral proteins can be released into the host's plasma.", [["plasma", "ANATOMY", 383, 389], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 35, 45], ["M pro", "GENE_OR_GENE_PRODUCT", 47, 52], ["plasma", "ORGANISM_SUBSTANCE", 383, 389], ["protease", "PROTEIN", 23, 31], ["protease", "PROTEIN", 215, 223], ["viral proteins", "PROTEIN", 336, 350], ["SARS-CoV", "SPECIES", 35, 43], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["the replication of the virus", "PROBLEM", 72, 100], ["this protease", "TREATMENT", 210, 223], ["the disease", "PROBLEM", 263, 274], ["the viral peptide", "PROBLEM", 287, 304], ["smaller viral proteins", "PROBLEM", 328, 350], ["main protease", "ANATOMY", 18, 31], ["SARS", "OBSERVATION", 35, 39], ["virus", "OBSERVATION", 95, 100]]], ["These structural data are extremely important for in silico design and development of compounds as well, being possible to quick and effectively identify potential inhibitors addressed to such enzyme's structure.", [["enzyme", "PROTEIN", 193, 199], ["potential inhibitors", "PROBLEM", 154, 174]]], ["Therefore, in order to identify potential inhibitors for M pro , we used virtual screening approaches based with the structure of the enzyme and two compounds libraries, targeted to SARS-CoV-2, containing compounds with predicted activity against M pro .", [["M pro", "GENE_OR_GENE_PRODUCT", 57, 62], ["enzyme", "PROTEIN", 134, 140], ["M pro", "PROTEIN", 247, 252], ["virtual screening approaches", "TEST", 73, 101], ["the enzyme", "TEST", 130, 140]]], ["In this way, we selected, through docking studies, the 100 top-ranked compounds, which followed for subsequent studies of pharmacokinetic and toxicity predictions.", [["toxicity", "DISEASE", 142, 150], ["docking studies", "TEST", 34, 49], ["subsequent studies", "TEST", 100, 118], ["pharmacokinetic and toxicity predictions", "PROBLEM", 122, 162]]], ["After all the simulations and predictions here performed, we obtained 10 top-ranked compounds that were again in silico analyzed inside the M pro catalytic site, together some drugs that are being currently investigated for treatment of COVID-19.", [["COVID-19", "CHEMICAL", 237, 245], ["some drugs", "TREATMENT", 171, 181], ["COVID", "TEST", 237, 242]]], ["After proposing and analyzing the interaction modes of these compounds, we submitted one molecule then selected as template to a 2D similarity study in a database containing drugs approved by FDA and we have found and indicated Apixaban as a potential drug for future treatment of COVID-19.IntroductionSince the first reports of novel pneumonia in Wuhan, Hubei province, China, considerable discussion on the origin of the causative virus SARS-CoV-2 (also referred to as HCoV-19) has emerged [1] .", [["Apixaban", "CHEMICAL", 228, 236], ["pneumonia", "DISEASE", 335, 344], ["SARS", "DISEASE", 439, 443], ["Apixaban", "CHEMICAL", 228, 236], ["COVID-19", "CHEMICAL", 281, 289], ["Apixaban", "SIMPLE_CHEMICAL", 228, 236], ["virus SARS-CoV-2", "ORGANISM", 433, 449], ["a 2D similarity study", "TEST", 127, 148], ["drugs", "TREATMENT", 174, 179], ["Apixaban", "TREATMENT", 228, 236], ["future treatment", "TREATMENT", 261, 277], ["COVID", "TEST", 281, 286], ["novel pneumonia", "PROBLEM", 329, 344], ["the causative virus SARS", "PROBLEM", 419, 443], ["HCoV", "TEST", 471, 475], ["pneumonia", "OBSERVATION", 335, 344]]], ["Infections with SARS-CoV-2 are now widespread, and efforts to contain the virus are ongoing; however, given the many uncertainties regarding pathogen transmissibility and virulence, the effectiveness of these efforts is unknown.", [["Infections", "DISEASE", 0, 10], ["SARS", "DISEASE", 16, 20], ["SARS-CoV-2", "ORGANISM", 16, 26], ["SARS-CoV", "SPECIES", 16, 24], ["Infections", "PROBLEM", 0, 10], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["the virus", "PROBLEM", 70, 79], ["pathogen transmissibility", "PROBLEM", 141, 166], ["virulence", "PROBLEM", 171, 180], ["widespread", "OBSERVATION_MODIFIER", 35, 45], ["virus", "OBSERVATION", 74, 79]]], ["The fraction of undocumented but infectious cases is a critical epidemiological characteristic that modulates the J o u r n a l P r e -p r o o f general symptoms are similar to SARS and MERS, causing cough, difficulty breathing, fatigue and fever and if not treated properly, eventually death [6, 7] .IntroductionCoronaviruses are enveloped structures, positive single-stranded large RNA viruses that infect humans, but also a wide range of animals.", [["SARS", "DISEASE", 177, 181], ["MERS", "DISEASE", 186, 190], ["cough", "DISEASE", 200, 205], ["difficulty breathing", "DISEASE", 207, 227], ["fatigue", "DISEASE", 229, 236], ["fever", "DISEASE", 241, 246], ["death", "DISEASE", 287, 292], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 313, 326], ["humans", "ORGANISM", 408, 414], ["humans", "SPECIES", 408, 414], ["humans", "SPECIES", 408, 414], ["The fraction", "TEST", 0, 12], ["general symptoms", "PROBLEM", 145, 161], ["SARS", "PROBLEM", 177, 181], ["MERS", "PROBLEM", 186, 190], ["cough", "PROBLEM", 200, 205], ["difficulty breathing", "PROBLEM", 207, 227], ["fatigue", "PROBLEM", 229, 236], ["fever", "PROBLEM", 241, 246], ["positive single-stranded large RNA viruses", "PROBLEM", 353, 395], ["infectious", "OBSERVATION", 33, 43], ["positive", "OBSERVATION_MODIFIER", 353, 361], ["stranded large", "OBSERVATION_MODIFIER", 369, 383], ["RNA viruses", "OBSERVATION", 384, 395], ["wide", "OBSERVATION_MODIFIER", 427, 431]]], ["The first virus in the family was described in 1966 by Tyrell and Bynoe, who cultivated the virus obtained of patients with common colds.", [["colds", "DISEASE", 131, 136], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["common colds", "PROBLEM", 124, 136]]], ["Due to its morphology with spherical grooves, with a central cap, and superficial projections similar to a solar corona, the name coronavirus (from Latin: corona: crown) was designated.", [["coronavirus", "ORGANISM", 130, 141], ["a central cap, and superficial projections", "PROBLEM", 51, 93], ["a solar corona, the name coronavirus", "PROBLEM", 105, 141], ["spherical grooves", "OBSERVATION", 27, 44], ["central", "OBSERVATION_MODIFIER", 53, 60], ["cap", "OBSERVATION_MODIFIER", 61, 64], ["superficial", "ANATOMY_MODIFIER", 70, 81], ["solar corona", "OBSERVATION", 107, 119]]], ["The coronavirus has four subfamilies: alpha-, beta-, gamma-and deltacoronaviruses.IntroductionWhile alpha-and betacoronaviruses apparently originate from mammals, in particular from bats, gamma-and delta-viruses originate from pigs and birds.", [["coronavirus", "ORGANISM", 4, 15], ["alpha-", "GENE_OR_GENE_PRODUCT", 38, 44], ["beta-", "GENE_OR_GENE_PRODUCT", 46, 51], ["gamma", "GENE_OR_GENE_PRODUCT", 53, 58], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 63, 81], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 110, 127], ["gamma", "GENE_OR_GENE_PRODUCT", 188, 193], ["delta-viruses", "GENE_OR_GENE_PRODUCT", 198, 211], ["pigs", "ORGANISM", 227, 231], ["alpha-, beta-, gamma-and deltacoronaviruses", "PROTEIN", 38, 81], ["gamma", "PROTEIN", 188, 193], ["pigs", "SPECIES", 227, 231], ["pigs", "SPECIES", 227, 231], ["alpha-", "TEST", 38, 44], ["deltacoronaviruses", "PROBLEM", 63, 81], ["alpha-and betacoronaviruses", "PROBLEM", 100, 127], ["coronavirus", "OBSERVATION", 4, 15]]], ["The genome size goes between 26 kb and 32 kb.", [["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Among the seven subtypes of coronaviruses that can infect humans, the beta-coronaviruses may cause severe disease and fatalities, whereas alpha-coronaviruses cause asymptomatic or mildly symptomatic infections [7] .IntroductionDuring the process of infection, there are two proteases that are essential in the process of maturation and infectivity of the virus.", [["fatalities", "DISEASE", 118, 128], ["alpha-coronaviruses", "DISEASE", 138, 157], ["infections", "DISEASE", 199, 209], ["infection", "DISEASE", 249, 258], ["coronaviruses", "ORGANISM", 28, 41], ["humans", "ORGANISM", 58, 64], ["beta-coronaviruses", "ORGANISM", 70, 88], ["proteases", "PROTEIN", 274, 283], ["humans", "SPECIES", 58, 64], ["humans", "SPECIES", 58, 64], ["coronaviruses", "PROBLEM", 28, 41], ["severe disease", "PROBLEM", 99, 113], ["asymptomatic or mildly symptomatic infections", "PROBLEM", 164, 209], ["infection", "PROBLEM", 249, 258], ["two proteases", "PROBLEM", 270, 283], ["the virus", "PROBLEM", 351, 360], ["seven subtypes", "OBSERVATION_MODIFIER", 10, 24], ["coronaviruses", "OBSERVATION", 28, 41], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["disease", "OBSERVATION", 106, 113], ["mildly", "OBSERVATION_MODIFIER", 180, 186], ["symptomatic", "OBSERVATION_MODIFIER", 187, 198], ["infections", "OBSERVATION", 199, 209], ["infection", "OBSERVATION", 249, 258]]], ["In the case of SARS-CoV-2, sequencing of its genome, revealed the papain-like protease (PL pro ) and the 3chymotrypsin-like protease (3CL pro , also known as the main protease-M pro ) [8] .IntroductionM pro is one of the most studied therapeutic targets at the present time, as a possible alternative to the fight against coronavirus, proving to be an accessible target for the development of inhibitors [9, 10] .", [["SARS", "DISEASE", 15, 19], ["coronavirus", "DISEASE", 322, 333], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 66, 86], ["PL pro", "GENE_OR_GENE_PRODUCT", 88, 94], ["3chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 105, 132], ["3CL pro", "GENE_OR_GENE_PRODUCT", 134, 141], ["coronavirus", "ORGANISM", 322, 333], ["papain-like protease", "PROTEIN", 66, 86], ["PL pro", "PROTEIN", 88, 94], ["3chymotrypsin-like protease", "PROTEIN", 105, 132], ["3CL pro", "PROTEIN", 134, 141], ["protease", "PROTEIN", 167, 175], ["M pro", "PROTEIN", 176, 181], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["CoV", "TEST", 20, 23], ["the papain", "TREATMENT", 62, 72], ["protease (PL pro", "TREATMENT", 78, 94], ["the 3chymotrypsin-like protease (3CL pro", "TREATMENT", 101, 141], ["coronavirus", "PROBLEM", 322, 333]]], ["M pro is a cysteine protease composed of three domains, (I, II, III), whose main functions are the maturation of viral particles and cleavage of the viral capsid, thus releasing viral polypeptides to the body and contributing to the infection to occur.", [["body", "ANATOMY", 204, 208], ["infection", "DISEASE", 233, 242], ["cysteine", "CHEMICAL", 11, 19], ["M pro", "GENE_OR_GENE_PRODUCT", 0, 5], ["body", "ORGANISM_SUBDIVISION", 204, 208], ["M pro", "PROTEIN", 0, 5], ["cysteine protease", "PROTEIN", 11, 28], ["I, II, III", "PROTEIN", 57, 67], ["viral capsid", "PROTEIN", 149, 161], ["a cysteine protease", "TREATMENT", 9, 28], ["viral particles", "PROBLEM", 113, 128], ["the viral capsid", "PROBLEM", 145, 161], ["releasing viral polypeptides", "TREATMENT", 168, 196], ["the infection", "PROBLEM", 229, 242], ["viral particles", "OBSERVATION", 113, 128], ["viral capsid", "OBSERVATION", 149, 161], ["infection", "OBSERVATION", 233, 242]]], ["In its active form, M pro is a homodimer, containing two protomers, and presents a non-canonical Cys-Hys dyad, located between I and II [11, 12] .IntroductionM pro is also structurally conserved among the known varieties of coronavirus, with several common characteristics of substrate shared among them, where the amino acids of the substrates C and N termini, are numbered as (-P4-P3-P2-P1 \u2193 P1\u2032-P2\u2032-P3\u2032-), and the cleavage site is located between the P1 and P1 \u2032, with the need for almost all substrates to have a glycine residue located at the position P1 [13, 14] .", [["coronavirus", "DISEASE", 224, 235], ["amino acids", "CHEMICAL", 315, 326], ["glycine", "CHEMICAL", 517, 524], ["Cys", "CHEMICAL", 97, 100], ["amino acids", "CHEMICAL", 315, 326], ["C", "CHEMICAL", 345, 346], ["N", "CHEMICAL", 351, 352], ["glycine", "CHEMICAL", 517, 524], ["M pro", "GENE_OR_GENE_PRODUCT", 20, 25], ["coronavirus", "ORGANISM", 224, 235], ["amino acids", "AMINO_ACID", 315, 326], ["M pro", "PROTEIN", 20, 25], ["homodimer", "PROTEIN", 31, 40], ["non-canonical Cys-Hys dyad", "PROTEIN", 83, 109], ["I and II [11, 12", "PROTEIN", 127, 143], ["C and N termini", "PROTEIN", 345, 360], ["P4-P3", "PROTEIN", 380, 385], ["P2", "PROTEIN", 386, 388], ["P1", "PROTEIN", 389, 391], ["P1", "PROTEIN", 394, 396], ["P2\u2032", "PROTEIN", 398, 401], ["P3", "PROTEIN", 402, 404], ["cleavage site", "PROTEIN", 417, 430], ["P1", "DNA", 454, 456], ["P1", "DNA", 461, 463], ["coronavirus", "PROBLEM", 224, 235], ["the amino acids", "TEST", 311, 326], ["P4-P3", "TEST", 380, 385], ["P1", "TEST", 394, 396], ["P2\u2032", "TEST", 398, 401], ["the cleavage site", "PROBLEM", 413, 430], ["a glycine residue", "PROBLEM", 515, 532], ["active", "OBSERVATION_MODIFIER", 7, 13], ["coronavirus", "OBSERVATION", 224, 235], ["glycine residue", "OBSERVATION", 517, 532]]], ["M pro 's active sites are highly conserved among the different varieties of coronavirus, usually being composed of 4 sites, usually referred to as S1 \u2032, S1, S2 and S4 [9] .IntroductionIn this work, considering the current pandemic of COVID-19 around the world, we propose use of drug design and lead discovery approaches as well, including virtual screening, ADME/Tox predictions and molecular docking [15] , to design new compounds for inhibiting the protease M pro , involved on the process of viral infection with SARS-CoV-2, thus preventing the viral peptide from being cleaved, and thereby preventing smaller viral charge from being released into the host's plasma [16] .", [["plasma", "ANATOMY", 663, 669], ["coronavirus", "DISEASE", 76, 87], ["infection", "DISEASE", 502, 511], ["M pro", "GENE_OR_GENE_PRODUCT", 0, 5], ["coronavirus", "ORGANISM", 76, 87], ["COVID-19", "CELL", 234, 242], ["protease M pro", "GENE_OR_GENE_PRODUCT", 452, 466], ["CoV-2", "ORGANISM", 522, 527], ["plasma", "ORGANISM_SUBSTANCE", 663, 669], ["M pro 's active sites", "DNA", 0, 21], ["S1", "PROTEIN", 147, 149], ["S1", "PROTEIN", 153, 155], ["S2", "PROTEIN", 157, 159], ["protease M pro", "PROTEIN", 452, 466], ["M pro 's active sites", "PROBLEM", 0, 21], ["coronavirus", "PROBLEM", 76, 87], ["drug design", "TREATMENT", 279, 290], ["virtual screening", "TEST", 340, 357], ["the protease M pro", "TREATMENT", 448, 466], ["viral infection", "PROBLEM", 496, 511], ["SARS", "PROBLEM", 517, 521], ["the viral peptide", "PROBLEM", 545, 562], ["smaller viral charge", "PROBLEM", 606, 626], ["different varieties", "OBSERVATION", 53, 72], ["coronavirus", "OBSERVATION", 76, 87], ["S1", "ANATOMY", 153, 155], ["S2", "ANATOMY", 157, 159], ["viral", "OBSERVATION_MODIFIER", 496, 501], ["infection", "OBSERVATION", 502, 511], ["smaller", "OBSERVATION_MODIFIER", 606, 613], ["viral charge", "OBSERVATION", 614, 626]]], ["For such purpose, we have compared some repositioned drugs in current clinical studies with SARS-CoV-2 and proposed novel compounds here designed using virtual screening in drug databases.Material and methodsThe main steps of the methodological procedure performed in virtual screening are shown in Figure 1 .Virtual ScreeningFor virtual screening, we downloaded structure files deposited in the Protein Data Bank (PDB) from the Research Collaboratory for Structural Bioinformatics related to the crystallographic structures of the M pro (PDB ID: 6LU7, resolution: 2.16\u212b ), in complex with an inhibitor called N3.", [["N3", "CHEMICAL", 610, 612], ["Protein Data Bank", "PROTEIN", 396, 413], ["M pro", "PROTEIN", 532, 537], ["some repositioned drugs", "TREATMENT", 35, 58], ["virtual screening", "TEST", 152, 169], ["the methodological procedure", "TREATMENT", 226, 254], ["virtual screening", "TEST", 268, 285], ["Virtual Screening", "TEST", 309, 326], ["virtual screening", "TEST", 330, 347], ["main", "OBSERVATION_MODIFIER", 212, 216]]], ["GOLD 2020.1 software (Genetic Optimization for Ligand Docking) performs docking simulations, using a genetic algorithm to generate and select conformers of flexible compounds that bind to the receptor site of a protein or DNA, in addition to be able to use amino acid rotamer libraries in such simulations [17] .Virtual ScreeningFirst, in order to proceed with the virtual screening experiments, we validated our results by redocking, calculating the root mean-square deviation (RMSD) between the crystallographic pose of the inhibitor and its docking pose.", [["root", "ANATOMY", 451, 455], ["amino acid", "CHEMICAL", 257, 267], ["amino acid", "CHEMICAL", 257, 267], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["a genetic algorithm", "TREATMENT", 99, 118], ["flexible compounds", "TREATMENT", 156, 174], ["amino acid rotamer libraries", "TREATMENT", 257, 285], ["the virtual screening experiments", "TEST", 361, 394], ["square deviation (RMSD)", "PROBLEM", 461, 484], ["the inhibitor", "TREATMENT", 522, 535], ["root", "OBSERVATION_MODIFIER", 451, 455]]], ["For docking-based virtual screening, we used the following coordinates for the center of the sphere: x = -10.59, y = 13.88 and z = 68.56.", [["virtual screening", "TEST", 18, 35], ["z", "TEST", 127, 128]]], ["Also, a radius of 12.5 \u212b was here considered.Virtual ScreeningTwo SARS-CoV-2 Targeted Libraries, available by OTAVA Chemicals, has been used, which contain compounds with predicted activity against M pro : SARS-CoV-2 Main Protease Targeted Library (SARS-CoV-2-Target, with 1017 compounds) and ML (Machine Learning) SARS Targeted Library (SARS-CoV-2-ML, with 1577 compounds).", [["SARS-CoV-2-ML", "CHEMICAL", 338, 351], ["a radius", "TEST", 6, 14], ["CoV", "TEST", 254, 257], ["radius", "OBSERVATION_MODIFIER", 8, 14]]], ["In sequence, a number of 100 topranked hits obtained was reduced, using ADME/Tox filters.Prediction of pharmacokinetic propertiesFor calculation of the pharmacokinetic properties of the drugs under study with SARS-CoV-2 (cobicistat, darunavir, favipiravir, hydroxychloroquine, lopinavir, oseltamivir, remdesivir and ritonavir) as well as of our molecules selected from the two libraries of M pro inhibitors here used -SARS-CoV-2-Target and SARS-CoV-2-ML, we used the QikProp software [18, 19] , selecting the following properties, in particular: permeability to the CNS (CNS, logBB and PSA), cell permeability (pCaco-2 and pMDCK), aggregation with serum albumin (logKhsa) and oral absorption (% Human Oral Absorption).Prediction of pharmacokinetic propertiesThe results obtained with this software were analyzed by comparing the values obtained for the investigated molecules with the average of the values obtained for 95% of the drugs made available in the software databases.", [["CNS", "ANATOMY", 566, 569], ["CNS", "ANATOMY", 571, 574], ["cell", "ANATOMY", 592, 596], ["serum", "ANATOMY", 648, 653], ["oral", "ANATOMY", 676, 680], ["SARS-CoV-2", "CHEMICAL", 209, 219], ["cobicistat", "CHEMICAL", 221, 231], ["darunavir", "CHEMICAL", 233, 242], ["favipiravir", "CHEMICAL", 244, 255], ["hydroxychloroquine", "CHEMICAL", 257, 275], ["lopinavir", "CHEMICAL", 277, 286], ["oseltamivir", "CHEMICAL", 288, 299], ["remdesivir", "CHEMICAL", 301, 311], ["ritonavir", "CHEMICAL", 316, 325], ["cobicistat", "CHEMICAL", 221, 231], ["darunavir", "CHEMICAL", 233, 242], ["favipiravir", "CHEMICAL", 244, 255], ["hydroxychloroquine", "CHEMICAL", 257, 275], ["lopinavir", "CHEMICAL", 277, 286], ["oseltamivir", "CHEMICAL", 288, 299], ["remdesivir", "CHEMICAL", 301, 311], ["ritonavir", "CHEMICAL", 316, 325], ["SARS-CoV-2", "SIMPLE_CHEMICAL", 209, 219], ["cobicistat", "SIMPLE_CHEMICAL", 221, 231], ["darunavir", "SIMPLE_CHEMICAL", 233, 242], ["favipiravir", "SIMPLE_CHEMICAL", 244, 255], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 257, 275], ["lopinavir", "SIMPLE_CHEMICAL", 277, 286], ["oseltamivir", "SIMPLE_CHEMICAL", 288, 299], ["remdesivir", "SIMPLE_CHEMICAL", 301, 311], ["ritonavir", "SIMPLE_CHEMICAL", 316, 325], ["CNS", "ANATOMICAL_SYSTEM", 566, 569], ["CNS", "ANATOMICAL_SYSTEM", 571, 574], ["PSA", "GENE_OR_GENE_PRODUCT", 586, 589], ["cell", "CELL", 592, 596], ["pCaco-2", "GENE_OR_GENE_PRODUCT", 611, 618], ["pMDCK", "SIMPLE_CHEMICAL", 623, 628], ["serum", "ORGANISM_SUBSTANCE", 648, 653], ["albumin", "GENE_OR_GENE_PRODUCT", 654, 661], ["logKhsa", "SIMPLE_CHEMICAL", 663, 670], ["oral", "ORGANISM_SUBDIVISION", 676, 680], ["Human", "ORGANISM", 695, 700], ["Oral", "ORGANISM_SUBDIVISION", 701, 705], ["PSA", "PROTEIN", 586, 589], ["pMDCK", "PROTEIN", 623, 628], ["serum albumin", "PROTEIN", 648, 661], ["Human", "SPECIES", 695, 700], ["ADME/Tox filters", "TREATMENT", 72, 88], ["the drugs", "TREATMENT", 182, 191], ["SARS", "TEST", 209, 213], ["CoV", "TEST", 214, 217], ["cobicistat", "TREATMENT", 221, 231], ["darunavir", "TREATMENT", 233, 242], ["favipiravir", "TREATMENT", 244, 255], ["hydroxychloroquine", "TREATMENT", 257, 275], ["lopinavir", "TREATMENT", 277, 286], ["oseltamivir", "TREATMENT", 288, 299], ["remdesivir", "TREATMENT", 301, 311], ["ritonavir", "TREATMENT", 316, 325], ["M pro inhibitors", "TREATMENT", 390, 406], ["SARS", "TEST", 418, 422], ["CoV", "TEST", 423, 426], ["the CNS", "TEST", 562, 569], ["PSA", "TEST", 586, 589], ["cell permeability", "TEST", 592, 609], ["pCaco", "TEST", 611, 616], ["serum albumin", "TEST", 648, 661], ["oral absorption (% Human Oral Absorption)", "TREATMENT", 676, 717], ["pharmacokinetic properties", "TREATMENT", 732, 758], ["this software", "TEST", 784, 797], ["the drugs", "TREATMENT", 927, 936], ["CNS", "ANATOMY", 566, 569], ["pharmacokinetic properties", "OBSERVATION", 732, 758]]], ["Under this comparison, the number of \"stars\" denotes the number of violations of these ranges of optimal J o u r n a l P r e -p r o o f values common to drugs, which are used as references/templates in QikProp [18, 19] .Prediction of pharmacokinetic propertiesIn brief, the following properties as well as their ranges of optimal values were considered and here analyzed using the QikProp CNS: -2 (low permeability) e >-2 (high permeability); \u2022 logBB (blood/brain barrier): <-1 (low) e >-1 (easy permeation); \u2022 PSA (Van der Waals surface area): >60 (does not cross the blood/brain barrier) e <60 (to cross the blood/brain barrier).Prediction of Toxicological PropertiesThe DEREK software (Deductive Estimate of Risk from Existing Know-edge) was used to predict the toxicity of the molecules here investigated.", [["blood", "ANATOMY", 452, 457], ["brain", "ANATOMY", 458, 463], ["blood", "ANATOMY", 569, 574], ["brain", "ANATOMY", 575, 580], ["blood", "ANATOMY", 610, 615], ["brain", "ANATOMY", 616, 621], ["toxicity", "DISEASE", 765, 773], ["blood", "ORGANISM_SUBSTANCE", 452, 457], ["brain", "ORGAN", 458, 463], ["blood", "ORGANISM_SUBSTANCE", 569, 574], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 575, 588], ["blood", "ORGANISM_SUBSTANCE", 610, 615], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 616, 629], ["PSA", "PROTEIN", 511, 514], ["drugs", "TREATMENT", 153, 158], ["pharmacokinetic properties", "TREATMENT", 234, 260], ["the QikProp CNS", "TEST", 377, 392], ["blood/brain barrier", "TEST", 452, 471], ["PSA", "TEST", 511, 514], ["Van der Waals surface area", "TEST", 516, 542], ["the blood/brain barrier", "TEST", 565, 588], ["the blood/brain barrier", "TREATMENT", 606, 629], ["the toxicity of the molecules", "PROBLEM", 761, 790], ["pharmacokinetic properties", "OBSERVATION", 234, 260], ["brain", "ANATOMY", 458, 463], ["brain", "ANATOMY", 575, 580], ["brain", "ANATOMY", 616, 621]]], ["This software is an expert-system that uses a methodology capable of making qualitative predictions by searches for 2D similarity shared between the investigated molecule and other structures of the database, which contain reported toxic moieties, predicting, by comparison, the associated toxicity [20] .", [["toxicity", "DISEASE", 290, 298], ["the associated toxicity", "PROBLEM", 275, 298], ["toxic moieties", "OBSERVATION", 232, 246]]], ["The results are obtained in the form of alerts that are fired about a possible / potential toxicity of the investigated molecule, which would cause a certain toxic effect on the organism [21] .Prediction of Toxicological PropertiesDEREK's decisions are based on the \"knowledge-based expert system\" method, for the most diverse and peculiar situations of toxicity, including skin sensitization, hepatotoxicity, nephrotoxicity, carcinogenicity, mutagenicity and other specific toxicities or endpoints [22] .Molecular DockingMolecular docking simulations between the selected molecules after the previous steps and the biological target M pro (PDB 6LU7) were performed with the aid of the GOLD 2020.1 software.", [["skin", "ANATOMY", 374, 378], ["toxicity", "DISEASE", 91, 99], ["toxicity", "DISEASE", 354, 362], ["skin sensitization", "DISEASE", 374, 392], ["hepatotoxicity", "DISEASE", 394, 408], ["nephrotoxicity", "DISEASE", 410, 424], ["carcinogenicity", "DISEASE", 426, 441], ["toxicities", "DISEASE", 475, 485], ["skin", "ORGAN", 374, 378], ["M pro", "PROTEIN", 634, 639], ["PDB 6LU7", "PROTEIN", 641, 649], ["the investigated molecule", "PROBLEM", 103, 128], ["a certain toxic effect", "PROBLEM", 148, 170], ["toxicity", "PROBLEM", 354, 362], ["skin sensitization", "PROBLEM", 374, 392], ["hepatotoxicity", "PROBLEM", 394, 408], ["nephrotoxicity", "PROBLEM", 410, 424], ["carcinogenicity", "PROBLEM", 426, 441], ["mutagenicity", "PROBLEM", 443, 455], ["other specific toxicities", "PROBLEM", 460, 485], ["skin", "ANATOMY", 374, 378]]], ["As previously mentioned, GOLD uses genetic algorithm to generate and select conformers of flexible compounds.", [["genetic algorithm", "TEST", 35, 52], ["flexible compounds", "OBSERVATION", 90, 108]]], ["For docking, we used the following coordinates for the center of the sphere: x = -10.59, y = 13.88 and z = 68.56, and a radius of 12.5 \u00c5 of docking grid was considered.", [["z", "TEST", 103, 104], ["a radius", "TEST", 118, 126], ["docking grid", "TEST", 140, 152], ["radius", "OBSERVATION_MODIFIER", 120, 126]]], ["The co-crystallized ligand, ions and water molecules were removed from the crystal structure before the docking simulations.", [["ions", "SIMPLE_CHEMICAL", 28, 32], ["water molecules", "SIMPLE_CHEMICAL", 37, 52], ["The co-crystallized ligand, ions and water molecules", "TREATMENT", 0, 52], ["ligand", "OBSERVATION_MODIFIER", 20, 26], ["crystal", "OBSERVATION_MODIFIER", 75, 82]]], ["Prior to the calculations, hydrogens were added to all the compounds, while the respective atomic charges were calculated using the PM3 method, for a better performance / accuracy of the molecular docking.Search based on structural similarityJ o u r n a l P r e -p r o o fSearch based on structural similarityThe BindingDB webserver offers the possibility of calculating structural similarity [23] using the Tanimoto coefficient (Tc) [24] , based upon JChem fingerprints, resulting in a numerical value of structural similarity between them.", [["hydrogens", "CHEMICAL", 27, 36], ["hydrogens", "SIMPLE_CHEMICAL", 27, 36], ["BindingDB webserver", "DNA", 313, 332], ["the calculations", "TEST", 9, 25], ["hydrogens", "TREATMENT", 27, 36], ["the PM3 method", "TREATMENT", 128, 142], ["fSearch", "PROBLEM", 271, 278], ["the Tanimoto coefficient (Tc)", "TREATMENT", 404, 433]]], ["As we do not know the active conformation of the molecule here selected as a pivot, 2D similarity provides satisfactory results for the virtual screening step.", [["the virtual screening step", "TEST", 132, 158]]], ["The Tc analyzed the similarities of the selected molecules, after the results of the previous step, with an FDA library from the webserver itself containing 1091 drugs and classified them according to their similarity.", [["drugs", "TREATMENT", 162, 167]]], ["A file of this classification was generated and analyzed using the Discovery Studio software [24] from which a group of molecules with similar activity, above or equal to 40%, was extracted [25] .Virtual screening in compounds databasesVirtual screening is the computational analogue of the High Throughput Screening (HTS), and it is characterized as the computational screening of chemical compounds deposited in typically large libraries, in order to find molecules that can complement biological targets of resolved structure, selecting the most potent ones, in potential [26] .", [["Virtual screening", "TEST", 196, 213], ["Virtual screening", "TEST", 236, 253], ["chemical compounds", "PROBLEM", 382, 400], ["activity", "OBSERVATION_MODIFIER", 143, 151]]], ["This technique has very low cost-effective as well as high speed to generate result, giving enormous benefits to pharmaceutical research that needs urgency, such as the SARS-CoV-2 pandemic.Virtual screening in compounds databasesThere are different and possible protocols for virtual screening, and a combined use of tools is important so that results could be even more robust, reliable and more likely to be validated/confirmed in in vitro assays.", [["SARS-CoV-2 pandemic", "DISEASE", 169, 188], ["CoV-2", "ORGANISM", 174, 179], ["urgency", "PROBLEM", 148, 155], ["the SARS", "TEST", 165, 173], ["pandemic", "PROBLEM", 180, 188], ["Virtual screening", "TEST", 189, 206], ["virtual screening", "TEST", 276, 293]]], ["Many studies use this technique in the search for chemical entities for the treatment, for example, of cancer, withdrawal syndrome, neuropathic and inflammatory pain [27, 28, 29] .Virtual screening in compounds databasesThe target structure here used in the screening was M pro (PDB ID: 6LU7), which belongs to a family of enzymes that has been extensively studied from viruses, such as the NS3 protease, from DENGUE virus [30] , the protease HIV-1 [31] and others from different viruses that have proteases with known structure as well.Virtual screening in compounds databasesThe two libraries here utilized contain compounds with predicted activity against M pro : SARS-CoV-2-Target and SARS-CoV-2-ML.", [["cancer", "ANATOMY", 103, 109], ["cancer", "DISEASE", 103, 109], ["withdrawal syndrome", "DISEASE", 111, 130], ["neuropathic and inflammatory pain", "DISEASE", 132, 165], ["cancer", "CANCER", 103, 109], ["NS3", "GENE_OR_GENE_PRODUCT", 391, 394], ["DENGUE virus [30", "ORGANISM", 410, 426], ["HIV-1", "ORGANISM", 443, 448], ["M pro", "PROTEIN", 272, 277], ["6LU7", "PROTEIN", 287, 291], ["enzymes", "PROTEIN", 323, 330], ["NS3 protease", "PROTEIN", 391, 403], ["proteases", "PROTEIN", 498, 507], ["HIV-1", "SPECIES", 443, 448], ["DENGUE virus", "SPECIES", 410, 422], ["HIV-1", "SPECIES", 443, 448], ["Many studies", "TEST", 0, 12], ["this technique", "TREATMENT", 17, 31], ["the treatment", "TREATMENT", 72, 85], ["cancer", "PROBLEM", 103, 109], ["withdrawal syndrome", "PROBLEM", 111, 130], ["neuropathic and inflammatory pain", "PROBLEM", 132, 165], ["Virtual screening", "TEST", 180, 197], ["enzymes", "TEST", 323, 330], ["viruses", "PROBLEM", 370, 377], ["the NS3 protease", "TREATMENT", 387, 403], ["DENGUE virus", "PROBLEM", 410, 422], ["the protease HIV", "TEST", 430, 446], ["different viruses", "PROBLEM", 470, 487], ["Virtual screening", "TEST", 537, 554], ["SARS", "TEST", 667, 671], ["CoV", "TEST", 672, 675], ["SARS-CoV", "TEST", 689, 697], ["cancer", "OBSERVATION", 103, 109], ["neuropathic", "OBSERVATION_MODIFIER", 132, 143], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["viruses", "OBSERVATION", 480, 487]]], ["The first library has been designed using structurebased virtual screening (flexible docking), using crystal structure of M pro ; the second one has been designed using machine learning (artificial neural networks and Bayesian statistics), based on compounds with known anti-SARS activity.Virtual screening in compounds databasesFrom each library, 100 hits were selected with highest values of affinity score with M pro , and they are thus selected to the next stages of this work.Pharmacokinetic properties analysisThe infection caused by COVID-19 is related to that of SARS, affecting the pneumocytes and macrophages of the lung, which is its target organ.", [["pneumocytes", "ANATOMY", 591, 602], ["macrophages", "ANATOMY", 607, 618], ["lung", "ANATOMY", 626, 630], ["organ", "ANATOMY", 652, 657], ["infection", "DISEASE", 520, 529], ["COVID-19", "CHEMICAL", 540, 548], ["SARS", "DISEASE", 571, 575], ["neural networks", "MULTI-TISSUE_STRUCTURE", 198, 213], ["anti-SARS", "GENE_OR_GENE_PRODUCT", 270, 279], ["COVID-19", "GENE_OR_GENE_PRODUCT", 540, 548], ["pneumocytes", "CELL", 591, 602], ["macrophages", "CELL", 607, 618], ["lung", "ORGAN", 626, 630], ["organ", "ORGAN", 652, 657], ["anti-SARS", "PROTEIN", 270, 279], ["pneumocytes", "CELL_TYPE", 591, 602], ["macrophages", "CELL_TYPE", 607, 618], ["structurebased virtual screening", "TEST", 42, 74], ["artificial neural networks", "TREATMENT", 187, 213], ["Virtual screening", "TEST", 289, 306], ["Pharmacokinetic properties analysis", "TEST", 481, 516], ["The infection", "PROBLEM", 516, 529], ["COVID", "TEST", 540, 545], ["SARS", "PROBLEM", 571, 575], ["the pneumocytes and macrophages of the lung", "PROBLEM", 587, 630], ["infection", "OBSERVATION", 520, 529], ["SARS", "OBSERVATION", 571, 575], ["pneumocytes", "OBSERVATION", 591, 602], ["macrophages", "OBSERVATION", 607, 618], ["lung", "ANATOMY", 626, 630]]], ["Also, it appears to be related to the ACE2 receptor, which may protect the host against lung injury, as well as to the TMPRSS2 protein, related to facilitating the entry of the virus into the organism, both present in the lung [32] .", [["lung", "ANATOMY", 88, 92], ["lung", "ANATOMY", 222, 226], ["lung injury", "DISEASE", 88, 99], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 38, 51], ["lung", "ORGAN", 88, 92], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 119, 126], ["lung", "ORGAN", 222, 226], ["ACE2 receptor", "PROTEIN", 38, 51], ["TMPRSS2 protein", "PROTEIN", 119, 134], ["the ACE2 receptor", "TREATMENT", 34, 51], ["lung injury", "PROBLEM", 88, 99], ["the TMPRSS2 protein", "TEST", 115, 134], ["appears to be related to", "UNCERTAINTY", 9, 33], ["lung", "ANATOMY", 88, 92], ["injury", "OBSERVATION", 93, 99], ["lung", "ANATOMY", 222, 226]]], ["This information presents us with the peripheral action of the virus, being a requirement for its future therapeutic agent.Pharmacokinetic properties analysisInitially, we analyzed the pharmacokinetic predictions of antiviral drugs as well as hydroxychloroquine, currently available ( Figure 2 ) and also under evaluation of biological activity as well as clinical tests, in the treatment of COVID-19 (Table 1) , in order to obtain parameters for comparison among our molecules, J o u r n a l P r e -p r o o f selected using virtual screening, whose results are presented in Tables 2 and 3 .", [["hydroxychloroquine", "CHEMICAL", 243, 261], ["hydroxychloroquine", "CHEMICAL", 243, 261], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 243, 261], ["the virus", "PROBLEM", 59, 68], ["therapeutic agent", "TREATMENT", 105, 122], ["antiviral drugs", "TREATMENT", 216, 231], ["hydroxychloroquine", "TREATMENT", 243, 261], ["clinical tests", "TEST", 356, 370], ["COVID", "TEST", 392, 397], ["virtual screening", "TEST", 525, 542]]], ["All the molecules here investigated showed results with median to high values for oral absorption, as well as median aggregation to plasma proteins.", [["oral", "ANATOMY", 82, 86], ["plasma", "ANATOMY", 132, 138], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["plasma", "ORGANISM_SUBSTANCE", 132, 138], ["plasma proteins", "PROTEIN", 132, 147], ["oral absorption", "PROBLEM", 82, 97], ["median aggregation to plasma proteins", "PROBLEM", 110, 147]]], ["Most of the evaluated drugs showed a prediction of high cellular permeability, both in the results for intestinal cells, as well as for renal cells (pCaco-2 and pMDCK), with the exception only for cobicistat and remdesivir.Pharmacokinetic properties analysisMost drugs here evaluated using the QikProp software tend to not permeate the CNS in potential (cobicistat, darunavir, lopiravir, remdesivir and ritonavir), but have high cellular permeability (darunavir, favipiravir, hydroxychloroquine, lopinavir, oseltamivir and ritonavir).", [["cellular", "ANATOMY", 56, 64], ["intestinal cells", "ANATOMY", 103, 119], ["renal cells", "ANATOMY", 136, 147], ["CNS", "ANATOMY", 336, 339], ["cellular", "ANATOMY", 429, 437], ["cobicistat", "CHEMICAL", 197, 207], ["remdesivir", "CHEMICAL", 212, 222], ["cobicistat", "CHEMICAL", 354, 364], ["darunavir", "CHEMICAL", 366, 375], ["lopiravir", "CHEMICAL", 377, 386], ["remdesivir", "CHEMICAL", 388, 398], ["ritonavir", "CHEMICAL", 403, 412], ["darunavir", "CHEMICAL", 452, 461], ["favipiravir", "CHEMICAL", 463, 474], ["hydroxychloroquine", "CHEMICAL", 476, 494], ["lopinavir", "CHEMICAL", 496, 505], ["oseltamivir", "CHEMICAL", 507, 518], ["ritonavir", "CHEMICAL", 523, 532], ["cobicistat", "CHEMICAL", 197, 207], ["remdesivir", "CHEMICAL", 212, 222], ["cobicistat", "CHEMICAL", 354, 364], ["darunavir", "CHEMICAL", 366, 375], ["lopiravir", "CHEMICAL", 377, 386], ["remdesivir", "CHEMICAL", 388, 398], ["ritonavir", "CHEMICAL", 403, 412], ["darunavir", "CHEMICAL", 452, 461], ["favipiravir", "CHEMICAL", 463, 474], ["hydroxychloroquine", "CHEMICAL", 476, 494], ["lopinavir", "CHEMICAL", 496, 505], ["oseltamivir", "CHEMICAL", 507, 518], ["ritonavir", "CHEMICAL", 523, 532], ["cellular", "CELL", 56, 64], ["intestinal cells", "CELL", 103, 119], ["renal cells", "CELL", 136, 147], ["pCaco-2", "CELL", 149, 156], ["pMDCK", "CELL", 161, 166], ["cobicistat", "SIMPLE_CHEMICAL", 197, 207], ["remdesivir", "SIMPLE_CHEMICAL", 212, 222], ["cobicistat", "SIMPLE_CHEMICAL", 354, 364], ["darunavir", "SIMPLE_CHEMICAL", 366, 375], ["lopiravir", "SIMPLE_CHEMICAL", 377, 386], ["remdesivir", "SIMPLE_CHEMICAL", 388, 398], ["ritonavir", "SIMPLE_CHEMICAL", 403, 412], ["cellular", "CELL", 429, 437], ["darunavir", "SIMPLE_CHEMICAL", 452, 461], ["favipiravir", "SIMPLE_CHEMICAL", 463, 474], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 476, 494], ["lopinavir", "SIMPLE_CHEMICAL", 496, 505], ["oseltamivir", "SIMPLE_CHEMICAL", 507, 518], ["ritonavir", "SIMPLE_CHEMICAL", 523, 532], ["intestinal cells", "CELL_TYPE", 103, 119], ["renal cells", "CELL_TYPE", 136, 147], ["high cellular permeability", "PROBLEM", 51, 77], ["intestinal cells", "PROBLEM", 103, 119], ["renal cells", "PROBLEM", 136, 147], ["pCaco", "TEST", 149, 154], ["cobicistat", "TREATMENT", 197, 207], ["remdesivir", "TREATMENT", 212, 222], ["Pharmacokinetic properties analysis", "TEST", 223, 258], ["cobicistat", "TREATMENT", 354, 364], ["darunavir", "TREATMENT", 366, 375], ["lopiravir", "TREATMENT", 377, 386], ["remdesivir", "TREATMENT", 388, 398], ["ritonavir", "TREATMENT", 403, 412], ["high cellular permeability", "PROBLEM", 424, 450], ["darunavir", "TREATMENT", 452, 461], ["favipiravir", "TREATMENT", 463, 474], ["hydroxychloroquine", "TREATMENT", 476, 494], ["lopinavir", "TREATMENT", 496, 505], ["oseltamivir", "TREATMENT", 507, 518], ["ritonavir", "TREATMENT", 523, 532], ["high cellular permeability", "OBSERVATION", 51, 77], ["intestinal cells", "ANATOMY", 103, 119], ["renal", "ANATOMY", 136, 141], ["cellular permeability", "OBSERVATION", 429, 450]]], ["Prediction is median aggregation to protein albumin for all drugs, in addition to prediction of low oral absorption (for cobicistat, darunavir, favipiravir, oseltamivir, remdesivir and ritonavir).", [["oral", "ANATOMY", 100, 104], ["cobicistat", "CHEMICAL", 121, 131], ["darunavir", "CHEMICAL", 133, 142], ["favipiravir", "CHEMICAL", 144, 155], ["oseltamivir", "CHEMICAL", 157, 168], ["remdesivir", "CHEMICAL", 170, 180], ["ritonavir", "CHEMICAL", 185, 194], ["cobicistat", "CHEMICAL", 121, 131], ["darunavir", "CHEMICAL", 133, 142], ["favipiravir", "CHEMICAL", 144, 155], ["oseltamivir", "CHEMICAL", 157, 168], ["remdesivir", "CHEMICAL", 170, 180], ["ritonavir", "CHEMICAL", 185, 194], ["albumin", "GENE_OR_GENE_PRODUCT", 44, 51], ["oral", "ORGANISM_SUBDIVISION", 100, 104], ["cobicistat", "SIMPLE_CHEMICAL", 121, 131], ["darunavir", "SIMPLE_CHEMICAL", 133, 142], ["favipiravir", "SIMPLE_CHEMICAL", 144, 155], ["oseltamivir", "SIMPLE_CHEMICAL", 157, 168], ["remdesivir", "SIMPLE_CHEMICAL", 170, 180], ["ritonavir", "SIMPLE_CHEMICAL", 185, 194], ["protein albumin", "PROTEIN", 36, 51], ["protein albumin", "TREATMENT", 36, 51], ["all drugs", "TREATMENT", 56, 65], ["low oral absorption", "PROBLEM", 96, 115], ["cobicistat", "TREATMENT", 121, 131], ["darunavir", "TREATMENT", 133, 142], ["favipiravir", "TREATMENT", 144, 155], ["oseltamivir", "TREATMENT", 157, 168], ["remdesivir", "TREATMENT", 170, 180], ["ritonavir", "TREATMENT", 185, 194]]], ["Hydroxychloroquine, although a drug indicated for the treatment of rheumatoid arthritis and other inflammatory diseases, has been used with initial satisfactory results in the treatment of COVID-19, and its pharmacokinetic profile, in comparison to that of antivirals and hydroxychloroquine, despite of indicating permeation to the CNS, has a high cellular distribution, presenting less aggregation to serum albumin (median aggregation), in addition to high oral absorption (similarly to Lopinavir).Pharmacokinetic properties analysisBased on the pharmacokinetic profile of antivirals and hydroxychloroquine as well as knowledge of the virus's peripheral performance, as well as due to their main clinical manifestations, we were able to evaluate the screened molecules.Pharmacokinetic properties analysisRegarding the evaluation of the molecules sorted from the SARS-CoV-2-Target library, the 25 molecules with the best pharmacokinetic profiles predicted are shown in Table 2 .", [["CNS", "ANATOMY", 332, 335], ["cellular", "ANATOMY", 348, 356], ["serum", "ANATOMY", 402, 407], ["oral", "ANATOMY", 458, 462], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["rheumatoid arthritis", "DISEASE", 67, 87], ["inflammatory diseases", "DISEASE", 98, 119], ["COVID-19", "CHEMICAL", 189, 197], ["hydroxychloroquine", "CHEMICAL", 272, 290], ["Lopinavir", "CHEMICAL", 488, 497], ["hydroxychloroquine", "CHEMICAL", 589, 607], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["COVID-19", "CHEMICAL", 189, 197], ["hydroxychloroquine", "CHEMICAL", 272, 290], ["Lopinavir", "CHEMICAL", 488, 497], ["hydroxychloroquine", "CHEMICAL", 589, 607], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["COVID-19", "SIMPLE_CHEMICAL", 189, 197], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 272, 290], ["CNS", "ANATOMICAL_SYSTEM", 332, 335], ["cellular", "CELL", 348, 356], ["serum", "ORGANISM_SUBSTANCE", 402, 407], ["albumin", "GENE_OR_GENE_PRODUCT", 408, 415], ["oral", "ORGANISM_SUBDIVISION", 458, 462], ["Lopinavir", "SIMPLE_CHEMICAL", 488, 497], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 589, 607], ["SARS-CoV-2-Target library", "DNA", 863, 888], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["a drug", "TREATMENT", 29, 35], ["rheumatoid arthritis", "PROBLEM", 67, 87], ["other inflammatory diseases", "PROBLEM", 92, 119], ["COVID", "TEST", 189, 194], ["antivirals", "TREATMENT", 257, 267], ["hydroxychloroquine", "TREATMENT", 272, 290], ["a high cellular distribution", "PROBLEM", 341, 369], ["serum albumin", "TEST", 402, 415], ["high oral absorption", "PROBLEM", 453, 473], ["Lopinavir", "TREATMENT", 488, 497], ["Pharmacokinetic properties analysisBased", "TREATMENT", 499, 539], ["antivirals", "TREATMENT", 574, 584], ["hydroxychloroquine", "TREATMENT", 589, 607], ["the evaluation", "TEST", 815, 829], ["the molecules", "TEST", 833, 846], ["the SARS", "TEST", 859, 867], ["CoV", "TEST", 868, 871], ["rheumatoid", "OBSERVATION_MODIFIER", 67, 77], ["arthritis", "OBSERVATION", 78, 87], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["CNS", "ANATOMY", 332, 335], ["high cellular distribution", "OBSERVATION", 343, 369], ["less aggregation", "OBSERVATION_MODIFIER", 382, 398]]], ["Considering the number of \"stars\", all the results here obtained indicate high reliability, indicating chemical similarity to known drug molecules of the QikProp software database.Pharmacokinetic properties analysisSuch as for the permeability to CNS, we chose to work with those molecules for which there is a prediction to act at the peripheral level, selecting the molecules that presented results for the three parameters evaluated (CNS, QPlogBB and PSA), with a prediction of not crossing the blood-brain barrier, since peripheral action is sought due to the clinical characteristics of the disease.Pharmacokinetic properties analysisIt can be seen that, compared to the profile of antivirals and hydroxychloroquine, the profile obtained for molecules from the SARS-CoV-2-Target library is even more satisfactory and adequate, in potential.", [["CNS", "ANATOMY", 247, 250], ["blood-brain barrier", "ANATOMY", 498, 517], ["hydroxychloroquine", "CHEMICAL", 702, 720], ["SARS", "DISEASE", 766, 770], ["hydroxychloroquine", "CHEMICAL", 702, 720], ["CNS", "ANATOMICAL_SYSTEM", 247, 250], ["CNS", "ANATOMICAL_SYSTEM", 437, 440], ["PSA", "GENE_OR_GENE_PRODUCT", 454, 457], ["blood", "ORGANISM_SUBSTANCE", 498, 503], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 504, 517], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 702, 720], ["PSA", "PROTEIN", 454, 457], ["SARS-CoV-2-Target library", "DNA", 766, 791], ["SARS-CoV", "SPECIES", 766, 774], ["Pharmacokinetic properties analysisSuch", "TREATMENT", 180, 219], ["the three parameters", "TEST", 405, 425], ["PSA", "TEST", 454, 457], ["the disease", "PROBLEM", 592, 603], ["Pharmacokinetic properties analysis", "TEST", 604, 639], ["antivirals", "TREATMENT", 687, 697], ["hydroxychloroquine", "TREATMENT", 702, 720], ["the profile", "TEST", 722, 733], ["the SARS", "TEST", 762, 770], ["CoV", "TEST", 771, 774], ["drug molecules", "OBSERVATION", 132, 146], ["brain", "ANATOMY", 504, 509], ["disease", "OBSERVATION", 596, 603], ["more satisfactory", "OBSERVATION_MODIFIER", 800, 817]]], ["Cell distribution was predicted from median to high for Caco-2 as well as MDCK cells, median binding to plasma proteins and median to high %HOA.Table 2Prediction of pharmacokinetic properties of molecules selected from the SARS-CoV-2-Target Library.", [["Cell", "ANATOMY", 0, 4], ["Caco-2", "ANATOMY", 56, 62], ["MDCK cells", "ANATOMY", 74, 84], ["plasma", "ANATOMY", 104, 110], ["HOA", "DISEASE", 140, 143], ["Cell", "CELL", 0, 4], ["Caco-2", "CELL", 56, 62], ["MDCK cells", "CELL", 74, 84], ["plasma", "ORGANISM_SUBSTANCE", 104, 110], ["Caco-2", "CELL_LINE", 56, 62], ["MDCK cells", "CELL_LINE", 74, 84], ["plasma proteins", "PROTEIN", 104, 119], ["Cell distribution", "PROBLEM", 0, 17], ["Caco-2", "TREATMENT", 56, 62], ["MDCK cells", "TREATMENT", 74, 84], ["plasma proteins", "TEST", 104, 119], ["the SARS", "TEST", 219, 227], ["CoV", "TEST", 228, 231]]], ["Evaluating the set of predictions made here, the 17 molecules, selected from the SARS-CoV-2-ML library and containing the best pharmacokinetic profiles are shown in Table 3 .", [["SARS-CoV-2-ML library", "DNA", 81, 102], ["the SARS", "TEST", 77, 85], ["CoV", "TEST", 86, 89]]], ["Considering the number of \"stars\", all molecules obtained highly reliable results.Molecule StarsAll molecules selected from the SARS-CoV-2-ML library that not showed permeability to CNS, in potential, showed indicative results for high oral absorption, whereas for none of them high aggregation to plasma proteins was predicted.Molecule StarsSuch as for permeability to CNS, those with prediction to act at the peripheral level were selected following the three parameters evaluated (CNS, logBB and PSA), for which the prediction was median to high cell distribution, both for intestinal cells as well as pCaco-2 and pMDCK cells.Molecule StarsIn comparison to the predicted profile for antivirals and hydroxychloroquine, it can be noted that the profile of cell distribution (pCaco-2 and pMDCK), logKhsa and %HOA of SARS-CoV-2-ML molecules is also superior.Table 3Prediction of pharmacokinetic properties of molecules selected from the SARS-CoV-2-ML Library.", [["CNS", "ANATOMY", 182, 185], ["oral", "ANATOMY", 236, 240], ["plasma", "ANATOMY", 298, 304], ["CNS", "ANATOMY", 370, 373], ["CNS", "ANATOMY", 484, 487], ["cell", "ANATOMY", 549, 553], ["intestinal cells", "ANATOMY", 577, 593], ["pCaco-2", "ANATOMY", 605, 612], ["pMDCK cells", "ANATOMY", 617, 628], ["cell", "ANATOMY", 757, 761], ["hydroxychloroquine", "CHEMICAL", 701, 719], ["SARS", "DISEASE", 816, 820], ["hydroxychloroquine", "CHEMICAL", 701, 719], ["CNS", "ANATOMICAL_SYSTEM", 182, 185], ["oral", "ORGANISM_SUBDIVISION", 236, 240], ["plasma", "ORGANISM_SUBSTANCE", 298, 304], ["CNS", "ANATOMICAL_SYSTEM", 370, 373], ["CNS", "ANATOMICAL_SYSTEM", 484, 487], ["PSA", "GENE_OR_GENE_PRODUCT", 499, 502], ["cell", "CELL", 549, 553], ["intestinal cells", "CELL", 577, 593], ["pCaco-2", "CELL", 605, 612], ["pMDCK cells", "CELL", 617, 628], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 701, 719], ["cell", "CELL", 757, 761], ["pCaco-2", "GENE_OR_GENE_PRODUCT", 776, 783], ["pMDCK", "GENE_OR_GENE_PRODUCT", 788, 793], ["SARS-CoV-2-ML library", "DNA", 128, 149], ["plasma proteins", "PROTEIN", 298, 313], ["PSA", "PROTEIN", 499, 502], ["intestinal cells", "CELL_TYPE", 577, 593], ["pCaco-2", "CELL_LINE", 605, 612], ["pMDCK cells", "CELL_LINE", 617, 628], ["pCaco", "PROTEIN", 776, 781], ["pMDCK", "PROTEIN", 788, 793], ["the SARS", "TEST", 124, 132], ["CoV", "TEST", 133, 136], ["high oral absorption", "PROBLEM", 231, 251], ["them high aggregation", "PROBLEM", 273, 294], ["plasma proteins", "TEST", 298, 313], ["permeability to CNS", "PROBLEM", 354, 373], ["PSA", "TEST", 499, 502], ["intestinal cells", "PROBLEM", 577, 593], ["pCaco", "TEST", 605, 610], ["antivirals", "TREATMENT", 686, 696], ["hydroxychloroquine", "TREATMENT", 701, 719], ["cell distribution", "TEST", 757, 774], ["pCaco", "TEST", 776, 781], ["pMDCK", "TEST", 788, 793], ["logKhsa", "TEST", 796, 803], ["SARS", "TEST", 816, 820], ["CoV", "TEST", 821, 824], ["pharmacokinetic properties of molecules", "TREATMENT", 878, 917], ["high cell distribution", "OBSERVATION", 544, 566], ["intestinal cells", "ANATOMY", 577, 593]]], ["[33] reported in their study the result of the combined use of the antivirals lopinavir and ritonavir as pharmacological alternatives initially used to treat atypical pneumonia caused by COVID-19.", [["lopinavir", "CHEMICAL", 78, 87], ["ritonavir", "CHEMICAL", 92, 101], ["pneumonia", "DISEASE", 167, 176], ["COVID-19", "CHEMICAL", 187, 195], ["lopinavir", "CHEMICAL", 78, 87], ["ritonavir", "CHEMICAL", 92, 101], ["lopinavir", "SIMPLE_CHEMICAL", 78, 87], ["ritonavir", "SIMPLE_CHEMICAL", 92, 101], ["their study", "TEST", 17, 28], ["the antivirals lopinavir", "TREATMENT", 63, 87], ["ritonavir", "TREATMENT", 92, 101], ["pharmacological alternatives", "TREATMENT", 105, 133], ["atypical pneumonia", "PROBLEM", 158, 176], ["COVID", "TEST", 187, 192], ["pneumonia", "OBSERVATION", 167, 176]]], ["Unfortunately, among the group of patients evaluated, there was no proven efficacy in the treatment, with patients who had a clinical evolution to acute respiratory failure, in addition to no reduction in viral charge, which remained similar to that of untreated patients.", [["respiratory", "ANATOMY", 153, 164], ["respiratory failure", "DISEASE", 153, 172], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 263, 271], ["acute respiratory failure", "PROBLEM", 147, 172], ["reduction in viral charge", "PROBLEM", 192, 217], ["no proven", "UNCERTAINTY", 64, 73], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["respiratory failure", "OBSERVATION", 153, 172], ["no", "UNCERTAINTY", 189, 191], ["reduction", "OBSERVATION_MODIFIER", 192, 201], ["viral charge", "OBSERVATION", 205, 217]]], ["Such information indicates the urgent need for a specific and effective pharmacological alternative against this pandemic disease.Toxicological properties analysisComputational tools used to predict the toxic potential of the most varied molecules can have a significant impact on the discovery and development of drugs, and toxicity is one of the fundamental parameters for the continuation of research in drug design and development [34] .Toxicological properties analysisZhang et. al. [35] revealed a highresolution structure of \u03b1-ketoamide bound to the protease, responsible for a block of the viral RNA replication.", [["toxicity", "DISEASE", 325, 333], ["\u03b1-ketoamide", "CHEMICAL", 532, 543], ["\u03b1-ketoamide", "CHEMICAL", 532, 543], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 532, 543], ["\u03b1-ketoamide", "PROTEIN", 532, 543], ["protease", "PROTEIN", 557, 565], ["this pandemic disease", "PROBLEM", 108, 129], ["drugs", "TREATMENT", 314, 319], ["toxicity", "PROBLEM", 325, 333], ["Toxicological properties analysis", "TEST", 441, 474], ["\u03b1-ketoamide bound", "PROBLEM", 532, 549], ["the protease", "TREATMENT", 553, 565], ["the viral RNA replication", "TREATMENT", 594, 619], ["viral RNA replication", "OBSERVATION", 598, 619]]], ["They report that \u03b1-ketoamide has a prolonged half-life in the blood plasma.", [["blood plasma", "ANATOMY", 62, 74], ["\u03b1-ketoamide", "CHEMICAL", 17, 28], ["\u03b1-ketoamide", "CHEMICAL", 17, 28], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 17, 28], ["blood plasma", "ORGANISM_SUBSTANCE", 62, 74], ["the blood plasma", "TEST", 58, 74]]], ["In addition, they tested their main inhibitory compound in mice, finding that inhalation was well tolerated and that the mice had no adverse effects.", [["mice", "ORGANISM", 59, 63], ["mice", "ORGANISM", 121, 125], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 121, 125], ["adverse effects", "PROBLEM", 133, 148]]], ["They suggested, therefore, that since human proteases with a similar cleavage specificity are not known, it is unlikely that this class of inhibitors will be toxic, which results in a useful structure for the development of drugs to combat the new coronavirus.Toxicological properties analysisIn this study, DEREK software was used to predict the toxicological properties of the drugs under study with SARS-CoV-2 (cobicistat, darunavir, favipiravir, hydroxychloroquine, lopinavir, oseltamivir, remdesivir and ritonavir) as well as the molecules selected from libraries of M pro inhibitors.", [["coronavirus", "DISEASE", 248, 259], ["SARS-CoV-2", "CHEMICAL", 402, 412], ["cobicistat", "CHEMICAL", 414, 424], ["darunavir", "CHEMICAL", 426, 435], ["favipiravir", "CHEMICAL", 437, 448], ["hydroxychloroquine", "CHEMICAL", 450, 468], ["lopinavir", "CHEMICAL", 470, 479], ["oseltamivir", "CHEMICAL", 481, 492], ["remdesivir", "CHEMICAL", 494, 504], ["ritonavir", "CHEMICAL", 509, 518], ["cobicistat", "CHEMICAL", 414, 424], ["darunavir", "CHEMICAL", 426, 435], ["favipiravir", "CHEMICAL", 437, 448], ["hydroxychloroquine", "CHEMICAL", 450, 468], ["lopinavir", "CHEMICAL", 470, 479], ["oseltamivir", "CHEMICAL", 481, 492], ["remdesivir", "CHEMICAL", 494, 504], ["ritonavir", "CHEMICAL", 509, 518], ["human", "ORGANISM", 38, 43], ["coronavirus", "ORGANISM", 248, 259], ["CoV-2", "SIMPLE_CHEMICAL", 407, 412], ["cobicistat", "SIMPLE_CHEMICAL", 414, 424], ["darunavir", "SIMPLE_CHEMICAL", 426, 435], ["favipiravir", "SIMPLE_CHEMICAL", 437, 448], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 450, 468], ["lopinavir", "SIMPLE_CHEMICAL", 470, 479], ["oseltamivir", "SIMPLE_CHEMICAL", 481, 492], ["remdesivir", "SIMPLE_CHEMICAL", 494, 504], ["ritonavir", "SIMPLE_CHEMICAL", 509, 518], ["human proteases", "PROTEIN", 38, 53], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["SARS-CoV", "SPECIES", 402, 410], ["human proteases", "PROBLEM", 38, 53], ["a similar cleavage specificity", "PROBLEM", 59, 89], ["inhibitors", "TREATMENT", 139, 149], ["toxic", "PROBLEM", 158, 163], ["drugs", "TREATMENT", 224, 229], ["the new coronavirus", "PROBLEM", 240, 259], ["this study", "TEST", 296, 306], ["the drugs", "TREATMENT", 375, 384], ["SARS", "TEST", 402, 406], ["CoV", "TEST", 407, 410], ["cobicistat", "TREATMENT", 414, 424], ["darunavir", "TREATMENT", 426, 435], ["favipiravir", "TREATMENT", 437, 448], ["hydroxychloroquine", "TREATMENT", 450, 468], ["lopinavir", "TREATMENT", 470, 479], ["oseltamivir", "TREATMENT", 481, 492], ["remdesivir", "TREATMENT", 494, 504], ["ritonavir", "TREATMENT", 509, 518], ["M pro inhibitors", "TREATMENT", 572, 588]]], ["This software has a system that makes predictions from a qualitative point of view and, thus, alerts are fired about the possible toxic action of the analyzed chemical compounds, being able to interpret toxicophoric substructures present in the compounds as possible inducers of certain types of toxicity, such as mutagenicity, carcinogenicity, skin sensitization, irritation, reproductive effects, neurotoxicity, among others, through correlation rules established by the software.", [["skin", "ANATOMY", 345, 349], ["toxicity", "DISEASE", 296, 304], ["carcinogenicity", "DISEASE", 328, 343], ["skin sensitization", "DISEASE", 345, 363], ["irritation", "DISEASE", 365, 375], ["neurotoxicity", "DISEASE", 399, 412], ["skin", "ORGAN", 345, 349], ["toxicity", "PROBLEM", 296, 304], ["skin sensitization", "PROBLEM", 345, 363], ["irritation", "PROBLEM", 365, 375], ["reproductive effects", "PROBLEM", 377, 397], ["neurotoxicity", "PROBLEM", 399, 412], ["skin", "ANATOMY", 345, 349]]], ["For the drugs here investigated, the fired alerts are described below: Favipiravir is an antiviral agent that selective and potently inhibits RNA-dependent RNA polymerase (RdRp) from RNA viruses.", [["Favipiravir", "CHEMICAL", 71, 82], ["Favipiravir", "CHEMICAL", 71, 82], ["Favipiravir", "SIMPLE_CHEMICAL", 71, 82], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 142, 170], ["RdRp", "GENE_OR_GENE_PRODUCT", 172, 176], ["RNA-dependent RNA polymerase", "PROTEIN", 142, 170], ["RdRp", "PROTEIN", 172, 176], ["the drugs", "TREATMENT", 4, 13], ["Favipiravir", "TREATMENT", 71, 82], ["an antiviral agent", "TREATMENT", 86, 104], ["RNA", "TEST", 142, 145], ["dependent RNA polymerase (RdRp", "PROBLEM", 146, 176], ["RNA viruses", "PROBLEM", 183, 194]]], ["Favipiravir was discovered by HTS screening of the chemical library for antiviral activity against the influenza virus by Toyama Chemical Co., Ltd.Toxicological properties analysisFavipiravir undergoes intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir-RTP (favipiravir ribofuranosyl-5B-triphosphate), which is recognized as a substrate for RdRp that inhibits the activity of RNA polymerase.", [["intracellular", "ANATOMY", 202, 215], ["Favipiravir", "CHEMICAL", 0, 11], ["influenza", "DISEASE", 103, 112], ["analysisFavipiravir", "CHEMICAL", 172, 191], ["favipiravir", "CHEMICAL", 258, 269], ["favipiravir-RTP", "CHEMICAL", 275, 290], ["favipiravir ribofuranosyl-5B-triphosphate", "CHEMICAL", 292, 333], ["Favipiravir", "CHEMICAL", 0, 11], ["analysisFavipiravir", "CHEMICAL", 172, 191], ["favipiravir", "CHEMICAL", 258, 269], ["favipiravir-RTP", "CHEMICAL", 275, 290], ["favipiravir ribofuranosyl-5B-triphosphate", "CHEMICAL", 292, 333], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["influenza virus", "ORGANISM", 103, 118], ["Ltd", "GENE_OR_GENE_PRODUCT", 143, 146], ["analysisFavipiravir", "SIMPLE_CHEMICAL", 172, 191], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 202, 215], ["favipiravir-RTP", "SIMPLE_CHEMICAL", 258, 273], ["favipiravir-RTP", "SIMPLE_CHEMICAL", 275, 290], ["favipiravir ribofuranosyl-5B-triphosphate", "SIMPLE_CHEMICAL", 292, 333], ["RdRp", "PROTEIN", 375, 379], ["RNA polymerase", "PROTEIN", 410, 424], ["influenza virus", "SPECIES", 103, 118], ["Favipiravir", "TREATMENT", 0, 11], ["HTS screening", "TEST", 30, 43], ["the chemical library", "TREATMENT", 47, 67], ["antiviral activity", "TREATMENT", 72, 90], ["the influenza virus", "PROBLEM", 99, 118], ["Toxicological properties analysisFavipiravir", "TREATMENT", 147, 191], ["intracellular phosphoribosylation", "TREATMENT", 202, 235], ["favipiravir", "TREATMENT", 258, 269], ["RTP (favipiravir", "TREATMENT", 270, 286], ["RTP (favipiravir ribofuranosyl", "TREATMENT", 287, 317], ["5B-triphosphate", "TREATMENT", 318, 333], ["RdRp", "PROBLEM", 375, 379], ["the activity of RNA polymerase", "PROBLEM", 394, 424]]], ["Because the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action supports a broader spectrum broad range of antiviral activities of favipiravir.", [["favipiravir", "CHEMICAL", 178, 189], ["favipiravir", "CHEMICAL", 178, 189], ["RdRp", "GENE_OR_GENE_PRODUCT", 32, 36], ["favipiravir", "SIMPLE_CHEMICAL", 178, 189], ["catalytic domain", "PROTEIN", 12, 28], ["RdRp", "PROTEIN", 32, 36], ["the catalytic domain of RdRp", "PROBLEM", 8, 36], ["RNA viruses", "PROBLEM", 73, 84], ["antiviral activities of favipiravir", "TREATMENT", 154, 189], ["RdRp", "OBSERVATION", 32, 36], ["RNA viruses", "OBSERVATION", 73, 84]]], ["Favipiravir is effective against a wide variety of influenza virus types and subtypes, including strains resistant to existing anti-influenza drugs, and is potentially promising for specifically intractable RNA viral infections [36] .Toxicological properties analysisOn the other hand, favipiravir presents a risk of teratogenicity and embryotoxicity.", [["Favipiravir", "CHEMICAL", 0, 11], ["viral infections", "DISEASE", 211, 227], ["favipiravir", "CHEMICAL", 286, 297], ["embryotoxicity", "DISEASE", 336, 350], ["Favipiravir", "CHEMICAL", 0, 11], ["favipiravir", "CHEMICAL", 286, 297], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["influenza virus", "ORGANISM", 51, 66], ["hand", "ORGANISM_SUBDIVISION", 280, 284], ["favipiravir", "SIMPLE_CHEMICAL", 286, 297], ["Favipiravir", "TREATMENT", 0, 11], ["influenza virus types", "PROBLEM", 51, 72], ["strains", "PROBLEM", 97, 104], ["existing anti-influenza drugs", "TREATMENT", 118, 147], ["intractable RNA viral infections", "PROBLEM", 195, 227], ["favipiravir", "TREATMENT", 286, 297], ["teratogenicity", "PROBLEM", 317, 331], ["embryotoxicity", "PROBLEM", 336, 350], ["influenza virus", "OBSERVATION", 51, 66], ["teratogenicity", "OBSERVATION", 317, 331]]], ["Therefore, the Ministry of Health, Labor and Welfare has granted conditional marketing approval with strict regulations for its production and clinical use [37] .Toxicological properties analysisIn a study by Furuta et al. [38] , it was found that favipiravir has a potent and selective inhibitory activity against the influenza virus.", [["favipiravir", "CHEMICAL", 248, 259], ["influenza", "DISEASE", 319, 328], ["favipiravir", "CHEMICAL", 248, 259], ["favipiravir", "SIMPLE_CHEMICAL", 248, 259], ["influenza virus", "ORGANISM", 319, 334], ["influenza virus", "SPECIES", 319, 334], ["influenza virus", "SPECIES", 319, 334], ["a study", "TEST", 198, 205], ["the influenza virus", "PROBLEM", 315, 334], ["influenza virus", "OBSERVATION", 319, 334]]], ["In an in vitro plaque reduction assay, favipiravir showed potent inhibitory activity against influenza A, B and C viruses, with 50% inhibitory concentrations (IC 50 ) of 0.013 to 0.48 g/ml, while showing no cytotoxicity in concentrations up to 1,000 g/ml in MDCK cells.Toxicological properties analysisHydroxychloroquine and chloroquine are respectively used in the treatment of malaria and rheumatoid arthritis, systemic lupus erythematosus and inflammatory rheumatic diseases, and are considered weak bases.", [["plaque", "ANATOMY", 15, 21], ["MDCK cells", "ANATOMY", 258, 268], ["favipiravir", "CHEMICAL", 39, 50], ["Hydroxychloroquine", "CHEMICAL", 302, 320], ["chloroquine", "CHEMICAL", 325, 336], ["malaria", "DISEASE", 379, 386], ["rheumatoid arthritis", "DISEASE", 391, 411], ["systemic lupus erythematosus", "DISEASE", 413, 441], ["rheumatic diseases", "DISEASE", 459, 477], ["favipiravir", "CHEMICAL", 39, 50], ["Hydroxychloroquine", "CHEMICAL", 302, 320], ["chloroquine", "CHEMICAL", 325, 336], ["favipiravir", "SIMPLE_CHEMICAL", 39, 50], ["influenza A", "ORGANISM", 93, 104], ["B and C viruses", "ORGANISM", 106, 121], ["MDCK cells", "CELL", 258, 268], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 302, 320], ["chloroquine", "SIMPLE_CHEMICAL", 325, 336], ["MDCK cells", "CELL_LINE", 258, 268], ["influenza A", "SPECIES", 93, 104], ["an in vitro plaque reduction assay", "TREATMENT", 3, 37], ["favipiravir", "TREATMENT", 39, 50], ["influenza A, B and C viruses", "PROBLEM", 93, 121], ["50% inhibitory concentrations", "TREATMENT", 128, 157], ["IC", "TEST", 159, 161], ["cytotoxicity in concentrations", "PROBLEM", 207, 237], ["Toxicological properties", "TREATMENT", 269, 293], ["Hydroxychloroquine", "TREATMENT", 302, 320], ["chloroquine", "TREATMENT", 325, 336], ["malaria", "PROBLEM", 379, 386], ["rheumatoid arthritis", "PROBLEM", 391, 411], ["systemic lupus erythematosus", "PROBLEM", 413, 441], ["inflammatory rheumatic diseases", "PROBLEM", 446, 477], ["weak bases", "PROBLEM", 498, 508], ["plaque", "OBSERVATION", 15, 21], ["no", "UNCERTAINTY", 204, 206], ["cytotoxicity", "OBSERVATION", 207, 219], ["malaria", "OBSERVATION", 379, 386], ["rheumatoid arthritis", "OBSERVATION", 391, 411], ["systemic", "OBSERVATION_MODIFIER", 413, 421], ["lupus erythematosus", "OBSERVATION", 422, 441], ["inflammatory", "OBSERVATION_MODIFIER", 446, 458], ["rheumatic diseases", "OBSERVATION", 459, 477], ["weak", "OBSERVATION_MODIFIER", 498, 502], ["bases", "ANATOMY_MODIFIER", 503, 508]]], ["These drugs interfere with lysosomal activity and autophagy, interact with membrane stability, and alter signaling pathways and transcriptional activity, which can result in the inhibition of cytokine production and the modulation of certain costimulatory molecules.", [["lysosomal", "ANATOMY", 27, 36], ["membrane", "ANATOMY", 75, 83], ["lysosomal", "CELLULAR_COMPONENT", 27, 36], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["cytokine", "PROTEIN", 192, 200], ["costimulatory molecules", "PROTEIN", 242, 265], ["These drugs", "TREATMENT", 0, 11], ["lysosomal activity", "TREATMENT", 27, 45], ["cytokine production", "PROBLEM", 192, 211], ["lysosomal activity", "OBSERVATION", 27, 45]]], ["These modes of action, together with the chemical properties of the drug, can explain the clinical efficacy and known adverse effects (such as retinopathy and cardiac arrythmia) of these drugs [39] .Toxicological properties analysisCortegiani et al. [40] systematically reviewed the evidence on chloroquine and hydroxychloroquine for the treatment of COVID-19.", [["cardiac", "ANATOMY", 159, 166], ["retinopathy", "DISEASE", 143, 154], ["cardiac arrythmia", "DISEASE", 159, 176], ["chloroquine", "CHEMICAL", 295, 306], ["hydroxychloroquine", "CHEMICAL", 311, 329], ["COVID-19", "CHEMICAL", 351, 359], ["chloroquine", "CHEMICAL", 295, 306], ["hydroxychloroquine", "CHEMICAL", 311, 329], ["COVID-19", "CHEMICAL", 351, 359], ["cardiac", "ORGAN", 159, 166], ["chloroquine", "SIMPLE_CHEMICAL", 295, 306], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 311, 329], ["known adverse effects", "PROBLEM", 112, 133], ["retinopathy", "PROBLEM", 143, 154], ["cardiac arrythmia", "PROBLEM", 159, 176], ["these drugs", "TREATMENT", 181, 192], ["chloroquine", "TREATMENT", 295, 306], ["hydroxychloroquine", "TREATMENT", 311, 329], ["COVID", "TEST", 351, 356], ["cardiac", "ANATOMY", 159, 166], ["arrythmia", "OBSERVATION", 167, 176]]], ["They found that chloroquine appears to be effective in limiting SARS-CoV-2 replication in vitro.", [["chloroquine", "CHEMICAL", 16, 27], ["SARS", "DISEASE", 64, 68], ["chloroquine", "CHEMICAL", 16, 27], ["chloroquine", "SIMPLE_CHEMICAL", 16, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["SARS-CoV", "SPECIES", 64, 72], ["chloroquine", "TREATMENT", 16, 27], ["CoV", "TEST", 69, 72]]], ["However, in this present study, hydroxychloroquine presented plausible hepatotoxicity probably due to the quinoline group, inhibition of the HERG channels, carcinogenicity and irritation of the respiratory tract (ethanolamine) and ocular toxicity (derived from 4-Aminoquinoline), demonstrating the high degree of toxicity of this drug.Toxicological properties analysisReaffirming, Yam and Kwok [41] cite that one of the main side effects of hydroxychloroquine is ocular toxicity, which can adversely affect the cornea, the ciliary body and the retina.", [["respiratory tract", "ANATOMY", 194, 211], ["ocular", "ANATOMY", 231, 237], ["ocular", "ANATOMY", 463, 469], ["cornea", "ANATOMY", 511, 517], ["ciliary body", "ANATOMY", 523, 535], ["retina", "ANATOMY", 544, 550], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hepatotoxicity", "DISEASE", 71, 85], ["quinoline", "CHEMICAL", 106, 115], ["irritation of the respiratory tract", "DISEASE", 176, 211], ["ethanolamine", "CHEMICAL", 213, 225], ["ocular toxicity", "DISEASE", 231, 246], ["4-Aminoquinoline", "CHEMICAL", 261, 277], ["toxicity", "DISEASE", 313, 321], ["hydroxychloroquine", "CHEMICAL", 441, 459], ["ocular toxicity", "DISEASE", 463, 478], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["quinoline", "CHEMICAL", 106, 115], ["ethanolamine", "CHEMICAL", 213, 225], ["4-Aminoquinoline", "CHEMICAL", 261, 277], ["hydroxychloroquine", "CHEMICAL", 441, 459], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 32, 50], ["quinoline", "SIMPLE_CHEMICAL", 106, 115], ["HERG", "GENE_OR_GENE_PRODUCT", 141, 145], ["respiratory tract", "ORGANISM_SUBDIVISION", 194, 211], ["ethanolamine", "SIMPLE_CHEMICAL", 213, 225], ["ocular", "ORGAN", 231, 237], ["4-Aminoquinoline", "SIMPLE_CHEMICAL", 261, 277], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 441, 459], ["ocular", "ORGAN", 463, 469], ["cornea", "MULTI-TISSUE_STRUCTURE", 511, 517], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 523, 535], ["retina", "MULTI-TISSUE_STRUCTURE", 544, 550], ["HERG channels", "PROTEIN", 141, 154], ["this present study", "TEST", 12, 30], ["hydroxychloroquine", "TREATMENT", 32, 50], ["plausible hepatotoxicity", "PROBLEM", 61, 85], ["the quinoline group", "TREATMENT", 102, 121], ["the HERG channels", "PROBLEM", 137, 154], ["carcinogenicity", "PROBLEM", 156, 171], ["irritation of the respiratory tract", "PROBLEM", 176, 211], ["ocular toxicity", "PROBLEM", 231, 246], ["Aminoquinoline", "TREATMENT", 263, 277], ["this drug", "TREATMENT", 325, 334], ["hydroxychloroquine", "TREATMENT", 441, 459], ["ocular toxicity", "PROBLEM", 463, 478], ["irritation", "OBSERVATION", 176, 186], ["respiratory tract", "ANATOMY", 194, 211], ["ocular", "ANATOMY", 231, 237], ["high degree", "OBSERVATION_MODIFIER", 298, 309], ["toxicity", "OBSERVATION", 313, 321], ["hydroxychloroquine", "OBSERVATION", 441, 459], ["ocular toxicity", "OBSERVATION", 463, 478], ["cornea", "ANATOMY", 511, 517], ["ciliary body", "ANATOMY_MODIFIER", 523, 535], ["retina", "ANATOMY", 544, 550]]], ["On the other hand, recent studies suggest that the internal retina is not significantly damaged with the development of human hydroxychloroquine toxicity [42] .Toxicological properties analysisToxicity of ethanolamine was studied by the Toxicology Committee in 1967.", [["internal retina", "ANATOMY", 51, 66], ["hydroxychloroquine", "CHEMICAL", 126, 144], ["toxicity", "DISEASE", 145, 153], ["ethanolamine", "CHEMICAL", 205, 217], ["hydroxychloroquine", "CHEMICAL", 126, 144], ["ethanolamine", "CHEMICAL", 205, 217], ["retina", "MULTI-TISSUE_STRUCTURE", 60, 66], ["human", "ORGANISM", 120, 125], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 126, 144], ["ethanolamine", "SIMPLE_CHEMICAL", 205, 217], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["recent studies", "TEST", 19, 33], ["human hydroxychloroquine toxicity", "TREATMENT", 120, 153], ["ethanolamine", "TREATMENT", 205, 217], ["internal retina", "ANATOMY", 51, 66]]], ["The study by Weeks et al. [43] indicated that skin and eye irritation in addition to immediate signs of irritability and restlessness followed by CNS depression were the main adverse effects observed in experimental animals not anesthetized and exposed to ethanolamine at 12-26 ppm for 24 h.", [["skin", "ANATOMY", 46, 50], ["eye", "ANATOMY", 55, 58], ["CNS", "ANATOMY", 146, 149], ["skin and eye irritation", "DISEASE", 46, 69], ["irritability", "DISEASE", 104, 116], ["restlessness", "DISEASE", 121, 133], ["depression", "DISEASE", 150, 160], ["ethanolamine", "CHEMICAL", 256, 268], ["ethanolamine", "CHEMICAL", 256, 268], ["skin", "ORGAN", 46, 50], ["eye", "ORGAN", 55, 58], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["ethanolamine", "SIMPLE_CHEMICAL", 256, 268], ["The study", "TEST", 0, 9], ["skin and eye irritation", "PROBLEM", 46, 69], ["irritability", "PROBLEM", 104, 116], ["restlessness", "PROBLEM", 121, 133], ["CNS depression", "PROBLEM", 146, 160], ["ethanolamine", "TREATMENT", 256, 268], ["skin", "ANATOMY", 46, 50], ["eye", "ANATOMY", 55, 58], ["irritation", "OBSERVATION", 59, 69], ["irritability", "OBSERVATION", 104, 116]]], ["Continuous exposure to 5-6 J o u r n a l P r e -p r o o f ppm produced some behavioral changes in the animals, but only after 2-3 weeks of exposure.Toxicological properties analysisSang et al. [44] chose six approved anti-HIV-1 drugs to investigate their interactions with M pro as well as to assess the potential to become clinical drugs for the new coronavirus pneumonia (COVID-19) caused by SARS-CoV-2 infection.", [["coronavirus pneumonia", "DISEASE", 351, 372], ["COVID-19", "CHEMICAL", 374, 382], ["SARS-CoV-2 infection", "DISEASE", 394, 414], ["coronavirus", "ORGANISM", 351, 362], ["SARS-CoV-2", "ORGANISM", 394, 404], ["SARS-CoV-2", "SPECIES", 394, 404], ["ppm", "TREATMENT", 58, 61], ["some behavioral changes", "PROBLEM", 71, 94], ["Toxicological properties analysis", "TEST", 148, 181], ["anti-HIV-1 drugs", "TREATMENT", 217, 233], ["clinical drugs", "TREATMENT", 324, 338], ["the new coronavirus pneumonia", "PROBLEM", 343, 372], ["COVID", "TEST", 374, 379], ["SARS", "PROBLEM", 394, 398], ["CoV-2 infection", "PROBLEM", 399, 414], ["pneumonia", "OBSERVATION", 363, 372], ["infection", "OBSERVATION", 405, 414]]], ["They found that darunavir has the best binding affinity for M pro among all tested inhibitors, indicating that it has the potential to become a clinical drug to treat COVID-19.", [["darunavir", "CHEMICAL", 16, 25], ["darunavir", "CHEMICAL", 16, 25], ["COVID-19", "CHEMICAL", 167, 175], ["darunavir", "SIMPLE_CHEMICAL", 16, 25], ["darunavir", "TREATMENT", 16, 25], ["all tested inhibitors", "TREATMENT", 72, 93], ["COVID", "TEST", 167, 172], ["darunavir", "OBSERVATION", 16, 25]]], ["However, the results of the toxicological properties of this drug point out warnings such as hepatotoxicity and mutagenicity as well, which deserve attention.Toxicological properties analysisQamar et al. [16] examined a database of medicinal plants containing 32 .297 phytochemicals as potential antivirals and selected nine promising drug-free and non-toxic natural products that can inhibit M pro activity and, therefore, virus replication.", [["hepatotoxicity", "DISEASE", 93, 107], ["M pro", "GENE_OR_GENE_PRODUCT", 393, 398], ["hepatotoxicity", "PROBLEM", 93, 107], ["medicinal plants", "TREATMENT", 232, 248], ["potential antivirals", "TREATMENT", 286, 306], ["non-toxic natural products", "TREATMENT", 349, 375], ["virus replication", "TREATMENT", 424, 441]]], ["The nine products are: 5,7,3',4'-Tetrahydroxy A study by Singh and Konwar [45] performed molecular coupling of the epigallocatechin gallate (EGCG) and its analogs against the virus M pro enzyme.", [["5,7,3',4'-Tetrahydroxy A", "CHEMICAL", 23, 47], ["epigallocatechin gallate", "CHEMICAL", 115, 139], ["EGCG", "CHEMICAL", 141, 145], ["5,7,3',4'-Tetrahydroxy A", "CHEMICAL", 23, 47], ["epigallocatechin gallate", "CHEMICAL", 115, 139], ["EGCG", "CHEMICAL", 141, 145], ["5,7,3',4'-Tetrahydroxy A", "SIMPLE_CHEMICAL", 23, 47], ["epigallocatechin gallate", "SIMPLE_CHEMICAL", 115, 139], ["EGCG", "SIMPLE_CHEMICAL", 141, 145], ["virus M pro enzyme", "PROTEIN", 175, 193]]], ["Previous reports have indicated EGCG as an M pro inhibitor, but with a low oral bioavailability, thus stimulating its molecular optimization.", [["oral", "ANATOMY", 75, 79], ["EGCG", "CHEMICAL", 32, 36], ["EGCG", "CHEMICAL", 32, 36], ["EGCG", "SIMPLE_CHEMICAL", 32, 36], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["EGCG", "TEST", 32, 36], ["an M pro inhibitor", "TREATMENT", 40, 58], ["a low oral bioavailability", "PROBLEM", 69, 95]]], ["According to these reported data, the analogues bound to the enzyme active site and these improved the pharmacological properties, estimated in comparison with the EGCG.", [["EGCG", "CHEMICAL", 164, 168], ["EGCG", "CHEMICAL", 164, 168], ["EGCG", "SIMPLE_CHEMICAL", 164, 168], ["enzyme active site", "PROTEIN", 61, 79], ["the analogues bound", "PROBLEM", 34, 53], ["the EGCG", "TEST", 160, 168]]], ["In predicting ADME/Tox of the analogs, the study revealed that they have improved pharmacological properties.Toxicological properties analysisFisher et al. [46] computationally examined a library of more than 687 million compounds for binding to the crystal structure of M pro .", [["M pro", "GENE_OR_GENE_PRODUCT", 271, 276], ["M pro", "PROTEIN", 271, 276], ["the study", "TEST", 39, 48], ["improved", "OBSERVATION", 73, 81]]], ["Compounds with an improvement in binding free energy in contrast to the cocrystallized inhibitor were considered for their potential toxicity.", [["toxicity", "DISEASE", 133, 141], ["the cocrystallized inhibitor", "TREATMENT", 68, 96], ["their potential toxicity", "PROBLEM", 117, 141], ["improvement", "OBSERVATION_MODIFIER", 18, 29]]], ["Among the compounds evaluated, the authors found that the natural compound containing the lowest value of free binding energy was taxifoline.Toxicological properties analysisAccording to Jo et al. [47] , coronaviruses have been the target of some flavonoids, where it is assumed that the antiviral activity of some flavonoids against CoVs is directly caused by the inhibition of M pro .Toxicological properties analysisRegarding the screened molecules, of 100 molecules selected from the SARS-CoV-2-Target library, 33 did not present any human toxicity alert (Table 4 ), 17 presented one alert, 17 presented two alerts and 15 molecules presented three alerts.", [["taxifoline", "CHEMICAL", 130, 140], ["flavonoids", "CHEMICAL", 315, 325], ["CoVs", "CHEMICAL", 334, 338], ["toxicity", "DISEASE", 544, 552], ["taxifoline", "CHEMICAL", 130, 140], ["flavonoids", "CHEMICAL", 247, 257], ["flavonoids", "CHEMICAL", 315, 325], ["taxifoline", "SIMPLE_CHEMICAL", 130, 140], ["coronaviruses", "ORGANISM", 204, 217], ["flavonoids", "SIMPLE_CHEMICAL", 247, 257], ["flavonoids", "SIMPLE_CHEMICAL", 315, 325], ["CoVs", "SIMPLE_CHEMICAL", 334, 338], ["M pro", "GENE_OR_GENE_PRODUCT", 379, 384], ["human", "ORGANISM", 538, 543], ["M pro", "PROTEIN", 379, 384], ["SARS-CoV-2-Target library", "DNA", 488, 513], ["human", "SPECIES", 538, 543], ["human", "SPECIES", 538, 543], ["the natural compound", "PROBLEM", 54, 74], ["free binding energy", "PROBLEM", 106, 125], ["coronaviruses", "PROBLEM", 204, 217], ["some flavonoids", "PROBLEM", 310, 325], ["CoVs", "PROBLEM", 334, 338], ["Toxicological properties", "TEST", 386, 410], ["the SARS", "TEST", 484, 492], ["CoV", "TEST", 493, 496], ["any human toxicity", "PROBLEM", 534, 552], ["flavonoids", "OBSERVATION", 247, 257]]], ["On the other hand, from the SARS-CoV-2-ML library, 21 molecules showed no warning signs (Table 4) , 24 showed only one alert, 20 showed two warning signs, and 16 molecules presented with three alerts.Table 4Molecules selected from SARS-CoV-2 libraries that did not present toxicity alerts according to the DEREK software.Molecular DockingConsidering the analysis of pharmacokinetic and toxicological properties, we selected 10 molecules (Figure 3 ), 9 from the SARS-CoV-2-Target library (m57, m74, m113, m135, m152, m351, m603, m808 and m824) and 1 from the SARS-CoV-2-ML library (m494) (Supplementary material), in order to analyze intermolecular interactions that could occur with M pro , in comparison with favipiravir, which presents satisfactory results, as well as hydroxychloroquine, since it is a drug that presents results in literature as a potential drug for treatment of COVID-19 [48] .Molecular DockingJ o u r n a l P r e -p r o o f Evaluating the amino acids HIS41 and CYS145, present in the active site of said protease (Protomer A) [49] , they were used with the purpose of comparing the docking results, in addition to the amino acid residues that showed the highest number of interactions with ligands.", [["toxicity", "DISEASE", 273, 281], ["favipiravir", "CHEMICAL", 710, 721], ["hydroxychloroquine", "CHEMICAL", 771, 789], ["amino acids", "CHEMICAL", 961, 972], ["CYS145", "CHEMICAL", 983, 989], ["amino acid", "CHEMICAL", 1140, 1150], ["favipiravir", "CHEMICAL", 710, 721], ["hydroxychloroquine", "CHEMICAL", 771, 789], ["COVID-19", "CHEMICAL", 883, 891], ["amino acids", "CHEMICAL", 961, 972], ["CYS145", "CHEMICAL", 983, 989], ["amino acid", "CHEMICAL", 1140, 1150], ["favipiravir", "SIMPLE_CHEMICAL", 710, 721], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 771, 789], ["amino acids", "AMINO_ACID", 961, 972], ["HIS41", "AMINO_ACID", 973, 978], ["CYS145", "SIMPLE_CHEMICAL", 983, 989], ["amino acid", "AMINO_ACID", 1140, 1150], ["SARS-CoV-2-ML library", "DNA", 28, 49], ["SARS-CoV-2 libraries", "DNA", 231, 251], ["SARS-CoV-2-Target library", "DNA", 461, 486], ["SARS-CoV-2-ML library", "DNA", 558, 579], ["CYS145", "PROTEIN", 983, 989], ["said protease", "PROTEIN", 1021, 1034], ["Protomer A", "PROTEIN", 1036, 1046], ["SARS-CoV", "SPECIES", 231, 239], ["SARS-CoV", "SPECIES", 558, 566], ["the SARS", "TEST", 24, 32], ["CoV", "TEST", 33, 36], ["warning signs", "TEST", 74, 87], ["two warning signs", "PROBLEM", 136, 153], ["Table 4Molecules", "TEST", 200, 216], ["SARS", "PROBLEM", 231, 235], ["the analysis", "TEST", 350, 362], ["the SARS", "TEST", 457, 465], ["CoV", "TEST", 466, 469], ["the SARS", "TEST", 554, 562], ["CoV", "TEST", 563, 566], ["favipiravir", "TREATMENT", 710, 721], ["hydroxychloroquine", "TREATMENT", 771, 789], ["COVID", "TEST", 883, 888], ["the amino acids HIS41", "TEST", 957, 978], ["CYS145", "TEST", 983, 989], ["the amino acid residues", "TEST", 1136, 1159], ["no", "UNCERTAINTY", 71, 73], ["highest", "OBSERVATION_MODIFIER", 1176, 1183]]], ["All the molecules interact with the amino acid residue CYS145, with the exception of m74.", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["CYS145", "CHEMICAL", 55, 61], ["amino acid", "AMINO_ACID", 36, 46], ["residue", "AMINO_ACID", 47, 54], ["CYS145", "AMINO_ACID", 55, 61], ["m74", "GENE_OR_GENE_PRODUCT", 85, 88], ["m74", "PROTEIN", 85, 88], ["the amino acid residue", "TEST", 32, 54]]], ["However, with the amino acid residue HIS41, only the hydroxychloroquine drug and the screened molecules m57, m113, m135 and m808 showed interactions.Molecular DockingMolecular docking results indicated the lowest number of interactions for the drug favipiravir -6 interactions, being 1 hydrophobic and 5 hydrogen bonds with the amino acids GLY143, SER144, CYS145 and HIS163; and 5 interactions for m824, 2 of which are hydrophobic and 3 are hydrogen bonds with the amino acids GLY143, SER144, CYS145 and MET165.", [["amino acid", "CHEMICAL", 18, 28], ["HIS41", "CHEMICAL", 37, 42], ["hydroxychloroquine", "CHEMICAL", 53, 71], ["favipiravir", "CHEMICAL", 249, 260], ["amino acids", "CHEMICAL", 328, 339], ["amino acids", "CHEMICAL", 465, 476], ["amino acid", "CHEMICAL", 18, 28], ["hydroxychloroquine", "CHEMICAL", 53, 71], ["favipiravir -6", "CHEMICAL", 249, 263], ["hydrogen", "CHEMICAL", 304, 312], ["amino acids", "CHEMICAL", 328, 339], ["GLY143", "CHEMICAL", 340, 346], ["SER144", "CHEMICAL", 348, 354], ["CYS145", "CHEMICAL", 356, 362], ["HIS163", "CHEMICAL", 367, 373], ["hydrogen", "CHEMICAL", 441, 449], ["amino acids", "CHEMICAL", 465, 476], ["GLY143", "CHEMICAL", 477, 483], ["SER144", "CHEMICAL", 485, 491], ["CYS145", "CHEMICAL", 493, 499], ["MET165", "CHEMICAL", 504, 510], ["amino acid", "AMINO_ACID", 18, 28], ["residue", "AMINO_ACID", 29, 36], ["HIS41", "AMINO_ACID", 37, 42], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 53, 71], ["favipiravir -6", "SIMPLE_CHEMICAL", 249, 263], ["amino acids", "AMINO_ACID", 328, 339], ["GLY143", "SIMPLE_CHEMICAL", 340, 346], ["SER144", "SIMPLE_CHEMICAL", 348, 354], ["HIS163", "GENE_OR_GENE_PRODUCT", 367, 373], ["amino acids", "AMINO_ACID", 465, 476], ["GLY143", "SIMPLE_CHEMICAL", 477, 483], ["SER144", "SIMPLE_CHEMICAL", 485, 491], ["CYS145", "GENE_OR_GENE_PRODUCT", 493, 499], ["MET165", "GENE_OR_GENE_PRODUCT", 504, 510], ["the amino acid residue HIS41", "TEST", 14, 42], ["the hydroxychloroquine drug", "TREATMENT", 49, 76], ["the drug favipiravir", "TREATMENT", 240, 260], ["the amino acids GLY143", "TEST", 324, 346], ["CYS145", "TEST", 356, 362], ["HIS163", "TEST", 367, 373], ["the amino acids GLY143", "TEST", 461, 483]]], ["The observed score value was 38.3 for the drug favipiravir, which is the lowest one observed among the molecules here investigated, and 70.18 for m824.Molecular DockingHydroxychloroquine and m494 molecules showed the highest number of interactions, 14 for each.", [["favipiravir", "CHEMICAL", 47, 58], ["Hydroxychloroquine", "CHEMICAL", 168, 186], ["favipiravir", "CHEMICAL", 47, 58], ["Hydroxychloroquine", "CHEMICAL", 168, 186], ["favipiravir", "SIMPLE_CHEMICAL", 47, 58], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 168, 186], ["The observed score value", "TEST", 0, 24], ["the drug favipiravir", "TREATMENT", 38, 58], ["Hydroxychloroquine", "TREATMENT", 168, 186]]], ["For the first, 11 hydrophobic interactions and 3 hydrogen bonds were observed with amino acid residues HIS41, MET49, GLY143, CYS145, HIS163, MET165 and GLU166, with a score value of 66.07.", [["amino acid", "CHEMICAL", 83, 93], ["hydrogen", "CHEMICAL", 49, 57], ["amino acid", "CHEMICAL", 83, 93], ["HIS41", "CHEMICAL", 103, 108], ["MET49", "CHEMICAL", 110, 115], ["GLY143", "CHEMICAL", 117, 123], ["CYS145", "CHEMICAL", 125, 131], ["HIS163", "CHEMICAL", 133, 139], ["MET165", "CHEMICAL", 141, 147], ["GLU166", "CHEMICAL", 152, 158], ["3 hydrogen bonds", "SIMPLE_CHEMICAL", 47, 63], ["amino acid", "AMINO_ACID", 83, 93], ["GLY143", "GENE_OR_GENE_PRODUCT", 117, 123], ["3 hydrogen bonds", "TEST", 47, 63], ["amino acid residues", "TEST", 83, 102], ["HIS41", "TEST", 103, 108], ["MET49", "TEST", 110, 115], ["GLY143", "TEST", 117, 123], ["CYS145", "TEST", 125, 131], ["HIS163", "TEST", 133, 139], ["MET165", "TEST", 141, 147], ["GLU166", "TEST", 152, 158], ["a score value", "TEST", 165, 178]]], ["Each of the amino acid residues HIS41, MET49, CYS145 and MET165 had at least two points of hydrophobic interaction with hydroxychloroquine, and GLU166 had two points of hydrogen bonding.", [["amino acid", "CHEMICAL", 12, 22], ["MET165", "CHEMICAL", 57, 63], ["hydroxychloroquine", "CHEMICAL", 120, 138], ["GLU166", "CHEMICAL", 144, 150], ["amino acid", "CHEMICAL", 12, 22], ["HIS41", "CHEMICAL", 32, 37], ["MET49", "CHEMICAL", 39, 44], ["MET165", "CHEMICAL", 57, 63], ["hydroxychloroquine", "CHEMICAL", 120, 138], ["GLU166", "CHEMICAL", 144, 150], ["hydrogen", "CHEMICAL", 169, 177], ["amino acid", "AMINO_ACID", 12, 22], ["MET165", "AMINO_ACID", 57, 63], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 120, 138], ["GLU166", "SIMPLE_CHEMICAL", 144, 150], ["hydrogen", "SIMPLE_CHEMICAL", 169, 177], ["the amino acid residues", "TEST", 8, 31], ["hydrophobic interaction", "PROBLEM", 91, 114], ["hydroxychloroquine", "TREATMENT", 120, 138], ["hydrogen bonding", "PROBLEM", 169, 185], ["hydrophobic interaction", "OBSERVATION", 91, 114], ["hydrogen bonding", "OBSERVATION", 169, 185]]], ["GLY143 presented only one hydrogen bonding point and HIS163 had a hydrophobic interaction point with the inhibitor.Molecular DockingFor m494, 4 hydrophobic interactions and 10 hydrogen bonds were identified with the amino acid residues LEU141, SER144, CYS145, MET165, GLU166, ARG188, GLN189 and THR190, obtaining a score value of 74.42.", [["GLY143", "CHEMICAL", 0, 6], ["HIS163", "CHEMICAL", 53, 59], ["amino acid", "CHEMICAL", 216, 226], ["GLY143", "CHEMICAL", 0, 6], ["hydrogen", "CHEMICAL", 26, 34], ["HIS163", "CHEMICAL", 53, 59], ["hydrogen", "CHEMICAL", 176, 184], ["amino acid", "CHEMICAL", 216, 226], ["LEU141", "CHEMICAL", 236, 242], ["MET165", "CHEMICAL", 260, 266], ["GLU166", "CHEMICAL", 268, 274], ["ARG188", "CHEMICAL", 276, 282], ["GLN189", "CHEMICAL", 284, 290], ["GLY143", "SIMPLE_CHEMICAL", 0, 6], ["HIS163", "SIMPLE_CHEMICAL", 53, 59], ["amino acid", "AMINO_ACID", 216, 226], ["CYS145", "GENE_OR_GENE_PRODUCT", 252, 258], ["MET165", "GENE_OR_GENE_PRODUCT", 260, 266], ["GLU166", "GENE_OR_GENE_PRODUCT", 268, 274], ["ARG188", "GENE_OR_GENE_PRODUCT", 276, 282], ["GLN189", "GENE_OR_GENE_PRODUCT", 284, 290], ["the inhibitor", "TREATMENT", 101, 114], ["10 hydrogen bonds", "TEST", 173, 190], ["the amino acid residues", "TEST", 212, 235], ["CYS145", "TEST", 252, 258], ["MET165", "TEST", 260, 266], ["GLU166", "TEST", 268, 274], ["ARG188", "TEST", 276, 282], ["GLN189", "TEST", 284, 290], ["a score value", "TEST", 313, 326], ["hydrogen bonding", "OBSERVATION", 26, 42]]], ["In this case, the amino acid residues MET165 and GLN189 had two points of hydrophobic interaction with SARS-CoV-2-ML_m494, while SER144 and CYS145 had two points of hydrogen bonding.", [["amino acid", "CHEMICAL", 18, 28], ["GLN189", "CHEMICAL", 49, 55], ["amino acid", "CHEMICAL", 18, 28], ["hydrogen", "CHEMICAL", 165, 173], ["amino acid", "AMINO_ACID", 18, 28], ["GLN189", "AMINO_ACID", 49, 55], ["CYS145", "SIMPLE_CHEMICAL", 140, 146], ["hydrogen", "SIMPLE_CHEMICAL", 165, 173], ["CYS145", "PROTEIN", 140, 146], ["the amino acid residues", "TEST", 14, 37], ["hydrophobic interaction", "PROBLEM", 74, 97], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["hydrogen bonding", "PROBLEM", 165, 181], ["hydrogen bonding", "OBSERVATION", 165, 181]]], ["The GLN189 residue, in addition to the two hydrophobic interactions, also showed a hydrogen bond with the inhibitor.", [["GLN189", "CHEMICAL", 4, 10], ["GLN189", "CHEMICAL", 4, 10], ["hydrogen", "CHEMICAL", 83, 91], ["GLN189", "GENE_OR_GENE_PRODUCT", 4, 10], ["The GLN189 residue", "PROBLEM", 0, 18], ["a hydrogen bond", "TREATMENT", 81, 96], ["the inhibitor", "TREATMENT", 102, 115], ["hydrogen bond", "OBSERVATION", 83, 96]]], ["Finally, the amino acid residues LEU141, GLU166, ARG188 and THR190 presented a hydrogen bonding point with the inhibitor, each one.Molecular DockingMolecules with intermediate number of interactions were m74 (8), m135 (8), m351 (9), m603 (8) and m808 (8) with satisfactory score values for the best pose equal to 75.3; 61.41; 70.36; 68.45 and 73.55, respectively.", [["amino acid", "CHEMICAL", 13, 23], ["ARG188", "CHEMICAL", 49, 55], ["THR190", "CHEMICAL", 60, 66], ["amino acid", "CHEMICAL", 13, 23], ["LEU141", "CHEMICAL", 33, 39], ["GLU166", "CHEMICAL", 41, 47], ["ARG188", "CHEMICAL", 49, 55], ["THR190", "CHEMICAL", 60, 66], ["hydrogen", "CHEMICAL", 79, 87], ["amino acid", "AMINO_ACID", 13, 23], ["THR190", "SIMPLE_CHEMICAL", 60, 66], ["the amino acid residues", "TEST", 9, 32], ["GLU166", "TEST", 41, 47], ["a hydrogen bonding point", "TREATMENT", 77, 101], ["the inhibitor", "TREATMENT", 107, 120], ["Molecular DockingMolecules", "PROBLEM", 131, 157], ["intermediate", "OBSERVATION_MODIFIER", 163, 175], ["number", "OBSERVATION_MODIFIER", 176, 182]]], ["M74 did not interact with the amino acid residues belonging to the catalytic site, unlike the m135 and m808 molecules that managed to interact with the HIS41 and CYS145 residues.Molecular DockingThe molecule that had the highest score value, 80.75, was m152.", [["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "AMINO_ACID", 30, 40], ["m135", "GENE_OR_GENE_PRODUCT", 94, 98], ["HIS41", "GENE_OR_GENE_PRODUCT", 152, 157], ["CYS145", "GENE_OR_GENE_PRODUCT", 162, 168], ["catalytic site", "PROTEIN", 67, 81], ["m135 and m808 molecules", "PROTEIN", 94, 117], ["HIS41 and CYS145 residues", "PROTEIN", 152, 177], ["the amino acid residues", "TREATMENT", 26, 49], ["the HIS41 and CYS145 residues", "TREATMENT", 148, 177]]], ["A total of 7 interactions were observed, with 4 hydrophobic interactions and 3 hydrogen bonds.", [["hydrogen", "CHEMICAL", 79, 87]]], ["In this case, each of the amino acid residues MET49, CYS145, GLU166 and LEU167 presented only one point of interaction as an inhibitor, these interactions being hydrophobic for MET49 and CYS145, and hydrogen bond for GLU166 and LEU167.", [["amino acid", "CHEMICAL", 26, 36], ["LEU167", "CHEMICAL", 72, 78], ["GLU166", "CHEMICAL", 217, 223], ["LEU167", "CHEMICAL", 228, 234], ["amino acid", "CHEMICAL", 26, 36], ["MET49", "CHEMICAL", 46, 51], ["CYS145", "CHEMICAL", 53, 59], ["GLU166", "CHEMICAL", 61, 67], ["LEU167", "CHEMICAL", 72, 78], ["MET49", "CHEMICAL", 177, 182], ["CYS145", "CHEMICAL", 187, 193], ["hydrogen", "CHEMICAL", 199, 207], ["GLU166", "CHEMICAL", 217, 223], ["LEU167", "CHEMICAL", 228, 234], ["amino acid", "AMINO_ACID", 26, 36], ["GLU166", "GENE_OR_GENE_PRODUCT", 61, 67], ["LEU167", "AMINO_ACID", 72, 78], ["MET49", "GENE_OR_GENE_PRODUCT", 177, 182], ["CYS145", "GENE_OR_GENE_PRODUCT", 187, 193], ["GLU166", "SIMPLE_CHEMICAL", 217, 223], ["LEU167", "SIMPLE_CHEMICAL", 228, 234], ["MET49", "PROTEIN", 177, 182], ["CYS145", "PROTEIN", 187, 193], ["the amino acid residues", "TEST", 22, 45], ["CYS145", "TEST", 53, 59], ["GLU166", "TEST", 61, 67], ["an inhibitor", "TREATMENT", 122, 134], ["MET49", "TEST", 177, 182], ["CYS145", "TREATMENT", 187, 193], ["hydrogen bond", "TEST", 199, 212], ["GLU166", "TEST", 217, 223]]], ["The amino acid residue PRO168 was the only one that showed multiple interactions with the m152 inhibitor, two hydrophobic interactions and one hydrogen bond.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["PRO168", "CHEMICAL", 23, 29], ["hydrogen", "CHEMICAL", 143, 151], ["amino acid", "AMINO_ACID", 4, 14], ["residue", "AMINO_ACID", 15, 22], ["PRO168", "AMINO_ACID", 23, 29], ["The amino acid residue PRO168", "TEST", 0, 29]]], ["However, there was no interaction with the amino acid residue HIS41 belonging to the catalytic site of M pro .Molecular DockingThe m57 and m113 molecules stand out for having a satisfactory number of interactions and score value, emphasizing that the first was the molecule studied that showed interaction with the largest number of amino acid residues (8) .", [["amino acid", "CHEMICAL", 43, 53], ["amino acid", "CHEMICAL", 333, 343], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "CHEMICAL", 333, 343], ["amino acid", "AMINO_ACID", 43, 53], ["residue", "AMINO_ACID", 54, 61], ["HIS41", "AMINO_ACID", 62, 67], ["amino acid", "AMINO_ACID", 333, 343], ["amino acid residue HIS41", "PROTEIN", 43, 67], ["catalytic site", "PROTEIN", 85, 99], ["M pro", "PROTEIN", 103, 108], ["m57 and m113 molecules", "PROTEIN", 131, 153], ["the amino acid residue", "TEST", 39, 61], ["score value", "TEST", 217, 228], ["amino acid residues", "TREATMENT", 333, 352], ["no", "UNCERTAINTY", 19, 21]]], ["For m57, 12 interactions were observed, 6 of them hydrophobic and 6 of hydrogen bonds the amino acids LEU27, HIS41, GLY143, CYS145, MET165, GLU166, PRO168 and GLN189, and the score value obtained for the best pose was 73, 69.", [["amino acids", "CHEMICAL", 90, 101], ["hydrogen", "CHEMICAL", 71, 79], ["amino acids", "CHEMICAL", 90, 101], ["HIS41", "CHEMICAL", 109, 114], ["GLY143", "CHEMICAL", 116, 122], ["CYS145", "CHEMICAL", 124, 130], ["MET165", "CHEMICAL", 132, 138], ["amino acids", "AMINO_ACID", 90, 101], ["GLY143", "GENE_OR_GENE_PRODUCT", 116, 122], ["CYS145", "GENE_OR_GENE_PRODUCT", 124, 130], ["MET165", "GENE_OR_GENE_PRODUCT", 132, 138], ["GLU166", "GENE_OR_GENE_PRODUCT", 140, 146], ["HIS41", "PROTEIN", 109, 114], ["GLY143", "PROTEIN", 116, 122], ["CYS145", "PROTEIN", 124, 130], ["MET165", "PROTEIN", 132, 138], ["GLU166", "PROTEIN", 140, 146], ["PRO168", "PROTEIN", 148, 154], ["GLN189", "PROTEIN", 159, 165], ["hydrogen bonds the amino acids", "TEST", 71, 101], ["HIS41", "TEST", 109, 114], ["GLY143", "TEST", 116, 122], ["CYS145", "TEST", 124, 130], ["MET165", "TEST", 132, 138], ["GLU166", "TEST", 140, 146], ["PRO168", "TEST", 148, 154], ["the score value", "TEST", 171, 186]]], ["For m113, 10 interactions were identified, 9 of them hydrophobic and 1 hydrogen bond with the amino acids HIS41, MET49, CYS145, MET165, GLU166, PRO168 and GLN189, and a score value of 72.57.", [["amino acids", "CHEMICAL", 94, 105], ["hydrogen", "CHEMICAL", 71, 79], ["amino acids", "CHEMICAL", 94, 105], ["MET49", "CHEMICAL", 113, 118], ["CYS145", "CHEMICAL", 120, 126], ["MET165", "CHEMICAL", 128, 134], ["GLU166", "CHEMICAL", 136, 142], ["PRO168", "CHEMICAL", 144, 150], ["amino acids", "AMINO_ACID", 94, 105], ["HIS41", "AMINO_ACID", 106, 111], ["MET49", "SIMPLE_CHEMICAL", 113, 118], ["CYS145", "GENE_OR_GENE_PRODUCT", 120, 126], ["MET49", "PROTEIN", 113, 118], ["CYS145", "PROTEIN", 120, 126], ["MET165", "PROTEIN", 128, 134], ["GLU166", "PROTEIN", 136, 142], ["PRO168", "PROTEIN", 144, 150], ["GLN189", "PROTEIN", 155, 161], ["the amino acids HIS41", "TEST", 90, 111], ["MET49", "TEST", 113, 118], ["CYS145", "TEST", 120, 126], ["MET165", "TEST", 128, 134], ["GLU166", "TEST", 136, 142], ["PRO168", "TEST", 144, 150], ["GLN189", "TEST", 155, 161], ["a score value", "TEST", 167, 180]]], ["It is important to note that both had score values higher than those obtained for the drugs studied.Molecular DockingConsidering the amino acids GLY143, CYS145, HIS163, HIS164, GLU166, GLN189, and TYR190 that bind with the crystallographic inhibitor N3, only the m494 molecule interacted with the TYR190 residue.", [["amino acids", "CHEMICAL", 133, 144], ["amino acids", "CHEMICAL", 133, 144], ["CYS145", "CHEMICAL", 153, 159], ["HIS163", "CHEMICAL", 161, 167], ["HIS164", "CHEMICAL", 169, 175], ["GLU166", "CHEMICAL", 177, 183], ["GLN189", "CHEMICAL", 185, 191], ["N3", "CHEMICAL", 250, 252], ["amino acids", "AMINO_ACID", 133, 144], ["GLY143", "AMINO_ACID", 145, 151], ["CYS145", "GENE_OR_GENE_PRODUCT", 153, 159], ["HIS163", "GENE_OR_GENE_PRODUCT", 161, 167], ["HIS164", "GENE_OR_GENE_PRODUCT", 169, 175], ["GLU166", "GENE_OR_GENE_PRODUCT", 177, 183], ["GLN189", "GENE_OR_GENE_PRODUCT", 185, 191], ["TYR190", "GENE_OR_GENE_PRODUCT", 197, 203], ["m494", "GENE_OR_GENE_PRODUCT", 263, 267], ["HIS163", "PROTEIN", 161, 167], ["HIS164", "PROTEIN", 169, 175], ["GLU166", "PROTEIN", 177, 183], ["GLN189", "PROTEIN", 185, 191], ["TYR190", "PROTEIN", 197, 203], ["m494 molecule", "PROTEIN", 263, 276], ["the drugs", "TREATMENT", 82, 91], ["the amino acids GLY143", "TEST", 129, 151], ["CYS145", "TEST", 153, 159], ["HIS163", "TEST", 161, 167], ["HIS164", "TEST", 169, 175], ["GLU166", "TEST", 177, 183], ["GLN189", "TEST", 185, 191], ["the crystallographic inhibitor N3", "TREATMENT", 219, 252]]], ["For the amino acid GLY143, there was interaction only with the favipiravir, hydroxychloroquine, m57 and m824 molecules.", [["amino acid", "CHEMICAL", 8, 18], ["GLY143", "CHEMICAL", 19, 25], ["favipiravir", "CHEMICAL", 63, 74], ["hydroxychloroquine", "CHEMICAL", 76, 94], ["amino acid", "CHEMICAL", 8, 18], ["favipiravir", "CHEMICAL", 63, 74], ["hydroxychloroquine", "CHEMICAL", 76, 94], ["m57", "CHEMICAL", 96, 99], ["m824", "CHEMICAL", 104, 108], ["amino acid", "AMINO_ACID", 8, 18], ["GLY143", "SIMPLE_CHEMICAL", 19, 25], ["favipiravir", "SIMPLE_CHEMICAL", 63, 74], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 76, 94], ["m57", "SIMPLE_CHEMICAL", 96, 99], ["m824 molecules", "SIMPLE_CHEMICAL", 104, 118], ["the amino acid GLY143", "TEST", 4, 25], ["the favipiravir", "TREATMENT", 59, 74], ["hydroxychloroquine", "TREATMENT", 76, 94]]], ["For the amino acid CYS145, all molecules interacted, with the exception of m74.", [["amino acid", "CHEMICAL", 8, 18], ["amino acid", "CHEMICAL", 8, 18], ["amino acid", "AMINO_ACID", 8, 18], ["CYS145", "AMINO_ACID", 19, 25], ["m74", "GENE_OR_GENE_PRODUCT", 75, 78], ["m74", "PROTEIN", 75, 78], ["the amino acid CYS145", "TEST", 4, 25]]], ["The HIS163 residue interacted only with the J o u r n a l P r e -p r o o f favipiravir, hydroxychloroquine, m74 and m135 molecules.", [["favipiravir", "CHEMICAL", 75, 86], ["hydroxychloroquine", "CHEMICAL", 88, 106], ["favipiravir", "CHEMICAL", 75, 86], ["hydroxychloroquine", "CHEMICAL", 88, 106], ["m74", "CHEMICAL", 108, 111], ["HIS163", "SIMPLE_CHEMICAL", 4, 10], ["favipiravir", "SIMPLE_CHEMICAL", 75, 86], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 88, 106], ["m74", "SIMPLE_CHEMICAL", 108, 111], ["m135 molecules", "SIMPLE_CHEMICAL", 116, 130], ["favipiravir", "TREATMENT", 75, 86], ["hydroxychloroquine", "TREATMENT", 88, 106]]], ["No linker interacted with the amino acid residue HIS164.", [["amino acid", "CHEMICAL", 30, 40], ["HIS164", "CHEMICAL", 49, 55], ["amino acid", "CHEMICAL", 30, 40], ["HIS164", "CHEMICAL", 49, 55], ["amino acid", "AMINO_ACID", 30, 40], ["residue", "AMINO_ACID", 41, 48], ["HIS164", "AMINO_ACID", 49, 55], ["linker", "PROBLEM", 3, 9], ["the amino acid residue", "TEST", 26, 48]]], ["The amino acid residue GLU166 showed interaction with all molecules, except with favipiravir and m824.", [["amino acid", "CHEMICAL", 4, 14], ["GLU166", "CHEMICAL", 23, 29], ["favipiravir", "CHEMICAL", 81, 92], ["amino acid", "CHEMICAL", 4, 14], ["GLU166", "CHEMICAL", 23, 29], ["favipiravir", "CHEMICAL", 81, 92], ["m824", "CHEMICAL", 97, 101], ["amino acid", "AMINO_ACID", 4, 14], ["residue", "AMINO_ACID", 15, 22], ["GLU166", "AMINO_ACID", 23, 29], ["favipiravir", "SIMPLE_CHEMICAL", 81, 92], ["m824", "SIMPLE_CHEMICAL", 97, 101], ["The amino acid residue", "TEST", 0, 22], ["favipiravir", "TREATMENT", 81, 92]]], ["The GLN189 residue, on the other hand, interacted only with the m57, m113 and m494 molecules.Molecular DockingThe amino acid residues CYS145, MET165, PRO168 and GLN189 proved to be capable of making multiple chemical interactions of different nature with the inhibitors.", [["GLN189", "CHEMICAL", 4, 10], ["amino acid", "CHEMICAL", 114, 124], ["PRO168", "CHEMICAL", 150, 156], ["GLN189", "CHEMICAL", 161, 167], ["amino acid", "CHEMICAL", 114, 124], ["CYS145", "CHEMICAL", 134, 140], ["MET165", "CHEMICAL", 142, 148], ["PRO168", "CHEMICAL", 150, 156], ["GLN189", "CHEMICAL", 161, 167], ["GLN189", "GENE_OR_GENE_PRODUCT", 4, 10], ["amino acid", "AMINO_ACID", 114, 124], ["GLN189", "SIMPLE_CHEMICAL", 161, 167], ["m57, m113 and m494 molecules", "PROTEIN", 64, 92], ["The amino acid residues", "TEST", 110, 133], ["the inhibitors", "TREATMENT", 255, 269], ["GLN189 residue", "OBSERVATION", 4, 18]]], ["Its multiple interactions are present both in the cases in which the inhibitors had the highest number of interactions with the target, and in the case in which the inhibitor presented the highest score value among the twelve selected molecules.", [["multiple", "OBSERVATION_MODIFIER", 4, 12], ["interactions", "OBSERVATION", 13, 25]]], ["Therefore, the amino acid residues MET165, PRO168 and GLN189 showed their relevance in multiple interactions of different chemical natures between the inhibitor and the target, in addition to the HIS41 and CYS145 residues already belonging to the active site of M pro , and we can select the m57 molecule as the most promising drug candidate for treatment of COVID-19 ( Figure 4) .Search based on structural similarityJ o u r n a l P r e -p r o o f Similar Property Principle (SPP) states that molecules that are similar in overall structure are likely to have similar biological activity [50] .Search based on structural similarityWith the similarity analysis, it was possible to select the drug Apixaban, which showed 42% similarity with the selected molecule m57.", [["amino acid", "CHEMICAL", 15, 25], ["PRO168", "CHEMICAL", 43, 49], ["GLN189", "CHEMICAL", 54, 60], ["Apixaban", "CHEMICAL", 697, 705], ["amino acid", "CHEMICAL", 15, 25], ["MET165", "CHEMICAL", 35, 41], ["PRO168", "CHEMICAL", 43, 49], ["GLN189", "CHEMICAL", 54, 60], ["COVID-19", "CHEMICAL", 359, 367], ["Apixaban", "CHEMICAL", 697, 705], ["amino acid", "AMINO_ACID", 15, 25], ["GLN189", "AMINO_ACID", 54, 60], ["HIS41", "GENE_OR_GENE_PRODUCT", 196, 201], ["M pro", "GENE_OR_GENE_PRODUCT", 262, 267], ["Apixaban", "SIMPLE_CHEMICAL", 697, 705], ["m57", "GENE_OR_GENE_PRODUCT", 762, 765], ["HIS41", "PROTEIN", 196, 201], ["M pro", "PROTEIN", 262, 267], ["m57 molecule", "PROTEIN", 292, 304], ["m57", "PROTEIN", 762, 765], ["the amino acid residues", "TEST", 11, 34], ["the inhibitor", "TREATMENT", 147, 160], ["the HIS41 and CYS145 residues", "TREATMENT", 192, 221], ["COVID", "TEST", 359, 364], ["the drug Apixaban", "TEST", 688, 705]]], ["Then, molecular docking calculations were performed for the target M pro (Figure 5 ), obtaining 12 interactions, 3 with the catalytic dyad, HIS41 and CYS145, and 9 other interactions with 8 more amino acids (MET49, LEU141, ASN142, GLY143, HIS163, MET165, PRO168 and ARG188), with a score value of 75.26.Search based on structural similarityApixaban is an anticoagulant, acts by selectively inhibiting the activated factor Xa in a reversible manner and has an oral bioavailability of ~50%.", [["oral", "ANATOMY", 459, 463], ["amino acids", "CHEMICAL", 195, 206], ["Apixaban", "CHEMICAL", 340, 348], ["CYS145", "CHEMICAL", 150, 156], ["amino acids", "CHEMICAL", 195, 206], ["MET49", "CHEMICAL", 208, 213], ["LEU141", "CHEMICAL", 215, 221], ["ASN142", "CHEMICAL", 223, 229], ["GLY143", "CHEMICAL", 231, 237], ["HIS163", "CHEMICAL", 239, 245], ["MET165", "CHEMICAL", 247, 253], ["PRO168", "CHEMICAL", 255, 261], ["ARG188", "CHEMICAL", 266, 272], ["Apixaban", "CHEMICAL", 340, 348], ["HIS41", "SIMPLE_CHEMICAL", 140, 145], ["CYS145", "SIMPLE_CHEMICAL", 150, 156], ["amino acids", "AMINO_ACID", 195, 206], ["MET49", "SIMPLE_CHEMICAL", 208, 213], ["Apixaban", "SIMPLE_CHEMICAL", 340, 348], ["Xa", "GENE_OR_GENE_PRODUCT", 422, 424], ["oral", "ORGANISM_SUBDIVISION", 459, 463], ["catalytic dyad", "PROTEIN", 124, 138], ["activated factor Xa", "PROTEIN", 405, 424], ["molecular docking calculations", "TEST", 6, 36], ["CYS145", "TEST", 150, 156], ["amino acids", "TEST", 195, 206], ["a score value", "TEST", 280, 293], ["Apixaban", "TREATMENT", 340, 348], ["an anticoagulant", "TREATMENT", 352, 368], ["an oral bioavailability", "TEST", 456, 479], ["anticoagulant", "OBSERVATION", 355, 368]]], ["It is excreted in urine and feces.", [["urine", "ANATOMY", 18, 23], ["feces", "ANATOMY", 28, 33], ["urine", "ORGANISM_SUBSTANCE", 18, 23], ["feces", "ORGANISM_SUBSTANCE", 28, 33], ["excreted", "OBSERVATION_MODIFIER", 6, 14], ["urine", "OBSERVATION", 18, 23], ["feces", "OBSERVATION", 28, 33]]], ["Apixaban is useful in atrial fibrillation, venous thromboembolism, and pulmonary embolism.", [["atrial", "ANATOMY", 22, 28], ["venous", "ANATOMY", 43, 49], ["pulmonary", "ANATOMY", 71, 80], ["Apixaban", "CHEMICAL", 0, 8], ["atrial fibrillation", "DISEASE", 22, 41], ["venous thromboembolism", "DISEASE", 43, 65], ["pulmonary embolism", "DISEASE", 71, 89], ["Apixaban", "CHEMICAL", 0, 8], ["Apixaban", "SIMPLE_CHEMICAL", 0, 8], ["atrial", "MULTI-TISSUE_STRUCTURE", 22, 28], ["venous", "MULTI-TISSUE_STRUCTURE", 43, 49], ["pulmonary", "ORGAN", 71, 80], ["Apixaban", "TREATMENT", 0, 8], ["atrial fibrillation", "PROBLEM", 22, 41], ["venous thromboembolism", "PROBLEM", 43, 65], ["pulmonary embolism", "PROBLEM", 71, 89], ["atrial", "ANATOMY", 22, 28], ["fibrillation", "OBSERVATION", 29, 41], ["venous", "ANATOMY", 43, 49], ["thromboembolism", "OBSERVATION", 50, 65], ["pulmonary", "ANATOMY", 71, 80], ["embolism", "OBSERVATION", 81, 89]]], ["Bleeding is the major side effect of Apixaban [51] .Search based on structural similarityIn a clinical study made by Tang et al. [52] with 449 patients with severe COVID-19, 99 of them received heparin (mainly with low molecular weight heparin, LMWH) for 7 days or longer.", [["Bleeding", "DISEASE", 0, 8], ["Apixaban", "CHEMICAL", 37, 45], ["COVID", "DISEASE", 164, 169], ["heparin", "CHEMICAL", 194, 201], ["heparin", "CHEMICAL", 236, 243], ["LMWH", "CHEMICAL", 245, 249], ["Apixaban", "CHEMICAL", 37, 45], ["Apixaban", "SIMPLE_CHEMICAL", 37, 45], ["patients", "ORGANISM", 143, 151], ["heparin", "SIMPLE_CHEMICAL", 194, 201], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 215, 243], ["LMWH", "SIMPLE_CHEMICAL", 245, 249], ["patients", "SPECIES", 143, 151], ["Bleeding", "PROBLEM", 0, 8], ["Apixaban", "TREATMENT", 37, 45], ["a clinical study", "TEST", 92, 108], ["severe COVID", "PROBLEM", 157, 169], ["heparin", "TREATMENT", 194, 201], ["low molecular weight heparin", "TREATMENT", 215, 243], ["LMWH", "TREATMENT", 245, 249]]], ["The 28-day mortality of heparin users were lower than nonusers in patients with SIC score \u22654 or D-dimer > 6 fold of upper limit of normal.", [["heparin", "CHEMICAL", 24, 31], ["heparin", "SIMPLE_CHEMICAL", 24, 31], ["patients", "ORGANISM", 66, 74], ["D-dimer", "SIMPLE_CHEMICAL", 96, 103], ["upper", "ORGANISM_SUBDIVISION", 116, 121], ["patients", "SPECIES", 66, 74], ["heparin users", "TREATMENT", 24, 37], ["SIC score", "TEST", 80, 89], ["D-dimer", "TEST", 96, 103], ["upper limit", "OBSERVATION_MODIFIER", 116, 127], ["normal", "OBSERVATION", 131, 137]]], ["They concluded that anticoagulant therapy, mainly with LMWH, appears to be associated with better prognosis in severe COVID-19 patients meeting sepsis-induced coagulopathy (SIC) criteria or with markedly elevated D-dimer.Search based on structural similarityInjectable anticoagulants such as heparin are prescribed when anticoagulation therapy is required for short duration.", [["LMWH", "CHEMICAL", 55, 59], ["COVID", "DISEASE", 118, 123], ["sepsis", "DISEASE", 144, 150], ["coagulopathy", "DISEASE", 159, 171], ["SIC", "DISEASE", 173, 176], ["heparin", "CHEMICAL", 292, 299], ["LMWH", "SIMPLE_CHEMICAL", 55, 59], ["patients", "ORGANISM", 127, 135], ["D-dimer", "GENE_OR_GENE_PRODUCT", 213, 220], ["heparin", "SIMPLE_CHEMICAL", 292, 299], ["D-dimer", "PROTEIN", 213, 220], ["patients", "SPECIES", 127, 135], ["anticoagulant therapy", "TREATMENT", 20, 41], ["LMWH", "TREATMENT", 55, 59], ["severe COVID", "PROBLEM", 111, 123], ["sepsis", "PROBLEM", 144, 150], ["coagulopathy", "PROBLEM", 159, 171], ["markedly elevated D-dimer", "PROBLEM", 195, 220], ["Injectable anticoagulants", "TREATMENT", 258, 283], ["heparin", "TREATMENT", 292, 299], ["anticoagulation therapy", "TREATMENT", 320, 343], ["anticoagulant therapy", "OBSERVATION", 20, 41], ["coagulopathy", "OBSERVATION", 159, 171], ["elevated", "OBSERVATION_MODIFIER", 204, 212], ["D-dimer", "OBSERVATION_MODIFIER", 213, 220]]], ["Absence of oral form of heparin makes it impractical for long-term use.", [["oral", "ANATOMY", 11, 15], ["heparin", "CHEMICAL", 24, 31], ["oral", "ORGANISM_SUBDIVISION", 11, 15], ["heparin", "SIMPLE_CHEMICAL", 24, 31], ["heparin", "TREATMENT", 24, 31]]], ["As an alternative, warfarin and coumarone derivatives are the best available oral anticoagulants in market [51] .", [["oral", "ANATOMY", 77, 81], ["warfarin", "CHEMICAL", 19, 27], ["coumarone", "CHEMICAL", 32, 41], ["warfarin", "CHEMICAL", 19, 27], ["coumarone", "CHEMICAL", 32, 41], ["warfarin", "SIMPLE_CHEMICAL", 19, 27], ["coumarone derivatives", "SIMPLE_CHEMICAL", 32, 53], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["warfarin", "TREATMENT", 19, 27], ["coumarone derivatives", "TREATMENT", 32, 53], ["oral anticoagulants", "TREATMENT", 77, 96]]], ["It has been found that apixaban has superiority over warfarin and aspirin in terms of efficacy and safety [53] .Search based on structural similarityIn the present study, a toxicity prediction study using DEREK software was done and no alerts were fired for the drug Apixaban.Search based on structural similarityJ o u r n a l P r e -p r o o fConclusionIn this work, we present proposals for new potential M pro inhibitors of the SARS-CoV-2 virus (PDB ID: 6LU7) as an alternative treatment for COVID-19.", [["apixaban", "CHEMICAL", 23, 31], ["warfarin", "CHEMICAL", 53, 61], ["aspirin", "CHEMICAL", 66, 73], ["toxicity", "DISEASE", 173, 181], ["Apixaban", "CHEMICAL", 267, 275], ["apixaban", "CHEMICAL", 23, 31], ["warfarin", "CHEMICAL", 53, 61], ["aspirin", "CHEMICAL", 66, 73], ["Apixaban", "CHEMICAL", 267, 275], ["apixaban", "SIMPLE_CHEMICAL", 23, 31], ["warfarin", "SIMPLE_CHEMICAL", 53, 61], ["aspirin", "SIMPLE_CHEMICAL", 66, 73], ["Apixaban", "SIMPLE_CHEMICAL", 267, 275], ["SARS-CoV-2 virus", "ORGANISM", 430, 446], ["SARS-CoV-2 virus", "SPECIES", 430, 446], ["apixaban", "TREATMENT", 23, 31], ["warfarin", "TREATMENT", 53, 61], ["aspirin", "TREATMENT", 66, 73], ["a toxicity prediction study", "TEST", 171, 198], ["DEREK software", "TEST", 205, 219], ["the drug Apixaban", "TREATMENT", 258, 275], ["new potential M pro inhibitors", "TREATMENT", 392, 422], ["the SARS", "PROBLEM", 426, 434], ["CoV", "TEST", 435, 438], ["an alternative treatment", "TREATMENT", 465, 489], ["COVID", "TEST", 494, 499], ["apixaban", "OBSERVATION", 23, 31]]], ["These compounds were designed from virtual screening experiments in two compound databases, one being previously built from docking compounds with M pro , and the other was built from compounds with known anti-SARS activity.", [["anti-SARS", "GENE_OR_GENE_PRODUCT", 205, 214], ["anti-SARS", "PROTEIN", 205, 214], ["virtual screening experiments", "TEST", 35, 64]]], ["From these virtual screening experiments here performed, we selected the 100 top-ranked hits from each base.", [["these virtual screening experiments", "TEST", 5, 40], ["base", "ANATOMY_MODIFIER", 103, 107]]], ["Their ADME/Tox properties were calculated and compared to those of drugs currently being tested with COVID-19, by attempting to reposition of the function, among known antivirals and hydroxychloroquine, a drug used in the treatment of rheumatoid arthritis, as well as others inflammatory diseases.", [["hydroxychloroquine", "CHEMICAL", 183, 201], ["rheumatoid arthritis", "DISEASE", 235, 255], ["inflammatory diseases", "DISEASE", 275, 296], ["COVID-19", "CHEMICAL", 101, 109], ["hydroxychloroquine", "CHEMICAL", 183, 201], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 183, 201], ["Their ADME/Tox properties", "TEST", 0, 25], ["drugs", "TREATMENT", 67, 72], ["COVID", "TEST", 101, 106], ["antivirals", "TREATMENT", 168, 178], ["hydroxychloroquine", "TREATMENT", 183, 201], ["a drug", "TREATMENT", 203, 209], ["rheumatoid arthritis", "PROBLEM", 235, 255], ["others inflammatory diseases", "PROBLEM", 268, 296], ["rheumatoid arthritis", "OBSERVATION", 235, 255], ["inflammatory", "OBSERVATION_MODIFIER", 275, 287]]], ["Our compounds designed and here presented showed pharmacokinetic and toxicological properties even more satisfactory and suitable than the drugs currently in test with COVID-19, in addition to maintain a network of favorable intermolecular interactions with the M pro of the new coronavirus, according to the docking studies here performed with such enzyme.", [["COVID-19", "CHEMICAL", 168, 176], ["COVID-19", "CHEMICAL", 168, 176], ["COVID-19", "SIMPLE_CHEMICAL", 168, 176], ["coronavirus", "ORGANISM", 279, 290], ["M pro", "PROTEIN", 262, 267], ["enzyme", "PROTEIN", 350, 356], ["pharmacokinetic and toxicological properties", "PROBLEM", 49, 93], ["the drugs", "TREATMENT", 135, 144], ["COVID", "TEST", 168, 173], ["the new coronavirus", "PROBLEM", 271, 290], ["the docking studies", "TEST", 305, 324], ["such enzyme", "TEST", 345, 356]]], ["Also, an inhibitor was selected serving as a template for study of similarity and drug repurposing and it was possible to identify Apixaban, an known anticoagulant administered by the oral route, which shows very promising results for future treatment of COVID-19.", [["oral", "ANATOMY", 184, 188], ["Apixaban", "CHEMICAL", 131, 139], ["Apixaban", "CHEMICAL", 131, 139], ["COVID-19", "CHEMICAL", 255, 263], ["Apixaban", "SIMPLE_CHEMICAL", 131, 139], ["oral", "ORGANISM_SUBDIVISION", 184, 188], ["an inhibitor", "TREATMENT", 6, 18], ["Apixaban", "TREATMENT", 131, 139], ["an known anticoagulant", "TREATMENT", 141, 163], ["COVID", "TEST", 255, 260]]], ["Due to the suitable pharmacotherapeutic profile as well as very low toxicity and adverse effects, thus estimated for our potential M pro inhibitors of the SARS-CoV-2 virus, we suggest our most promising compound as well as Apixaban as proposals for alternative tests with COVID-19, for future treatment of patients affected with this severe acute respiratory syndrome.", [["toxicity", "DISEASE", 68, 76], ["SARS", "DISEASE", 155, 159], ["Apixaban", "CHEMICAL", 223, 231], ["acute respiratory syndrome", "DISEASE", 341, 367], ["Apixaban", "CHEMICAL", 223, 231], ["SARS-CoV-2 virus", "ORGANISM", 155, 171], ["Apixaban", "SIMPLE_CHEMICAL", 223, 231], ["patients", "ORGANISM", 306, 314], ["CoV-2 virus", "SPECIES", 160, 171], ["patients", "SPECIES", 306, 314], ["SARS-CoV-2 virus", "SPECIES", 155, 171], ["very low toxicity", "PROBLEM", 59, 76], ["our potential M pro inhibitors", "TREATMENT", 117, 147], ["the SARS", "PROBLEM", 151, 159], ["CoV-2 virus", "PROBLEM", 160, 171], ["Apixaban", "TREATMENT", 223, 231], ["alternative tests", "TEST", 249, 266], ["COVID", "TEST", 272, 277], ["future treatment", "TREATMENT", 286, 302], ["this severe acute respiratory syndrome", "PROBLEM", 329, 367], ["severe", "OBSERVATION_MODIFIER", 334, 340], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory syndrome", "OBSERVATION", 347, 367]]]], "PMC7122897": []}